Interleukin-22 in human allergy and asthma by Venn, Pascal
Interleukin-22  
in human allergy and asthma 
 
 
A thesis submitted for the degree of 
Doctor of Philosophy 
Imperial College London 
 
 
 
Pascal Venn 
B.Sc. (hons), M.Sc. 
 
 
 
 
Supervisors 
Prof. Carsten Schmidt-Weber 
Dr. Paul Lavender 
 
2012 
 
Department of Allergy and Clinical Immunology 
MRC and Asthma UK centre in Allergic Mechanisms of Asthma 
National Heart and Lung Institute, Faculty of Medicine 
Imperial College London 
 
2 
 
Abstract 
 
Interleukin 22 (IL-22) is а newly-described Т helper cytokine which has been implicated in 
tissue regenerative processes in the gut and skin. Allergic asthma results from exposure to 
otherwise harmless environmental inhaled allergens that trigger Th2 Т Iymphocyte-driven 
IgE-аssосiаtеd immune responses in atopic individuals that contribute to airway 
inflammation and reversible airflow obstruction. In the long-term, this aberrant immune 
response is believed to increase in complexity and contribute to the permanent changes in 
the airways, including tissue remodelling and associated irreversible airway obstruction. In 
view of the known effects of IL-22 in wound healing, the overall aim of this research was to 
establish whether IL-22 is present in allergy and allergic asthma and to understand the 
influence of IL-22 on structural cells of the airway, with particular emphasis оп tissue 
remodelling. We, therefore, explored the presence of IL-22 and its receptors during allergen-
induced late responses in the bronchi and skin and measured IL-22 production and its 
regulation in peripheral blood mononuclear cells (PBMCs), Т cell lines and clones derived 
from asthmatic bronchial muсоsa. IL-22 was increased in bгonchoalveolaг lavage after 
allergen inhalation in asthmatics but not in control subjects. While we were unable to reliably 
immunostain IL-22, its receptors were present within the cutaneous connective tissue and 
co-Iocalised with HSP-47, а marker of early fibrobIasts. In PBMCs, IL-22 increased after 
allergen stimulation whereas there was nо difference between atopics and control subjects. 
In Т cell lines derived from asthmatic bronchial mucosa, IL-22 was mainly found in СD4+ Т 
helper cells of Th1 and Th22 origin. IL-22 receptors were expressed by cultured bronchial 
epithelial cells, smooth muscle cells and pulmonary fibroblasts and were increased in 
expression in the presence of interferon- (IFN-). IL-22 was able to accelerate wound 
closure of bronchial epithelial cells independent of effects on cellular proliferation. Thus, IL-
22 appears to be а Th1-related cytokine that may have а dual role in airway inflammation 
and repair. 
  
3 
 
Declaration of Originality  
The following thesis is based on my own work and else has been appropriately referenced.  
London,12th October 2012  
Pascal Venn 
Contributions: 
The bronchial segmental and intradermal allergen provocations were carried out by the 
medical staff of the Upper Respiratory Medicine group at the Royal Brompton Hospital under 
the supervision of Prof. Stephen R Durham. The clinical data as well as eosinophil counts 
were kindly provided by Dr. Stephen Till (bronchial segmental challenge) and Dr. Graham K 
Banfield (intradermal challenge).  
All the following experiments were designed, validated, carried out, and analysed by myself. 
These included the development of the IL-22RA2 ELISA, the measurements of cytokine 
expression within the bronchoalveolar lavage, the immunofluorescent staining of cutaneous 
biopsies and their analysis, the isolations of T cell populations from peripheral blood, the 
creation of T cell lines and clones from bronchial tissue, all cell culture work including the 
allergen stimulation of PBMCs and subsequent measurement of [methyl3H]-thymidine 
incorporation, the RT-PCR analysis and design of missing primer pairs, the flow cytometric 
staining and analysis, the validation and analysis of protein expression by western blotting, 
the development of functional assays such as the wound healing assay, and the 
establishment of cell cycle analysis of adherent structural cells. 
During the PhD I received supervision from Prof. Stephen R Durham (clinical challenge 
studies), Prof. Carsten Schmidt-Weber (T cell studies), and Dr. Paul Lavender (functional in 
vitro studies) and am grateful for technical support and guidance by Dr. Mikila R Jacobson 
(immunohistochemistry) and Davide Pennino (T cell cloning). 
Acknowledgements: 
Bronchial tissue from asthmatic individuals was kindly provided by Prof. Kian Fan Chung of 
the Experimental Studies group at the National Heart and Lung Institute at Imperial College 
London. Primary airway smooth muscle cell lines were kindly provided by Dr. Paul Lavender 
of the Asthma, Allergy & Respiratory Science group at Kings College London. I would like to 
thank Dr. Mohamed H Shamji for helping with the volunteer recruitment in time of need and 
Dr. Steven Till for providing feedback throughout the final year of my studies.  
Last, but not least, I like to say special thanks to my second supervisor Dr. Paul Lavender 
and, in particular, to the head of my department, Prof. Stephen R Durham, for their 
continued guidance, support, and mentorship, without which these studies would not have 
been possible. 
  
4 
 
 
 
 
 
 
 
 
 
To 
my wonderful Reetu  
& my family 
 
  
5 
 
Table of Contents 
 
Abstract .......................................................................................................................................... 2 
Table of Contents ......................................................................................................................... 5 
List of ............................................................................................................................................ 12 
Abbreviations ......................................................................................................................... 12 
Tables .................................................................................................................................... 14 
Figures ................................................................................................................................... 17 
Diagrams................................................................................................................................ 20 
Introduction ................................................................................................................................. 21 
Allergy and Asthma ................................................................................................................ 21 
Allergy .................................................................................................................................... 21 
Background ........................................................................................................................ 21 
Pathogenesis ..................................................................................................................... 23 
Sensitisation ................................................................................................................... 23 
Acute phase response .................................................................................................. 23 
Late phase response ..................................................................................................... 23 
Treatment ........................................................................................................................... 24 
Asthma ................................................................................................................................... 25 
Background ........................................................................................................................ 25 
Pathogenesis ..................................................................................................................... 27 
Airway remodelling ........................................................................................................ 28 
Treatment ........................................................................................................................... 30 
T helper cells ........................................................................................................................... 34 
Current T helper classifications ........................................................................................... 34 
Th1 and Th2 subsets .......................................................................................................... 35 
Th17 subset ......................................................................................................................... 37 
Regulatory T cells ............................................................................................................. 38 
The novel Th22 subset........................................................................................................... 39 
T helper subset heterogeneity and plasticity ...................................................................... 41 
Interleukin-22 ........................................................................................................................... 42 
IL-22 ....................................................................................................................................... 42 
Gene and Protein .............................................................................................................. 42 
Expression ......................................................................................................................... 45 
6 
 
Innate Immune cells ...................................................................................................... 45 
Monocytes, macrophages and dendritic cells ......................................................... 45 
Lymphoid-Tissue-inducer (LTi), LTi-like, and NK cells ........................................... 45 
Innate T lymphocytes ................................................................................................ 47 
Adaptive Immune cells .................................................................................................. 47 
CD4+ T lymphocytes .................................................................................................. 47 
CD8+ T lymphocytes .................................................................................................. 48 
IL-22 Receptors ..................................................................................................................... 48 
IL-22RA1 ............................................................................................................................ 48 
Gene and Protein .......................................................................................................... 48 
Expression ..................................................................................................................... 49 
Immune system.......................................................................................................... 49 
Structural cells ........................................................................................................... 49 
IL-22RA2 ............................................................................................................................ 50 
Gene and Protein .......................................................................................................... 50 
Expression ..................................................................................................................... 52 
Immune system.......................................................................................................... 52 
Structural cells ........................................................................................................... 53 
Function of IL-22 ................................................................................................................... 53 
General Function ............................................................................................................... 53 
IL-22 administration ....................................................................................................... 53 
IL-22 blockade ............................................................................................................... 54 
IL-22 Knock out mouse ................................................................................................. 54 
Cell specific functions ....................................................................................................... 55 
Immune cells .................................................................................................................. 55 
Structural cells ............................................................................................................... 55 
Epithelium ................................................................................................................... 55 
Endothelium ............................................................................................................... 59 
Fibroblasts .................................................................................................................. 59 
Specialised tissue cells ............................................................................................. 59 
Regulation by IL-22RA2 ................................................................................................... 60 
Clinical associations of Il-22 ................................................................................................. 60 
Disease association .......................................................................................................... 60 
Allergy ............................................................................................................................. 60 
7 
 
Autoimmunity ................................................................................................................. 61 
Infection .......................................................................................................................... 62 
Other ............................................................................................................................... 64 
Rationale................................................................................................................................... 66 
Hypothesis, Aims, and Objectives .......................................................................................... 67 
Hypothesis ............................................................................................................................... 67 
Aims and Objectives .............................................................................................................. 68 
Materials and Methods .............................................................................................................. 70 
1. IL-22 expression in allergic inflammation ...................................................................... 70 
1.1. Local bronchial segmental allergen challenge ............................................................ 70 
Participants ........................................................................................................................ 70 
Segmental allergen challenge, Spirometry and Fibreoptic bronchoscopy ................... 70 
Bronchoalveolar lavage processing ................................................................................. 70 
Eosinophil counts .............................................................................................................. 70 
Cytokine ELISA ................................................................................................................. 71 
IL-22RA2 ELISA ................................................................................................................ 72 
1.2. Intradermal allergen challenge ..................................................................................... 74 
Participants ........................................................................................................................ 75 
Intradermal allergen challenge, Late phase response and Punch biopsies ................ 75 
Biopsy processing ............................................................................................................. 75 
Eosinophil counts .............................................................................................................. 76 
Immunofluorescent staining ............................................................................................. 76 
2. IL-22 expression in T cells ................................................................................................ 79 
2.1. from peripheral blood .................................................................................................... 79 
2.1.1. long term allergen PBMC culture .......................................................................... 79 
Participants .................................................................................................................... 79 
PBMCs from peripheral blood ...................................................................................... 79 
In vitro culture ................................................................................................................ 79 
[methyl3H]-Thymidine incorporation ............................................................................. 80 
Cytokine ELISA.............................................................................................................. 80 
Flow Cytometry .............................................................................................................. 80 
2.1.2. polarised naive T cells ............................................................................................ 81 
T cell isolation from PBMCs ......................................................................................... 81 
T helper cell differentiation............................................................................................ 83 
8 
 
Flow cytometry ............................................................................................................... 84 
2.1.3. memory T cells........................................................................................................ 84 
T cell enrichment using anti-fluorchrome beads ......................................................... 84 
Flow cytometry ............................................................................................................... 85 
In vitro culture of T cells in the presence of putative Th22 receptor-ligands ............. 85 
Real-time-PCR ............................................................................................................... 86 
2.2. from human asthmatic bronchial mucosa .................................................................... 88 
Participants ........................................................................................................................ 88 
Creation of lung T cell lines .............................................................................................. 89 
Creation of lung T cell clones ........................................................................................... 89 
Flow cytometry of T cell lines and clones ....................................................................... 90 
3. IL-22 in human tissue regeneration and repair ............................................................. 91 
3.1. IL-22 Receptor expression in human lung cell lines ................................................... 91 
Study design and primary lung cell lines ......................................................................... 91 
In vitro culture .................................................................................................................... 91 
Western Blotting ................................................................................................................ 92 
Flow cytometry .................................................................................................................. 94 
RT-PCR .............................................................................................................................. 94 
3.2. Effect of IL-22 on bronchial epithelial cells .................................................................. 95 
3.2.1. Wound healing ........................................................................................................ 95 
Wound healing assay .................................................................................................... 95 
Cell Cycle analysis /Proliferation .................................................................................. 96 
RT-PCR .......................................................................................................................... 97 
Results .......................................................................................................................................... 99 
1. IL-22 expression in allergic inflammation ...................................................................... 99 
1.1. Local bronchial segmental allergen challenge ............................................................ 99 
1.1.1. Demographics of study participants ...................................................................... 99 
1.1.2. Spirometry and Bronchoalveolar lavage eosinophils ........................................ 100 
1.1.3. Cytokine expression in Bronchoalveolar lavage ................................................ 102 
IL-5 and IFN ............................................................................................................... 102 
IL-22, IL-17, and IL-22RA2 ......................................................................................... 104 
1.2. Intradermal allergen challenge ................................................................................... 106 
1.2.1. Demographics of study participants .................................................................... 106 
1.2.2. Late phase skin response and cutaneous eosinophils ...................................... 107 
9 
 
1.2.3. IL-22 Immunofluorecent staining of skin sections .............................................. 109 
IL-22 vs T cells ............................................................................................................. 109 
IL-22 vs IL-22RA1........................................................................................................ 112 
IL-22 vs. endothelial cells ........................................................................................... 113 
1.2.4. IL-22 Receptor Immunofluorecent staining of skin sections ............................. 113 
Overall IL-22RA1 and –RA2 expression ................................................................... 114 
Expression in immune cells ........................................................................................ 115 
Expression in structural cells ...................................................................................... 118 
1.3. Summary ...................................................................................................................... 121 
2. IL-22 expression in T cells .............................................................................................. 122 
2.1. from peripheral blood .................................................................................................. 122 
2.1.1. long term allergen PBMC culture ........................................................................ 122 
Demographics of study participants ........................................................................... 122 
[methyl3H]-Thymidine incorporation ........................................................................... 123 
Cytokine expression in culture supernatants ............................................................ 124 
Flow cytometry analysis of IL-22+ CD4+ T cells ........................................................ 128 
2.1.2. polarised naive T cells .......................................................................................... 129 
IL-22 expression after Th22 differentiation ................................................................. 129 
2.1.3. memory T cells...................................................................................................... 130 
Occurrence of putative Th22 receptors FGFR2, PDGFR, TIE1 on T cells .............. 130 
IL-22 expression in putative Th22 receptor enriched cells ........................................ 131 
IL-22 expression in putative Th22 receptor-ligand stimulated cells .......................... 132 
2.2. from human asthmatic bronchial mucosa .................................................................. 133 
2.2.1. Demographics of study participants .................................................................... 133 
2.2.2. IL-22 expression in lung T cell lines .................................................................... 133 
γδ and β T cells ......................................................................................................... 134 
CD4 and CD8 T cells .................................................................................................. 135 
T helper subsets .......................................................................................................... 136 
2.2.3. IL-22 expression in lung T cell clones ................................................................. 138 
Flow cytometry of IL-22+ T cell clones ....................................................................... 138 
2.3. Summary ...................................................................................................................... 139 
3. IL-22 in human tissue regeneration and repair ........................................................... 140 
3.1. IL-22 Receptor expression in human lung cell lines ................................................. 140 
Protein expression by Western Blot .............................................................................. 140 
10 
 
Surface expression by flow cytometry ........................................................................... 141 
Regulation by RT-PCR ................................................................................................... 142 
3.2. Effect of IL-22 on bronchial epithelial cells ................................................................ 143 
3.2.1. Wound healing ...................................................................................................... 143 
IL-22 time and dose response .................................................................................... 144 
Effect of IL-17A on IL-22-associated wound closure ................................................ 146 
3.2.2. Proliferation ........................................................................................................... 146 
Cell Cycle Analysis ...................................................................................................... 147 
3.2.3. Gene Expression .................................................................................................. 148 
Injury-associated genes .............................................................................................. 148 
Regeneration and repair-associated genes .............................................................. 149 
3.3. Summary ...................................................................................................................... 151 
Discussion ..................................................................................................................................... 152 
1. IL-22 expression in allergic inflammation .................................................................... 152 
1.1. Local bronchial segmental allergen challenge .......................................................... 152 
1.2. Intradermal allergen challenge ................................................................................... 154 
2. IL-22 expression in T cells .............................................................................................. 157 
2.1. Peripheral blood mononuclear cell cultures .............................................................. 157 
2.1.1. Long term allergen-stimulated peripheral blood mononuclear cells................. 158 
2.1.2. Polarised naive T cells ......................................................................................... 160 
2.1.3. Memory T cells...................................................................................................... 161 
2.2. Human asthmatic bronchial mucosa .......................................................................... 162 
3. IL-22 in human tissue regeneration and repair ........................................................... 164 
3.1. IL-22 Receptor expression in human bronchial epithelial cell lines......................... 164 
3.2. Effect of IL-22 on bronchial epithelial cells ................................................................ 166 
3.2.1. Wound healing ...................................................................................................... 166 
3.2.2 Proliferation ............................................................................................................ 168 
3.2.3 Gene expression .................................................................................................... 168 
In relation to hypothesis...................................................................................................... 171 
Hypothesis 1 ........................................................................................................................ 171 
Hypothesis 2 ........................................................................................................................ 171 
Hypothesis 3 ........................................................................................................................ 172 
Relevance of IL-22 in allergy and asthma ........................................................................ 173 
Conclusion ................................................................................................................................. 176 
11 
 
Future Outlook .......................................................................................................................... 178 
References ................................................................................................................................. 179 
Appendix .................................................................................................................................... 214 
Additional experimental figures ......................................................................................... 214 
Raw data tables ..................................................................................................................... 216 
 
  
12 
 
List of 
Abbreviations 
Abbreviation Name 
% percentage 
AHR Aryl hydrocarbon receptor 
AIM-V Adoptive immunotherapy media V 
ALT alanine transaminase  
APC Antigen presenting cell 
ARDS Acute respiratory distress syndrome 
aSMA alpha smooth muscle actin 
AST Aminotransferase 
BAL bronchoalveolar lavage 
BCA Bicinchoninic acid 
BCL-2 B-cell lymphoma-2 
BMP Bone morphogenic protein 
BSA Bovine serum albumin 
CCR Chemokine C-C motif receptor 
CD Cluster of differentiation 
cDNA copy Deoxyribonucleic acid  
CPM counts per minute 
CRTAM Class-I MHC-restricted T-cell-associated molecule 
CTLA4 Cytotoxic T-Lymphocyte Antigen 4 
DAPI 4',6-diamidino-2-phenylindole 
DMSO  Dimethyl sulfoxide 
dNTP Deoxyribonucleotide 
EAE experimental autoimmune encephalomyelitis  
ECL Enhanced Chemoluminescence 
EDTA Ethylenediaminetetraacetic acid 
EGF Endothelial growth factor 
ELISA Enzyme-linked immunosorbent assay 
EMTU epithelial-mesenchymal-tropic unit  
EPO Erythropoietin 
ERK Extracellular signal-regulated kinases 
FACS Flow assisted cell sorting 
Fc R Immunoglobulin Fc (Fragment, crystallizable) region receptor 
FCS Fetal calv serum 
FEV1 one second forced expiratory volume,  
FGFR1 Fibroblast growth factor receptor 1 
FICZ tryptophan photoproduct 6-formylindolo[3,2-b]carbazole 
FOXP3 Forkhead box P3 
G0/1 Cell cycle Gap phase 0/1 
G2/M Cell cycle Gap phase 2/Mitosis phase 
GATA3 GATA binding protein 3 
GMCSF  Granulocyte macrophage colony-stimulating factor 
GP general practitioner 
HCL Hydrogen chloride 
HIV Human immunodeficiency virus 
HMBPP phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate  
HRP Horseradish peroxidase 
HSP-47 Heat shock protein-47 
ICAM Intercellular adhesion molecule 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
IRF4 Interferon regulating factor 4’  
IU International units 
JAK Janus kinase 
13 
 
JNK c-Jun N-terminal kinases 
kDA kilo Dalton 
LFA1 Lymphocyte function-associated antigen 1  
LPS Lipopolysaccharide 
LS large sized  
LTi  Lymphoid tissue inducer 
M Molar 
MACS Magnetic bead associated cell sorting 
MBP major basic protein 
MCT Mast cell tryptase 
MDM1 Mdm4, transformed 3T3 cell double minute 1, p53 binding protein 
MES 2-(N -morpholino)ethanesulfonic acid 
MHC Major histocompatibility complex 
MMP Matrix metalloproteinase 
MOG myelin oligodendrocyte antigen  
mRNA messenger Ribonucleic acid 
MW Molecular weight 
NE Neutrophil elastase 
NK cell Natural killer cell 
NOS2 Nitric oxide synthase, inducible 
OCT Optimal cutting temperature 
OD optical density 
OVA Ovalbumin 
PBMCs peripheral blood mononuclear cells  
PBS Phosphate buffered saline 
PC20 Provocating Concentration 20 
PDGFR Platelet derived growth factor receptor 
PGE2 Prostaglandin E2 
PHA Phytohaemagglutinin 
Phl p Phleum pratense 
PI propidium iodide  
PMA phorbol 12-myristate 13-acetate  
PPD Tuberculin purified protein derivative  
RAG Recombination activating gene 
RAST Radioallergosorbent test 
RORC2 Rar related orphan nuclear receptor C 2 
RPM rotations per minute 
RPMI Roswell Park Memorial Institute medium 
RT-PCR Real Time polymerase chain reaction 
SAA serum amyloid A1  
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SLE systemic lupus erythemotsus  
SNP Single-nucleotide polymorphism 
SOCS suppressor of cytokine signaling proteins 
S-phase Cell cycle synthesis phase 
STAT Signal transducer and activator of transcription 
TB Tuberculosis 
TBET T-box expressed in T cells 
TCR T cell receptor 
TGF transforming growth factor 
Th T helper 
TIE1 Tyrosine kinase with immunoglobulin-like and EGF-like domains 1 
TLR Toll like receptor 
TMB 5,5’-Tetramethylbenzidine  
TNF tumer necrosis factor 
TRAPS TNF-receptor-associated periodic syndrome 
VEGF Vascular endothelial growth factor 
VCAM-1 vascular cell adhesion molecule-1  
v/v Volume/Volume 
  
14 
 
Tables 
No. Title Page 
Introduction  
1 Proposed endophenotypes of asthma 26 
2 Structural alterations and airway remodelling 29 
3 Current medications used to control asthma 32 
4 New biological treatments for asthma based on immunological insights 33 
5 Th1 and Th2 subset classification 36 
6 Th17 subset classification 37 
7 T regulatory subset classification 38 
8 Factors influencing the expression of IL-22 in CD4 T cells 40 
9 Th22 subset classification 41 
10 IL-22 expressing NK, LTi, and LTi-like cell populations 47 
11 Evidence of IL-22RA1 expression in immune cells 49 
12 IL-22RA1 expression in human structural cells 49 
13 Expression of IL-22RA2 mRNA in cells of the immune system 53 
14 IL22RA2 mRNA expression in the human tissue lysates 53 
15 General functions of IL-22 55 
16 Function of IL-22 in keratinocytes 57 
17 Function of IL-22 in lung epithelial cells 58 
18 Function of IL-22 in intestinal epithelial cells 58 
19 Function of IL-22 in fibroblasts 59 
20 Function of IL-22 in hepatocytes 60 
21 Evidence of IL-22RA2 expression during inflammation 60 
22 IL-22 association in autoimmunity 62 
23 Evidence of IL-22 association in viral infection 63 
24 Evidence of IL-22 association in bacterial infection 64 
Methods  
25 Inclusion and exclusion criteria for participants of the bronchial segmental allergen 
challenge  
70 
26 Cytokine ELSIA assays utilised throughout the study 71 
27 Antibodies incorporated in the IL-22RA2 sandwich ELISA design 72 
28 Final IL-22RA2 Sandwich ELISA protocol 74 
29 Inclusion and exclusion criteria for participants of the intradermal allergen challenge 
study 
75 
30 Conversion factors for histological cell counts 77 
31 Antibodies and reagents used in the immunofluoresent analysis of allergen 
challenged skin 
77 
32 FACS antibodies used in the analysis of T cells derived from allergen PBMC co-
cultures 
81 
15 
 
33 Magnetic bead isolation kits used in the enrichment of individual T cell populations 81 
34 FACS antibodies used in validating T cells after magnetic bead isolation 83 
35 Reagents used in culturing naive T cells during in vitro Th1 and Th22 cell 
differentiation 
83 
36 FACS antibodies used in the assessment of Th1 and Th22-primed T cells 84 
37 FACS Antibodies used in the analysis of novel Th22 surface receptor expression 84 
38 Anti-fluorchrome beads used in the isolation of surface receptor-positive T cells 84 
39 FACS antibodies used in the assessment of Th22 receptor-enriched T cells 85 
40 Recombinant FGF and PDGF proteins used in CD4 T cell co-culture  86 
41 RNA isolation reagents utilised throughout the study 86 
42 Composition of the cDNA reaction mixture (20μl) 87 
43 PCR reaction setup used in the conversion of RNA to cDNA 87 
44 RT-PCR primer and SYBR green reaction mixture 87 
45 RT-PCR primer sequences used to analyse PDGFR enriched and depleted T cells 88 
46 Components of the T cell cloning media 89 
47 Serial dilution setup employed in the generation of T cell clones 90 
48 Individual steps in expanding T cell clones over time 90 
49 FACS antibodies used in the characterisation of T cell lines and clones 91 
50 Description of primary lung structural cell lines used 91 
51 Individual cytokines used in the stimulation of structural cell lines in vitro 92 
52 Composition of the protein lysis buffer  92 
53 Composition of the SDS PAGE loading buffer (4x)  93 
54 Antibodies used in the analysis of IL-22 receptor expression by western blot analysis 94 
55 FACS antibodies used in the analysis of IL-22RA1 surface expression 94 
56 RT-PCR primer sequences used in studying IL-22 receptor regulation in structural 
cell lines 
95 
57 Composition of the propidium iodide staining solution 97 
58 Recombinant cytokines used in the bronchial epithelial wound healing assay 97 
59 RT-PCR primer sequences used in the assessment of bronchial epithelial gene 
expression 
98 
Results  
60 Clinical data of allergic asthmatic and healthy non-atopic controls who underwent 
fiberoptic bronchoscopy with segmental allergen challenge 
99 
61 Clinical data of individuals who underwent intradermal grass pollen challenge and 
subsequent cutaneous punch biopsy 
106 
62 Summary of the clinical parameters of individuals whose blood was taken and used 
for the in vitro allergen PBMC co-culture experiments 
122 
63 Effect of 24 hour FGF-1,-2,-5 and PDGF-BB exposure on T cytokine mRNA 
expression of cultured peripheral blood CD4
+
 T cells 
132 
64 Summary of the clinical parameters of individuals who underwent fibreoptic 133 
16 
 
bronchoscopies and had a subsequent tissue biopsy taken for further T cell studies 
65 Effect of IL-22 on IFN regulated inflammatory gene expression in bronchial epithelial 
cells 
149 
66 Effect of IL-22 on IFN regulated repair associated gene expression in bronchial 
epithelial cells 
150 
Appendix  
67 Individual clinical data as well as experimental results of the bronchial segmental 
allergen challenge study 
217 
68 Individual clinical data as well as experimental results of the intradermal allergen 
challenge study 
218 
69 Individual clinical data as well as experimental results of the in vitro allergen PBMC 
challenge study 
219 
70 Individual clinical data of patients taking part in the study of T cell lines and clones 
derived from asthmatic bronchial mucosal tissue 
220 
 
 
  
17 
 
Figures 
No. Title Page 
Introduction  
1 Genomic relationship between all species with known IL-22 genes 42 
2 Genomic location of the IL-22 gene 43 
3 Overview of the IL-22 gene and its mRNA transcripts 43 
4 Genomic location of the IL-22RA1 gene  48 
5 Genomic location of the IL-22RA2 gene  50 
6 Overview of the IL-22RA2 gene and its mRNA transcripts 51 
Methods  
7 Validation of -human IL-22RA2 antibody-binding (N16, T16, T16-biotin) by direct 
ELISA using plate bound recombinant IL-22RA2 
72 
 
8 Detection of fluid phase rIL-22RA2 in pg/ml and ng/ml range using a sandwich IL-
22RA2 ELISA protocol 
74 
9 Optimisation of antibody concentrations and detection time within the sandwich IL-
22RA2 ELISA protocol 
74 
10 Immunofluorescent staining of IL-22 in cytospin preparations of polyclonally 
stimulated (PMA/Ionomycin) and paraformaldehyde-fixed peripheral blood CD4
+
 
CD45RO
+
 T cells 
78 
11 
 
Flow cytometric analysis of CD45RA,-RO, CD25 and CD69 expression on purified 
naive peripheral blood T cells used in CD4
+ 
T cell differentiation 
82 
12 
 
Flow cytometric analysis of CCR10 and CD45RO expression on peripheral blood T 
cells before and after CCR10 enrichment using anti-fluorochrome-coupled magnetic 
bead isolation. 
85 
13 Inter and Intra-assay variability of the in vitro wound healing assay 96 
14 Analysis of individual bronchial epithelial cell cycle stages using Propidium Iodide  97 
Results  
15 Percentage-predicted Forced Expiratory Volume (FEV1) before and after segmental 
allergen challenge 
100 
16 Total eosinophil counts (10
6
) in Bronchoalveolar lavage (BAL) before and after 
segmental allergen challenge 
101 
17 IL-5 and IFN cytokine ELISA measurements in BAL before and 24 hours after 
segmental allergen challenge 
102 
18 IL-22, IL-17A/F and IL-22RA2 ELISA measurements in BAL before and 24 hours after 
segmental allergen challenge 
104 
19 Measurement of cutaneous swelling and reddening 8 hours after intradermal grass 
pollen challenge 
107 
20 Quantification of cutaneous eosinophil (MBP
+
) cell numbers in tissue section taken 
from individuals who underwent intradermal grass pollen challenge 
108 
21 Immunofluorescent co-staining of IL-22 and CD3 in skin sections prepared from 109 
18 
 
punch biopsies taken 8 hours post grass allergen-diluent or allergen challenge from 
grass allergic individuals 
22 Immunofluorescent staining and quantification of CD3+ and IL-22+ cells in skin 
sections taken 8 hours post grass allergen or allergen-diluent challenge from 3 grass 
allergic individuals 
111 
23 IL-22 Immunofluorescent co-staining to IL-22 Receptor (RA1) in skin sections taken 8 
hours after intradermal grass pollen challenge from grass allergic individuals 
112 
24 IL-22 Immunofluorescent co-staining to endothelial cells (CD31) in skin sections 
taken 8 hours after intradermal grass pollen challenge from grass allergic individuals 
113 
25 Immunofluorescent staining of IL-22 Receptor RA1 and RA2 positive cells in acetone-
fixed skin sections taken 8 hours after intradermal allergen diluent or grass pollen 
challenge from 3 grass allergic individuals 
114 
26 IL-22 Receptor (RA1/RA2) Immunofluorescent costaining to T cells (CD3) in acetone-
fixed skin sections taken 8 hours after intradermal grass pollen challenge from grass 
allergic individuals 
115 
27 IL-22 Receptor RA2 co-staining to innate immune cells in acetone-fixed skin sections 
taken 8 hours after intradermal grass pollen challenge from grass allergic individuals 
116 
28 IL-22 Receptor RA1/RA2 co-staining to endothelial (CD31) and mesenchymal 
(Vimentin) cells in acetone-fixed skin sections taken 8 hours after intradermal grass 
pollen challenge from 3 grass allergic individuals 
118 
29 IL-22 Receptor 2 co-staining to fibroblasts in skin sections taken 8 hours after 
intradermal grass pollen challenge from 3 grass allergic individuals 
120 
30 Measurement of [methyl
3
H]-Thymidine incorporation over 16 hours in PBMCs 
obtained after 6 days of allergen PBMC co-culture from grass pollen atopic and 
normal individuals 
123 
31 Quantification of IL-5 and IFN in culture supernatants obtained from 6 day allergen-
PBMC cultures of both grass allergic and normal donors 
124 
32 Quantification of IL-22  and IL-17A/F in culture supernatants obtained from 6 day 
allergen-PBMC cultures of both grass allergic and normal donors 
126 
33 Flow cytometric analysis of IL-22 expression in CD4
+
 T cells obtained after 6 days of 
grass allergen PBMC co-culture and subsequent PMA/Ionomycin stimulation 
128 
34 Flow cytometric analysis of IL-22 and IL-17A expression in  T cells obtained after 
naive (CD45RO
-
) peripheral blood T cell differentiation using Th22 and Th1 polarising 
conditions 
129 
35 Flow cytometric analysis of putative novel Th22 receptor FGFR2, TIE1, PDGFR 
expression on peripheral blood CD4
+
 T cells 
130 
36 Flow cytometric analysis of IL-22 and IL-17A expression in magnetic-bead enriched 
peripheral blood T cells expressing putative Th22 receptors PDGFR, FGFR2, TIE1 or 
chemokine receptor CCR4, CCR6, CCR10 
131 
37 Flow cytometric analysis of IL-22 expression of β- and δ T cell receptor positive 134 
19 
 
cells from T cell lines created from asthmatic bronchial mucosa  
38 Flow cytometric analysis of IL-22 and CD4
+
 / CD8
+
 expression of cells obtained from 
T cell lines created from asthmatic bronchial mucosa  
135 
39 Flow cytometric analysis and T helper cell classification of IL-22
+
 CD4
+
 T cells 
obtained from asthmatic bronchial mucosa 
136 
40 Flow cytometric analysis of IL-22, IL-17A, IL-4 and IFN co-expression in CD4
+
 T cell 
clones obtained from asthmatic bronchial mucosa  
138 
41 Western Blot analysis of IL-22 Receptor RA1 and RA2 expression in primary lung 
bronchial epithelial, fibroblasts, smooth muscle cell lines and peripheral blood CD4
+
 T 
cells 
140 
42 Flow cytometric analysis of IL-22 Receptor RA1 expression on primary bronchial 
epithelial, fibroblasts, smooth muscle lung cell lines and peripheral blood CD4
+
 T cells 
141 
43 RT-PCR analysis of IL-22 Receptor RA1/RA2 gene expression in bronchial epithelial 
cells cultured in the presence of different T cell cytokines 
142 
44 Dose and time response of IFN on bronchial epithelial IL-22RA1 expression 143 
45 Light microscopic analysis of the effect of IL-22 on bronchial epithelial wound closure 
over time 
144 
46 Software-assisted analysis of the effect of IL-22 on bronchial epithelial wound closure 
over time 
145 
47 IL-22-associated epithelial wound closure in the presence and absence of IL-17A 146 
48 Analysing the effect of IL-22 on proliferation by quantifying epithelial cell cycle stages 
using Propidium Iodide 
147 
49 Regulation of ICAM-1 (CD54) gene expression by IL-22 and IFN in bronchial 
epithelial cells 
148 
Appendix  
50 Flow cytometric analysis of flow-assisted-cell-sorted CCR10
+
CD45RO
+ 
CD4
+
 T cells 214 
51 RT-PCR analysis of the induction of IL-22RA1 mRNA by IFN in airway smooth 
muscle cells and fibroblasts over time 
215 
 
 
  
20 
 
Diagrams 
No. Title Page 
Introduction  
1 T cell phenotypes and subset associations 35 
2 Predicted 3-dimensional structure of IL-22 44 
3 The 3-dimensional configuration of IL-22RA2 binding to IL-22 52 
Methods  
4 Assessing bronchial epithelial cell wound closure 95 
Conclusion  
5 Potential expression and function of IL-22 during allergic inflammation 177 
21 
 
Introduction 
Allergy and Asthma 
Allergy 
Background  
Definition 
Allergy is an adverse immune reaction to a substance in the environment (allergen) which is 
normally harmless. In most allergies, this process is characterised by the production of 
allergen-specific IgE and the development of a Th2 cell memory. In sensitised individuals, 
allergen contact provokes a biphasic inflammatory response that can be divided into early 
and late phases. The early phase response results from IgE-dependent mast cell activation 
with release of mediators that, depending on the site of exposure, cause discomfort to the 
skin (itch, wheals), nose (sneeze and watery discharge) and lung (wheeze and shortness of 
breath). The late response is T-cell mediated and characterised by eosinophilic infiltration. 
This response is accompanied by further symptoms including swelling, mucus 
overproduction, as well as airway hyperreactivity. 
Epidemiology 
In the United Kingdom, the overall prevalence of allergic rhinitis has been estimated at 23 
percent (%) (Bauchau and Durham 2004). It is estimated that, in England, each year about 3 
million people consult their general practitioner (GP) with conditions related to allergy. The 
prevalence of multiple allergic diseases was observed to increase by 48.9% between the 
years 2001 and 2005 (House of Lords - Science and Technology - Sixth Report 2007).  
Mechanisms of allergy 
There are three main processes which have been identified to be altered in allergic 
individuals. These include weakened epithelial barriers (Wang at el 2008b), a predisposition 
to produce Immunoglobulin class E (IgE) and an inability to regulate the aberrant immune 
response (Robinson 2009). These three processes are controlled not by one but multiple 
genetic and environmental factors. Alterations in the immune system are manifested 
systemically throughout the body yet allergic disorders are often organ specific (e.g. skin, 
gut, and airways) based on the route of allergen exposure and organ or tissue specific 
alterations. 
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Genetic versus Environmental influences 
Family studies have shown that allergic disorders follow a hereditary pattern (Skadhauge et 
al 1999, Hanson et al 1991, Lawrence et al 1994). It was once hypothesized that the basis of 
altered IgE responses was inherited as an autosomal dominant trait (Cookson and Hopkin 
1988). Subsequent studies revealed that the clinical manifestations of allergy are not 
controlled by a single gene but, rather, multiple smaller genetic variations that are often 
influenced or directly controlled by environmental factors (Vercelli et al 2005).  
Allergy is, thus, believed to have a genetic component but dependent on multiple 
environmental factors. While environmental insults (e.g. malnutrition, stress, chronic illness, 
pollution, exercise and viral infections) are known to influence the threshold for disease 
manifestation temporarily as well as permanently, events in early life are believed to be 
particularly damaging and influence the progression from a predisposed to allergic state.  
In allergy, the deficient regulation of the Th2 response is thought to have occurred due to 
altered environmental exposures in early life when the adaptive immune system and 
immunological memory is in development. The fact that immunologic tolerance may be re-
established in allergic individuals through immunological interventions such as allergen 
immunotherapy implies that allergic disease progression is under the control of 
environmental factors. 
The hygiene hypothesis suggests a link between the development of allergy (and loss of 
immune tolerance to common environmental allergens) with exposure to an altered microbial 
flora during early life. The hypothesis was based on the observation of an inverse 
relationship between family size and the risk of developing atopic disorders (Strachan 1989), 
younger siblings being ‘protected’, possibly by increased exposure to infections. Support 
came from the higher prevalence of allergic diseases that were associated with a more 
‘westernised’ lifestyle. This was originally observed as a much lower prevalence of atopic 
sensitisation and hay fever in underdeveloped Leipzig in East Germany compared to Munich 
(von Mutius et al 1992) whereas within 5 years of the re-unification of East and West 
Germany, the prevalence had tended to equalise (Weiland et al 1999). Our modern way of 
living (urbanisation, sanitation, dietary changes and medication) has been associated with a 
marked reduction in our natural microbial environment. It has been suggested that the loss 
of toll-like receptor stimulation during early life may alter the development of our acquired 
immune system from a Th1-biased microbial protective state to a more polarised Th2-type 
response (Strachan 2000), whereas, more recently, it has been suggested that the observed 
increase in both allergic disorders and auto-immune diseases may be explained by a 
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decrease in T regulatory cell function, resulting in unrestrained Th1- (and Th17-) and Th2-
biased immune responses (Kamradt et al 2005). These alterations might provide the basis 
for progression from a predisposed to an allergic state (Eder et al 2006).  
While this hypothesis has received much support (Ege et al 2006, Waser et al 2007), it also 
has been challenged with suggestions that allergic disease progression cannot be explained 
by reduced microbial exposure alone (Platts-Mills et al 2005, Bresciani et al 2005). 
Pathogenesis 
Sensitisation 
Before an allergic response can develop, the immune system must first encounter the 
allergen and develop specific immunological memory against the allergen. In an allergic 
individual, dendritic cells within the mucosal epithelium will capture the allergen, recognise it 
as harmful and migrate to the draining lymph node (Takano et al 2005). The, now, activated 
dendritic cells present the processed allergen through an Major histocompatibility complex 
(MHC) class II-mediated mechanism to allergen-specific T helper cells. This priming will 
predominantly induce Th2 cells capable of releasing IL-4, IL-5 and IL-13 (Romagnani et al 
2002). Allergen-specific Th2 cells in turn licence allergen specific B cells to class switch their 
B cell receptor in favour of allergen specific IgE production (Kay 2001, Gould et al 2003). 
This allergen-specific IgE in the circulation binds to high affinity Fcε receptors on various 
innate cells, including mast cells and basophils. These FcεR1-expressing cells are now 
poised to recognise the allergen upon secondary encounter. 
Acute phase response 
The secondary exposure will lead directly to recognition of allergen by resident mast cells 
and basophils within the exposed tissue. Upon cross-linking of the allergen with the surface 
bound IgE, these cells will degranulate and release several mediators including vasoactive 
amines (e.g. histamine), cytokines, chemokines, reactive oxygen species, and lipid 
mediators such as leukotriene C4, D4, and E4 as well as prostaglandin D2 (Kraft et al 2003). 
This immediate release of inflammatory mediators is referred to as type-1 hypersensitivity 
(Gell and Coombs 1963) and is responsible for the immediate clinical symptoms such as 
itching (atopic dermatitis), nasal congestion (allergic rhinitis), and airway constriction (allergic 
asthma) (Bradding et al 1992, Pease 2006) within minutes of allergen exposure. 
Late phase response 
Following the early response, a proportion of individuals go on to develop a delayed-in-time 
response (the allergen-induced late response) peaking between 6 and 12 hours. The late 
response is characterised by large cellular infiltration caused by the release of 
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chemoattractants during the early phase including eosinophils, and CD4+ T lymphocytes, as 
well as other immune cells at the site of allergen exposure (Kay 2001). The influx of T cells, 
particularly Th2 cells produce Th2 cytokines. These include IL-4 resulting in Th2 T cell 
differentiation and local IgE-switching (Takhar et al 2005), IL-13 IgE-switching, mucus 
hypersecretion (Lachowicz-Scroggins et al 2010) and, along with IL-4, there is an increase in 
the expression of vascular cell adhesion molecule-1 (VCAM-1). Furthermore, IL-5 release 
results in tissue eosinophilia during the late-phase immune response resulting in further 
clinical symptoms through tissue swelling and mucus hypersecretion. T cells, in particular, 
hold a critical role in orchestrating the late phase response which can be observed even in 
the absence of mast cell activation and eosinophil infiltration (Ali et al 2007).  
Treatment 
For allergic rhinitis, when avoidance of the provoking allergen is not possible, the use of anti-
histamines and topical corticosteroids in combination with symptoms-relieving medication is 
prescribed. Similarly, asthma is treated with corticosteroids and beta-agonists for 
symptomatic relief. However, these treatments are for symptomatic use and have no effect 
on the long-term course of the disease. The only long-term disease-modifying treatment 
option available, so far, is allergen immunotherapy (Ewbank et al 2003, Holgate and Polosa 
2008). Immunotherapy aims to reduce allergic symptoms by inducing immunologic tolerance 
and has been shown to be effective leading to long-term benefits (Robinson et al 2004, 
Shamji and Durham 2011) however it is not used in allergic asthma due to safety concerns.  
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Asthma 
Background  
Definition 
Bronchial asthma is a respiratory disorder characterised by reversible airflow obstruction 
either spontaneously or as a result of treatment. In asthma, the airways are hypersensitive to 
certain endogenous and exogenous stimuli that trigger spontaneous muscle contraction with 
associated airway constriction. The airway narrowing, in asthma, occurs in the context of 
airway inflammation that is typically characterised by bronchial mucosal eosinophilia, 
disruption of the integrity of the epithelium, mucus hypersecretion, thickening of the sub-
basement membrane zone and smooth muscle hypertrophy that increases bronchial wall 
thickness. The progressive loss of airway function, particularly in chronic asthma, is often 
associated with aberrant changes in the lung described under the term airway remodelling.  
Epidemiology 
In England, 5.7 million people suffer from asthma (House of Lords - Science and Technology 
- Sixth Report 2007). As for other disorders associated with allergy, a relatively high 
prevalence of asthma is found in ‘westernised’ countries (about 15% to 20%) while the 
prevalence in developing countries remains much lower (about 2% to 4%) (Zock et al 2006). 
Very recently, this trend has changed and the prevalence of asthma has shown signs of 
levelling off in western countries (Moorman et al 2007) while it continues to rise in 
developing countries (Pearce et al 2007). 
Endophenotypes of asthma 
The current definition of asthma encompasses a diverse group of conditions which do not 
always share the same underlying disease mechanism or progression. Characterising 
asthma by phenotype (e.g. Eosinophilic vs. Neutrophilic, Early vs. Late-onset, Moderate vs 
Severe) helped to understand this diversity allowing a more tailored treatment. Yet the 
phenotypic classification alone remains insufficient in fully understanding the molecular 
mechanisms and differences in treatment outcomes. The advent of large scale genetic and 
genomic studies has helped to shed more light on common molecular patterns between 
different patient groups. This molecular characterisation of asthma patients has prompted 
researchers to redefine asthma into endophenotypes (see table 1; Loetvall Akdis 2011, 
Anderson 2008, Wenzel 2012, Poon Hamid 2012). This classification combines the 
emerging molecular insight together with the phenotype and observed treatment response. 
While endophenotype classifications promise a more targeted intervention (Kazani and 
Israel 2012) their definition remain ongoing (see table 1). 
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Table 1: Proposed Endophenotypes of Asthma 
Asthma Endophenotypes Reference 
General Aspirin-sensitive 
Allergic bronchopulmonary mycosis 
Adult allergic 
Asthma-predictive indices-positive preschool weezer 
Severe late-onset hypereosinophilic 
Cross-country skiers asthma 
 
Lotvall et al 2011 
Severe Asthma Early-onset allergic 
Persistent eosinophilia 
Allergic bronchopulmonary mycosis 
Obese-female 
Neutrophilic severe asthma 
Wenzel et al 2012 
 
Development of asthma 
Asthma is a complex disorder controlled by multiple minor and major factors which are both 
inherited as well as acquired in early life. Alterations of the epithelial cell function, its barrier 
integrity, innate defence and repair response are thought to be some of the main underlying 
mechanisms of asthma. There is a strong relationship between allergy and asthma as the 
allergic airway inflammation can act as the asthmatic trigger for bronchoconstriction. Both 
atopic disorders and asthma are often characterised by a dysfunctional epithelium (Holgate 
et al 2009). However, allergy or atopy is not a prerequisite to develop asthma and, thus, 
allergic asthma forms a separate sub phenotype of asthma. 
Genetic and environmental determinants of asthma 
Family studies have confirmed that asthma follows a hereditary pattern (von Mutius et al 
1996, Laitinen et al 1998). The contribution of genetic associations has been the subject of 
numerous genome wide association studies and, in particular, early-onset asthma shows a 
strong influence of genetic inheritance (Moffatt et al 2007 & 2010). It is now believed that the 
genetic alterations underlying asthma are predominantly related to genes altering epithelial, 
mesenchymal and smooth muscle cell function (Cookson 2004, Vendelin et al 2005, Holgate 
and Polosa 2008). However, environmental factors are known to play the major role in 
disease expression in asthma. For example, studies of migrating families have shown that 
the duration of residence in a new environment can alter asthma prevalence in young and 
newborn children (Cohen et al 2007, Wang et al 2008a, Wong and Chow 2008). The 
development of asthma is influenced, particularly, by environmental factors in early life. 
While changes to the still developing immune system can contribute to the development of 
allergy, the development of asthma may additionally depend on factors that influence normal 
lung development in prenatal (Sporik et al 1990, Dietert and Zelikoff 2008, Patel and Miller 
2009) and early life (Sigurs et al 2005, Carroll et al 2009). The risk factors are very diverse 
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and include air pollution (Tzivian 2011), viral (Johnston et al 2007) and bacterial infections 
(Cosentini et al 2008), nutrition (Noal et al 2011), medication (Nuttall et al 2000), stress 
(Sandberg et al 2000) amongst other factors. 
Pathogenesis 
An asthma attack results from a loss of lung function (fall in peak expiratory flow rate and the 
one second forced expiratory volume, FEV1) that causes mild to severe difficulties in 
breathing. It is associated with the rapid contraction of airway smooth muscle leading to 
narrowing of the bronchi. ‘Brittle’ asthma (Paganin et al 1996) represents an asthma 
phenotype characterised by very rapid onset of airway narrowing which may be largely 
explained by smooth muscle constriction. With the exception of pauci granulocytic asthma, 
cellular infiltration and tissue inflammation is also observed during acute asthma. Swelling 
and inflammation further contributes to the difficulty in breathing. 
A diverse range of stimuli including allergen, cold air, exercise and irritants may represent 
triggers that may provoke smooth muscle constriction and bronchial wall thickening with 
airway narrowing via inflammatory or non-inflammatory events. The threshold for 
bronchoconstriction is influenced by the level of nonspecific bronchial hyperreactivity which, 
in turn, can be influenced by numerous factors such as chronic allergen exposure, viral 
infections, diet, stress, and medication. Nonspecific bronchial hyperreactivity can be 
assessed by inhalation challenge with histamine or methacholine and expressed as the 
provocation concentration of inhaled agent that provokes a 20% fall in FEV1  (e.g. histamine 
PC20 (Juniper et al 1978).  
In allergic asthma, the encounter of allergen will lead to clinical symptoms such as airway 
narrowing and airway inflammation. The allergic response is often biphasic, leading to an 
early and late asthmatic reaction.  
The early phase occurs within minutes, leading to acute bronchoconstriction. It is initiated by 
IgE-mediated allergen recognition on the surface of mast cells and basophils leading to their 
activation, rapid degranulation and release of mediators of hypersensitivity (eg. histamine, 
prostaglandins, leukotrienes). Mast cells, which are widely distributed throughout the tissue 
including the smooth muscle tissue, release potent smooth muscle contractile agents, 
initiating bronchoconstriction (Holgate 1996). In addition to mast cell activation T cell 
recognition will lead to a burst of Th2-type cytokines (e.g. IL-4, IL-5, IL-13) influencing the 
early as well the ensuing late phase response (Wenzel et al 2007). 
The late asthmatic response is experienced by half of allergic asthmatics and causes a 
second episode of airway narrowing but with marked differences in symptoms and features 
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to the early asthmatic response (Robertson et al 1974, O’Byrne et al 1987). This delayed 
reaction to the allergen, which is displayed at about 3-8 hours after the initial allergen 
encounter, is characterised by inflammation, swelling, mucus over-production and 
significantly airway hyper reactivity. This airway hyper reactivity can resolve within 24 hours 
but occasionally can last for several days or even weeks following a single allergen exposure 
(Cartier et al 1982, O’Bryne et al 1987). The inflammation which is displayed during the late 
phase response is caused by recruitment of eosinophils (De Monchy et al 1985, Gauvreau et 
al 1999) as well as T cells (predominantly Th2 phenotype) into the airways (Robinson et al 
1993).  
The symptoms of the late phase response are largely controlled by the preventive use of 
corticosteroids indicating a clear functional role of the immune system (Cockroft et al 1987, 
Kidney et al 1997). The blockade of the hallmark eosinophilic infiltration reduces asthma 
exacerbations (Green et al 2002), signs of airway injury and remodelling (airway-wall 
thickness and total wall area), but not airway hypersensitivity (Leckie 2000, Haldar 2009). 
The airway hypersensitivity depends on the early phase IgE-mediated immune cell activation 
(Cartier et al 1982, Kirby et al 1986, Fahy et al 1997) and subsequent mediator release 
(Wenzel et al 2007). However its later mechanisms and occurrence during the late phase 
remain far less understood. One avenue which has been revisited recently is the potential 
activation of sensory nerves during the early phase. This early activation may, through 
delayed reflex responses, account for airway hypersensitivity during the late phase response 
(Pavord and Tattersfield 1995, Tilley et al 2003, Raemdonck et al 2012). 
Airway remodelling 
The progression of the asthma is associated with changes in the underlying cellular 
composition of and structure of the bronchial epithelium and submucosa. These aberrant 
changes (Table 2) are often described under the term airway remodelling and may cause a 
further reduction in the overall lung function with more severe exacerbations (Jain et al 2005) 
and the development of an irreversible component. 
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Table 2. Structural alterations and airway remodelling  
Cell type Observation Effect 
Goblet cells Number of goblet cells increase 
Mucin 5AC dominates and are largely responsible 
(Morcillo and Cortijo 2006) 
Reduction of airflow through difficulty in 
expectoration of sputum 
Smooth 
muscle 
Hypertrophy and hyperplasia.  Narrowing of the airways due to bronchial wall 
thickening with luminal narrowing and increased 
bronchoconstriction during an asthmatic attack 
Fibroblasts Myofibrobalst increase (Choe et al 2006, Wicks et al 
2006),  
Increased scarring 
Vessels Angiogenesis leading  to an increase in microvessels 
(Zanini et al 2010) 
Oedema of the bronchial wall with narrowing of 
the airways, increased immune and 
inflammatory cell recruitment. 
Epithelial cells Epithelial damage, decrease in tight junctions and 
increase in permeability (Montefort et al 1992). 
Decrease in barrier function and increased risk 
of inflammation and exposure to asthmatic 
triggers 
Basal lamina Extracellular matrix proteins and proteoglycan deposition 
(Knight and Holgate 2003) 
Increased thickening  
 
The presence of persistent changes within the airway wall is believed to be controlled by 
inherent and acquired defects connected to aberrant tissue repair responses.  
Non-Immune contribution 
The structural cells within the asthmatic lung display altered physiological functions 
associated with oxidant handling (Bayram et al 2002, Bucchieri et al 2002), inflammation 
(Mullings et al 2001, Sampath et al 1999) and repair (Amishima et al 1998, Payne et al 
2004). This altered functionality is believed to influence the normal resolution of airway 
inflammation, alter the normal repair processes and cause permanent structural changes 
within the lung. 
Signs of this aberrant airway remodelling were detectable in children at risk of developing 
asthma even when inflammation was moderated by corticosteroid use and long term use of 
corticosteroids did not significantly prevent the progression of asthma (Pauwels et al 2003, 
Bisgaard et al 2006, Guilbert et al 2006, Murray et al 2006). 
These early paediatric studies especially support the notion that airway remodelling is not 
necessarily caused by inflammation but may occur in parallel or even precede airway 
inflammation. The aberrant healing and repair processes observed within the asthmatic lung 
are believed to be similar to events occurring during early lung development. One hypothesis 
is that airway remodelling could be caused by reactivation of embryological pathways, in 
particular the epithelial-mesenchymal-tropic unit (EMTU) causing aberrant and irreversible 
structural alterations (Holgate and Polosa 2006). While the hypothesis of a re-activated 
EMTU has gained some recognition, it remains difficult to confirm.  
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Airway remodelling, either controlled by re-activated embryological pathways or otherwise 
caused by functional damage in structural cells, is likely influenced by inheritance and 
environmental exposure (Lloyd and Robinson 2007). While inherited genetic alterations in 
asthmatic epithelial cell function are likely providing a predisposition for airway remodelling, 
one theory is that particularly severe and repeated respiratory infections in early life are a 
risk factor. These viral infections may overwhelm the inexperienced immune system causing 
significant damage to the developing lung and provide the necessary initial insult for airway 
remodelling to occur and progress (Openshaw and Hewitt 2000). 
Immune contribution 
Inflammation remains the hallmark of asthma and allergic asthma is associated with Th2 type 
inflammation. The release of tissue damaging mediators such as superoxide and nitric oxide 
(e.g. by mast cells, eosinophils and basophils) cause cellular damage and the release of 
potent cytokines (e.g. by T cells) alter the functional state of structural cells (Vignola et al 
2000). In the normal lung, these changes would be almost always resolved without leaving 
significant long term effects. In the asthmatic lung, however, aberrant tissue repair 
processes are observed. The occurrence of repetitive or chronic inflammation is thought to 
trigger these processes and exacerbate airway remodelling (Holgate 2006). The moderation 
of inflammation by the help of corticosteroid use caused a reduction in epithelial damage 
(Lundgren et al 1988, Gavett et al 1994), goblet cell hyperplasia (Chanez et al 2004), micro 
vessel formation (Feltis et al 2007), subepithelial fibrosis and basement membrane thickness 
(Trigg et al 1994, Olivieri et al 1997, Laitinen et al 1997).  
Treatment 
Current interventions 
For asthma two distinct types of mediation are being prescribed (see Table 3). They provide 
either immediate relief (e.g. reliever medication) or reduce or prevent the potential symptoms 
during the encounter of a future asthmatic trigger (e.g. preventer mediation). 
Reliever medication  
Reliever medication reverses the airflow obstruction dilating the bronchi. They are thus often 
referred to as bronchodilators and encompass short-acting β2 adrenergic receptor agonists, 
anti-cholinergic drugs, as well as dimethylxanthine.  
Short-acting β2 adrenergic receptor agonists (also referred to as β2 agonist) are the 
mainstay medication and reverse smooth muscle constriction by binding and activating the 
beta-adrenergic receptors on the smooth muscle fibres. Anticholinergic drugs on the other 
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hand interfere with the signal transmission from the nerve ending to the smooth muscle fibre. 
This blockade of acetylcholine signalling allows the smooth muscle to relax. As they act 
slower than β2 agonist, the two types of drugs are often combined. Theophylline (or 
dimethylxanthine) is another reliever medication which is a non-specific antagonist of the 
adenosine receptor and inhibitor of phosphoesterase. Both actions will cause the 
downstream inactivation of myosin light chain kinase and phosphatase leading to smooth 
muscle relaxation. 
Symptom controllers  
Long-acting β2 agonist provide muscle relaxation for up to 12 hours and are thus used to 
control symptoms that may occur later on or during night time. They are often combined with 
a type of preventer medication providing a more comprehensive symptom control. 
Preventer medication  
Preventer mediation aims to reduce the severity of airway inflammation and immune-
mediated airflow obstruction. They include steroid analogues (e.g. of glucocorticosteroids) as 
well as non-steroidal drugs (such as mast cell stabilisers and leukotriene modifiers).  
Glucocorticosteroid analogues (also refrerred to as glucocorticoids) mimic the effect of the 
natural occurring hormones within the human body. As regulators of the glucose metabolism 
they have wide ranging physiological effects. Most importantly, they interfere with immune 
cell activation (Coutinho and Chapman 2011). The preventive use of their analogues is thus 
effective in dampening the inflammatory response which would normally occur during an 
asthma attack and trigger clinical symptoms (Rhen and Cidlowski 2005). To restrict their 
effects, gluococorticoids are often administered locally using an inhaler. However, if 
inhalation provides insufficient control, oral administration in either tablet or liquid form may 
be prescribed. Non-steroidal drugs, often regarded as less effective than glucocorticoids, 
represent an alternative when the side-effects of the broad-acting steroids (e.g. 
osteoporosis, cardiovascular and metabolic disease; Vegiopoulos and Herzig 2007) are 
judged to be too great (e.g. in children; Fanta et al 2009). They include mast cell stabilisers 
as well as leukotriene modifiers. Mast cell stabilisers prevent mast cell degranulation and 
mediator release but also influence neural reflexes and cytokine transcription (Heinke et al 
1995, Yang 2010). Leukotriene modifiers such as Leukotriene receptor antagonists and 5-
lipoxygenase synthesis inhibitors limit the activity of the crucial family of inflammatory 
mediators (incl. Leukotriene D4), limiting vascular permeability, immune cell recruitment, as 
well as smooth muscle constriction.  
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Table 3: Current medications used to control asthma 
Medication Example Mechanism 
Reliever 
Medication 
 
Short-acting β2 adrenergic receptor agonist 
e.g. salbutamol, terbutaline 
Bind & activate beta-adrenergic receptors on smooth 
muscle leading to cAMP production, intracellular Ca
2+
 
depletion and smooth muscle relaxation (Taylor 2006) 
 Anti-cholinergic drugs 
e.g. ipratropium bromide 
 
Blocks muscarinic acetylcholine receptors & 
acetylcholine signalling causing smooth muscle 
relaxation (Baigelman, Chodosh 1977) 
 Theophylline (dimethylxanthine) 
 
Non-selective phosphoesterase & adenosine receptor 
antagonist causing increased cAMP & cGMP activity and 
smooth muscle relaxation (Daly 1986, Essayan 2001) 
Symptom  
Controller 
Long-acting β2 agonist (+preventer medication) 
e.g. formoterol,salmeterol (+e.g. glucocorticoids) 
 
Same as short-acting beta2 agonists. Relieve 
bronchospasm for up to 12 hrs 
Preventer 
Medication 
Steroidal drugs 
 Inhaled glucocorticosteroid analogues 
e.g. beclomethasone dipropionate, 
budesonide, fluticasone propionate 
 Oral glucocorticosteroids analogues 
e.g. prednisolon, prednisone 
 
 
Agonism of the glucocorticoid receptor. Dampening the 
activity of key inflammatory regulators such as NF-κB 
and AP-1 (McKay and Cidlowski 1999) as well as 
supporting immune regulatory gene transcription (Clark 
2007) 
 Non-steroidal drug 
 
A)mast cell stabilisers 
e.g.sodium cromoglycate, nedocromil sodium 
 
 
 
The mechanisms are not fully understood. They reduce 
Ca2+ channel activity and act as G-coupled receptor 
agonists. In addition to blocking mast cell degranulation 
they alter neural reflexes as well as cytokine release 
(Heinke et al 1995, Yang et al 2010) 
 B)leukotriene modifiers 
 Leukotriene receptor antagonists 
e.g. montelukast sodium, zafirlukast 
 
 
antagonism of the Cysteinyl leukotriene receptor-1 
limiting LTD4 but also LTC4, and LTE4 activity 
(Montuschi and Peters-Golden 2010) 
 
  5-lipoxygenase synthesis inhibitors 
e.g. zileuton 
inhibit the enzyme arachidonate 5-lipoxygenase 
reducing the conversion of essential fatty acids into 
leukotrienes (Pergola and Werz 2010) 
 
New biological treatments for asthma based on immunological insights 
The success of corticosteroids has shown that controlling the airway inflammation is an 
important strategy in the control of asthma. While new and improved broad-acting immune 
modulators are being developed (e.g. improved corticosteroids, phosphodiesterase 
inhibitors), more selective and specific immunologic interventions have come into focus (see 
table 4).  
This more selective intervention also requires that the specific underlying molecular 
mechanisms are well understood. Their potential use and application has increased by the 
current drive to define better asthma endophenotypes.  
In the focus of allergic asthma are especially molecules released during the early phase of 
inflammation. These include IgE, mast cell mediators as well as Th2 cytokines. The potency 
of blocking a single mediator such as a cytokine can be significant as they act not only 
during the immediate early phase response but also trigger the ensuing late phase 
response. Anti-IL-5 treatment for example lowered the activation, maturation and recruitment 
of eosinophils into the airways and significantly reduced asthma exacerbations (Haldar et al 
33 
 
2009). Due to the heterogeneity of asthma, not only Th2 but also Th1 (e.g. TNF) as well as 
Th17 (IL-17) cytokines have come into view (Pelaia et al 2012).  
A different treatment strategy is to use of immunotherapy. Since its conception, the idea of 
treating the occurrence of allergic inflammation has been very attractive. Yet the risk of 
anaphylactic reactions, which in allergic asthma could be severe, has hampered its adoption. 
A systematic review of over 88 clinical trials however has documented significant reductions 
of asthma symptoms, medication use, and allergen-specific bronchial reactivity after 
subcutaneous immunotherapy (Abramson et al 2003 & 2010). Therefore new developments 
such as sublingual administration or use of modified allergen (Vrtala et al 2001) could 
potentially lead to a wider adoption in future.  
Table 4: New biological treatments for asthma based on immunological insights 
Target Mediators under evaluation Mechanism 
Signalling 
pathways 
 
Phosphodiesterase inhibitors 
e.g. Roflumilast (Gavreau 2011) 
 
p38 MAPK inhibitor s 
e.g. SD-282 
 
Block phosphodiesterase  thus preventing inactivation of 
cAMP & cGMP within immune  cells (Spina 2008) 
 
Interfere with MAPK signalling cascade dampening cellular 
responses such as cytokine transcription (Goldstein and 
Gabriel 2005) 
IgE Anti-IgE  
e.g. omalizumab; 8D6 (Shiung 2011) 
 
Humanised IgG1 antibody binds free but not FcεRI bound 
IgE. The removal of free IgE causes the gradual loss of 
receptor bound IgE on Mast cells reducing allergen 
recognition (Holgate et al 2005) 
Cytokines 
 
IL-4  
 Anti-IL-4 (pascolizumab) 
 IL-4mutant (pitrakina) 
 IL-4Ra (altrakinacept) 
 
Blockade of IL-4 function  by targeting IL-4 directly, using a 
decoy receptor or a competitive non-functioning IL-4 
mutant  
IL-5 
 Anti-IL-5 (mepolizumab) 
 Anti-IL-5Ra (Benralizumab) 
 
Blockade of IL-5 function by targeting IL-5 directly  or using 
a decoy receptor causing reduction of airway eosinophilia 
IL-13 
 Anti-IL-13 (lebrikizumab, 
Traklokinumab) 
TNF 
 Anti-TNF (golimumab, Wenzel 
Barnes 2009) 
 IgG1/TNFR2 (etanercept, Erin 
Leaker 2006) 
 
Blockade of IL-13 function by targeting IL-13 directly (anti-
IL5) 
 
Blockade of TNF function by targeting TNF directly 
(anti-TNF) or using a decoy receptor 
  
CRTH2  CRTH2 agonist  
e.g. OC000459 (Barnes Pavord 2011) 
 
Interfere with Mast cell mediated activation of Th2 and 
eosinophils (Gyles 2006) 
Immunotherapy Subcutaneous, sublingual  Reduction of Th2-type inflammation by induction of 
tolerance e.g. T regulatory cells, blocking antibodies 
(Shamji and Durham 2011) 
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T helper cells 
 
CD4 T cells (also called T helper cells) are a group of lymphocytes playing an essential role 
in the adaptive immune response. They are considered to be bone marrow derived and 
undergo positive and negative selection within the thymus (Asthon-Rickardt et al 1994) to 
enter the body’s circulation as competent naive CD4 T cells. These naive CD4 T cells enter 
and exit secondary lymphoid tissue (e.g. lymph nodes) where they are brought into contact 
with professional antigen presenting cells (APC). This interaction may lead to their antigen 
specific activation (Janeway 1989, Hugues 2010). Depending on the antigen itself, as well 
the environmental signals which the antigen presenting cell received, the APC will prime the 
naive T cell through activation of specific transcription factors (e.g. FOXP3, GATA3, T-BET) 
to acquire specific T helper cell functions (Abbas et al 1996, Ho and Glimcher 2002, 
Rothenberg et al 2005). Once activated, the T cell can migrate to the T cell B cell zone to 
provide help for B cell activation (Parker et al 1993) or migrate, guided by chemotactic 
signals, to the inflamed tissue (Krüger and Mooren 2007). After resolution of inflammation, a 
small proportion of activated CD4 T cells will remain and form part of the immunological 
memory (Swain and Bradley 1992). 
Current T helper classifications 
It was proposed that the different T helper cell profiles, induced during T cell priming, may 
not only be distinct from each other but also remain stable over time. The first evidence of 
stable and distinct T helper cell profiles was made when clonal memory T cell lines could be 
broadly categorised into two stable and distinct IFN and IL-4 expressing CD4 T cell 
populations (Mossmann et al 1986, Killar et al 1987, Romagnani et al 1991). This gave rise 
to the first Th1 and Th2 subset classification and has, since, significantly shaped our 
understanding of CD4 T biology. The most widely accepted T helper cell subsets today are 
the Th1, Th2, Th17 as well as the T regulatory subset (Diagram 1, page 35). In addition, 
several new classifications have been proposed which include the follicular (Vinuesa et al 
2005), Th9 (Dardalhorn et al 2008, Veldhoen et al 2008), as well as the Th22 subset (Duhen 
et al 2009, Eyerich et al 2009, Nograles et al 2009, Trifani and Spitz 2010). 
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Diagram 1. T cell phenotypes and subset associations (taken from Schmidt-Weber et al 2007). 
 
Th1 and Th2 subsets 
While Th1 and Th2 cells were originally characterised by their separate IFN
+ and IL-4+ 
production, additional cytokines have since been classified as either Th1 or Th2-associated. 
Examples of these include the Th1- associated cytokines TNF, lymphotoxin (Cherwinski et 
al 1987, Fiorentino et al 1989) as well as Th2- associated cytokines IL-5, IL-9, IL-13, and IL-
31 (Castellani et al 2010). With the emergence of more T helper subsets, some of the 
previously Th1 (e.g. IL-17, IL-22) and Th2-associated cytokines (e.g. IL-9, IL-10) have since 
been reclassified.  
In addition to their differential cytokine expression profiles, it was shown that Th1 and Th2 
cells could be distinguished by different surface receptors. These include chemokine 
receptors such as CCR5 and CXCR3 (Th1 associated) and CCR3, CCR4, CCR8, CXCR4 
(Th2 associated) (O’Garra et al 1998, Cosmi et al 2001).  
Th1 and Th2 differentiation 
IL-12 and IFN are essential cytokines in the development of Th1 cells (Hsieh et al 1992, 
Lighvani et al 2001). Th2 cells, on the other hand, only developed in the absence of IFN and 
IL-12 when IL-2 and IL-4 are present (le-Gros et al 1990, Swain et al 1990) inducing further 
IL-4 release within the differentiating Th2 cell (Noben-Trauth et al 2002).  
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Transcriptional regulation 
As all naive T cells have the capacity to differentiate into any type of T helper cell, the 
induction of transcription factors, their co-operation and antagonism is important to confer a 
specific T helper cell identity. 
The essential transcription factor for Th1 development is T-box expressed in T cells (T-bet; 
Zsabo et al 2000) while Th2 are dependent on GATA binding protein 3(GATA3) expression 
(Zheng et al 1997). The essential transcription factors are often referred to as master 
regulators which control much wider array of functions related their development as well as 
specific effector functions. GATA3, for example, was also shown to be essential for Th2 
development and IL-5 and IL-13 cytokine expression (Siegel et al 1995, Zhu et al 2004). In 
addition, Signal transducer and activator of transcription (STAT) proteins interact with these 
transcription factors and are indispensible for T helper fate determination. While the same 
type of STAT protein can play important roles in several T helper subsets, their strongly 
increased expression is often subset specific. STAT1 (Lighvani et al 2001, Afkarian et al 
2002) and STAT4 (Kaplan et al 1996, Thierfelder et al 1996) were shown to be important for 
Th1 cells while STAT5 (Zhu et al 2003) and STAT6 (Kaplan et al 1996, Schimoda et al 1996, 
Takeda et al 1996) were essential for Th2 development. An overview of the Th1 and Th2 cell 
classifications is given in the table below (Table 5). 
 
Table 5. Th1 and Th2 subset classification 
Subset Lead Cytokine Assoc. 
cytokines 
Transcription 
Factors 
Surface 
Expression 
Stat regulation Polarising 
cytokines 
Th1 IFN TNF 
lymphotoxin 
T-bet CCR5 
CXCR3 
IL-12RB2 
IFNR 
STAT1 
STAT4 
 
IL-12 
IFN 
Th2 IL-4 IL-5 
IL-9* 
IL-13 
IL-31 
GATA-3 
 
 
CCR3 
CCR4 
CCR8 
CXCR4 
IL-17RB 
STAT5 
STAT6 
IL-4 
 
*proposed to represent a distinct T helper (Th9) subset 
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Th17 subset 
IL-17 was originally classified as Th1-associated cytokine before studies showed that IFN
+ 
and IL-17+ T cells were divergently regulated (Oppmann et al 2000, Cua et al 2003) and 
occurred as two separate subsets in vivo (Langrish et al 2005, Park et al 2005, Harrington et 
al 2005). Today, Th17 cells are a widely accepted T helper subset with distinct functions from 
Th1 and Th2 cells. Their expression profile has, since, expanded to not only include IL-17A 
and IL-17F but also IL-21, IL-22, and IL-26 (Wilson et al 2007, Dambacher et al 2009).  
Th17 differentiation 
Th17 cell development was dependent on IL-6 and Transforming growth factor β1(TGFβ1; 
Veldhoen et al 2006, Bertelli et al 2006, Mangan et al 2006). While the presence of TGFβ1 
was important (Li et al 2007, Manel et al 2008), IL-6 appeared to be pivotal in determining 
Th17 rather than T regulatory cell development (Zhou et al 2006). Other cytokines which 
have, since, been shown to be important include IL-1β (Acosta-Rodriguez et al 2007, Wilson 
et al 2007), IL-21 (Korn et al 2007, Nurieva et al 2007) as well as IL-23 (McGeachy et al 
2007, Korn et al 2009).  
Transcriptional regulation 
The transcription factor Rar related orphan nuclear receptor C 2 (RORC2; in mice: RORt) 
was shown to be essential for controlling IL-17 expression and Th17 development (Ivanov et 
al 2006, Zhang et al 2008). While RORt/RORC2 is often quoted as the master regulator of 
Th17 cells, Interferon regulating factor 4 (IRF4) has shown to be essential for IL-17 
expression as well (Brustle et al 2007). 
Th17 cells show strong STAT3 expression which is essential for Th17 development (Zhou et 
al Spolski et al 2007, Nurieva et al 2007) e.g. down regulating FOXP3 (Korn et al 2007) and 
Th17 cell function (Xang et al 2007, Nishihara et al 2007) binding directly to the IL-17 and IL-
21 promoter (Wei et al 2007, Chen et al 2006). An overview of the Th17 cell classifications is 
given in the table below (Table 6). 
Table 6. Th17 subset classification 
Subset Lead Cytokine(s) Assoc. 
cytokines 
 
Transcription 
Factors 
Surface 
Expression 
Stat regulation Polarising 
cytokines 
Th17 IL-17A
1 
IL-17F  
 
IL-21 
IL-22
12 
IL-26 
 
RORC2
1 
IRF4 
CCR6
1
  
IL-1R1 
IL-12RB 
IL-23R
1
 
CD161
2
 
IL-13Ra1 
STAT3
3
 TGFβ1
4 
IL-1β 
IL-6 
IL-21
5
 
IL-23 
Based on (
1
Annunziato Cosmi 2007,
2
Cosmi De Palma 2008, 
3
Nishihara Ogura 2007, 4Veldhoen Stockinger 2006, 5Korn 2007) 
induces IL-22 during Th17 differentiation (McGeachy 2007) 
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Regulatory T cells 
A hallmark of the adaptive immune system is the regulation of the inflammatory response 
through tolerance induction. CD4 T cells can exhibit regulatory properties and form an 
integral part of the immune regulation within the body (Sakaguchi et al 1995). Regulatory 
CD4 T cells, themselves, represent a diverse group of cells. They include thymus-derived 
natural T regulatory cells as well as inducible T regulatory cells (Ito et al 2008). The 
mechanism in which they induce tolerance is by contact dependent (e.g. CTLA-4, OX40, 
ICOS) as well as contact independent means (e.g. IL-10, TGFβ1) (Shevach et al 2009). As 
regulatory T cells themselves represent a large and heterogeneous group, individual sub-
classifications have been proposed (e.g. IL-10 producing Tr1 and TGFβ1 producing Th3 cells, 
Groux et al 1997, Chen et al 1994). 
Treg differentiation 
The induction of T regulatory cells is influenced by the strength of TCR engagement 
(Bautista et al 2009, Leung et al 2009), the binding of co-stimulation molecules (e.g. CD28, 
CD80/86; Salomon et al 2000, Tai et al 2005) as well as the soluble factors expressed 
during activation (e.g. IL-2, TGFβ1; Fontenot et al 2005, Kretschmer et al 2005). 
Transcriptional regulation 
While not all regulatory T cells express FOXP3 (e.g. Tr1 cells), the transcription factor is 
essential for T regulatory cell development and function (Fontenot et al 2003, Fontenot et al 
2005). Similarly, STAT5 expression activated by the presence of IL-2 was shown to bind to 
FOXP3 promoter and enhance its expression (Davidson et al 2007, Burchill et al 2007). An 
overview of the T regulatory cell classification is given in the table below (Table 7). 
 
Table 7. T regulatory subset classification 
Subset Lead Cytokine Assoc. 
Cytokines  
Master 
Regulator 
Surface 
Expression 
Stat regulation Polarising 
cytokines 
Tregs IL-10 or TGFβ1  FOXP3 CD25
high
 STAT5 TGFβ1 
IL-2 
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The novel Th22 subset 
 
IL-22, itself, was known to be expressed by CD4 T cells (Dumoutier et al 2000) and, early 
on, was classified as a Th1 rather than Th2 associated cytokine (Gurney et al 2004). With the 
growing acceptance of new Th17 subset, IL-22 was re-classified to be a Th17-associated 
cytokine (Liang et al 2006, Chung et al 2006). Not long after its re-classification, it became 
apparent that the expression of IL-22 and IL-17 were controlled by differential regulatory 
pathways (Zheng et al 2007) and could be largely observed as distinct IL-17+ and IL-22+ T 
cell populations in vivo (Scriba et al 2008). These observations questioned the new Th17 
association and led to the hypothesis that IL-17+ and IL-22+ T cells should be viewed as two 
distinct Th17 and Th22 subsets (Duhen et al 2009, Eyerich et al 2009, Nograles et al 2009, 
Trifani and Spitz 2010). 
Th22 expression profile 
The consensus is that Th22 cells express IL-22 in the absence of IFN, IL-4 and IL-17. 
However, this research group identified that memory Th22 cells derived from skin were 
always able to co-express the Th1-associated cytokine TNF (Eyerich et al 2009). In 
addition, the research highlighted a selective expression of growth factor genes such as 
fibroblast growth factors (Eyerich et al 2009). 
An initial survey of chemokine receptor expression profile showed that CCR4 (Trifani and 
Spitz 2010, Duhen et al 2009), CCR6 (Trifani and Spitz 2010, Duhen et al 2009) and CCR10 
(Trifani and Spitz 2010, Duhen et al 2009, Eyerich et al 2009) were preferentially expressed 
on Th22 cells. While their selective enrichment of Th22 cells remained poor, other receptors 
identified to be Th22 specific (e.g. PDGFR, FGFR and TIE1; Eyerich et al 2009) still need to 
be verified. 
Th22 differentiation 
Research showed that IL-22+ IL-17- CD4 T cells could be primed by APC  including 
langerhans cells, dermal dendritic cells as well as plasmacytoid dendritic cells in vitro (Fujita 
et al 2009, Duhen et al 2009). All of these cells were able to induce IL-22 expression in the 
absence of additional antigen mediator stimulation (Fujita et al 2009, Duhen et al 2009). Yet, 
the maturation of plasmacytoid dendritic cells in CpG rather than LPS containing medium 
increased their ability to prime IL-22+ T cells (Duhen et al 2009).  
The T cell priming is dependent on both signals relayed via cell-cell contact (e.g. surface 
molecules) as well as soluble mediators (e.g. cytokines). Contact dependent signals which 
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were shown to be important include T cell receptor (TCR), CD28, ICAM1 (Gurney et al 2004) 
as well as CRTAM engagement (Yeh et al 2008). The importance of CRTAM was 
highlighted using a CRTAM -/- knockout mice which had strongly reduced IL-22 (and IFN) 
levels while IL-17A expression remained unaffected (Yeh et al 2008).  
Soluble mediators important in priming of Th22 cells were IL-6 and TNF as well as IL-23. IL-
6 and TNF have never been linked to IL-22 expression before but their combination was 
recently shown to drive in vitro Th22 differentiation in the absence of APC stimulation (Duhen 
et al 2009). IL-23, on the other hand, is known to be important for IL-22 expression in vitro 
and in vivo (Zheng et al 2007, Chung et al et al 2006, Kreymborg et al 2007, Volpe et al 
2009). While the IL-23 receptor is not found on naive T cells, it is believed to be induced 
after T cell activation (Wilson et al 2007) and APC  were shown to be a major source of early 
IL-23 (Siegemund et al 2009). The dependence on IL-23 signalling was proven using both 
IL-23 blocking antibodies (Liang et al 2007) as well as knockout mice (Aujla et al 2008, 
Zheng et al 2008, Godinez et al 2009, Siegemund et al 2009, de Luca et al 2010). In all 
studies, IL-22 expression was reduced to either small or undetectable levels. Interestingly, 
other IL-23 induced cytokines such as IL-1β, IL-6, and IL-17A were not as severely affected 
suggesting that there is little or no redundancy in the induction of IL-22 (Kleinscheck et al 
2010). In addition, other factors influencing the expression of IL-22 in CD4 T cells are listed 
in the table below (Table 8). 
Table 8. Factors influencing the expression of IL-22 in CD4 T cells 
Mediator +/- Function Reference 
IL-23 + Induction of IL-22 Zheng et al 2007, Chung, Yang et al 2006 
TNF + IL-6 + Induction of IL-22 but not IL-17 Duhen et al 2009 
IL-1β + Synergy with IL-23 Liu et al 2008, Liang et al 2006, Kleinscheck et al 
2009 
IFNγ + may block IL-17a but not IL-22 induction Scriba et al 2008 
IL-2 + May block IL-17a but not IL-22 induction Veldhoen et al 2009 
IL-12p40 + May help IL-22 induction Kreymborg et al 2007 
1,25(OH)2D3 + Induction of IL-23 receptor Ikeda et al 2010 
1,25(OH)2D3 - Blockade of IL-22, IL-17a and IFNγ Colin et al 2010 
IL-4 - Blockade of IL-22 and IL-17a Zheng et al 2007, Veldhoen et al 2009, Schnyder et 
al 2010 
IL-10 - Decrease in  IL-22 Gu et al 2008 
IL-12p35 (IL-
12/IL35) 
+/- No role in IL-22 induction/inhibition Siegemund et al 2009 
IL-17a - Weakly inhibited IL-22 Sonnenberg et al 2010, de Luca et al 2010 
PGE2 - Blockade of IL-22 induction of IL-17a Chizzolini et al 2008 
EBI3 (IL27/Il35) - Blockade of IL-22 and IL-17a Yang et al 2008 
Collagen V - Reduction of IL-22 and IL-17a Brown et al 2010 
 
Transcriptional regulation  
IL-22 expression is dependent on Notch (Alam et al 2010) as well as aryl hydrocarbon 
receptor (AHR) signalling (Velhoen et al 2008 & 2009). The importance of AHR signalling 
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was demonstrated using artificial AHR agonists (e.g. bNF and FICZ) which increased IL-22 
expression in CD4 T cells (Veldhoen et al 2008) while decreasing IL-17A (Trifani et al 2010). 
While the knock down of AHR by siRNA showed only a small reduction in IL-22 expression, 
(Trifani et al 2010) the AHR -/- knock out mouse was unable to mount an IL-22 response 
(Veldhoen et al 2008 & 2009). Due to its strong connection to IL-22, AHR is often quoted as 
the master regulator of Th22 cells. However, AHR is also essential for the development of 
FOXP3 negative IL-10+ T cells (Mezrich et al 2010, Apetoh et al 2010, Gandhi et al 2010) 
and the essential factors in regulating Th22 cell development, therefore, remain to be 
explored. An overview of the proposed Th22 cell classifications is given in the table below 
(Table 9). 
Table 9. Th22 subset classification 
Subset Lead Cytokine Assoc. 
Cytokines  
Master 
Regulator 
Surface 
Expression 
Stat regulation Polarising 
cytokines 
Th22 IL-22
1,2,4,5
 TNF
1
 
 
AHR
3
 CCR4
2,4
 
CCR6
2,4
 
CCR10
1,2,4
 
PDGFR 
FGFR2 
TIE1* 
 IL-6
2
 
TNF
2
 
Based on (
1
Eyerich 2009, 
2
Duhen 2009, 
3
Velhoen 2008, 
4
Trifani 2009, 
5
Nograles 2009,* Eyerich & Schmidt-Weber 
unpublished) 
 
T helper subset heterogeneity and plasticity 
The original definition of CD4 T cells into Th1 and Th2 T helper subsets has advanced our 
understanding of T cell biology significantly. As more evidence emerges, it becomes 
apparent that T helper cell priming may not necessarily lead to terminal differentiation and 
confer a stable and distinct T helper subset identity.  
In fact, it is likely that CD4 T cells retain some degree of plasticity after activation allowing 
different signals within the inflamed tissue to alter their expression profile. This is supported 
by observations showing the partial or full conversion of Th2 -> Th1 (Fujimura et al 1997) as 
well as Th1 <-> Th17 <-> Treg in vitro and in vivo (Annunziato et al 2007, Osorio et al 2008, 
Martin-Orozco et al 2009). Not just the stability of T helper cell identities is questioned but 
also the definition of a distinct T helper subset. The ever more detailed delineation of existing 
T helper subsets such as Th2 -> Th9 and Th17 -> Th22, in particular, highlights the need to 
study T helper cell lineages in a more comprehensive way. While large scale epigenetic 
studies are under way to re-define T helper cell fate development (Wei et al 2009, Placek et 
al 2009, Wilson et al 2009), our current model of T helper subsets and their definitions 
remain in place.  
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Interleukin-22 
IL-22 
Gene and Protein 
 
Figure 1. Genomic relationship between all species with known IL-22 genes (source: www.esembl.org)
  
The Interleukin 22 gene is an evolutionary conserved gene that appears in most parts of the 
animal kingdom including birds (e.g. chicken, zebra finch), fish (e.g. zebra fish), mammals, 
marsupials, primates, rodents and cetaceans (e.g. dolphin) but not reptiles or amphibians 
(Figure 1). IL-22 may have arisen at the same time when antigen specificity (occurrence of 
RAG genes) and the adaptive immunity developed and is induced after Lipopolysaccharide 
(LPS) encounter across species form fish to man (Igawa et al 2006).  
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Figure 2. Genomic location of the IL-22 gene (source: www.ncbi.nlm.nih.gov) 
The human IL-22 gene is found near the IL-26 (AK155) gene and, in close proximity, to the 
Mdm4, transformed 3T3 cell double minute 1, p53 binding protein (MDM1) and IFNγ genes 
(Figure 2). The genomic region is frequently found under the name 12q15 and has been 
under extensive research in many genome wide disease association studies (e.g. 12q15 
association with asthma, Barnes et al 1996). The IL-22 and IL-26 genes show some limited 
homology with IL-10 (10-27%; Kotenko et al 2001) and have, thus, both been classified as 
IL-10-related cytokines. More modern analysis has shown that IL-22 is more closely related 
to IFN- and, in particular, IFN-3 (Gad et al 2009).  Yet, studies remained inconclusive 
about the functional relationship between IL-22 and IL-10 (Lecart et al 2002, Wolk et al 
2005) as well as IL-22 and IFN (Pagliaccetti et al 2010). 
 
Figure 3. Overview of the IL-22 gene and its mRNA transcript (source: www.ensembl.org) 
The IL-22 gene has five exons (Figure 3) and is transcribed into a single mRNA 
(NM_020525). While in humans only one gene copy exist, several strains of mice were 
shown to have a second IL-22 gene copy which, likely, arose during gene duplication and is 
classified as a pseudogene (B10.S, SWR, C57BI/6, FVB, 129/Sv, C3H, DBA/1; Levillayer et 
al 2007).  
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The IL-22 core promoter region is believed to be 641 nucleotides upstream and includes the 
first IL-22 exon (Dumoutier et al 2000b). This presumed IL-22 promoter region has no 
TATAAT motif, which is not uncommon, as only about 50% of genes are known to be TATA 
box regulated (Lewin, Genex IX 2008). Today, however, analysing gene promoter regions 
would include wider genomic regions. This is due to the fact that many important promoter, 
enhancer and silencer regions have been found several thousand nucleotides upstream or 
downstream of the start codon (Lewin, Genex IX 2008). A more recent computer guided 
analysis and gel shift assay of the bovine IL-22 gene showed that the -1132 and -879 region 
in the 5' upstream gene sequence was a likely promoter site contained putative transcription 
factor binding sites for STATx, Sox-5/9, Sp1, Ik-1, and AREB6 (Ma et al 2010).  
IL-22 Protein 
The IL-22 mRNA is transcribed into a single 179 amino acid long protein (NP_065386.1). It 
contains 6 α-helices which are arranged in anti-parallel conformation and result in a 
monomeric, bundle-like protein (Diagram 2; Nagem et al 2002, Xu et al 2005). The 
monomeric conformation of crystallised IL-22, at least at physiologically relevant 
concentrations, was confirmed by gel filtration chromatography and dynamic light scattering 
studies (Nagem et al 2002, Logsdon et al 2002). The IL-22 primary structure contains four 
Cys which form two intramolecular disulfide bridge bonds (Cys40-Cys132 linking the N 
terminus to the DE loop and Cys89-Cys178 linking helix C to helix F; Nagem et al 2002). IL-
22 is glycosylated on helix A (Asn54-Arg55-Thr56), in the AB loop (Asn68-Asn69-Thr70) and 
in helix C (Asn97-Phe98-Thr99) of which the glycosylation on Asn54 in helix A has been 
found to be essential for the interaction with IL-10R2 (Logsdon et al 2004). 
 
Diagram 2. Predicted 3-dimensional structure of IL-22 (http:// modbase.compbio.ucsf.edu/) 
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Expression 
Interleukin 22 is a mediator exclusively produced and secreted by cells of the immune 
system. Originally believed to be released only by CD4 T cells, depletion studies of innate 
and adaptive T cells as well as NK cells showed that IL-22 could be expressed by a wider 
range of cell types (Hedrick et al 2009, Munoz et al 2009, de Luca et al 2010, van Maele et 
al 2010). Today, three broad categories of cell types have been identified to be capable of 
producing IL-22. These include the myeloid-derived cells (monocyte/ macrophage/ dendritic 
cell), the NK/ LTi/ LTi-like cells and the innate/ adaptive T lymphocyte populations.   
Innate Immune cells 
Monocytes, macrophages and dendritic cells  
Evidence that IL-22 is produced by myeloid cells has become more substantial over the 
years. The earliest description of monocytes to express IL-22 came from a study 
investigating gene expression profiles of adherent PBMCs  after bypass surgery (Hsing et al 
2006). These cells expressed high levels of IL-22 but also IL-19 and IL-20 mRNA. More 
direct evidence of IL-22 expression was obtained by culturing monocytes in IL-23 or LPS 
containing media (Zheng et al 2008). In vivo macrophages identified by CD11b+MAC3+ or 
CD11b+CD86+ were shown to be able to secrete IL-22 as well (Kapessidou et al 2008, Gu et 
al 2008). CD11b+ and CD11c+ cells which could represent either macrophages or dendritic 
cells showed to express the IL-23 receptor and respond similarly to IL-23 challenge with IL-
22 release (Awasthi et al 2009). CD11c+ cells generally categorised specifically as dendritic 
cells were found to produce IL-22 in several studies (Zheng et al 2007 & 2008, Pickert et al 
2008). While depletion of T cells has shown that monocytes, macrophages and dendrtic cells 
only produce small amounts of IL-22 in vivo, their IL-22 expression capacity may still be 
important on a local cell to cell level.  
Lymphoid-Tissue-inducer (LTi), LTi-like, and NK cells  
Several studies have shown that IL-22 together with IFN is essential effector cytokine of 
Lymphoid tissue inducer (LTi) cells (Satoh-Takayama et al 2008, Luci et al 2009, Cupedo et 
al 2009). LTi cells developed, in parallel, with the adaptive immune response   facilitate the 
association of CD4+ T cells with dendritic cells in several species (e.g. fish, birds) in the 
absence of secondary lymphoid tissue and even, in humans, are thought to still facilitate 
interactions between CD4+ T cells and dendritic cells within the submucosa (Lane et al 
2008). Indeed, in the gut submucosa, LTi cells have been found in close contact with CD1c+ 
dendritic cells and CD4+ T cells. Through their expression of LTαβ2, they interact with 
stromal cells which, in turn, start to secrete and attract B cells (through CXCL13), T cells and 
dendritic ells (through CCL21, CCL19). LTi cells express OX40-ligand and CD30L which act 
as survival signals for CD4+ T cells thus maintain peripheral T cell memory. In addition, LTi 
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cells were shown to differentiate into CD11c+ dendritic cells under IL-3 and TNFα conditions. 
However, LTi cell numbers both in mice and human are very high. This suggests that they 
may have acquired additional immune functions. The identity of LTi cells is not always easily 
established as they can express many of the NK cell associated surface receptors 
(NKp44/46, CD56) leading to some misclassification between the two cell populations. 
Classic Natural killer (NK) cells have shown to be IL-22 positive as well. NK cells utilize their 
surface receptor repertoire to discriminate between healthy and infected or abnormal cells 
and cause their destruction. In an immature state, they produce only cytokines like IFNγ 
(CD56bright) while, in a mature state, they can produce perforin and granzyme (CD56dim). IL-
22 production in NK cells was identified very early on (Wolk et al 2002 & 2004) but was, 
then, believed not to be of any significance. However, this view changed significantly as 
many NK cells in the tissue have, now, been found to produce IL-22 at the front line of 
mucosal defences. This led to the classification of so called NK22 cells. 
However, their close anatomical location to IL-22+ LTi cells and the shared expression of NK 
cell surface markers by both cell types has questioned the true identity of these innate IL-22+ 
cells. Several years ago, it was shown than LTi cells can convert into classical NK cells 
demonstrating a developmental relationship between both cell types (Mebius et al 1997). For 
the moment, however, NK and LTi cells are still being treated separately in the literature. 
One discriminating feature between NK cells and LTi cells is the dependency on IL-15 or IL-
7 respectively. Therefore, IL-7α receptor expression would suggest an LTi-associated 
development path while the dependency on IL-15 would suggest that of NK cells. In addition, 
IL-22 producing cells appear to be RORc positive. RORc is required for LTi development but 
is not essential for NK cell formation.  
For both NK (Cella et al 2009, Guo et al 2010, Dhiman et al 2009, Satoh-Takayama et al 
2009) and LTi (Takatori et al 2009) cell populations, IL-23 appears to be the essential trigger 
for IL-22 release. In addition, IL-1β (Cella et al 2009, Hughes et al 2010), IL-15 (Dhiman et al 
2009) and IL-18 (Satok-Takayama et al 2009) have been shown to trigger IL-22 release in 
NK cells while, in LTi cells, IL-15 down regulated IL-22 expression (Kim et al 2010). An 
overview of the current evidence of IL-22+ NK, LTi, and LTi-like cell populations is given in 
the table below (Table 10). 
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Table 10. IL-22 expressing NK, LTi, and LTi-like cell populations 
Classified as Discriminating factor Species Reference 
NK (IL-22+) NKp44+ cells Human Crellin et al 2010 
NKp44+CD56+ Human  Cella et al 2009 
NK1.1+CD27- Mouse Guo et al 2010 
NK1.1+CD3- Mouse Veldhoen et al 2009 
CD3-CD56- Human Dhiman et al 2009 
CD117+CD161+ Human Hughes et al 2009 & 2010 
RORγt+NKp46+ Mouse Luci et al 2009 
LTi/-like (IL-
22+) 
CD127+RORC+ Human Crellin et al 2010 
CD56+CD127+RORC+NKp46+ Human Crelin et al 2010 
CD117+CD3- Human Satoh-Takayama et al 2008, Luci et al 2009 
CD3-CD19-CD14-CD127+RORC+ Human Cupedo et al 2009 
CD4+CD3-NK1.1-CD11b-Gr1-CD11c-
B220- 
Mouse Takatori et al 2009 
CD56+CD127+ Human Cupedo et al 2009 
NKp46+RORgt+ Mouse Sanos et al 2009 
  
Innate T lymphocytes 
Innate T lymphocytes are important first line defences in mucosal surfaces but can only 
recognise a limited antigen repertoire.  γδT cells (Zheng et al 2007, Yao et al 2010, Ness-
Schwickerath et al 2010, Ma et al 2010, Sutton et al 2009, Martin et al 2009), iNKT and NKT 
cells (Wahl et al 2009, Goto et al 2009, Ma et al 2009, Sutton et al 2009, Martin et al 2009) 
were shown to be IL-22+ in vitro and in vivo. 
Of these cells, γδT cells are best researched and were shown to produce IL-22 after IL-23 
(Zheng et al 2007, Sutton et al 2009), IL-1β (Sutton et al 2009), AHR, TLR-2, and Dectin-1 
agonist challenge (Martin et al 2009). Down regulation of IL-22 was seen when γδT cells 
were stimulated with phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate 
(HMBPP) which is produced by some mycobacteria and opportunistic pathogens (Yao et al 
2010). In humans, IL-22 production by γδT cells can be significant and account for up to 
50% of T cell-released IL-22 (Ness-Schwickerath et al 2010).  
Adaptive Immune cells 
Adaptive Immune cells are divided into T and B lymphocytes but, until now, B cells have 
never been identified to produce IL-22. Adaptive T cells are further classified according to 
their MHC class recognition. CD8 T cells recognise MHC class I and CD4 T cells recognise 
MHC class II. 
CD4+ T lymphocytes  
CD4+ T cells are believed to be the major source of IL-22 in humans and IL-22 expression 
has, so far, been identified in several different T helper subsets (see chapter T helper 
subsets; page 34).  
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CD8+ T lymphocytes  
In humans, CD8+ T cells were shown to contribute to the overall IL-22 release (Zheng et al 
2007, Hamada et al 2009). Their selective expression of IL-22 was dependent on IL-23 lead 
to a similar classification of a Tc22 subset of CD8
+ T cells (Scriba et al 2008, Sellge et al 
2010).  
IL-22 Receptors 
IL-22RA1  
Gene and Protein 
 
Figure 4. Genomic location of the IL-22RA1 gene 
(http://www.ncbi.nlm.nih.gov/nuccore/NC_000001.10?from=24445094&to=24470778&strand=true&report=
graph) 
The IL-22RA1 gene is classified as Interferon receptor related having interferon receptor 
activity (source: amigo.geneontology.org). In humans, the IL-22RA1 gene is located on 
chromosome 1 (NC_000001.10) between 24446261 and 24469611 of the complement 
strand in close proximity to the IL28RA and MYOM3 genes (Figure 4). The gene encodes 7 
exons and is transcribed into a single mRNA (NM_021258.2) and translated into a single 
receptor precursor (NP_067081.2).  
Function - IL-22 signalling complex 
IL-22RA1 can form two signalling complexes either with IL-10RB for IL-22 signalling or IL-
20RA2 for IL-24 signalling. IL-22 signalling was shown to activate ERK1/2, pSAPK, JNK (Xie 
et al 2000, Brand et al 2006 & 2007), JAK (Xie et al 2000), pAKT (Zenewicz et al 2008) and 
STAT 1,2,3, and 5 (Xie et al 2000, Brand et al 2006 & 2007, Wolk et al 2007, Dumoutier et al 
2009). STAT3, in particular, has been shown to become phosphorylated and, together with a 
chimeric STAT3/STAT5 protein, was constitutively associated with the C-terminal of the IL-
22RA1 receptor (Dumoutier et al 2009). Another direct link in the IL-22RA1 signal 
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transduction is Shp2 which is essential for IL-22 induced MAP kinase activation (Meng et al 
2010). 
Expression 
Immune system 
Comprehensive early studies found no evidence that IL-22RA1 was expressed by either B 
cells, T cells, monocytes, macrophages, dendritic cells or NK cells (Kunz et al 2006, Wolk et 
al 2008). All other evidence linking IL-22RA1 to immune cells has remained indirect (Table 
11).  
Table 11. Evidence of IL-22RA1 expression in immune cells 
Type Specific Cell  Evidence 
Immune cells Monocytes/Neutrophils  Indirect evidence – CD66
+
IL-22RA1
+
 cells in synovial fluid 
(Kragstrup 2008) 
 Macrophages Indirect evidence – responsive to IL-22 in vitro (Dhiman et al 2009) 
 Dendritic cells Indirect evidence – responsive to IL-22 in vitro (Schnyder et al 
2010) 
 
Structural cells 
IL-22RA1 expression shows a strong correlation to structural cells and, in particular, those of 
epithelial origin (Table 12). In addition, IL-22RA1 is expressed by specialised cells such as 
hepatocytes in the liver and islet cells in the pancreas. The expression of IL-22RA1 in other 
cell types such as endothelial cells, muscle cells, and fibroblasts is less well documented 
and remains controversial.  
Table 12: IL-22RA1 expression in human structural cells 
Tissue Specific Cell type Evidence 
Epithelial cells Keratinocytes 6% IL-22RA1 surface expression in culture (Kragstrup et al 2008), 
IL-22RA1 mRNA increase afteTNF (Wolk et al 2009) and IFN 
(Kunz et al 2006) exposure 
 Bronchial epithelial cells 
 
15% IL-22RA1 surface expression in culture (Aujla et al 2008), 
mRNA and protein (Kotenko et al 2001,Ramanathan et al  2007, 
Aujla et al  2008) 
 Sinosinal bronchial epithelial cells IL-22RA1 mRNA and protein (Kotenko et al 2001, Ramanathan et 
al 2007) 
 Intestinal epithelial cells Increased IL-22RA1 after LPS, IL-1β, and TNF exposure (Brand 
et al 2006) 
 Retinal pigment epithelial cells  
 
IL-22RA1 protein (Li et al 2008) 
Endothelial 
cells 
Blood-brain barrier cells (caveolin-
1
+
) 
16% IL-22RA surface expression in culture (Kebir et al 2007) 
Fibroblasts Synovial fibroblasts (vimentin
+
) IL-22RA1 protein (Ikeuchi et al 2005) 
 Skin fibroblast IL-22RA1 protein (Wolk et al 2009) 
Muscle cells Skeletal muscle IL-22RA1 mRNA (Kotenko et al 2001)  
 Heart muscle IL-22RA1 mRNA (Kotenko et al 2001, Wolk et al 2004) 
Specialised 
cells 
Pancreatic islets of Langerhans IL-22RA1 mRNA (Aggarwal et al 2001) 
 Hepatocytes IL-22RA1 mRNA and protein (Aggarwal et al 2001, Kotenko et al 
2001, Wolk et al 2005, Brand et al 2006, Wolk et al 2007, 
Dambacher et al 2008) 
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IL-22RA2 
Gene and Protein 
 
Figure 5. Genomic location of the IL-22RA2 gene 
(http://www.ncbi.nlm.nih.gov/nuccore/NC_000006.11?from=137463466&to=137496276&strand=true&repor
t=graph) 
The Interleukin 22 Receptor alpha two gene (IL-22RA2) is found across all IL-22 expressing 
species suggesting that it may have evolved at a similar point in time and was retained 
throughout evolution indicating a selective advantage. In humans, the IL-22RA2 gene is 
located on chromosome 6 (NC_000006.11) between 137464957 and 137494785 of the 
complement strand. It is in close proximity to the IFNGR1 gene and evolutionary,  
functionally and closely related IL-20RA gene (Figure 5).  
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Figure 6. Overview of the IL-22RA2 gene and its mRNA transcripts (source: www.ensembl.org) 
The IL-22RA2 gene is translated into 4 distinct mRNA’s of which all are protein coding. The 
longest transcript IL-22RA2-002 includes a 7th exon and is translated into a 263 amino acid 
long protein. The 7th exon in the transcript may be a relatively recent addition in the history of 
the IL-22RA2 gene that occurred prior to the divergence of Apes and Old World monkeys by 
the action of retrotransposon (Piriyapongsa et al 2007). This longest IL-22RA2 protein failed 
to bind IL-22 and it is, yet, unknown if the protein has a ligand partner or is non-functional 
(Dumoutier et al 2001, Wolk et al 2007). Both the IL-22RA2-003 and very short IL-22RA2-
201 mRNAs are translated but too may be non-functional (Kotenko et al 2001). The second 
longest transcript IL-22RA2-001 (NM_181309) is translated into a 231 amino acid long 
protein (NP_851826.1). This protein does bind IL-22 (Dumoutier et al 2001a &2001b, 
Kotenko et al 2001, Xu et al 2001) and is generally considered when speaking about IL-
22RA2.  
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Function - IL-22 agonist 
 
Diagram 3. The 3-dimensional configuration of IL-22RA2 binding to IL-22 (de Moura et al 2009) 
 
It has been well established that IL-22RA2 is a naturally occurring antagonist of IL-22 (Xu et 
al 2001, Dumoutier et al 2001) and blockade of IL-22 signalling is achieved by binding the 
same binding site of IL-22 with higher affinity than IL-22RA1 (Diagram 3; de Moura et al 
2009, Jones et al 2008, Wolk et al 2007, Wu et al 2008).   
Expression 
Immune system 
Over the years, particular cells of the myeloid lineage (e.g. monocytes, macrophages, 
dendritc cells) have been shown to express IL-22RA2 mRNA. However, other immune cells 
such as tonsilar B cells (Xu et al 2001, Lecart et al 2002) and neutrophils (Whittington et al 
2004) have been identified (Table 13).  
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Table 13. Expression of IL-22RA2 mRNA in cells of the immune system 
Organ or Cell type Detail Evidence Reference 
PBMC In Graft-vs-Host disease IL-22RA2 mRNA Yang et al 2007 
Infiltrating mononuclear 
cells 
Inflammation IL-22RA2 mRNA  Xu et al 2001 
Monocytes Blood derived IL-22RA2 mRNA Whittington et al 2004 
Mouse monocytes IL-22RA2 mRNA Wei et al 2003 
Macrophages In vitro derived 
macrophages 
IL-22RA2 mRNA  Wolk et al 2004 
Alveolar macrophages IL-22RA2 mRNA Whittington et al 2004 
Dendritic cells In vitro derived dendritic 
cells 
IL-22RA2 mRNA  Wolk et al 2004 
Presumed dendritic cells 
(CD1a,CD34) 
IL-22RA2 mRNA  Nagalakshmi et al 2004 
Presumed dendrtic cells 
(DC1) 
IL-22RA2 mRNA Nagalakshmi et al 2004 
B cells Activated CD19+ cells IL-22RA2 mRNA Xu et al 2001, Doumetier et al 2001 
Activated tonsilar B cells IL-22RA2 mRNA Xu et al 2001 
Neutrophils Alveolar neutrophils IL-22RA2 mRNA Whittington et al 2004 
 
Structural cells 
IL-22RA2 mRNA expression in structural cells is less well studied and, with a few 
exceptions, restricted to studies of tissue homogenates (Table 14).  
Table 14. IL-22RA2 mRNA expression in the human tissue lysates 
Organ/Region Tissue/Cell type Reference 
Respiratory System Lung Xu et al 2001, Dumoutier et al 2001 
Type II pneumocytes  
 
Xu et al 2001 
Digestive System Colon (weak) 
Colon (strong) 
Xu et al 2001 
Dumoutier et al 2001 
Human hepatoma cell (HepG2) Wei et al 2003 
Small intestine (weak) Xu et al 2001 
Pancreas 
 
Xu et al 2001 
Reproductive System Placenta (very strong) Xu et al 2001 
Breast (strong) Dumoutier et al 2001 
Prostate (weak) Xu et al 2001 
Testis Dumoutier et al 2001 
Ovary (epithelial) carcinoma 
 
Xu et al 2001 
Integumentary System Skin 
 
Xu et al 2001 
Cardiovascular System Heart (weak) 
Heart 
 
Xu et al 2001 
Dumoutier et al 2001 
Nervous System Brain (weak) Dumoutier et al 2001 
 
Function of IL-22 
General Function 
The function of IL-22 has been studied in animal models in which IL-22 is either inhibited or 
administered in order to identify its functional significance in health and disease.  
IL-22 administration 
Intravenous injection of rIL-22 into mice was show to decrease the red blood cell count, 
serum albumin and body weight. Injection increased serum amyloid A1 (SAA) and fibrinogen 
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which  led to basophilia in proximal renal tubules (Lambert et al 2001). The injection of IL-22 
before inflammation was shown to inhibit hepatic cell damage (Radaeva et al 2004). While 
the administration of IL-17 changed the number of infiltrating neutrophils in the lung, IL-22 
did not (Liang et al 2007). Adoptive transfer of IL-22- treated dendritic cells was observed to 
lower eosinophil counts in bronchoalveolar lavage fluid after ovalbumin challenge in 
ovalbumin (OVA)-sensitised mice (Schnyder et al 2010) 
IL-22 blockade 
Neutralising IL-22 before inflammation led to an increase in liver damage (Radaeva et al 
2004). In the murine OVA-challenge model, IL-22 blockade increased eosinophil and 
neutrophil infiltration (Schnyder et al 2010). After IL-22 blockade in a Conconavalin A-
induced injury model, IL-6 was lowered and IFNγ increased after Il-22 blockade (Wahl et al 
2009). IL-22 was elevated in an IL-4R-/- knockout mouse and, when inhibited, led to an 
increase in eosiniphil recruitment, eosinophil peroxidase activity and slight increase in 
neutrophils (Schnyder et al 2010). IL-22 antagonism with rIL-22RA2 administration during 
infection showed  reduced bacterial clearance and an increase in neutrophils, macrophages, 
CXCL1, TNF, IL-6, and IL-10 (Weber et al 2007). In a murine model of colitis, blockade of 
IL-22 by IL-22RA2 administration suppressed goblet cell reconstitution during the recovery 
phase (Sugimoto et al 2008) 
 
 IL-22 Knock out mouse 
It was shown that IL-22 deletion did not impact on the overall development of the mice. They 
were viable, fertile and had normal liver, spleen, pancreas, kidney, thymus and skin 
development (Zenewicz et al 2007). Injection of FASL into IL-22-/- mice showed no 
difference to the wild type suggesting that loss of IL-22 did not lead to increased apoptosis. 
They were fully susceptible to experimental autoimmune encephalitis (EAE) (Kreymborg et 
al 2007) and showed to mount a normal response towards Listeria monocytogenes 
(Zenewicz et al 2007). However, these mice were more sensitive to chronic inflammation 
(chronic hepatitis). This was later linked to an increase in the enzyme alanine transaminase 
(ALT) and increased hepatocyte damage which only occurred in the context of inflammation 
in IL-22-/- mice (Zenewicz  et al 2008). This observation was unique and not seen in, for 
example, the IL-17-/- mouse. Investigation of IL-23-induced responses demonstrated that IL-
22-/- mice showed lowered IL-23 induced ear skin ancanthosis and inflammation (Zheng et 
al 2007). This suggests that IL-22 may be a downstream mediator of IL-23 and contributor to 
acanthosis (epidermal hyperplasia). IL-22 -/- knockout mice also were shown to be more 
susceptible to oropharyngeal candidias infection (Conti et al 2009). During worm infestation 
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with S.mansoni, IL-22 -/- mice were shown to have increased levels of IL-17a and decreased 
levels of IL-4, IL-13, IL-10, and TNFα (Wilson et al 2010). IL-22-/- mice also demonstrated 
an association of IL-22 with BCL2 whose expression decreased by 20% compared to 
wildtype. It was also hypothesised that IL-22-/- mice have a breakdown of mucosal defences 
and increased risk of infection and inflammation. Cross of the IL-22-/- mice with the RAG2-/- 
mice resulted in a loss of IL-23 production. This suggested that innate IL-22 may be a trigger 
of IL-23 (Satoh-Takayama et al 2009). 
 
Summary 
An overview is given in the table below (Table 15).  
Table 15. General functions of IL-22  
Type Evidence Reference 
IL-22 administration Reduced Red blood cells
1
, reduced Serum Albumin
1
, reduced 
weight
1
, SAA
1
, fibrinogen
1
, Basophilia in kidney
1
, Protection of liver 
damage
2
, IL-22 exposed DC caused less eosinophilia
3
 
Lambert et al 2001
1
, 
Radaeva et al 2004
2
, 
Schnyder et al 2010
3
 
IL-22 blockade Increase in liver damage
1
, Increase in eosinophils
2
, increase in EPO 
activity
2
, suppressed goblet cell reconstitution
6
, reduced bacterial 
clearance
7
 
Radaeva et al 2004
1
, 
Schnyder et al 2010
2
, 
Sugimoto et al 2008
6
, Weber 
et al  2007
7  
 
IL-22 knockout more sensitive to chronic hepatitis
1
, increased liver damage
1
, 
reduced ear skin ancanthosis and inflammation
2
, mildly more 
susceptible to oropharyngeal candidias infection
3
, decreased BCL2,-
2/1 expression
4
, Increased IgGc2 production
5
 
Zenewicz  et al  2008
1
, Zheng 
et al 2007
2
, Conti et al 2009
3
, 
Satoh-Takayama et al 2009
5
 
 
Cell specific functions 
Immune cells 
Immune cells are not generally believed to be a target of IL-22 but recent studies have 
identified that the addition of IL-22 reduced the CD80/86 expression on cultured dendritic 
cells (Schnyder et al 2010). In addition, macrophages have been shown to respond to IL-22 
with increased phago-lysosomal fusion leading to improved killing of Mycobacterium 
tuberculosis (Dhiman et al 2009). 
Structural cells 
Epithelium 
Epithelia are layers of cells covering internal or external surfaces. They share several 
important characteristics. They are tightly interconnected, show polarity (dipolar organisation 
& distribution), are attached to a thin basal lamina, are avascular and have a high rate of self 
renewal (through divisions of stem cells). They usually serve four essential functions. They 
control the passage of substances (physical barrier but also selective transport), control 
permeability, provide sensation and produce specialised secretions.   
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Keratinocytes 
One of the general effects of IL-22 administration was increased proliferation of cells, 
thickening of the epidermis (Sa et al 2007) and the ability to improve the closure of an 
artificial gap or wound in a layer of cutaneous epithelial cells (Eyerich et al 2009). IL-22 was 
found to be strongly expressed in re-epithliasing skin wounds and IL-22 appeared to induce 
marapsin, a serine protease commonly associated with hyperproliferative epidermis (e.g. 
psoriasis) and regenerating wounds (Li et al 2009). IL-22 down regulated genes were found 
to be associated with cell differentiation and epidermal alterations (Nograles et al 2008). 
Several of the IL-22 induced immune genes in keratinocytes were also shown to be induced 
by IL-17a (e.g. CXCL1, CXCL8; Wolk et al 2009, CCL20; Harper et al 2009). More close 
investigation revealed synergistic effects between IL-22 and IL-17a on the upregulation of 
several immune response genes. These genes include HDB2, S100A7,-8,-9 (Liang et al 
2006), CCL20, IL8, HB-EGF (Tohyama et al 2009) and IL-20 (Wolk et al 2009). Antagonisms 
between IL-22 and IL-17a have also been reported. These include the induction of GMCSF 
and VEGF by IL-17a (Koga et al 2008). Other interactions of IL-22 with other cytokines have 
been reported. TNFα and IL-22 together synergised in the induction of keratin-16 (K16) and 
CXCL8 (Wolk et al 2009). Interestingly, many genes, which were induced by synergies 
between TNFα and IL-22, were not observed in the IL-22 only treated cells. These included 
IL7, -15, -32, CCL2, -5, -20, -26, CXCL9, -10, -11, C1s, -r, CFH, CFB, TLR3, and -6 (Eyerich 
et al 2009). This would suggest that IL-22 boosts the action of the early inflammatory 
mediator TNFα and then, later on, to some extent the action of IL-17a. Some functional 
overlap was identified between IL-22 and IL-20. Both down regulated DSC1, K1,-10, CALM5 
and LCE1B but together they did not synergise (Wolk et al 2009). Addition of rIL-22 to 
keratinocytes resulted in the up regulation of IL-1α, IL-6, TNFα, and the anti-microbial 
peptides S1008-9, DEFB1 and cathelicidin (Ma et al 2008). An overview is given in the table 
below (Table 16). 
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Table 16. Function of IL-22 in keratinocytes  
Evidence IL-22 administration IL-22 blockade 
General Epidermal thickening
1 
Proliferation independent of EGFR
1 
Increased Wound closure
2,14 
STAT1/3/5 phosphorylation
3 
 
 
Protein  Increase IL-6
3
, CXCL1
3
, CXCL8
3
, Marapsin
6
, 
IL-20
10 
 
 
mRNA (RT-PCR) Increase S100A7
1,7,8,9,11,14
, S100A8
9,14
, 
S100A9
9,14
, HDB2
9,14
, CK16
1
, TGFα
4
, 
MIP3α
4
, IL8
4,12
, HB-EGF
4
,  CCL20
5
, 
CXLC8
7,10
, DEFB4
8
, 
K16
10
,MMP3
14
,PDGFA
14
, CXL5
14
,  
Decreased: DSC1
10
, K1
10
, KRT10
10,14
, 
CALM5
10
, LCE1B
10 
 
 
mRNA (Microarray) Increase S100A7
1
, S100A12
1
, CCL20
1
, 
CXCL14
1
, DLX2
1
, LCN2
1
, C1s
1
, VWP1
1
, 
SNX10
1
, HTR3A
1
, SERPINA1
1
, PRSS27
1
, 
IL-1α
13
, IL-6
13
, TNFα
13
, S100A8
13
, S100A9
13
, 
DEFB1
13
, CAMP
13
,  
Decreased: PPM1K
1
, MSMB
1
, APOL3
1
, 
DCN
1
 
 
(source: Sa et al 2007
1
, Eyerich et al 2009
2
, Wolk et al 2004
3
, Tohyama et al 2009
4
, Harper et al 2009
5
, Li et al 2009
6
,Nograles 
et al 2008
7
, Boniface et al 2007
8
, Liang et al 2006
9
,Wolk et al 2009
10
, Pene et al 2008
11
, Koga et al 2008
12
, Ma et al 2008
13
, 
Boniface et al 2005
14
) 
 
Airway Epithelial cells 
Two recent studies have looked at the functional relevance of Il-22 (Aujla et al 2008, 
Sonnenberg et al 2010). Injured bronchial epithelial cells were shown to re-establish 
epithelial resistance more quickly when IL-22 was added. Synergies between IL-22 and IL-
17 in IL-6 and CXCL1 up-regulation were confirmed and an increase in neutrophils (Gr1+ 
cells) observed when both IL-22 and IL-17A were present in the lung (Sonnenberg et al 
2010). In the transformed lung, alveolar epithelial cell line A549 IL-22 administration led to 
increased survival by up regulation of BCL2, and BCL-XL (Zhang et al 2008). The blockade 
of IL-22 led during stress led to a 20% decrease of BCL-2, BCL-2/1 expression (Sonnenberg 
et al 2010). This decrease was also observed when IL-17A was added to the IL-22 
containing media, showing some antagonism between the two cytokines. An overview is 
given in the table below (Table 17). 
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Table 17. Function of IL-22 in lung epithelial cells  
Evidence IL-22 administration IL-22 blockade 
General Re-establishment of barrier integrity 
GR1+cell increase
2 
 
 
Protein  Increase G-CSF, IL-6
2 
 
Decrease IL-6, CXCL1, CCL3 (BAL fluid) 
mRNA (RT-PCR) Increase CSF, CSF3, LCN2, CXCL1
2
, 
BCL2
3
, BCL-XL
3 
 
Decrease BCL-2
2
, BCL-2/1
2
 
mRNA (Microarray) Increase DEFB4, S100A7, S100A12, IL-19, 
IL-1F9, DUOX2, CXCL1, CXCL5, CCL3, 
CXCL9, MUC1, PIGR, SCGB3A1 
 
(source: Aujla et al 2008; Sonnenberg et al 2010
2
, Zhang et al 2008
3
) 
Intestinal Epithelial cells 
Similarly to keratinocytes, IL-22 restored the integrity of a physically injured layer of epithelial 
cells (Brand et al 2006, Pickert et al 2009). This function could be inhibited by PI3K inhibitors 
suggesting that migration played a major part in would closure while proliferation may only 
contribute to a minor extent (Brand et al 2006). The study of the IL-22-/- mice confirmed that 
the regulation of the two innate defence proteins REGIIIβ and –γ (Zheng et al 2008) was 
completely dependent on IL-22 while the protein expression for S100A8 and -9 only halved 
(de Luca et al 2010). A second study identified that TLR5 triggering by flagellin was one of 
the upstream initiators of IL-22 expression and downstream REG protein induction 
(Kinnebrew et al 2010). Studying the REG family of proteins more closely an IL-22-
responsive element in the REGIa promoter region was identified (Sekikawa et al 2010). IL-
22 helped the IFNγ induced expression of the two surface molecules of LY6A,-C which when 
crosslinked participate in chemokine release (Flanagan et al 2008). It was also identified that 
IL-22 was able to induce several mucin genes (MUC1, 3, 10, 13) and mucin secretion 
(Sugimoto et al 2008). IL-22 was shown to induce mainly Lipocalin2 (LCN2) while MUC4, 
CCL20 and NOS2 were also up regulated in a microarray analysis of IL-22 exposed T84 
human colonic adenocarcinoma cells (Schulz et al 2008). An overview is given in the table 
below (Table 18). 
 Table 18: Function of IL-22 in intestinal epithelial cells  
Evidence IL-22 administration IL-22 blockade 
General Wound closure by migration
1,4 
Mucus production
8 
 
 
Protein  Increase IL8
1
,  
 
Decrease: REGIIIβ
2
, REGIIIγ
2
, S100A8
2
, S100A9
2
 
mRNA (RT-PCR) Increase IL8
1
, hDB2
1
, SOCS3
1
, REGIa
3,7
 
REGIIIβ
5,7
, REGIIIγ
5
, LY6A
6
, LY6B
6
, MUC1
8
, 
MUC3
8
, MUC10
8
, MUC12
8
, LCN2
9 
 
 
mRNA (Microarray) Increase MUC4
9
, CCL20
9
, NOS2
9
  
(Brand et al 2006
1
, de Luca et al 2010
2
, Sekikawa et al 2010
3
, Pickert et al 2009
4
, Kinnebrew et al 2010
5
, Flanagan et al 2008
6
, 
Zheng et al 2008
7
, Sugimoto et al 2008
8
, Schulz et al 2008
9
) 
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Endothelium 
Blood-brain-barrier endothelial cells were shown to be IL-22RA1 (Kebir et al 2007) but the 
addition of IL-22 showed no alteration in the expression of the tight junction proteins occludin 
or Zo1. 
Fibroblasts 
So far, four different studies have identified fibroblasts as an IL-22 target cell population. IL-
22 cultured subepithelial myofibroblasts were shown to have increased IL-19 and MMP1,-3 
protein production (Andoh et al 2005). Synovial fibroblasts responded to IL-22 by increased 
cell growth and CCL2 protein production (Ikeuchi et al 2005). Skin fibroblasts responded to 
IL-22 with weak STAT3 phosphorylation (Wolk et al 2009). Human ganglia fibroblasts 
responded to IL-22 with CXCL10 protein release. This was either further increased by 
addition of IFNγ or decreased by TNFα (Hosokawa et al 2009). An overview is given in the 
table below (Table 19). 
Table 19. Function of IL-22 in fibroblasts  
Evidence IL-22 administration IL-22 blockade 
General Cell growth
2 
STAT3 phosphorylation
3 
 
 
Protein  Increase IL-19
1
,MMP1
1
, MMP3
1
, CCL2
2
, 
CXCL10
4 
 
 
mRNA (RT-PCR)  
 
 
mRNA (Microarray) Increase MMP1
1
, MMP3
1
, MMP10
1
, CCL7
1
, 
CXCL1
1
, CXCL2
1
, CXCL3
1
, CXCL6
1
, IL-6
1
, 
IL8
1
, IL-11
1
, IL-13RA2
1
, LIF
1
, Follistatin
1
, 
Stanniocalin1
1
, SOCS2
1
, Amphiregulin
1
, 
Neuregulin1
1
, 
 
(source: Andoh et al 2005
1
, Ikeuchi et al 2005
2
, Wolk et al 2009
3
, Hosokawa et al 2009
4
) 
 
Specialised tissue cells 
Hepatocytes 
Hepatocytes are specialised cells which adjust several nutrient and mediator levels in the 
blood stream. In agreement with studies of epithelial cells, IL-22 facilitated reconstitution of a 
wounded layer of hepatocytes (Brand et al 2007). IL-22 showed to dampen aspartate 
aminotransferase (AST) and alanine transaminase (ALT) secretion (Yang et al 2010). IL-22 
was shown to induce LPS-binding protein (LPSBP) to a similar level as seen with IL-6 (Wolk 
et al 2007. This induction was further enhanced in combination with IL-1β and TNFα. 
Blocking IL-22 with IL-22RA2 was shown to block all LPSBP suggesting  that secretion of 
the protein was IL-22 dependent. Studying IL-22’s role during viral infection of the liver 
(Hepatitis B and C) showed that it only slightly reduced viral burden (Dambacher et al 2008) 
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as well as  demonstrated limited functional similarity to IFN but more functional similarity to 
IL-6 (Pagliaccetti et al 2010). In another study, administration of rIL-22 did not increase 
heptocyte proliferation but blockade of IL-22 led to a decrease in proliferation (Ren et al 
2010). Blockade of IL-22 also led to a reduction in TNF levels. An overview is given in the 
table below (Table 20). 
 
Table 20. Function of IL-22 in hepatocytes  
Evidence IL-22 administration IL-22 blockade 
General 
 
Wound closure
2
 Decreased proliferation
6
 
Protein  
 
Increase SAA
1
, LPSBP
5
 Decrease: AST
4
, 
ALT
4
 
Decrease: LPSBP
5
, TNFα
6
 
mRNA (RT-PCR) 
 
Increase SAA
1
, IL-6
3
,IL8
3
, TNFα
3
, SOCS3
3
   
mRNA (Microarray)   
( Wolk et al 2005
1 
, Brand et al 2008
2
, Brand et al 2007
3
, Yang et al 2010
4
, Wolk et al 2007
5
, Ren et al 2010
6
) 
 
Regulation by IL-22RA2 
While IL-22RA2 is known to bind IL-22 and block IL-22 signalling in vitro, very little is known 
about its occurrence and function in vivo (Table 21).  
Table 21. Evidence of IL-22RA2 expression during inflammation 
Model Evidence Function 
Mouse model of 
Infection  
mRNA up regulation 30 days post infection 
in the liver 
Unknown (Wilson et al 2010) 
   
Experimental Colitis 
model 
Drop of IL-22RA2 mRNA expression in the 
inflamed intestine 
Unknown (Wolk et al 2007) 
 
Clinical associations of Il-22 
Disease association 
Allergy 
With the identification of Th17 cells, allergic disorders were re-evaluated and shown to 
express their cytokines during phases of chronic and more severe phases of inflammation 
(Souwer et al 2010).  The specific increase in IL-22 but not IL-17 was first identified during 
chronic atopic dermatitis supporting the occurrence of a novel Th22 T cell subset (Nograles et 
al 2009, Trifani et al 2010, Duhen et al 2009, Eyerich et al 2009). Apart from atopic 
dermatitis, a selective increase of IL-22 and IL-22RA1 expression was also identified in 
nickel contact dermatitis, a non-IgE mediated allergic disorder (Ricciardi et al 2009, Larsen 
et al 2008). Early studies in allergic asthma showed that IL-17+ but especially IL-22+ cells 
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were increased in T cells from peripheral blood while the number of IFNγ remained 
unchanged (Zhao et al 2009). Also in experimental asthma, using an OVA-challenge mouse 
model, IL-22 appeared to be increase more than IL-17 (Wang et al 2009).  
Autoimmunity 
Patients with systemic lupus erythmatosus (SLE) were shown to have decreased serum IL-
22 expression which correlated with disease severity (Cheng et al 2009, Pan et al 2008). In 
the digestive system, IL-22 is associated with ulcerative colitis and Crohn’s disease. Early 
on, high levels of IL-22 (especially from CD4+Tcells) were identified in both conditions but 
the association of IL-22 was particularly significant in Crohn’s disease (compared to 
ulcerative colitis; Andoh et al 2005). This high expression of IL-22 blood and tissue was 
confirmed (Wolk et al 2007) and correlated with disease severity (Schmechel et al 2008, 
Veny et al 2009 published online 2009). A mouse model for inflammatory bowel disease 
showed that IL-22 lead to reduction of colon thickness and overall disease score (Sugimoto 
et al 2008). In another model, blockade of IL-22 significantly delayed the recovery from 
colitis (Neufert et al 2010). An EAE mouse model showed that myelin oligodendrocyte 
antigen (MOG) led to a IL-22 (IL-17a, IFNg) increase (Kreymborg et al 2007, Thessen-
Hedreul et al 2009). EAE still occurred when an IL-22 -/- knockout mouse was used 
(Kreymborg et al 2007). 
However, the bulk of studies have researched the occurrence of IL-22 in psoriasis. Psoriasis 
is an autoimmune disease of the skin characterised by increased growth and proliferation of 
skin cells. Early on, a link between the cytokine and this skin condition was identified (Wolk 
et al 2005). It was shown that IL-22 was up regulated in infiltrating T cells and not in 
circulating T cells. Interestingly, the skin was shown to have reduced IL-22RA1 mRNA 
expression in these patients (Boniface et al 2007). Especially in psoriasis vulgaris, high IL-22 
(and IFNg, IL-17a) was identified (Liu et al 2007, Lowes et al 2008). The relevance of IL-22 
in the disease was confirmed when administration of anti-IL-22 blocked the disease 
development of murine psoriasis-like disease (Ma et al 2008). A genetic study showed that 
polymorphisms of the IL-22 in the population were not associated to chronic plaque psoriasis 
(Weger et al 2009). Another presumed autoimmune disorder, Vitiligo, which affects the skin, 
showed to be significantly associated with IL-22 expression. This was especially true when 
vitiligo was active (Ratsep et al 2008). High levels of serum IL-22 were found in autoimmune 
hepatitis (Dambacher et al 2008) and Hashimoto thyroiditis patients (Figueroa-Vega et al 
2010). Patients with TNF-receptor-associated periodic syndrome (TRAPS) have a mutation 
in the TNFRSF1A gene which led to shedding of the TNFa receptor into the plasma thus 
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preventing normal TNFa signalling (Rezaei  2006) that was associated with increased levels 
of IL-22 (Nakamura et al 2010). 
Autoimmune diseases associated with infection 
Patients with chronic mucocutaneous candidiasis have reduced levels of IL-22 and IL-17a 
(Eyerich et al 2008) that correlated with the increased production of neutralising auto-
antibodies against IL-22 (91%), IL-17F (75%) and IL-17a (41%) (Kiesand et al 2010, Puel et 
al 2010). Similarly, in autoimmune polyendocrine syndrome type I, auto-antibodies against 
IL-22 were identified (Puel et al 2010).  In chronic sinusitis, decreased IL-22RA1 expression 
was associated with chronic disease and the development of nasal polyps (Ramanathan et 
al 2007) and it was later identified that polymorphisms in the IL-22RA1 gene highly 
correlated to disease severity (Endam et al 2009). An overview is given in the table below 
(Table 22). 
 
Table 22. IL-22 association in autoimmunity 
Disorder Evidence In Reference 
SLE Decreased IL-22  
Correlation to disease severity 
 
Human 
Human 
Cheng et al 2009  
Pan et al 2009 
Ulcerative colitis 
Crohn’s disease 
High levels of IL-22 
Correlated to disease severity 
IL-22 lowered disease score  
Delayed recovery when IL-22 is blocked 
Human 
Human 
Mouse 
Mouse 
Andoh et al 2005 
Schmechel et al 2008 
Sugimoto et al 2008 
Neufert et al 2010 
 
EAE 
 
MOG antigen causes IL-22 expression 
Not essential to disease development 
 
Mouse 
Kreymborg et al 2007 
Theussen-Hedreul et al 
2009 
 
Psoriasis 
 
High IL-22  
Blockade of IL-22 reduced disease severity 
 
Human 
Mouse 
Liu et al 2007 
 Ma et al 2008  
 
Vitiligo 
 
Associated with IL-22 expression 
 
Human 
Ratsep et al 2008 
Autoimmune 
hepatitis 
High IL-22 Human Dambacher et al 2008 
Hashimoto 
thyroiditis 
High IL-22 Human Figueroa-Vega et al 2010  
TNFRSF1A 
mutation 
High IL-22 Human Nakamura et al 2010 
Chronic candida 
infection 
Auto-antibodies against IL-22  Human 
 
Kiesand et al 2010 
Puel et al 2010  
Chronic sinusitis Defect in IL-22RA1 gene Human Endam et al 2009 
 
Infection 
Viral 
IL-22 production was increased during Hepatitis C infection (Dambacher et al 2008) and two 
single nucleotide polymorphisms (SNP) in the IL-22 gene were shown  to affect the 
treatment response and viral clearance in patients (Hennig et al 2007). Yet, a mouse model 
of Heptatitis B infection showed that IL-22 indicated only limited antiviral properties and the 
response was different from the structurally related IFN (Pagliaccetti et al 2010). The IL-22 
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response was much more similar to that of IL-6. HIV-1 patients had high levels of IL-22 
mRNA  and protein expression while exposed individuals had less (Misse et al 2007). A link 
between IL-22 and the induction of the HIV1 protective SAA was postulated. According to 
the hypothesis, IL-22 induces SAA which down regulates of CCR5 expression on dendritic 
cells and, thus, limits viral spread. Chronic persistence of the Theiler virus in the central 
nervous system was linked to the 12q15 chromosome locus (Bureau et al 1993). While the 
locus harbours many genes including the two cytokines IL-22 and IL26, a mouse model of 
Theiler virus infection showed more direct evidence. In the model, IL-22 controlled mortality 
during acute encephalomyelitis (Levillayer et al 2007). In the serum of patients with the skin 
rash, pityriasis rosea, presumed to be triggered by herpes simplex,  increased levels of IL-22 
were found (Gangemi et al 2009). An overview is given in the table below (Table 23). 
 
Table 23. Evidence of IL-22 association in viral infections 
Viral infection Evidence In Reference 
Hepatitis B IL-22 only limited antiviral activity Human Pagliaccetti et al 2010 
Hepatitis C Increased IL-22 
2 SNP in IL-22 gene affect positive treatment 
outcome 
Human 
Human 
Dambacher et al 2008 
Hennig  et al 2007 
HIV-1 High levels of IL-22 in infected patients 
IL-22 may induce SAA which lowers CCR5 
Human Misse et al 2007 
Theiler virus More efficient immune response which also leads 
to increased mortality 
Mouse Levillayer et al 2007 
Herpes simplex Increased IL-22 Human Gangemi et al 2009 
 
Bacterial 
Administration of Lipopolysaccaride (LPS), an endotoxin of gram-negative bacteria, led to 
the up regulation of IL-22 mRNA throughout the body (e.g. gut, thymus, spleen, lung, liver, 
kidney, stomach, heart; Dumoutier et al 2000). The gram negative bacteria Klebsiella 
pneumonia showed up regulation of IL-22 after 6 hours (Zheng et al 2008). Neutralisation led 
to the breakdown of tissue defences and systemic dissemination (Zheng et al 2008, Aujla et 
al 2008). This was only seen when IL-22 was blocked and not IL-17A (Aujla et al 2008). In a 
mouse model of mycobacterium tuberculosis (TB) infection, culturing macrophages with 
recombinant IL-22 improved their phagolysosomal fusion and their TB killing activity. In 
addition, it was shown that IL-22+NK cells helped to reduce the overall TB burden (Dhiman 
et al 2009). In a primate model of TB infection, homing of IL-22+ cells to the lung was 
observed at the late stage of infection (Yao et al 2010). A mouse model of Salmonella 
enterica infection showed that IL-22, together with IFN, was highly up regulated (Godinez et 
al 2008). In addition, protection was associated with IL-23 dependent IL-22 and not IL-17A 
(Schulz et al 2008). An overview is given in the table below (Table 24). 
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Table 24. Evidence of IL-22 association in bacterial infections 
Bacterial infection Evidence In Reference 
LPS Increase in IL-22 Mouse Zheng et al 2008 
Klebsiella 
pneumoniae 
Increase in IL-22 
Breakdown of tissue integrity when IL-22 blocked 
Mouse 
Mouse 
Zheng et al 2008 
Aujla et al 2008 
M. tuberculosis Improved phago-lyso-somal killing of 
macrophages 
Human Dhiman et al 2009 
Salmonella 
enterica 
Increase in IL-22 
Protection IL-23/IL-22 dependent not IL-17A 
Mouse 
Mouse 
Godinez et al 2008 
Schulz et al 2008 
 
Fungal 
A mouse model of candida albicans infection showed that IL-22 was critical as a first line 
defence while IL-17A and IL-17F were dispensable (de Luca et al 2010). IL-22 was shown to 
contribute to epithelial integrity and control the yeasts growth. Interestingly, it was further up 
regulated in the absence of a Th1 response. Blockade of IL-22 or IL-23 led to a decrease in 
T cell mediated defence against fungal hyphae (de Luca et al 2010). The saliva of IL-23p19 -
/- knockout mouse exhibited  lowered antifungal activity (Conti et al 2009). 
Protozoan 
Studying severe malaria anemia research identified that a polymorphism in the IL-22 (708th 
position after ATG) was associated with protection which remained significant after 
stratification of the cohort according to  ethnicity (European, African) (Koch et al 2005). 
Infection and induction of ileitis by the protozoan Toxoplasma gondii showed that IL-22 was 
associated with inflammation. In addition, IL-22, and not IL-17A, was IL-23 dependent and 
both cytokines were inversely regulated during the infection (Munoz et al 2009). Blockade of 
IL-22, therefore, displayed less intestinal pathology while the parasite burden remained 
unchanged. The decreased pathology was associated with overall reduced IL-17a, IL-17f, 
IFNγ and TNFα expression (Wilson et al 2010).  
 
Other 
Transplantation 
In Graft versus Host disease, high levels of IL-22RA2 (together with IL2, IL2RA, AIRE) were 
found to be expressed in patients PBMCs (Yang et al 2007). A mouse model showed that 
transplants were rejected quicker in IL-22 deficient mice whereas in the wild type mice IL-22 
production was identified to be in Mac3+CD11b+ cells and not lymphocytes (Kapessidou et al 
2008).  
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Cancer 
In two forms of cancer, ALK+ anaplastic large cell lymphoma and non small lung carcinoma, 
expression of IL-22 and IL-22RA1 was shown to be linked to increased survival in mice 
(Zheng et al 2008, Bard et al 2008). Recently, a single nuclear polymorphism (rs1179251) in 
IL-22 was associated with colon cancer (Thompson et al 2010). 
Arthritis 
Arthritis can be caused by age and injury but can also have autoimmune triggers. In arthritic 
joints of patients, an increased number of IL-22+ and IL-17A+ T cell were found which were 
inversely related to Treg cell numbers (Nistala et al 2008). 
Asthma, COPD, ARDS, Pulmonary Sarcoidosis 
Reduced levels of IL-22 were found in the epithelial lining fluid of ARDS patients (Whittington 
et al 2004). In asthma, early on, the 12q15 locus was identified in large scale genome 
association studies (Ober et al 1998, Satsangi et al 1996, Duerr et al 1998, Barnes et al 
1996). While only two cytokine genes are found in this locus (IL-22, IL-26), the locus 
contains a further 66 genes (including 8 pseudogenes). Culturing T cells derived from 
peripheral blood ofasthmatic patients showed no alteration in IL-22 expression upon 
activaton (anti-CD3/CD28 and IL-23) compared to healthy individuals (Wong et al 2009). The 
phenotype of CD4+ T cells from peripheral blood of asthmatics appeared to be mixture of IL-
17A/IL-22 and IL-4 producing T cells (Cosmi et al 2010). In a mouse model for ventilation 
induced injury, IL-22 induced SOCS3 and reduced and lowered CXCL2, IL-6, and MMP9 
and the overall biotrauma (Hoegl et al 2010). The causes of pulmonary sarcodis are 
unknown but it was shown that the bronchoalveolar lavage fluid of patients contained far less 
IL-22 protein as compared to that of healthy individuals (Whittington et al 2004).  
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Rationale 
 
Allergy is an adverse immune reaction to an otherwise harmless environmental substance. 
The inflammatory response is characterised by IgE-dependent mast cell activation, 
eosinophil infiltration, and Th2-cytokine release causing clinical symptoms such as itch 
(atopic dermatitis), runny nose and watery eyes (allergic rhinitis) or wheezing and shortness 
of breath (asthma).  
While the predisposition to produce IgE and the inability to regulate the ensuing Th2 
response are a hallmark of the allergic response, non-immune contributions such as the role 
of a defective epithelium are increasingly recognised to play a role in disease progression. 
This is particularly evident, in asthma, where a potential reactivation of the EMTU may 
explain the observed aberrant tissue remodelling. Recent data also indicate a potential role 
of other T cell subsets in allergy and asthma. Whereas seasonal allergic rhinitis displays a 
classic Th2-driven response (e.g. Th2 cytokine expression and eosinophil activation; Durham 
1992 & 1993), other atopic disorders are not as clearly defined. In atopic dermatitis, not only 
Th2 cells increase during inflammation but also a delayed Th1+Th2 cell response can be 
observed (Yamanaka and Mizutani 2011). Similarly in asthma, the inflammatory response 
may not always be characterised Th2 cytokine expression and eosinophilic infiltration (e.g. 
neutrophilic asthma). Similarly, the chronicity of inflammation may alter the normally Th2 
driven response leading to an increased T helper subset diversity.  
IL-22 recently gained attention in chronic atopic dermatitis, where it was selectively 
increased by a new T helper cell subset, called Th22. The cytokine IL-22 is structurally 
related to IL-10 and IFN. IL-22 signals through the IL-22RA1/IL-10RB signalling complex 
and is regulated by IL-22RA2, a soluble decoy receptor that binds IL-22 with high affinity. IL-
22 is believed to be predominantly expressed by CD4+ T cells while IL-22RA1 has been 
mainly identified on structural cells of epithelial origin. Many of IL-22’s functions relate to the 
induction of pro-inflammatory mediators within epithelial cell, yet IL-22 has also been shown 
to regulate inflammation by dampening eosinophilic infiltration and contribute to tissue 
regeneration and repair.  
While expressed in atopic dermatitis, the role of IL-22 in human allergy and asthma remains 
poorly understood. Outstanding questions therefore include: Is IL-22 expressed in human 
allergy and asthma? What is the dominant T cell subset expressing IL-22? Do Th22 cells 
represent a distinct T helper cell subset? What is the biological role of IL-22 in allergy and 
asthma? 
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Hypothesis, Aims, and Objectives 
Hypothesis 
 
Hypothesis 1:  
Interleukin-22 is a T cell cytokine that is expressed during human allergic inflammation. 
 This was tested by measuring Interleukin-22 and its receptors in bronchoalveolar 
lavage and skin biopsies after local allergen provocation 
 
Hypothesis 2:  
Interleukin-22 is produced by distinct Th22 cells as well as other T cell subsets (Th1, Th2, 
Th17).  
 This was tested by measuring Interleukin-22 production by peripheral-blood-
mononuclear cells and T cells from peripheral blood, as well as T cell lines and 
clones derived from bronchial biopsies 
 
Hypothesis 3:  
Interleukin-22 is involved in tissue regeneration and repair. 
 This was tested by evaluating the expression of Interleukin-22 receptors on human 
epithelial, smooth muscle and fibroblast lung cell lines and examining the influence of 
IL-22 on epithelial wound healing. 
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Aims and Objectives 
 
In relation to Hypothesis 1: IL-22 is expressed in allergic inflammation 
 Local segmental allergen challenge was performed in atopic asthmatics and controls. 
Bronchoalveolar Lavage was collected before and after allergen challenge and IL-22 
concentrations were compared with levels of IFN, IL-5, and IL-17 as well as BAL 
eosinophil counts. 
 Intradermal allergen challenge was performed in atopic allergic subjects. Cutaneous 
biopsies taken at 8 hours post challenge were analysed for IL-22 and its receptors. 
Results were compared with a control challenge using allergen diluent. 
 
In relation to Hypothesis 2: IL-22 expression in human T cells 
 Human peripheral-blood-mononuclear cells from grass pollen allergic subjects were 
cultured with Timothy-grass (Phleum pratense) allergen extract for 6 days. IL-22 
expression was determined by ELISA and flow cytometry. Results for IL-22 and other 
cytokines were compared with PBMC [cultures] from non-atopic healthy controls. 
 “Naive” (CD4+ CD45RA+) T helper cells were purified from PBMCs of grass pollen 
atopic donors. Expression of IL-22 and other cytokines after 2 weeks of culture in 
Th22-polarising conditions (IL-6 + TNF) was compared with IL-22 expression under 
Th1-polarising conditions (IL-12, IFN, IL-4). 
 Freshly purified “memory” (CD4+ CD45RO+) T helper cells were obtained from 
PBMCs of normal healthy donors by negative selection. CD4+CD45RO+ cells were 
enriched for distinct chemokine receptors (CCR4, CCR6, CCR10) and putative novel 
Th22-associated receptors (FGFR2, PDGFR, TIE1). The capacity of the enriched 
cells to produce IL-22 and Th1/Th2 and Th17 cytokines was examined by flow 
cytometry. 
 T cell lines and clones obtained from bronchial biopsies of allergic and non-allergic 
asthmatics were examined by flow cytometry. IL-22 expression and co-expression 
with Th1, Th2, and Th17-associated cytokines were examined by intracellular staining. 
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In relation to Hypothesis 3: IL-22 is involved in tissue regeneration and repair 
 Structural cells from human lung were examined as potential target cells for IL-22. 
Cell lines from human lung epithelium, smooth muscle, and fibroblasts were 
examined for expression of IL-22 Receptors (IL-22RA1, IL-22RA2) by Western Blot 
and Flow cytometry. IL-22 Receptor regulation in response to stimulation by IL-22 
and other T cell derived cytokines were analysed by RT-PCR and Flow cytometry. 
 A human in vitro model of bronchial epithelial wound closure was developed to 
assess the potential function of IL-22 in regeneration and repair. Potential 
antagonism of IL-17 on IL-22 on wound healing was assessed in the same system 
 Novel assays were developed to assess the mechanism of the effects of IL-22 on 
epithelial cell wound closure. These included quantifying epithelial cell proliferation 
and survival (reduction in apoptosis) 
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Materials and Methods 
1. IL-22 expression in allergic inflammation 
1.1. Local bronchial segmental allergen challenge 
Participants 
The study was approved by the ethics committee of the Royal Brompton and Harefield 
Hospital NHS Trust and written informed consent was given prior to the study. All study 
participants were selected using strict inclusion and exclusion criteria (Table 25). Regular 
use of inhaled gluocortico-steroids was discontinued 2 weeks before the start of the study 
and none of the participants required use of leukotreine receptor agonists. Note: For more 
detail on individual patient data please refer to appendix (Table 67, page Error! Bookmark 
not defined.). 
Table 25. Inclusion and exclusion criteria for participants of the bronchial segmental allergen 
challenge  
Inclusion Criteria Exclusion criteria 
Asthma (defined by clinical history, reversibility of airflow 
obstruction, and increased methacholine airway 
responsiveness) 
Atopy (against timothy grass pollen (Phleum pratense) or 
house dust mite (Dermatophagoides pteronyssinus), 
confirmed by positive skin prick test [5mm] and detectable 
allergen-specific IgE [RAST IU/ml]) 
 
Smoker 
Low Resting FEV1 (less than 70% predicted) 
Oral glucocortico-steroid use (within 6 month prior to the 
study) 
Allergen immunotherapy (within 5 years prior to the study) 
Neither skin prick test positivity [5mm] or detectable 
allergen-specific IgE [RAST IU/ml]) 
 
Segmental allergen challenge, Spirometry and Fibreoptic bronchoscopy 
Participants were admitted to hospital for 24 hours. Normal values for forced expiratory 
volume (FEV1) were predicted based on the participant’s age, sex, height, weight and 
ethnicity (Quanjer et al 1993) and measured before and after allergen provocation. Broncho-
alevolar lavage was taken immediately prior and 24 hours after allergen provocation. The 
peak expiratory flow rate was monitored hourly for the first 8 hours and then at 22 and 24 
hours after challenge.  
Bronchoalveolar lavage processing  
The BAL was filtered through sterile gauze (50μm mesh), centrifuged at 1300rpm for 6 
minutes and stored at -80C for later use.   
Eosinophil counts 
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The insoluble fraction of the BAL was stained for eosinophils using a May-Gruenwald-
Giemsa stain (Fischer-Scientific ES8150). In brief: 
The insoluble fraction of the BAL was re-suspended in Roswell Park Memorial Institute 
medium (RMPI 1640) and two drops applied to a microscope slide and smeared across 
using a cover slide. The slide was briefly air dried and placed for 30 seconds in Methanol. 
One drop of May-Gruenwald stain was then applied and left to stain for 5 minutes. The 
staining solution was then displaced using oxidising May-Gruenwald Wright-Giemsa buffer 
mixture and left for 3 minutes. The slides were then placed for 14 minutes in Giemsa 
Stain/Buffer mixture, then rinsed with Wright-Giemsa staining buffer for 2 minutes and left to 
air dry. The slides were then examined under light microscopy. Eosinophils were 
characterised based on a blue cytoplasm, blue to dark purple nuclei, and red to orange-red 
granules. 
Cytokine ELISA 
Commercially available ELISA assays were obtained from R&D Systems (Table 26) and 
used according to the manufacturer’s instructions. In brief: 
MaxiSorp 96-well plates (Nunc) were coated with 100μl per well (1/180 Phosphate buffered 
saline (PBS) diluted) capture antibody and left overnight at room temperature. Plates were 
washed 3 times with wash buffer (0.05% Tween-20 [Sigma P1379] PBS) and blocked for 1 
hour using filtered 1% BSA PBS. Plates were washed 3 times and cytokine standards and 
samples were added for 2 hours. Plates were washed again 3 times and 100μl of (1/180 1% 
Bovine serum albumin (BSA) PBS-diluted) detection antibody was added and left to bind for 
2 hours. Plates were washed 3 times and 100μl of (1/10 in 1%BSA PBS-diluted) 
Streptavidin- Horseradish peroxidase (HRP) was added per well for 20 minutes. Plates were 
washed again 3 times and 100μl of 5,5-Tetramethylbenzidine (TMB) substrate solution was 
added and left in the dark for 20 minutes. The reaction was stopped using 100μl of 1.8M 
sulphuric acid and analysed immediately using a Teacan Sunrise optical plate reader. 
Optical density readings were obtained at 450nm and 540nm (for background correction) 
and a standard curve was plotted. The equation of the line was determined for standards 
within linear range and used to calculate the concentrations of unknown samples. 
Table 26. Cytokine ELISA assays utilised throughout the study 
Name Company ID Detection Limit 
Human IFNγ Duoset R&D Systems DY285 15pg/ml 
Human IL-5 Duoset R&D Systems DY205 8-15pg/ml 
Human IL-17 Duoset R&D Systems DY317 15pg/ml 
Human IL-22 Duoset R&D Systems DY782 15pg/ml 
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IL-22RA2 ELISA 
The IL-22RA2 Sandwich ELISA was developed using two anti-IL-22 antibodies binding 
different IL-22 target epitopes. The only available antibody combination consisted of 2 
polyclonal antibodies raised both in goat (Table 27). 
Table 27. Antibodies incorporated in the IL-22RA2 sandwich ELISA design 
Name Company ID Epitope Stock Concentration  
IL-22RA2 (T16) Santacruz biotechnology sc-67640 Internal region 200μg/ml 
IL-22RA2 (N16) Santacruz biotechnology sc-67637 Near N-terminus 200μg/ml 
IL-22RA2 (T16)-BIOTIN created during PhD Not available Internal region 1mg/ml 
   
Validation of IL-22RA2 antibodies 
Maxisorp ELISA plates (NUNC) were coated overnight with 100μl of PBS containing either 
different concentrations of recombinant IL-22RA2-Fc chimera (R&D) or protease free bovine 
serum albumin (PAA K45-012). The ELISA was carried out as previously described. For 
detection a horse anti-goat-biotin-labelled secondary antibody (Vector BA-9500) diluted in 
1%BSA PBS was incorporated.  
 
The results showed that increasing concentrations of IL-22RA2 antibodies led to a liner 
increase in optical density (OD) (Figure 7A-B). 
 
Biotin labelling 
Figure 7. Validation of -human IL-22RA2 antibody (N16, T16, T16-biotin) binding
by direct ELISA using plate bound recombinant L-22RA2.
A) N16 antibody B) T16 antibody C) T16-Biotin labelled antibody
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To label the IL-22RA2 (T16) antibody with biotin its concentration had to be increased from 
200μg/ml to 1mg/ml. To do so 30kDa cut off spin filter tubes (Millipore Amicon) were 
employed. The centrifugation was carried out at 2500rpm and a total volume of 500μl was 
reduced to 100μl giving a concentration of 1mg/ml. The Biotin labelling was carried out using 
the Biotin-XX Microscale Protein labelling kit (Invitrogen B30010). In brief: 
100μl of 1mg/ml IL-22RA2 (T16) antibody was transferred to a supplied reaction tube. 10μl 
of 1M sodium bicarbonate was added into the tube and mixed by pipetting. 10μl of deionised 
water was added to one vial of reactive biotin. The amount of required reactive biotin was 
calculated using following formula:  
             
             
                  
     
                        
In this case 100μl of 1mg/ml IL-22RA2 antibody (MW= 144kDa) and a molar ratio of 18 (see 
manufacturer guidelines) required 0.84μl reactive biotin.  
      
        
           
     
          
This amount was transferred into the reaction tube and mixed by pipetting and left to react at 
room temperature for 15 minutes. The reaction solution of 100μl was split between 2 
previously prepared and activated gel resin spin filter tubes. The two spin filter tubes were 
then centrifuged at 16000g for 1 minute. The biotin-labelled antibody was then validated by 
direct ELISA (Figure 7C, page 72).  
IL-22RA2 Sandwich ELISA 
The sandwich ELISA was carried out as previously described using the IL-22RA2 (N16) 
antibody as capture and the IL-22RA2-Bition antibody for detection. 
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The results showed that without optimisation, the sandwich ELISA produced a weak non-
linear signal in ng/ml range but was unable to detect IL-22RA2 in pg/ml range (Figure 8A-B).  
 
 
Changes in antibody concentrations, detection time, streptavidin-peroxidase ratios (Figure 
9A-B) led to an improved ELISA protocol (Table 28) enabling detection of increasing rIL-22-
RA2-Fc concentrations of 8-500ng/ml in a liner fashion (Figure 9C). 
Table 28. Final IL-22RA2 Sandwich ELISA protocol 
ELISA steps Reagent Company Concentration Incubation time 
Capture antibody hu IL-22RA2 SCBT (sc67640) 1:500 (400ng/ml) Overnight  
Detection Antibody  hu IL-22RA2-biotin Based on SCBT (sc67637) 1:1000 (1μg/ml)  4 hrs 
Streptavidin-Enzyme Extravidin-Peroxidase Sigma (E2886) 1:1000 45 min 
Enzyme substrate TMB liquid solution Sigma (T0440) neat 30 min (max) 
 
1.2. Intradermal allergen challenge 
Figure 8. Detection of fluid phase rIL-22RA2 in pg/ml and ng/ml range using a the
sandwich IL-22RA2 ELISA protocol
A) pg/ml rIL-22RA2 range B) ng/ml rIL-22RA2 range
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Figure 9. Optimisation of antibody concentrations and detection time within the
sandwich IL-22RA2 ELISA protocol
A) Detection antibody concentrations B) Detection time C) Final ELISA protocol
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Participants 
The study was approved by the ethics committee of the Brompton and Harefield Hospitals 
NHS Trust and informed written consent was obtained prior to the study. Participants were 
classified using their clinical history, current allergen skin prick responses and allergen 
specific serum IgE concentrations. The inclusion and exclusion criteria are listed in table 29. 
Note: For more details on individual patients please refer to appendix (Table 68, page Error! 
Bookmark not defined.). 
 
 
 
 
Table 29. Inclusion and exclusion criteria for participants of the intradermal allergen 
challenge study 
Inclusion Exclusion 
Age 18-55 years 
Atopic group  
Seasonal allergic rhinoconjunctivitis for at least 2 years 
Positive skin prick response (>3mm) and RAST levels greater 
> IU/ml 
Normal control group 
No clinical history of allergy, no skin prick response, no RAST  
Atopic group 
History of serious allergic responses incl. anaphylaxis 
History of immunotherapy within last 5 years 
No use of anti histamine 10 days prior to the study 
Severe atopic dermatitis or asthma requiring medication 
Both groups 
The use of prednisolone or other immunosuppressive agents 
Pregnant or breastfeeding 
Evidence of alcohol or drug abuse 
Any significant systemic disease 
 
Intradermal allergen challenge, Late phase response and Punch biopsies 
The intradermal challenge was performed by medical staff at the Brompton hospital outside 
the UK pollen season. 10 biological units of timothy grass extract in 0.02ml (ALK Abello, 
Denmark) were given to the extensor surface of one forearm. An injection of allergen 
diluents was administered to the opposite forearm. After 8 hours, the size of the response 
was measured. Under local anaesthetic (2% Lidocaine), a 4mm biopsy was removed from 
the challenge site using a sterile punch, forceps and scalpel. The wound was then closed 
using two interrupted 5.0 Nylon sutures. 
Biopsy processing  
Cut into half, one part of the biopsy was placed into 4% paraformaldehyde containing PBS 
for 2 hours and then transferred into 15% sucrose PBS for 1 hour. Both treated and 
untreated halves were embedded in drops of optimal cutting temperature (OCT) medium 
(Tissuetek, England), placed on labelled cards and dipped into liquid-nitrogen cooled 
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isopentane solution (BDH 103614T). From these 5 µm thin tissue sections were cut using a 
Bright OTF Cryostat (Bright Instrument Company, UK) and placed on Superfrost Plus Gold 
microscope slides (BDH chemicals, UK). Slides destined for acetone fixation were left for 10 
minutes in ice-cold acetone and then briefly air dried. Acetone and previously 
paraformaldehyde fixed tissue slides were then wrapped in aluminium foil and stored at -
80C. 
Eosinophil counts 
Eosinophils were detected using a mouse anti-human Major Basic Protein antibody (clone 
BMK-13, donated by Barry Kay & Julie Barkans) at 1/30 dilution and detected using the 
Vector anti mouse horseradish-peroxidase detection kit. The eosinophils were detected and 
quantified by light microscopy. 
 
Immunofluorescent staining 
General fluorescent staining protocol 
Slides were defrosted at room temperature and each tissue section was encircled using 
water resistant ImmEdge pen (Vector Laboratories H-4000). Slides were pre-treated for 30 
minutes in 0.1% saponin containing PBS. Slides were blocked using 20% donkey serum 
(Jackson 017-000-01) PBS for 30 minutes. The serum was tipped off and the primary 
antibodies diluted in 5% normal human serum PBS were added for 1 hour. Slides were 
washed 3 times for 5 minutes in 1X PBS before the second layer of antibodies (e.g. donkey 
anti-goat-biotin) diluted in 10% normal human serum PBS were added for an additional 1 
hour. The wash steps were repeated and the third layer was added (e.g. streptavidin-Alexa 
Fluor 594) for 30 minutes in the dark. (Note: Streptavidin-Alexa conjugates were centrifuged 
at 13000rpm for 3min before use). Slides were washed again and 1 drop of Vectashield 
containing 4',6-diamidino-2-phenylindole (DAPI) was added and the slide and covered with a 
cover slip. Slides were analysed using a Nikon Eclipse E400 Fluorescent Microscope. Digital 
images were obtained and further analysed using Lucia 4.8 software. Average cell counts 
were derived from >10 images obtained through a checker board system and converted 
from cells per section to cells per mm2 (Table 30). Note: Please refer to table 31 for 
complete list of antibodies used. 
Table 30. Conversion factors for histological cell counts 
Magnification Dimension of the image (mm) Area of the image (mm
2
) Multiplication factor (cells/mm
2
) 
100x 1.19 x 0.940 1.1186 0.9 
200x 0.60 x 0.474 0.2844 3.5 
400x 0.30 x 0.237 0.0711 14 
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Table 31. Antibodies and reagents used in the immunofluoresent analysis of allergen 
challenged skin  
Name Species Company ID Concentration used 
α-IL-22 Goat polyclonal  ABcam AB18498 Various (20μg/ml) 
α-IL-22 Goat polyclonal  Santa Cruz Biotechnology Sc-14437 Various (20μg/ml) 
α-IL-22 Goat polyclonal  R&D Systems AF782 Various (20μg/ml) 
α-IL-22RA1 Goat polyclonal  Santa Cruz Biotechnology Sc-67640 1/100 (2μg/ml) 
α-IL-22RA2 Goat polyclonal  Santa Cruz Biotechnology Sc-67637 1/100 (2μg/ml) 
α-CD3 Mouse monoclonal  Dako M7254 1/15 
α-CD3 Rabbit polyclonal  Abcam ab28364 1/10 (200μg/ml) 
α-CD31 Mouse monoclonal  Dako M0823 1/40 
α-CD31 Rabbit polyclonal  Abcam ab28364 1/100  
α-Vimentin Mouse monoclonal  Dako M7020 1/100 (0.27μg/ml) 
α-Vimentin Goat polyclonal  Abcam ab89996 1/200 (5μg/ml) 
α-CD68 Mouse monoclonal  Dako M0718 1/26.5 (20μg/ml) 
α-Neutrophil elastase Mouse monoclonal  Dako M0752 1/100 (1.1μg/ml) 
α-Mast cell tryptase Mouse monoclonal  Dako M7052 1/42.5 (2μg/ml) 
α-Major basic protein Mouse monoclonal  AbD Serotec 4180-2008 1/100 (2μg/ml) 
α-HSP47 Mouse monoclonal  Enzo Life Sciences ADI-SPA-470-D 1/800 (1.25μg/ml) 
α-alpha SMA Mouse monoclonal  Dako M0851 1/800 (87.5pg/ml) 
Goat isotype Goat polyclonal R&D Systems AB-108-C Various 
Mouse isotype Mouse monoclonal Santa Cruz Biotechnology sc-3877 Various 
Rabbit isotype Rabbit polyclonal Abcam ab125938 various 
α-goat IgG-BIOTIN Donkey polyclonal Jackson 705-065-003 1/170 
α-mouse IgG-BIOTIN Goat polyclonal Vector BA-9200 1/300 (5μg/ml) 
α-rat IgG-BIOTIN Goat polyclonal Vector BA-9400 1/300 (5μg/ml) 
α-rabbit IgG-TRITC Swine polyclonal Dako R0156 1/200 (7.5μg/ml) 
α-mouse IgG-FITC Rabbit polyclonal Dako F0261 1/30 (13.3μg/ml) 
α-goat IgG-FITC Rabbit polyclonal Dako F0250 1/30 (1μg/ml) 
Streptavidin-A488 - Molecular Probes S11223 1/1250 (1.6μg/ml) 
Streptavidin-A594 - Molecular Probes S11227 1/400 (5μg/ml) 
 
 
Validation of IL-22 antibodies 
Memory CD4+ T cells were obtained from peripheral blood and polyclonally activated as 
previously described. Using a Shendon-3 cytospin centrifuge, 100μl of 0.3x106 cells/ml cell 
suspension were added to each cytospin holder. Each holder contained filter paper, 
microscope slide and cytospin funnel and was centrifuged for 3 minutes at 450rpm. The 
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slides were air dried, fixed for 15 minutes in 4% paraformaldehyde (BDH 294474L) PBS and 
transferred into 15% sucrose (BDH 102747E) PBS for 15 minutes. The slides were then 
transferred to a second sucrose solution for 15min before being rinsed in PBS and dried 
overnight using an oven (at 37°C). The slides were then checked by light microscopy for 
successful cell adherence and intact cell morphology by staining two randomly selected 
slides with 2 drops of Harris haematoxylin solution (VWR 351945S). Successful cytospins 
were wrapped in aluminium foil and stored at -80°C. 
 
 
IL-22 antibodies were validated using paraformadehyde-fixed cytospin preparations of 
activated peripheral blood CD4+CD45RA- T cells (Figure 10). The results showed that a 
small proportion of memory T cells stained positive using any of the three anti-human IL-22 
antibodies after permebelisation (saponin treatment).  
 
  
B) Saponin Permebealisation Treatment
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Figure 10. IL-22 Immunofluorescent staining of cytospin preparations of polyclonally
stimulated (PMA/Ionomycin) and paraformaldehyde-fixed peripheral blood CD4+ CD45RO+
T cells 
A) Regular Immunofluorescence staining protocol B) pre-treatment of slides  with Saponin. 
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2. IL-22 expression in T cells  
2.1. from peripheral blood 
2.1.1. long term allergen PBMC culture 
Participants 
Study participants were recruited by the medical staff at the Brompton hospital (London, UK) 
based on their clinical history of allergic rhinitis, positive timothy grass pollen skin prick test, 
and significantly elevated timothy grass specific serum IgE levels. Recruited normal healthy 
control participants had no reported history of allergy. In addition normal control participants 
tested negative for common allergens by skin prick testing, had no elevated levels of 
allergen specific IgE or total IgE. Prior to the study all participants had given written informed 
consent.  For more details on individual patients please refer to appendix (Table 69, page 
Error! Bookmark not defined.). 
PBMCs from peripheral blood 
Blood was taken by medical staff at the Brompton hospital and transferred within 30 minutes 
to the laboratory for PBMC isolation by Ficoll-Paque separation. In brief: 
The blood was diluted 1:4 using sterile PBS and 30ml was layered on top of 15ml of Ficoll-
Paque Plus (GE 17-1440-03) in 50ml Falcon tubes and then centrifuged at 2000 rpm for 25 
minutes (without brakes) inside swing-buckets (Hettich Rotina 420R centrifuge).  After 
centrifugation the PBMC layer was taken off using a sterile plastic dropper and collected in a 
new 50ml falcon tube. The dense PBMC solution was diluted using PBS and centrifuged at 
1500rpm for 10minutes. The PBS was discarded and the cell pellet suspended in fresh PBS 
and centrifuged once more at 1500rpm for 10min. After the final wash, the cell pellet 
suspended in a small volume of PBS and counted using a haemocytometer. 
In vitro culture 
PBMCs were cultured for 6 days in RPMI-1640 +L-Glutamine (Invitrogen/Gibco 52400) 
substituted with 5% human AB Serum and 1/10 diluted Penicilin/Streptomycin Solution 
(Invitrogen 15140-122). Depending on the condition the tissue culture media contained 
either no stimulus, 5μg/ml whole Phleum pratense extract (ALK-Abello 11372), 10μg/ml PHA 
(Sigma-Aldrich L1668), 10μg/ml Tuberculin purified protein derivative (PPD) (Statens Serum 
Institute 2390). 
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[methyl3H]-Thymidine incorporation 
Using a 96-well U-bottomed plate (Nunc 167008) 5x105 PBMCs were added to each 96- well 
in a total volume of 200μl tissue culture media and incubated at 37°C with 5%CO2. After 6 
days, 20 μl of 1/20 RPMI-diluted [Methyl-H3]-Thymidine solution (5mCi/185 MBq; MP Bio 
2405905) was added to each well. After 16hrs at 37°C the cells were harvested using a 96-
well plate harvester (Tomtec Harvester 96 Mach III-M). Before harvesting, the harvester was 
washed twice using the wash-aspirate program and an empty 96 well plate. Then a filter mat 
(PerkinElmer 1450-421) was added and pulse-washed. The empty plate was exchanged 
with the sample plate and the cells were pulsed onto a filter mat using the pulse-wash 
program. The filter mat was removed from the harvester and left to dry for 1 hour at room 
temperature. After air drying, the filter mat was inserted into a small plastic bag (PerkinElmer 
1450-432) together with 4 ml of Scintillation fluid (PerkinElmer 1205-440) and sealed using 
an electric heat sealing machine (Hulme Martin). The scintillation fluid was distributed evenly 
across the filter mat using a roller. Radioactivity was measured using a Scintillation counter 
(Wallac Trilux 1450 Microbeta counter) and background corrected. 
Cytokine ELISA 
100μl of PBMC culture supernatant was analysed as previously described (see Method 1.1, 
page 71) 
Flow Cytometry 
Activation 
Cells were washed twice in fresh culture media and re-suspended at 1x106 cells/ml. Using a 
24-well plate (NUNC) cells were polyclonally activated for 6 hours using 20ng/ml phorbol 
myristate acetate (PMA) and 1μg/ml ionomycin. In addition 0.6μl/ml GolgiStop was added 
from the start and 1μl/ml GolgiPlug after 2 hours of culture to stop protein secretion. 
Staining and fixation 
200μl containing 2x105 cells were transferred per well into a 96-well plate. The plate was 
centrifuged at 1500rpm for 5 minutes and the media removed. 20μl of Fc blocking solution 
(1/10 diluted Mitenyi Fc block stock solution) was added to per well and left in the dark for 20 
minutes at room temperature. Surface FACS antibodies (e.g. CD4 and CD8) and their 
respective isotype controls were added into each well at a ratio of 1/20 and left for 30 
minutes in the dark at 4C. The plate was washed using 250μl Perm/Wash buffer per well 
and centrifuged at 1500rpm for 5 minutes. The Perm/Wash buffer was replaced with 100μl of 
BD Cytofix/Cytoperm solution and left for 20 minutes to incubate in the dark at 4C. The 
plates were washed twice with 250μl Perm/Wash buffer and the intracellular FACS 
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antibodies were added at a ratio of 1/20 into final volume of 20μl of Perm/Wash buffer. The 
cells were left in the dark for 30 minutes at 4C and then washed twice more using 250μl 
Perm/Wash buffer. The cells were then fixed in 200μl BD Cellfix solution (BD 340181) and 
stored at 4C overnight. Individual FACS antibodies used are given in the table below (Table 
32). 
Table 32. FACS antibodies used in the analysis of T cells derived from allergen PBMC co-
cultures 
Name Species Company Clone ID Concentration used 
α-CD4-PE CY7 Mouse IgG1 BD Bioscience SK3 557852 1 in 20 
α-CD8-Amcyan Mouse IgG1 BD Bioscience SK1 339188 1 in 20 
α-IFN-V450 Mouse IgG1 BD Bioscience B27 560371 1 in 20 
α-IL-4-A488 Mouse IgG1 BD Bioscience 8D4-8 557990 1 in 20 
α-IL-5-PE Rat IgG2a BD Bioscience JES1-39D10 554489 1 in 20 
α-IL-9-PERCP CY5.5 Mouse IgG1 BD Bioscience MH9A3 561461 1 in 20 
α-IL-17A-A488 Mouse IgG1 R&D Systems 41802 IC3171A 1 in 20 
α-IL-22-PE Mouse IgG1 R&D Systems 142928 IC7821P 1 in 20 
α-IL-22-APC Mouse IgG1 R&D Systems 142928 IC7821A 1 in 20 
Isotype-PE CY7 Mouse IgG1 BD Bioscience MOPC-21 557872 1 in 20 
Isotype-Amcyan Mouse IgG1 BD Bioscience X40 339185 1 in 20 
Isotype-V450 Mouse IgG1 BD Bioscience X40 642268 1 in 20 
Isotype-A488 Mouse IgG1 R&D Systems G94-56 554008 1 in 20 
Isotype-PE Rat IgG2a BD Bioscience R35-95 554689 1 in 20 
Isotype-PERCP CY5.5 Mouse IgG1 BD Bioscience MOPC-21 550795 1 in 20 
 
Acquisition and analysis 
The fixed cells were assayed using a FACS Canto II machine. Lymphocytes were pre-
selected using the forward and side scatter. Fluor chrome compensation was carried out 
using the auto compensation setup of the FACS Canto machine. The cytometer settings 
were saved and used for all acquisitions. In total, 10000 cells were acquired and analysed 
using the BD FACS DIVA software.  
2.1.2. polarised naive T cells 
T cell isolation from PBMCs 
PBMCs from healthy non-atopic donors were obtained by Ficoll-Paque isolation as 
previously described (see Methods 2.1.1, page 79). CD4+ T helper cells were isolated from 
PBMCs by depleting non-CD4+ T cells such as CD8+ CD14+ CD16+ CD19+ CD36+ CD56+ 
CD123+ TCR/δ+ Glycophorin A+ cells. The obtained fraction was further depleted using 
CD45RO and enriched using CD45RA beads to obtain CD4(+) CD45RO- CD45RA+ cells 
(Table 33).  
Table 33. Magnetic bead isolation kits used in the enrichment of individual T cell populations 
Isolation kit Type Company ID 
CD4
+
 T Cell Isolation Kit II negative selection Miltenyi Biotec 130-091-155 
CD45RA Microbeads positive selection Miltenyi Biotec 130-045-901 
CD45RO Microbeads positive selection Miltenyi Biotec 130-046-001 
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Magnetic labelling  
The PBMC cell pellet was re-suspended in 40μl MACS buffer (0.5% BSA 2mM EDTA PBS) 
per 107 cells. 10μl of non-CD4 depletion antibody cocktail was added per 107 cells, mixed, 
and incubated for 10 minutes at 4°C. 30μl MACS buffer and 20μl anti-biotin magnetic beads 
were then added in succession, mixed and left for 15 minutes at 4°C. Cells were then 
washed using 10x volume of MACS buffer and centrifuged at 1500rpm for 10 minutes. The 
supernatant was taken and the cell pellet was re-suspended in 500μl MACS buffer per 108 
cells. 
Magnetic isolation 
A large sized (LS) magnetic column (Miltenyi) was used to isolate a maximum of 108 cells 
from a given cell suspension. The column was placed into a supplied magnet and 3ml 
1%BSA PBS was rinsed through before the cell suspension was applied. The unlabelled 
cells were collected and the LS column washed 3x using 3ml 1% BSA PBS. The magnetic 
field was removed and the labelled cells eluted using 3ml of 1% BSA PBS. Both labelled and 
unlabelled fractions were counted using a haemocytometer and either used directly or 
labelled for additional magnetic bead isolation (e.g. CD45RO depletion). 
Validation of naive T cell isolation 
The isolated “naïve T cell”-fractions were analysed by FACS as previously described (see 
Methods 2.1.1, page 80) using FACS antibodies listed in the table below (Table 34). 
 
The results showed that CD45RA expression was >95% and CD45RO expression less then 
<5% (Figure 11A) and both activation markers CD25 and CD69 expression were low (<2%) 
or absent (Figure 11B). 
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Figure 11. Flow cytometric analysis of CD45RA,-RO, CD25, and CD69 expression 
on purified naive peripheral blood T cells used in CD4+ T cell differentiation
Surface expression of A)CD45RA and CD45RO as well as B) T cell activation marker CD25 and CD69
A) B)
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Table 34. FACS antibodies used in validating T cells after magnetic bead isolation 
Name Species Company Clone ID Concentration used 
α-CD45RA-FITC Mouse IgG1 BD Bioscience OX-33 554883 1/20 
α-CD45RO-FITC Mouse IgG2a BD Bioscience UCHL1 555492 1/20 
α-CD25-FITC Mouse IgG1 BD Bioscience OX-39 554865 1/20 
α-CD69-PE Mouse IgG1 BD Bioscience L78 341652 1/20 
Isotype-FITC Mouse IgG1 R&D Systems 11711 IC002F 1/20 
Isotype-FITC Mouse IgG2b R&D Systems 133303 IC0041F 1/20 
Isotype-PE Mouse IgG1 BD Bioscience MOPC-21 551436 1/20 
 
T helper cell differentiation 
The original Th22 in vitro differentiation protocol (Duhen et al 2009): 
Naïve T cells were isolated from buffy coats by flow assisted cell sorting as CD4+ CD45RA+ 
CCR7+ CD45RO- CD25- cells to a purity of 99%. Naïve T cells (5x104) were cultured in U-
bottom 96 well plates in the presence or absence of 10ng/ml IL-6 and 5ng/ml TNF. Cells 
were stimulated using beads coated with anti-CD3 and anti-CD28 at a ratio of 1 cell per 1 
bead. After 5 days, cultures were supplemented 50U/ml IL-2. At day 12, cells were activated 
using PMA and Ionomycin for 5 hours, stained for intracellular cytokines and assessed by 
flow cytometry. 
Alterations made: 
Fresh blood was used instead of buffy coat and naive T cells were obtained through 
magnetic bead isolation rather than FACS isolation. Both serum-free (AIM-V, 
Invitrogen/Gibco 12055-091) and serum-containing RPMI-1640 +L-Glutamine 
(Invitrogen/Gibco 52400) substituted with 5% human AB Serum and 1/10 diluted 
Penicilin/Streptomycin Solution (Invitrogen 15140-122) media were trialled. In addition we 
used a range of cytokine concentrations and carried out Th22 priming in the presence and 
absence of anti-IL-4 and anti-IL-12 blocking antibodies.  
Control cells were differentiated in Th1 polarising conditions containing 25ng/ml IL-12 and 
5μg/ml anti-IL-4 blocking antibody. The individual reagents utilised are given in the table 
below (Table 35). 
Table 35. Reagents used in culturing naive T cells during in vitro Th1 and Th22 cell 
differentiation 
Reagent Company Comment ID Concentration used 
Rec. Human IL-6 Peprotech Expressed in E.coli. 200-06 10ng/ml 
Rec. Human TNFα Peprotech Expressed in E.coli. 300-01A 5ng/ml 
Rec. Human IL-12 Peprotech Expressed in E.coli. 200-12 25ng/ml 
α-IL-4 Abcam Clone 8F12 ab13780 5μg/ml 
α-IL-12 (p40/p70) BD Bioscience Clone C11.5 554573 5μg/ml 
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Flow cytometry 
T cells were stained and analysed as previously described (see Methods 2.1.1, page 80) 
using the FACS antibodies listed below (Table 36). 
Table 36. FACS antibodies used in the assessment of Th1 and Th22-primed T cells 
Name Species Company Clone ID Concentration 
used 
α-IL-17A-APC Mouse IgG1 eBioscience eBio64DEC17 17-7179-41 1/20 
α-IL-22-PE Mouse IgG1 R&D Systems 142928 IC7821P 1/20 
α-IL-22-APC Mouse IgG1 R&D Systems 142928 IC7821A 1/20 
α-IFN-PE Mouse IgG1 BD Bioscience 4S.B3 559326 1/20 
α-IFN-V450 Mouse IgG1 BD Bioscience B27 560371 1/20 
Isotype-APC Mouse IgG1 R&D Systems 11711 IC0041F 1/20 
Isotype-PE Mouse IgG1 BD Bioscience MOPC-21 551436 1/20 
Isotype-V450 Mouse IgG1 BD Bioscience X40 642268 1/20 
 
2.1.3. memory T cells 
T cell enrichment using anti-fluorchrome beads 
5x107 CD4 T cells were suspended in 500μl 1%BSA PBS containing 25μl anti-receptor 
antibody (Table 37) and was left at 4°C in the dark. After 10 minutes the cells were washed 
using 2ml of 1% BSA PBS and centrifuged at 1500rpm for 5 minutes. The resulting cell pellet 
was suspended in 500μl 1%BSA PBS containing 50μl anti-fluorchrome beads (Table 38) 
and left to incubate in the dark at 4°C for 15 minutes. The cells were washed as previously 
described and the supernatant taken off. The resulting cell pellet was suspended in 500μl 
1%BSA PBS and magnetic bead isolation was carried out as previously described (see 
Methods 2.1.2, page 81). 
Table 37. FACS Antibodies used in the analysis of novel Th22 surface receptor expression 
Name Species Company Clone ID Concentration used 
α-FGFR2-FITC Mouse IgG1 R&D Systems 98725 FAB684F 1/20 
α-TIE1-PE Goat IgG R&D Systems polyclonal FAB619P 1/20 
α-PDGFR-APC Mouse IgG1 R&D Systems PR7212 FAB1263A 1/20 
α-CCR4-FITC Mouse IgG2B R&D Systems 205410 FAB1567F 1/20 
α-CCR6-A488 Rat IgG2A R&D Systems 140706 FAB590G 1/20 
α-CCR10-APC Rat IgG2A R&D Systems 314305 FAB3478A 1/20 
Isotype-FITC Mouse IgG1 R&D Systems 11711 IC002F 1/20 
Isotype-FITC Mouse IgG2b R&D Systems 133303 IC0041F 1/20 
Isotype-A488 Rat IgG2A R&D Systems 54447 IC006G 1/20 
Isotype-PE Goat IgG R&D Systems polyclonal IC108P 1/20 
Isotype-APC Mouse IgG1 R&D Systems 11711 IC002A 1/20 
Isotype-APC Rat IgG2A R&D Systems 54447 IC006A 1/20 
 
Table 38. Anti-fluorchrome beads used in the isolation of surface receptor-positive T cells 
Reagent Company ID 
α-FITC Microbeads Miltenyi Biotec 130-048-701 
α-PE Microbeads Miltenyi Biotec 130-048-801 
α-APC Microbeads Miltenyi Biotec 130-090-855 
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Validation of Receptor+ T cell enrichment 
 
The flow cytometric analysis of CCR10-receptor-enriched T cells showed that CCR10 
expression within the depleted fraction dropped from 4% to 0% (Figure 12). While CCR10 
could not be stained in the enriched fraction, CD45RO expression increased from 40% to 
78%. Isolation of Isotype stained and magnetically labelled T cells showed no enrichment in 
either CD45RO or CCR10 positive T cells. 
Flow cytometry 
The cells were stained and analysed as previously described (see Methods 2.1.1, page 80) 
using FACS antibodies listed below (Table 39). 
Table 39. FACS antibodies used in the assessment of Th22 receptor enriched T cells 
Name Species Company Clone ID Concentration used 
α-IL-17A-A488 Mouse IgG1 R&D Systems 41802 FAB3171G 1/20 
α-IL-22-APC Mouse IgG1 R&D Systems 142928 IC7821A 1/20 
α-CD45RO-FITC Mouse IgG2a BD Bioscience UCHL1 555492 1/20 
α-CD45RO-APC Mouse IgG2a BD Bioscience UCHL1 559865 1/20 
Isotype-FITC Mouse IgG2a R&D Systems 133303 IC0041F 1/20 
Isotype-A488 Mouse IgG1 R&D Systems G94-56 554008 1/20 
Isotype-APC Mouse IgG1 R&D Systems 11711 IC002A 1/20 
 
In vitro culture of T cells in the presence of putative Th22 receptor-ligands 
CD4+ T cells were activated using CD3/CD28 microbeads (Miltenyi) at a ratio of 1 bead to 4 
cells and cultured in 5% human AB serum containing RPMI1640 substituted with FGF-1, -5, 
-7, or PDGF-BB (Table 40). Cultured T cells were obtained after 24, 48, and 72 hours for 
RT-PCR analysis. 
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Figure 12. Flow cytometric analysis of CCR10 and CD45RO expression on peripheral 
blood T cells before and after CCR10 enrichment using anti-fluorochrome-coupled 
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Table 40. Recombinant FGF and PDGF proteins used in CD4 T cell co-culture 
Reagent Company Comment ID Biological 
Conc. 
Concentration 
used 
Rec. Human FGF-1 (acidic) Peprotech Expressed in E.coli. 100-17A 0.5-10ng/ml 5 ng/ml 
Rec. Human FGF-2 (basic) Peprotech Expressed in E.coli. 100-18B 0.1-0.5ng/ml 0.25 ng/ml 
Rec. Human FGF-5 Peprotech Expressed in E.coli. 100-34 <0.5ng/ml 0.25 ng/ml 
Rec. Human PDGF-BB ProSpec Expressed in E.coli. CYT-501 1-3ng/ml 2 ng/ml 
 
Real-time-PCR 
RNA isolation 
RNA isolation was carried out using the Qiagen RNA isolation kit (Table 41). Between 
2.5x105-5x105 T cells (or tissue cells) were suspended in RLT buffer (Qiagen RNeasy Kit) 
containing 2-β-mecaptoethanol (diluted 1/100) and immediately frozen and stored at -20C. 
After a maximum of 14 days, samples were defrosted, transferred into a Qiagen shredder 
spin tube and centrifuged at 13000rpm for 2 min using an Eppendorf 4075 bench centrifuge.  
After centrifugation an equal volume of 70% ethanol was added to the homogenised lysate 
and mixed by pipetting. The mixture was then transferred to RNA spin columns and briefly 
centrifuged for 15 seconds at 10000rpm. 700μl of RW1 buffer was added and centrifuged 
again for 15 seconds at 10000rpm. 500μl RPE buffer was then added to the spin column 
and centrifuged for 15 sec at 1000rpm. The step was repeated using a longer centrifugation 
of 2 minutes. The spin column was then centrifuged empty for 1 minute at full speed to 
remove any remaining liquid. The column was then placed into a fresh eppendorf tube and 
30μl of dH2O was added. The RNA was eluted by centrifugation for 1 minute at 10000rpm 
and stored at -80C. 
Table 41: RNA isolation reagents utilised throughout the study 
Name Company ID Containing 
Shredder/Homogeniser Qiagen  79656 Homogenising spin columns 
RNeasky kit 
“ 
“ 
“ 
Qiagen  
“ 
“ 
“ 
740106 
“ 
“ 
“ 
RNA Spin columns 
RLT Buffer (+2βME) 
RW1 Buffer 
RPE Buffer (+ethanol) 
 
Reverse transcription 
The cDNA synthesis was carried out using the RevertAid First Strand cDNA Synthesis Kit 
(Fermentas K1621). Before the sample RNA was reverse transcribed, the quality and 
quantity of the RNA was assessed using a Nanodrop analyser. 1μg of sample RNA was 
added to the cDNA reaction mixture (Table 42) and added to a benchtop PCR machine 
(Sensoquest Labcycler) programmed to the recommended cycling times and temperatures 
(Table 43). The resulting cDNA was diluted 1:5 before use. 
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Table 42. Composition of the cDNA reaction mixture (20μl) 
Amount/Volume Reagent (from Fermentas ReverseAid kit) 
4 μl 5X cDNA Buffer 
2 μl dNTPs 
1 μl Hexamere Primers 
0.5 μl Rnase Inhibitor  
1 μl RT Enzyme  
11.5 μl  dH2O containing 1ug Target RNA 
 
Table 43. PCR reaction setup used in the conversion of RNA to cDNA 
Step  Time Temperature 
1  10 minutes 25C 
2  60 minutes 42C 
3  10 minutes 70C 
4   4C 
 
RT-PCR reaction and analysis 
All primers were tested before use. Using serial diluted cDNA each primer pair produced a 
linear amplification pattern (r2≥0.95). None of the primers produced a signal in the absence 
of cDNA. In addition the dissociation (or melting) curve was analysed and nonspecific 
amplification was further eliminated by excluding ct values above 30. 
The RT-PCR reaction was carried out using SYBR green detection. Using an automated 
robot (Eppendorf Epimotion 5075) 3.4μl of 1/5 diluted cDNA and 6.6μl of Primer/SYBR green 
mix (Table 44) was pipetted in triplicate into a 384-well clear optical reaction plate (AB 
4309849). The plate was covered with a clear adhesive cover (AB MicroAmp 4311971) and 
sealed. The RT-PCR reaction was carried out using an AB 7900HT RT-PCR machine 
programmed using the SDS 2.3.Sequence Detection System software. Please refer to table 
42 for individual primer sequences used. 
Table 44. RT-PCR Primer and SYBR green reaction mixture 
Amount/Volume Reagent 
75μl Power SYBR Green (AB 4367659) 
1μl 100uM Forward Primer 
1μl 100um Reverse Primer 
23μl dH2O 
 
  
88 
 
Table 45. RT-PCR primer sequences used to analyse PDGFR enriched and depleted T cells 
Gene Primer 5’-3’ DNA sequence Baseline Ct (Media Control) 
IFNγ Forward TCT CGG AAA GGA TGA AAT ATA CAA GTT 19-20 
 Reverse GTA ACA GCC AAG AGA ACC CAA  
IL-4 Forward AAA CGG CTC GAC AGG AAC CT 27-29 
 Reverse ACT CTG GTT GGC TTC CTT CAC  
IL-5 Forward GCT CTT GGA GCT GCC TAC GT 26-27 
 Reverse AAG GTC TCT TTC ACC AAT GCA CT  
IL-9 Forward ATC CTG GAC ATC AAC TTC CTC ATC 27-28 
 Reverse CAG AGA CAA CTG GTC ACA TTA GCA  
IL-13 Forward GAT TCC AGG GCT GCA CAG TA 23-26 
 Reverse GGT CAA CAT CAC CCA GAA CC  
IL-17A Forward CCA TCC CCA GTT GAT TGG AA 24-25 
 Reverse CTC AGC AGC AGT AGC AGT GAC A  
IL-22 Forward GGC CAG GCT CAG CAA CAG 19-20 
 Reverse CCT CTG GAT ATG CAG GTC ATC AC  
TGFβ1 Forward AAA TTG AGG GCT TTC GCC TTA 22-23 
 Reverse GAA CCC GTT GAT GTC CAC TTG  
IL-10 Forward TGC CTA ACA TGC TTC GAG ATC TC 25-26 
 Reverse GTT GTC CAG CTG ATC CTT CAT TT  
PDGFA Forward ACG GGG GCC AGA TCA GGA AG 31-32 
 Reverse AAT TTC GCC GCC ACA GGA GA  
PDGFB Forward GCG CTC TTC CTG TCT CTC TG 30-31 
 Reverse TCG AGT GGT CAC TCA GCA TC  
18S Forward CAG CCA CCC GAG ATT GAG CA 9-10 
 Reverse TAG TAG CGA CGG GCG GTG TG  
 
The resulting data was checked for errors and the raw ct values were exported into Microsoft 
excel files. The relative expression of each gene was calculated using the   ct method 
using 18s as a housekeeping gene (see below). 
                                                                                                         
                                 
=        
For example: 
                                                                            
             
                           
 
 2.2. from human asthmatic bronchial mucosa 
Participants 
Participants were recruited from patients at the Asthma Unit of the Brompton Hospital. All 
recruited participants were previously diagnosed as asthmatics and qualified for the study by 
having no additional health problems. Steroid use was not prohibited but recorded. After 
taking written informed consent tissue biopsies were taken during a fiberoptic bronchoscopy 
by medical staff at the Brompton Hospital. The bronchial tissue was immediately placed into 
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a falcon tube containing sterile RPMI media (incl. penicillin and streptomycin) briefly stored 
at 4C for 30-45 minutes before being transferred to the laboratory. Note: For more detail on 
individual patients refer to appendix (Table 70, page Error! Bookmark not defined.). 
Creation of lung T cell lines 
The bronchial tissue was centrifuged three times at 2000rpm for 5 minutes, with media 
changes in between. The bronchial biopsy was then placed into a 48-well plate and left 
overnight at 37°C. The next day the biopsy was transferred together with fresh media into a 
CD3/CD28 (0.5μg/ml; R&D MAB100, MAB342) pre-coated well. After one week the tissue 
was discarded and the media centrifuged at 2000rpm for 5 minutes. The resulting cell pellet 
was suspended in fresh RPMI media containing 20ng/ml IL-2 (Peprotech) and transferred to 
a CD3/CD28 pre-coated well and placed back in the incubator. After a further 14 days a 
small aliquot of cell suspension was taken and analysed by FACS for CD3, CD4 and CD8 
expression. 
Creation of lung T cell clones 
Lung T cell lines were diluted in cloning media (Table 46) to a concentration of 1.75-3x105 
cells/ml. This cell suspension was further diluted using a dilution series (Table 47) and 100μl 
of cell suspension (8 cells/ml) was added per well to a clear round bottom 96 well plate 
resulting in a theoretical concentration of 0,8 cells per well. 
To maintain and stimulate T cell expansion during cloning, irradiated feeder cells were used 
(e.g. PBMCs from a different donor). These cells were counted and reconstituted at 2x106 
cells/ml cloning medium. After irradiation at 4000rads the cells were adjusted to a total 
concentration of 3.5x105 cells/ml and 2% PHA and 40ng/ml IL-2 were added. 100μl of the 
feeder cell solution was then added to each well in the round bottom 96-well plate. 
Table 46. Components of the T cell cloning media  
Amount/Volume Reagent 
50ml Fetal Bovine Serum (FBS) 
25ml Human Serum (Invitrogen H4522) 
5ml 200mM Glutamin (Invitrogen 25030-024) 
5ml 100x Antibiotic/-mycotic Solution (PAA P11-002) 
5ml 100x Non-essential amino acids (Invitrogen 11140-35) 
5ml 100mM Sodium-Pyruvate (Invitrogen 11360-039) 
0.5ml 50mM 2β-mercaptoethanol (Sigma) 
404,5ml RPMI (Invitrogen 31870-025) 
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Table 47. Serial dilution setup employed in the generation of T cell clones 
Step Dilution Final concentration Determined by 
A 1:2, 1:4, 1:8, 1:16... 1.75-3x10
5
 cells/ml Haemocytometer 
B 1:10 followed by 
1:10 
1750-3000 cells/ml 
175-300 cells/ml 
Theoretical 
Theoretical 
C 400 cells into 50ml 8 cells/ml Theoretical 
 100μl per well 0,8 cells/well Theoretical 
 
Maintenance & T cell clone expansion 
Due to the long term culture extreme care was taken to disinfect incubators, tissue culture 
hoods and equipment on a regular basis. On day 7 100μl of media was removed and 100μl 
of new irradiated feeder cell suspension was added and from now onwards changed every 
second day.  
From day 10 T cell clones could be spotted as pear shaped as watery, shiny cells 
overgrowing the feeder cell pellet. Potential clones were split into two new 96 wells and new 
100μl cloning medium containing 40ng/ml IL-2 was added. The media was changed every 
second day until the cells reached 70% confluence. At that stage these cells were 
transferred into a larger well in a 24 well plate. IL-2 was increased by 20ng/ml steps to 
60ng/ml and 80ng/ml if the cell proliferation appeared to arrest. After cell numbers increased 
to sufficient levels a small aliquot was taken and assessed for intracellular cytokine 
production by flow cytometry.  See the table below for an overview of the individual steps 
involved (Table 48). 
Table 48. Individual steps in expanding T cell clones over time 
Day Setup/Maintenance Comment 
1 Setup of serial T cell dilution & first feeder cell stimulation +PHA +IL-2  
7 Re-stimulation with new feeder cells +PHA +IL-2  
9 Remove 100μl media and replace with new media +IL-2  
11 Remove 100μl media and replace with new media +IL-2 Look for visible clones 
14 Remove 100μl media and replace with new media +IL-2 Look for visible clones/Expansion 
15 Remove 100μl media and replace with new media +IL-2 Expansion 
17 Remove 100μl media and replace with new media +IL-2 Expansion 
19 Remove 100μl media and replace with new media +IL-2 Expansion 
21 Re-stimulation with new feeder cells +PHA +IL-2 Expansion 
.. Media change (every second day) Feeder cells (every 14days).. Expansion 
Flow cytometry of T cell lines and clones 
Polyclonal T cell stimulation, fixation, staining, and acquisition were carried out as previously 
described (see Methods 2.1.1, page 80) using FACS antibodies listed below (Table 49). 
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Table 49. FACS antibodies used in the characterisation of T cell lines and clones 
Name Species Company Clone ID Concentration used 
α-(αβ)TCR-FITC Mouse IgG1 BD Bioscience WT31 333140 1/20 
α-(γδ)TCR-FITC Mouse IgG1 BD Bioscience B1 561995 1/20 
α-CD4-PERCP Mouse IgG1 BD Bioscience L200 550631 1/20 
α-CD8-APC H7 Mouse IgG1 BD Bioscience SK1 560273 1/20 
α-IFN-V450 Mouse IgG1 BD Bioscience B27 560371 1 in 20 
α-IL-4-PE Mouse IgG1 BD Bioscience 8D4-8 562046 1/20 
α-IL-17A-A488 Mouse IgG1 R&D Systems 41802 FAB3171G 1/20 
α-IL-22-PE Mouse IgG1 R&D Systems 142928 IC7821P 1 in 20 
α-IL-22-APC Mouse IgG1 R&D Systems 142928 IC7821A 1/20 
Isotype-FITC Mouse IgG1 R&D Systems 11711 IC002F 1/20 
Isotype-APC H7 Mouse IgG1 BD Bioscience MOPC-21 560167 1/20 
Isotype-V450 Mouse IgG1 BD Bioscience X40 642268 1 in 20 
Isotype-PE Mouse IgG1 BD Bioscience MOPC-21 551436 1/20 
Isotype-A488 Mouse IgG1 R&D Systems G94-56 554008 1/20 
Isotype-APC Mouse IgG1 R&D Systems 11711 IC002A 1/20 
 
3. IL-22 in human tissue regeneration and repair 
3.1. IL-22 Receptor expression in human lung cell lines 
Study design and primary lung cell lines 
Lung cell lines  
All structural cell lines were obtained from healthy non-asthmatic donors. Bronchial epithelial 
and pulmonary fibroblast cell lines were obtained from Lonza while airway smooth muscle 
cell lines were kindly provided by Dr. Paul Lavender from Kings College London. Lung 
epithelial cells and lung fibroblasts were classified by Lonza based on questionnaire. Both 
donors reported no respiratory related disorders including Asthma, COPD or Cystic Fibrosis. 
All three donors of smooth muscle tissue had no respiratory related disease, did not smoke 
and showed no abnormal spirometry (FEV1) or methacholine (PC20) measurements. 
Aliquots of early passage cells were made, frozen in 15% Dimethyl sulfoxide (DMSO) 50% 
serum containing media and stored in liquid nitrogen and otherwise grown until passage 5-6. 
See table below for individual cell lines used (Table 50). 
Table 50. Description of primary structural cell lines studied 
Cell type Culture Gender Age Status ID 
Bronchial Epithelium Primary M 43 Healthy Non-Asthmatic Lonza 7F4167  
Pulmonary Fibroblasts Primary M 45 Healthy Non-Asthmatic Lonza 120188  
Airway Smooth Muscle Primary n.a. n.a. Healthy Non-Asthmatic, Normal FEV1 & PC20 KCL-PL-HB129 
Airway Smooth Muscle Primary n.a. n.a. Healthy Non-Asthmatic, Normal FEV1 & PC20 KCL-PL-HB138 
Airway Smooth Muscle Primary n.a. n.a. Healthy Non-Asthmatic, Normal FEV1 & PC20 KCL-PL-HB139 
 
In vitro culture 
Cells were cultured in dedicated cell culture media in the presence or absence of various 
cytokines (Table 51) over time. For epithelial cells Bronchial Epithelial Cell Growth Medium 
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(BEGM Bulletkit; Lonza), for fibroblasts cells Fibroblast Growth Medium-2 containing 2% 
serum (FGM-2; Lonza) and for smooth muscle cells Dulbecco Modified Eagle Medium 
(DMEM; Gibco) supplemented with 10% FCS, 4 mmol/L l-glutamine, 100 U/mL penicillin, 
100 μg/mL streptomycin, and 2.5 μg/mL amphotericin B media was used. Cells were 
detached using TrypLE (Invitrogen 12604-021). 
Table 51. Individual cytokines used in the stimulation of structural cell lines in vitro 
Name Company ID Concentration  used 
Rec. human IFNγ Peprotech 300-02 10ng/ml (variable) 
Rec. human TNFα Peprotech 300-01A 10ng/ml (variable) 
Rec. human IL-4 Peprotech 200-04 50ng/ml (variable) 
Rec. human IL-5 Peprotech 200-05 50ng/ml (variable) 
Rec. human IL-9 Peprotech 200-09 50ng/ml (variable) 
Rec. human IL-13 Peprotech 200-13 50ng/ml (variable) 
Rec. human IL-17A Peprotech 200-17 50ng/ml (variable) 
Rec. human IL-22 R&D Systems 782-IL-010/CF 50ng/ml (variable) 
Rec. human TGFβ1 R&D Systems 240-B-002 10ng/ml (variable) 
Rec. human IL-10 Peprotech 200-10 50ng/ml (variable) 
 
Western Blotting 
One T25 flask of adherent cells was lysed in protein lysis buffer (Table 52). The lysate was 
subjected to repeated cycles of freeze thawing using liquid nitrogen and a water bath at 
37C. After 3 cycles the lysate was centrifuged at 13000rpm for 30 minutes using a bench 
top Eppendorf 5424 centrifuge. The soluble fraction was removed and stored at -80°C.  
Table 52. Composition of the protein lysis buffer  
Amount/Volume Reagent 
132 µl Aprotonin from bovine lung (Sigma A6279) 
10 µl Igepal CA-630 (Sigma I3021) 
10 µl Phenylmethanesulfonyl fluoride solution (Sigma/Fluka 93482) 
4 µl Iodoacetate solution (Sigma A3221) 
4 µl EDTA (Gibco 15575-038) 
10 µl Protease inhibitor cocktail (Roche) 
830 µl 1X PBS 
 
Determining Protein Concentration (BCA assay) 
The total protein concentration in each cell lysate was measured using the Bicinchoninic acid 
(BCA) assay (Pierce BCA Protein Assay Kit 23225). Bovine serum albumin standards (20-
2000pg/ml) were used to determine a standard curve of protein concentrations. The assay 
itself was carried out in a standard clear 96-well plate. In brief: 
The BCA working reagent was prepared fresh by mixing 50 parts BCA reagent A to 1 part 
BCA reagent B. 200μl of the mixture was then pipetted into the 96-well plate. Then 25μl of 
unknown cell lysate or BSA standard was pipette in triplicate into the 96-well plate. The plate 
was covered and left in a tissue incubator at 37°C for 30 minutes. After the incubation the 
plate was briefly cooled to room temperature. The absorbance of each well (at 562nm) was 
93 
 
determined using a spectrophotometer (Teacan Sunrise plate reader & Magellan Software). 
The raw data was exported to Microsoft excel and the standard curve determined. Using the 
equation of the line derived from the linear part of the standard curve cell lysates protein 
concentrations were determined.  
Equation of the line:  
                      
     
                                         
For example: 
                       
        
                  
 
SDS-PAGE & Transfer to nitrocellulose membrane 
50μg of protein in a total volume of 20μl containing 5μl loading buffer (Table 53) was loaded 
onto a 4%-12% Bis-Tris Gel (Novex NP0323) inside a gel tank (Invitrogen X cell Surelock) 
containing MES SDS running buffer (Invitrogen). For example; 7.5μl epithelial extract [e.g. of 
3.326μg/μl protein lysate] + 5μl 4X loading buffer +7.5μl lysis buffer. In addition 5μl of 
Benchmark protein ladder (Invitrogen 107480-010) was loaded in the wells flanking the 
protein samples of interest. The Gel was run for 45 minutes at 200 Volt using 104mA. 
Table 53. Composition of the SDS PAGE loading buffer (4x)  
Amount/Volume Reagent 
2 ml 1M Tris-HCL (pH 6.8) 
0.8 g SDS (Sigma SDS7) 
4 ml 10% Glycerol (G5516) 
0.4 ml 14.7M 2-β-mercaptoethanol (Sigma M7154) 
1 ml 0.5M EDTA (Gibco 15575-038) 
8 mg Bromophenol Blue (Sigma B0126) 
 
The proteins were transferred from the Nupage Gel onto a 0.45um porse-size Nitrocellulose 
membrane (Invitrogen Lc2001) using an X cell II blotting module (Invitrogen). 10% Methanol 
and 0.1% NuPage Reducing agent (Invitrogen) was added to the transfer buffer and the 
electrophoresis was carried out using 30 V for 1 hour. 
Western Blotting and detection 
The membrane was blocked for 1 hour in 0.1% Tween-20 5% dried skimmed milk (Marvel) 
containing PBS. The membranes were rinsed 3 times in PBS. The primary antibodies (e.g. 
goat-anti human IL-22RA2 and mouse anti alpha tubulin) diluted in 5% dried skimmed milk 
(Marvel) PBS were added to the membrane. The membrane was left overnight at 4C on a 
platform shaker (Sturat Scientific) at 20 rpm. After three PBS rinses the secondary antibody 
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(e.g. donkey anti goat IgG) was added to the membrane for 1 hour. After 3 additional PBS 
rinses the membrane was incubated with the other secondary antibody (e.g. goat anti mouse 
IgG). After 3 more washes the membrane was incubated in the dark with activated ECL 
reagent (GE Health ECL+ RPN2132). Chemilumiescence was detected on GE hyperfilm 
(28906825). The ECL film was developed manually using the two component Agfa medical 
X-ray film developer G153. The film was left for 30 seconds in the pre-prepared developer 
(1l Sol A, 0.35l Solution B, 1,5l dH2O) and then fixed for a 30 seconds using pre-prepared 
Agfa Rapid Fixer G353 (0.5l Stock sol, 1.5l dH2O). The developed films were rinsed, dried 
and marked for the location of the protein ladder. See the table below for individual 
antibodies and concentrations used (Table 54). 
Table 54. Antibodies used in the analysis of IL-22 receptor expression by Western Blot 
analysis 
Name Species Company ID Concentration used 
α-IL-22RA1 Mouse monoclonal R&D systems MAB2770 1/500 (1μg/ml) 
α-IL-22RA2  (T16) Goat polyclonal Santa Cruz Biotechnology Sc64640 1/100 (2μg/ml) 
α-alpha-tubulin Mouse monoclonal eBioscience 14-4502-80 1/1000 (0.5μg/ml) 
α-mouse Ig –HRP Goat polyclonal Dako P044701 1/1000 
α-goat Ig – HRP Donkey polyclonal Santa Cruz Biotechnology sc-2020 1/5000 
 
Flow cytometry 
Fc receptor blocking solution (Miltenyi 120-000-442) was staining using the antibodies listed 
in the table below (Table 55). The flow cytometric staining was carried out as previously 
described (see Methods 2.1.1, page 80). Before the cells were acquired the cell suspension 
was strained through cell pre-separation filters (Miltenyi 130-041-407). 
Table 55. FACS antibodies used in the analysis of IL-22RA1 surface expression 
Name Species Company Clone ID Concentration used 
α-IL-22RA1-APC Mouse IgG1 R&D Systems 305405 FAB2770A 1/20 
Isotype-APC Mouse IgG1 R&D Systems 11711 IC002A 1/20 
 
RT-PCR 
RNA isolation, cDNA transcription and RT-PCR acquisition was carried out as described 
previously (see Methods 2.1.3, page 86) using RT-PCR primer sequences listed below 
(Table 56).  
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Table 56. RT-PCR primer sequences used in studying IL-22 receptor regulation in structural 
cell lines 
Gene Primer 5’-3’ DNA sequence Baseline Ct (Media Control) 
IL-22RA1  Forward CCC TAC ATG TGC CGA GTG AA 27-28 
 Reverse CCG GAG AAG GAG TAG GTC CAT  
IL-22RA2 Forward TTA CCA AAA GGA AGA CAG CAT CTG 29-30 
 Reverse GAC TGT TCA GGC AAC CAG TGT TC  
18S Forward CAG CCA CCC GAG ATT GAG CA 5-6 
 Reverse TAG TAG CGA CGG GCG GTG TG  
 
 
3.2. Effect of IL-22 on bronchial epithelial cells 
3.2.1. Wound healing 
Wound healing assay 
 
The assay was designed using a normal 12-well tissue culture plate. Guide marks were 
drawn on the bottom of the plate using a water-resistant blue pen (Diagram 4B). Within each 
culture well bronchial epithelial cells were cultured until 90%-95% confluence was reached. 
Using a p10 pipette tip and a ruler a scratch was made in the middle of each confluent layer 
(Diagram 4A). Cells were then grown in the presence or absence of IL-22. At each time point 
images were taken of each sample area (Diagram 4C) using a digital camera. The images 
were then analysed using imaging software (Motic Images Plus 2.0) and the changes in 
surface area calculated. 
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Diagram 4. Analysing epithelial cell wound closure
A) Full confluent epithelial cell layers are injured using a P10 pipette tip (3 wells per condition). B) 3 Guide 
marks on the bottom of each well intersect the scratch and  facilitate the relocation of identical analysis areas 
over time  (3 per well). C) The area investigated is highlighted in green. Its calculated surface area is set to 
100% at time point 0 (maximum injury).
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Reproducibility of the wound healing assay 
 
The results showed that the remaining injured area varied greatly within one experiment 
from less than 20% to ca. 60% (Figure 13). A comparison of 3 experiments carried out on 
different days of the week (Figure 13, Exp.1-3) showed that the intra-assay variation was 
much lower and within an acceptable range.    
 
Cell Cycle analysis /Proliferation 
Cell cycle analysis was carried out using propidium iodide (PI). In brief: Epithelial cells were 
cultured for 24 hours under normal conditions using 10ng/ml TGFβ1, 200ng/ml IL-22 or 
media control. Cells were detached using TrypLE and counted on a haemocytometer. 2x106 
cells were added to individual FACS tubes and centrifuged for 5 minutes at 2000rpm. The 
media was removed and the cell pellet was suspended drop wise under continuous 
vortexing in 1ml ice-cold 80% ethanol. The cells were left on ice for 1 hour and washed twice 
with ice cold PBS. The cells were then re-suspended in 0.5ml PI staining solution (Table 57) 
and left to incubate on ice for 3 hours. After incubation the cell solution was strained through 
a filter (Miltenyi) removing large cell aggregates prior to FACS analysis.  
Figure 13. Inter and intra-experimental variability of the wound healing assay
Represented are 3 experiments which were carried out on different days. Within each experiment 9 data points 
were collected and are represented . Represented are Mean and Standard deviation. Coefficient of variation  
Exp.1(43.9%), Exp.2(65.8%), Exp.3(49.9%). Coefficient of variation between experiments 1-3 (16.7%).
1 2 3
0
20
40
60
80
100
Experiments
In
ju
re
d
 a
re
a
 a
ft
e
r 
1
6
h
rs
 [
%
]
97 
 
 
Using a BD FACS Calibur machine cells were gated using channel FL3 fluorescence (Figure 
14). By displaying PI-width and PI-area, debris (low PI-width and area) and aggregates (high 
PI-width and/or area) were excluded from further analysis through cell gating (Figure 14A). 
The gated cell population was then displayed using individual histograms of PI-area and its 
spectra divided into different cell cycle stages (Figure 14B). The resulting % of cells in G/01, 
S and G2/M-phase recorded and used for further analysis (Figure 14C). 
Table 57. Composition of the Propidium Iodide staining solution 
Amount/Volume Reagent 
0.1% Triton X-100 (Sigma X100) 
0.1 mM EDTA (Gibco 15575-038) 
50 μg/ml Rnase A (Sigma R-4875) 
50 μg/ml Propidium Iodide (Sigma P-4170) 
 
RT-PCR 
Human bronchial epithelial cells were cultured in the presence or absence of cytokines 
(Table 58). Bronchial epithelial RNA isolation, subsequent cDNA transcription and RT-PCR 
acquisition was carried out as previously described (see Methods 2.1.3, page 86) using RT-
PCR primer pairs listed below (Table 59).  
Table 58. Recombinant cytokines used in the bronchial epithelial wound healing assay 
Gene Company ID Concentration used 
Rec. human IL-22 R&D Systems 782-IL-010/CF 50ng/ml (variable) 
Rec. human IFNγ Peprotech 300-02 10ng/ml (variable) 
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Figure 14. Analysis of individual bronchial epithelial cell cycle stages using 
propidium iodide 
A) Cell gating strategy to exclude debris and aggregates B) Histogram of PI-Area identifying individual cell 
cycle stages (G0/1, S, and G2/M) C) Reproducibility of  results  of  control cultured bronchial epithelial cells
A) B) C)
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Table 59. RT-PCR primer sequences used in the assessment of bronchial epithelial gene 
expression 
Gene Primer 5’-3’ DNA sequence Baseline Ct (Media Control) 
ICAM1 Forward AGG GTA AGG TTC TTG CCC AC 24-26 
 Reverse TGA TGG GCA GTC AAC AGC TA  
IL-6 Forward TGG CTG AAA AAG ATG GAT GC 28 
 Reverse GAT GAT TTT CAC CAG GCA ACT CT  
IL-7 Forward TCA TTA TTC AGG CAA TTG CTA CC 29-30 
 Reverse TGA AGG TAA AGA TGG CAA ACA A  
IL-15 Forward TCC ACG ATG CCT CCT ACA A 29-30 
 Reverse TGT TCC ATC ATG TTC CAT GC  
CCL2 Forward AGG TGA CTG GGG CAT TGA T 33-34 
 Reverse GCC TCC AGC ATG AAA GTC TC  
CCL5 Forward TGT ACT CCC GAA CCC ATT TC 32-33 
 Reverse TAC ACC AGT GGC AAG TGC TC  
CXCL8 Forward TTG GCA GCC TTC CTG ATT TC  27-28 
 Reverse AAC TTC TCC ACA ACC CTC TG  
CXCL9 Forward TCA CAT CTG CTG AAT CTG GG 31-33 
 Reverse CCT TAA ACA ATT TGC CCC AA  
CXCL10 Forward GCT GAT GCA GGT ACA GCC T 33-34 
 Reverse CAC CAT GAA TCA AAC TGC GA  
CXCL11 Forward ATG CAA AGA CAG CGT CCT CT 29-30 
 Reverse CAA ACA TGA GTG TGA AGG GC  
MMP1 Forward AGG TGG ACC AAC AAT TTC AGA GA 25-26 
 Reverse AAG AGA ATG GCC GAG TTC ATG A  
MMP3 Forward TGA ACA ATG GAC AAA GGA TAC A 28-29 
 Reverse TTT CAT GAG CAG CAA CGA GAA  
MMP10 Forward CTG ATC GGC CCA GAA CTC ATT 26 
 Reverse ATT TTG GCC CTC TCT TCC AT  
TGFα Forward GGG CAG TCA TTA AAA TGG GA 21-22 
 Reverse GCT CTG GGT ATT GTG TTG GC  
EGF  Forward TGG TTC CTT CTG TGT CAA TCC 32-34 
 Reverse GTA CTC CGC AGG AAA TGG G  
EGFR Forward TCC TCT GGA GGC TGA GAA AA 20-21 
 Reverse GGG CTC TGG AGG AAA AGA AA  
18S Forward CAG CCA CCC GAG ATT GAG CA 8-9 
 Reverse TAG TAG CGA CGG GCG GTG TG  
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Results 
1. IL-22 expression in allergic inflammation 
To determine the expression of Interleukin-22 and its receptors during an allergic reaction, 
biological samples from two human allergen challenge models were analysed. These 
included a local bronchial segmental allergen challenge and an intradermal allergen skin 
challenge.  
1.1. Local bronchial segmental allergen challenge 
In this first study, a human bronchial segmental allergen challenge was performed (see 
Method 1.1, page 70) mimicking a natural exposure of allergen to the lower airways. 
1.1.1. Demographics of study participants 
 
20 individuals were recruited of whom 15 were allergic asthmatics and 5 normal healthy 
controls (Table 60). Asthmatics and normal healthy controls were matched for their age and 
gender. Compared to the normal healthy controls, allergic asthmatics had significantly 
higher total serum IgE (p=0.001). In addition, allergic asthmatics had high levels of specific 
IgE to the inhaled allergen (RAST; p=0.001) and raised bronchial responsiveness to 
methacholine inhalation challenge (Methacholine PC20; p=0.008).  
  
Treatment Group Patients
(n=15)
Controls
(n=5)
Age (Y) 32.5 (2.0) 23 (2.4)*1
Gender (M/F) 7/8 3/0*1
Challenged (Grass/HDM) 10/5 0/5
Multiple atopy (Yes/No) 7/8 None
Total IgE (IU/ml) 358.3 (74.2) <40
RAST (IU/ml) GP:62.2 (10.5) 
HDM: 38.1 (17.9)
<0.35
<0.35
PC 20 (mg/ml) 3.5 (1.4)*2 >32
FEV1 % predicted 109.8 (4.8) >100
% Fall in FEV1 25.3 (2.4) ≤ 8
*1 Age and Gender for 2 control subjects (Ac18, Ac23) were missing. *2 PC20 data is represented in log scale.
If not otherwise described, data is represented as Mean (SEM=Standard Error of the mean).
Table 60. Clinical data of allergic asthmatic and healthy non-atopic controls who
underwent fiberoptic bronchoscopy with segmental allergen challenge
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1.1.2. Spirometry and Bronchoalveolar lavage eosinophils 
Spirometry 
 
To assess a positive physical reaction towards the allergen, the reduction in lung function by 
measuring the 1 second forced expiratory volume (FEV1) was determined. Compared to 
normal healthy controls, asthmatics showed a significant reduction in lung function after 
allergen challenge by 25.3 (2.4)% points in FEV1-% predicted (p=0.013) (Figure 15).  
  
Figure 15. Percentage-predicted forced expiratory volume (FEV1) before and after
segmental allergen challenge
Analysis: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001 (Before vs. After: Wilcoxon; Allergic
Asthmatic vs. Normals: Mann-Witney U-test)
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Bronchoalveolar lavage eosinophils 
 
 
As a positive cellular marker of an allergic immune response, the numbers of eosinophils in 
bronchoalveolar lavage before and after allergen challenge were determined. The analysis 
showed that only allergic asthmatics had increased numbers of eosinophils in their 
bronchoalveolar lavage after challenge. In these asthmatics, eosinophil numbers increased 
333-fold from 0.03x106(0.1) before to 10x106(1.2) after challenge (p=0.001) (Figure 16).  
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Figure 16. Total eosinophil counts (106) in bronchoalveolar-lavage (BAL) before
and after segmental allergen challenge
Analysis: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001 (Before vs. After: Wilcoxon; Allergic
Asthmatic vs. Normals: Mann-Witney U-test)
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1.1.3. Cytokine expression in Bronchoalveolar lavage 
IL-5 and IFN 
 
During an allergic immune response, Th2 -type cytokines increase in expression while Th1 –
type cytokines remain low or absent.  To validate that the BAL could reflect the underlying 
Th2 –type immune response, IL-5 and IFN concentrations were determined before and after 
allergen challenge by ELISA. 
The ELISA results showed that after allergen challenge IL-5 increased in 11/15 asthmatics 
but none of the normal healthy controls (Figure 17). BAL IL-5 increased from less than 15 
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Figure 17. IL-5 and IFN cytokine ELISA measurements in (BAL) before and 24 hrs
after segmental allergen challenge
Analysis: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001 (Before vs. After: Wilcoxon; Allergic
Asthmatic vs. Normals: Mann-Witney U-test)
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pg/ml to 134.2(4.2) pg/ml (p=0.001). The results of the IFN ELISA showed increased 
expression in 2/15 asthmatics and none of the normal healthy controls. The increase of IFN 
in allergic asthmatics was not found to be significant (p=0.500). 
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IL-22, IL-17, and IL-22RA2 
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Figure 18. IL-22, IL-17A/F and IL-22RA2 ELISA measurements in (BAL) before and
24 hrs after segmental allergen challenge
Analysis: * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001 (Before vs. After: Wilcoxon; Allergic
Asthmatic vs. Normals: Mann-Witney U-test)
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IL-22 is commonly classified under a Th17 cell response and was thus measured together 
with IL-17A and IL-17F. In addition, a newly developed IL-22RA2 Sandwich ELISA (see 
Methods 1.1, page 72) was used to quantify the soluble IL-22 receptor before and after the 
allergen challenge.  
The ELISA results showed that after allergen challenge IL-22 and IL-22RA2 increased in 
allergic asthmatics but not normal healthy controls (Figure 18).  IL-22 increased in 8/15 
asthmatics (p=0.008) from below the detection limit to 32.2(1.5) pg/ml. IL-22RA2 increased 
in 6/10 asthmatics (p=0.031) from less than 15 ng/ml to 5.74(0.03) μg/ml. IL-17A/F levels 
remained unchanged in both groups after allergen exposure. 
  
106 
 
1.2. Intradermal allergen challenge 
The second study, a human intradermal allergen challenge to the skin (see Methods 1.2, 
page 74), allowed the study of tissue samples taken directly from the site of inflammation.  
1.2.1. Demographics of study participants 
 
14 atopic individuals with allergic rhinitis and 4 normal healthy controls were recruited (Table 
61). Both groups were matched for their age and gender. Compared to normal healthy 
controls, atopic individuals had increased levels of total serum IgE (p= 0.002). In addition, 
atopic participants reacted positive to timothy grass by the skin prick test (>3mm) and had 
significantly elevated levels of timothy grass specific IgE in their bloodstream (RAST; p= 
0.001). 
  
Treatment Group Patients
(n=14)
Controls
(n=5)
Age (Y) 31.4(2.7) 30.2(2.9)
Gender (M/F) 9/5 4/1
Skin Prick Test-positive (Yes/No) 14/0 0/5
Multiple allergen (Yes/No) 8/6 0/5
Total IgE (IU/ml) 394.0(125.5) 16.4(4.1)
RAST (IU/ml) 46.2(9.6) 0.4(0.0)
Mean +/- standard error of mean (Std.Dev./n)
Table 61. Clinical data of individuals who underwent intradermal grass pollen
challenge and subsequent cutaneous punch biopsy
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1.2.2. Late phase skin response and cutaneous eosinophils 
Late phase skin response 
 
To assess a positive physical reaction towards the allergen, reddening and swelling of the 
skin was measured. Only atopic individuals showed a weal and flare reaction after 15 
minutes (early response) and a delayed-in time swelling after 8 hours (late skin response). 
The measurements at 8 hours post challenge showed that allergen injection had caused 
significant swelling of 42.4(0.8) cm2 compared to 2.2(0.6) cm2 at baseline (p=0.001) (Figure 
19).  
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Figure 19. Measurement of the cutaneous swelling and reddening 8 hours after
intradermal grass pollen challenge
Atopics (p=0.0005 Wilcoxon), Atopics vs Normals (p=0.0010 Mann Witney U test).
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Cutaneous eosinophils 
 
To determine a positive allergic immune response in the biopsies taken from the site of 
allergen injection, tissue sections were stained against eosinophil-associated major basic 
protein (MBP) by immunohistochemistry and analysed by light microscopy.  
The results of the immunohistochemical stain showed that MBP+ cells increased at the site 
of allergen injection in 14/14 atopics and 3/4 normal healthy controls. In atopics MBP+ cells 
increased 82-fold from 2.8(0.6) cells/mm2 to 230.5(21.7) cells/mm2 (p=0.001) (Figure 20). In 
normal healthy controls MBP+ cells increased non-significantly from 1.6(1.6) to 8.0(6.3) 
cells/mm2 (p=0.351).  
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Figure 20. Quantification of cutaneous eosinophil (MBP-positive) cell numbers in
tissue sections taken from individuals who underwent intradermal grass pollen
challenge
Atopics (p=0.0005 Wilcoxon), Atopics vs Non-Atopics (p=0.0005 Mann Witney U test). Immunohistochemistry
of MBP-positive cells (BMK13) Mean +/- standard error of mean.
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1.2.3. IL-22 Immunofluorecent staining of skin sections 
To test the hypothesis that T cells are the main source of IL-22 during the human allergic 
immune response, allergen challenged skin tissue was stained by immunohistochemistry 
and analysed by fluorescent microscopy (see Methods 1.2, page 76). 
IL-22 vs T cells 
 
Figure 21. Immunofluorescent co-staining of IL-22 and CD3 in skin sections prepared from 
punch biopsies taken 8hrs post grass allergen-diluent or allergen challenge from grass 
allergic individuals.
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To identify IL-22, allergen challenge skin tissue was fixed in paraformaldehyde. Compared 
to Acetone fixation, this increases the likelihood of detecting a released mediator such as IL-
22.  
The results of the dual-immunofluorescent staining showed evidence of CD3 but not IL-22 
expression in paraformaldehyde-fixed skin tissue (Figure 21A). None of the 3 previously 
validated IL-22 antibodies (see Methods 1.2, Figure 10, page 77) generated a visible signal 
in tissue taken either from the site of allergen or diluent injection. IL-22+ cells were only 
detected in acetone-fixed skin tissue by 1 of the 3 IL-22 antibodies (Figure 21B, IL-22 in 
red). This IL-22 antibody (R&D AF782) stained in both allergen and diluent challenged skin 
elongated and clustered as well as round and individually dispersed IL-22+ cells. On the 
other hand, CD3+ cells were only detectable after allergen injection and showed no 
immediate association with IL-22 (Figure 21, CD3 green). 
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Having identified a positive IL-22 signal, individual CD3+, IL-22+, as well as CD3+IL-22+ cell 
numbers were quantified using a checkerboard counting system in allergen challenged skin 
tissue taken from 3 atopic individuals (Figure 22). 
The cell counting confirmed that IL-22+ cells occurred both in allergen and diluent 
challenged skin across 3/3 atopic individuals (Figure 22A).  IL-22+ cells increased only 
minimally from 62.0(25.5) cells/mm2 to 77.2(39.0) cells/mm2 after allergen injection (p>0.05). 
CD3+ cells, on the other hand, increased 5.5-fold from 27.3(14.2) to 150.6(33.3) cells/mm2 
(p=0.02). Double positive CD3+ IL-22+ cells were rare (<2 cells/mm2) and remained 
unchanged after allergen injection. 
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Figure 22. Immunofluorescent staining and quantification of CD3+ and IL-22+ cells in skin 
sections taken 8hrs post grass allergen challenge from 3 grass allergic individuals
A) Individual CD3, IL-22, and CD3/IL-22 cell counts ,increase in CD3 cell numbers (p= 0.0246 paired T-test) B) 
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IL-22 vs IL-22RA1 
 
To discover if the observed IL-22 was receptor-bound, IL-22 was co-stained against IL-
22RA1 (Figure 23). The results showed no overlap between IL-22 and IL-22RA1. The 
majority of IL-22+ (red) and IL-22RA1+ cells (green) were separate and morphologically 
distinct from each other.  
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Figure 23. IL-22 Immunofluorescent co-staining to IL22 Receptor (RA1) in skin sections 
taken 8 hours after intradermal grass pollen challenge from grass allergic individuals
Shown are examples 1-3 were close proximity of IL-22 and IL-22RA1 staining occurred. For better visual examination 
each example is represented as a co-stain as well as individual single stain.
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IL-22 vs. endothelial cells 
 
To understand if endothelial cells could account for the large and elongated IL-22 positive 
cells, IL-22 was co-stained against the endothelial marker CD31 (Figure 24). The result of 
the CD31/IL-22 co-stain showed that both stains strongly overlapped generating a yellow 
fluorescent signal. Not only long and elongated IL-22+ cells (Figure 24, Example 1-2) but 
also round and individually dispersed IL-22+ cells co-localised to CD31+ cells (Figure 24, 
Example 3). 
1.2.4. IL-22 Receptor Immunofluorecent staining of skin sections 
To understand the IL-22 receptor expression during allergic inflammation and discover the 
identity of IL-22 receptor positive cells, both IL-22RA1 and IL-22RA2 were investigated by 
immunohistochemistry and analysed by fluorescent microscopy (see Methods 1.2, page 76). 
  
Example 2
IL-22
CD31
DAPI
ISO
ISO
DAPI
Example 2
IL-22
DAPI
Example 2
CD31
DAPI
Example 3
IL-22
CD31
DAPI
Example 3
CD31
DAPI
Example 1
IL-22
CD31
DAPI
Figure 24. IL-22 Immunofluorescent co-staining to endothelial cells (CD31) in skin 
sections taken 8 hours after intradermal grass pollen challenge from grass allergic 
individuals
Shown are examples 1-3 were close proximity of IL-22 and CD31 staining occurred. For better visual examination each 
example is represented as a co-stain as well as individual single stain.
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Overall IL-22RA1 and –RA2 expression  
 
The results of the dual-immunofluorescence staining showed that IL-22RA1+ and -RA2+ cells 
occurred in both allergen and diluent challenged skin and remained unchanged during 
allergic inflammation (Figure 25). 3 times more IL-22RA2+ (77.4[8.4] cells/mm2) than IL-
22RA1+ (27.8[3.8] cells/mm2) were identified in allergen and diluent challenged skin (Figure 
25A).  
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Figure 25. Immunofluorescent staining of IL-22 Receptor RA1 and RA2 positive cells  in 
acetone-fixed skin sections taken 8 hours after intradermal grass pollen challenge from 3 
grass allergic individuals
A) Individual IL-22RA1, RA2, and IL-22RA1/RA2 cell counts B) Immunofluorescent co-staining of 3 atopic patients  with IL-
22RA1 and RA2 (from left to right G6,-7,-13)
B) IL-22RA1 vs. IL-22RA2
A) Cell Counts
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Expression in immune cells 
To understand if resident and infiltrating immune cells expressed IL-22RA1 or -RA2, both 
receptors were co-stained against adaptive and innate immune cell markers and assessed 
by fluorescent microscopy.  
IL-22RA1 and –RA2 vs adaptive immune cells 
 
First, infiltrating T (CD3) and B cells (CD19) were investigated for IL-22RA1, and –RA2 
expression. The dual-immunofluorescent stain showed no evidence that infiltrating CD3+ 
cells expressed IL-22RA1 or -RA2 (Figure 26). CD3+ cells were morphologically distinct and 
approximately 1.2-1.5 times smaller than IL-22RA1+ and RA2+ cells. While CD3+ cells were 
readily identified, CD19+ cells were absent in tissue obtained 8 hours after allergen injection 
(data not shown). 
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B) IL-22RA2 vs. CD3
Figure 26. IL-22 Receptor (RA1/RA2) Immunofluorescent co-staining to T cells (CD3) in 
acetone-fixed skin sections taken 8 hours after intradermal grass pollen challenge from 
grass allergic individuals
A) IL-22RA1  and CD3 co-stain  B) IL-22RA2 and CD3 co-stain. Represented are 3 examples were both Receptor and CD3 
staining occurred in close proximity. The tissue was fixed in acetone.
Example 2 Example 3
Example 2 Example 3
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IL-22RA2 vs innate immune cells 
 
A) Macrophages (CD68)
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Figure 27. IL-22 Receptor RA2 co-staining to innate immune cells in acetone-fixed skin 
sections taken 8 hours after intradermal grass pollen challenge from grass allergic 
individuals
IL-22RA2 was co-stained to A) CD68 B) Neutrophil elastase C) Mast cell tryptase D) Major basic Protein. 
Represented are 3 examples were both IL22 Receptor 2 and the respective co-stain occurred in close proximity. The 
tissue was fixed in acetone.
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IL-22RA2 was co-stained against the cellular markers of macrophages/dendritic cells 
(CD68), neutrophils (neutrophil elastase), mast cells (mast cell tryptase), and eosinophils 
(major basic protein). 
Each of the cell populations was readily identified within the allergen challenged skin tissue 
(Figure 27). IL-22RA2 did neither co-localise to macrophages, neutrophils, mast cells, nor 
eosinophils (Figure 27A-D).  
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Expression in structural cells 
 
To understand if IL-22RA1 and –RA2 could be expressed by structural cells, an analysis of 
their expression in the epidermis, blood vessels and connective tissue was carried out. The 
analysis of the epidermis showed that it stained positive for both IL-22RA1 and –RA2.  This 
stain remained inconclusive as the epidermis was stained by both isotype control antibodies 
(data not shown). 
Example 1
IL-22BP(RA2)
CD31
DAPI
ISO
ISO
DAPI
ISO
ISO
DAPI
Example 1
IL-22RA1
CD31
DAPI
A) Endothelial cells (CD31)
Example 2 Example 3
Example 2 Example 3
B) Mesenchymal cells (Vimentin)
Example 1
IL-22RA1
Vimentin
DAPI
Example 1
IL-22BP(RA2)
Vimentin
DAPI
Example 2 Example 3 ISO
ISO
DAPI
Example 2 Example 3 ISO
ISO
DAPI
Figure 28. IL-22 Receptor RA1/RA2 co-staining to endothelial (CD31) and mesenchymal
(Vimentin) cells in acetone-fixed skin sections taken 8 hours after intradermal grass pollen 
challenge from 3 grass allergic individuals
A) IL-22RA1 and RA2 co-staining against CD31 B) IL-22RA1 and RA2 co-staining against Vimentin
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To identify the expression of IL-22RA1 and –RA2 on blood vessels, the endothelial cell 
marker CD31 was used. The results showed that neither IL-22RA1+ or –RA2+ cells co-
localised to CD31 (Figure 28A).  
Cells of the connective tissue were identified using the mesenchymal cell marker vimentin. 
The results showed that both IL-22RA1+ and -RA2+ cells almost exclusively co-localised to 
vimentin+ cells (Figure 28B).  
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IL-22RA2 in Fibroblasts 
 
A major constituent of the connective tissue are fibroblasts. To investigate if fibroblasts 
accounted partially for the vimentin+ stain, IL-22RA2 was co-stained against an early and 
late stage marker of fibroblasts. 
To identify the early stage fibroblasts, Heat-shock-protein-47 (HSP47), a chaperone protein 
for collagen was stained against. The results showed that HSP47+ cells were almost always 
co-stained with IL-22RA2 (Figure 29A) but could not account for all IL-22RA2+ cells. A 
substantial number of IL-22RA2+ cells were HSP47 negative.  
To identify late stage fibroblasts, alpha-smooth-muscle-actin (-SMA), which forms an 
integral part of the contractive apparatus of mature fibroblasts (Arora et al 1994) was stained 
against. Co-staining of IL-22RA2 against -SMA showed no obvious association between 
the two (Figure 29B). The morphology of -SMA+ cells was very distinct from IL-22RA2+ 
cells. -SMA+ cells appeared in clusters and as thin and highly elongated cells while IL-
22RA2 + cells were round and individually dispersed. 
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Figure 29. IL-22 Receptor RA2 co-staining to fibroblasts in skin sections taken 8 hours after 
intradermal grass pollen challenge from 3 grass allergic individuals
A) IL-22RA2  and Heat shock protein 47 co-stain  (Paraformaldehyde fixed tissue) B) IL-22RA2 and alpha-Smooth-Muscle-
Actin co-stain (acetone fixed tissue).
Paraformaldehyde Paraformaldehyde Paraformaldehyde
Acetone Acetone Acetone
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1.3. Summary 
Bronchial segmental allergen challenge 
 Bronchial segmental allergen challenge caused a significant immediate reduction in 
lung function (FEV1) in allergic asthmatics but not normal controls 
 Bronchoalveolar lavage of allergic asthmatics taken 24 hours after allergen challenge 
showed a significant influx of eosinophils and IL-5 but not IFN expression 
 Measurement of IL-22, IL-22RA2 and IL-17 showed that IL-22 and IL-22RA2 but not 
IL-17A/F significantly increased  after allergen challenge 
Intradermal allergen challenge 
 Intradermal allergen challenge caused both an early and significant late phase 
cutaneous swelling in atopic allergic subjects but not normal controls 
 Tissue biopsies taken from the site of allergen inflammation showed  a significant 
increase in eosinophils and T cells 8 hours after challenge 
 Detection of IL-22 remained inconclusive and could not be convincingly assessed 
using Immunfluorescence 
 IL-22RA1 and RA2 receptor expression showed a wide constitutive expression 
pattern within the skin which remained unchanged after allergen challenge 
 Both IL-22RA1+ and RA2+ were largely confined to the vimentin+ cells 
 Co-localistaion of IL-22RA2 showing some co-expression with HSP47 but not SMA 
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2. IL-22 expression in T cells  
We hypothesised that T cells were the main source of IL-22 during the allergic inflammation. 
As we were unable to stain IL-22 in tissue taken from the site of allergen inflammation (see 
Results 1.2.3, page 108), we set out to test our hypothesis in vitro. 
2.1. from peripheral blood 
Using peripheral blood, an in vitro allergen challenge model was set up to measure the 
induction of IL-22 and IL-22+ T cells. In addition the study aimed to investigate IL-22+ T cells 
more generally. To do so naïve T cells were polarized in newly described Th22 differentiating 
conditions and the expression of putative Th22 receptors in memory T cells was evaluated.  
2.1.1. long term allergen PBMC culture 
To study the induction of IL-22 and IL-22+ T cells as a response to allergen, an in vitro 
challenge model, in which peripheral blood mononuclear cells (PBMCs) were stimulated 
with purified allergen over a period of 6 days, was set up. (see Methods 2.1.1, page 79). 
Demographics of study participants 
 
In total, 12 atopic individuals with seasonal allergic rhinitis and 11 normal healthy control 
individuals were recruited (Table 62). Both groups had a similar distribution of age and 
gender. Compared to normal healthy controls, atopic individuals had significantly higher 
levels of total serum IgE (p=0.003). All atopic patients tested positive by skin prick testing to 
timothy grass (Phleum pratense ) and had significantly elevated levels of specific IgE in their 
serum (RAST; p= 0.0001). 
  
Treatment Group Atopic
(n=12)
Normal Control
(n=11)
Age (Y) 33.2(2.5) 45.4(4.2)
Gender (M/F) 5/7 7/4
Skin prick test positive (Yes/No) 12/0 0/12
Multiple allergen (Yes/No) 9/3 0/12
Total IgE (IU/ml) 290.5(82.9) ** 28.8(9.2)
RAST (IU/ml) 24.3(7.1) **** 0.01(0.0)
Skin Prick test against Timothy Grass (Phleum pretanse). *Total IgE and RAST for one normal control (Tc209)
were not available; Mean +/- Standard Error of the Mean (Std.Dev./n). Statistical test (Mann-Witney U test)
Table 62. Summary of the clinical parameters of individuals whose blood was
taken and used for the in-vitro allergen PBMC co-culture experiments
123 
 
[methyl3H]-Thymidine incorporation 
 
To determine a positive proliferative response of PBMCs to Phleum pratense [methyl3H]-
thymidine was added in a subset of participants to their culture and its incorporation 
quantified (see Methods 2.1.1, page 79). The results of the [methyl3H]--thymidine 
incorporation showed that cultures derived from atopic donors showed an 80% increase in 
[methyl3H]-thymidine incorporation from 426.1(4.6)cpm to 767.2(7.6)cpm after allergen 
challenge (Figure 30). This increase was convincing in 5/6 atopics but due to one outlier 
failed to reach significance (p=0.09).  
The [methyl3H]-thymidine incorporation results of cultures derived from normal donors 
showed a more mild increase in [methyl3H]-thymidine absorption of 37%. This increase was 
found in 5/6 normal donors. The difference between atopic and normal PBMC cultures in the 
proliferative response towards allergen was visible but not significant (p=0.394). 
  
Figure 30. Measurement of [methyl3H]-Thymidine incorporation over 16 hours in
PBMCs obtained after 6 days of allergen-PMBC co-culture from grass pollen atopic
and normal individuals
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Cytokine expression in culture supernatants 
IL-5 and IFN  
 
To determine that Phleum pratense  stimulation caused a Th2 -type immune response in the 
PBMC cultures, the expression of the Th2 cytokine Interleukin-5 and the Th1 cytokine IFN- 
within culture supernantants were quantified. 
The measurement of IL-5 by ELISA showed that the cytokine increased in 8/12 atopic 
(p=0.004) PBMC cultures after allergen stimulation (Figure 31A). This observation was 
significantly different to the normal PBMC cultures (p=0.004) where only 1/11 had detectable 
levels of IL-5 after allergen stimulation. The measurement of IFN- showed that the cytokine 
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Figure 31. Quantification of IL-5 and IFN in culture supernatants obtained from 6
day allergen-PMBC cultures of both grass allergic and normal donors.
A) Change in IL5 Atopics p=0.0039 Wilcoxon. Change in IL-5 Atopics vs Normals p=0.0042 Mann-Witney U
test.
A) Interleukin-5
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remained unchanged after allergen stimulation in both atopic and normal PBMC cultures 
(Figure 31B). 
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IL-22 and IL-17  
 
  
IL
-1
7
A
/F
 (
C
o
m
b
in
e
d
)
IL-17A/F [pg/ml]
C
on
tro
l
g/
m
l]
m
Ph
l P
 [5
8
1
2
1
6
1
0
0
2
0
0
3
0
0
4
0
0
F
ig
u
re
3
2
.
Q
u
a
n
ti
fi
c
a
ti
o
n
o
f
IL
-2
2
a
n
d
IL
-1
7
A
/F
in
c
u
lt
u
re
s
u
p
e
rn
a
ta
n
ts
o
b
ta
in
e
d
fr
o
m
6
d
a
y
a
ll
e
rg
e
n
-P
M
B
C
c
u
lt
u
re
s
o
f
b
o
th
g
ra
s
s
a
ll
e
rg
ic
a
n
d
n
o
rm
a
l
d
o
n
o
rs
.
S
ta
ti
s
ta
ic
a
la
n
a
ly
s
is
(p
=
0
.0
0
4
;
W
ilc
o
x
o
n
m
a
tc
h
e
d
p
a
ir
e
d
T
te
s
t)
A
) 
In
te
rl
e
u
k
in
-2
2
IL
-2
2
 (
C
o
m
b
in
e
d
)
IL-22 [pg/ml]
C
on
tro
l
g/
m
l]
m
Ph
l P
 [5
1
0
1
5
2
0
2
5
5
0
7
5
1
0
0
1
2
5
1
5
0
3
0
0
3
5
0
4
0
0
B
) 
In
te
rl
e
u
k
in
-1
7
A
/F
C
o
m
b
in
e
d
**
C
o
m
b
in
e
d
IL
-1
7
a
 (
A
to
p
ic
 P
a
ti
e
n
ts
)
C
on
tro
l
g/
m
l]
m
Ph
l P
 [5
8
1
2
1
6
1
0
0
2
0
0
3
0
0
4
0
0
1
1
3
8
4
-A
1
1
6
2
0
-A
1
1
9
9
4
-A
1
2
1
6
0
-A
T
c
3
1
0
-A
T
c
3
1
1
-A
T
c
1
8
4
-A
T
c
1
8
5
-A
T
c
1
8
7
-A
T
c
1
8
8
-A
T
c
1
9
2
-A
T
c
1
9
3
-A
IL-17a [pg/ml]
IL
-1
7
a
 (
N
o
rm
a
l 
C
o
n
tr
o
ls
)
C
on
tro
l
g/
m
l]
m
Ph
l P
 [5
8
1
2
1
6
1
0
0
2
0
0
3
0
0
4
0
0
T
c
4
0
9
-N
T
c
2
0
3
-N
T
c
2
0
4
-N
T
c
2
0
8
-N
T
c
2
0
9
-N
T
c
1
8
9
-N
T
c
1
9
0
-N
T
c
1
9
1
-N
T
c
1
9
5
-N
T
c
1
9
6
-N
T
c
1
9
7
-N
IL-17a [pg/ml]
IL
-2
2
 (
A
to
p
ic
 P
a
ti
e
n
ts
)
C
on
tro
l
g/
m
l]
m
Ph
l P
 [5
1
5
2
0
1
0
0
2
0
0
3
0
0
4
0
0
T
c
1
8
4
-A
T
c
1
8
5
-A
T
c
1
8
7
-A
T
c
1
8
8
-A
T
c
1
9
2
-A
T
c
1
9
3
-A
1
1
3
8
4
-A
1
1
6
2
0
-A
1
1
9
9
4
-A
1
2
1
6
0
-A
T
c
3
1
0
-A
T
c
3
1
1
-A
IL-22 [pg/ml]
IL
-2
2
 (
N
o
rm
a
l 
C
o
n
tr
o
ls
)
C
on
tro
l
g/
m
l]
m
Ph
l P
 [5
1
5
2
0
1
0
0
2
0
0
3
0
0
4
0
0
T
c
1
8
9
-N
T
c
1
9
0
-N
T
c
1
9
1
-N
T
c
1
9
5
-N
T
c
1
9
6
-N
T
c
1
9
7
-N
T
c
4
0
9
-N
T
c
2
0
3
-N
T
c
2
0
4
-N
T
c
2
0
8
-N
T
c
2
0
9
-N
IL-22 [pg/ml]
A
to
p
ic
s
A
to
p
ic
s
N
o
rm
a
ls
N
o
rm
a
ls
n
.s
.
n
.s
.
IL-17A/F [pg/ml]
IL-17A/F [pg/ml]
IL-17A/F [pg/ml]
127 
 
IL-22 is commonly classified under a Th17 cell response and was thus quantified together 
with IL-17A and IL-17F by ELISA. The combination of both atopic and normal PBMC culture 
results (n=23) showed that IL-22 was significantly up-regulated after allergen challenge 
regardless of atopic status (p=0.004).The results showed that IL-22 increased in 3/12 atopic 
and 5/11 normal PBMC cultures after allergen stimulation (p>0.05) (Figure 32A). A power 
analysis showed that the additional recruitment of 37 atopics and 28 normal healthy controls 
may have achieved statistical significance in each group (p<0.05 Wilcoxon). The results of 
the IL-17A/F ELISA showed no evidence that IL-17 was elevated after allergen stimulation in 
either atopics or normal healthy controls (Figure 32B). 
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Flow cytometry analysis of IL-22+ CD4+ T cells 
 
To investigate if the allergen-induced IL-22 was released by T cells, the cultures were 
analysed further using flow cytometry (see method 2.1.1, page 80). At day 6, the allergen 
challenged PBMC cultures were polyclonally activated and stained for IL-22, IL-17A, IFN-, 
IL-4, IL-5, and IL-9 expression. 
The flow cytometry results showed only traces of IL-22 expression in 0/12 atopic and 2/11 
normal PBMC cultures (Figure 33). These small amounts of IL-22 were located exclusively 
in the CD4+ T cell population. In the rare instance where IL-22 was detected, it did not co-
A) Atopic 
Figure 33. Flow cytometric analysis of IL-22 expression in CD4+ T cells obtained
after 6 days of grass allergen PBMC co-culture and subsequent PMA/Ionomycin
stimulation.
A) Atopic allergen-PBMC culture (donor Tc188) B) Normal allergen-PBMC co-culture (donor Tc189). FACS
plots are representative
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localise to the Th2 cytokines IL-4, IL-5 or IL-9 but partially overlapped with The Th1 and Th17 
cytokines IFN and IL-17A.   
2.1.2. polarised naive T cells 
To study IL-22+ T cells and their relationship to other T helper subsets in more detail, a Th22 
differentiation culture using naive CD4+ T cells was set up (see methods 2.1.2, page 81).  
IL-22 expression after Th22 differentiation 
 
The newly described Th22 conditions of IL-6 and TNF were used to deform naive T cells 
over a period of two weeks (Duhen et al 2009). After the differentiation, each T cell culture 
was polyclonally activated and analysed by flow cytometry for their IL-22 and IL-17A 
expression.  
The results showed that IL-22 expression was low (<1%) and remained unchanged in cells 
exposed either to IL-6+TNF, IL-6, or TNF alone (Figure 34). These findings were identical 
when the serum free media (AIM-V) was replaced with serum containing media (RPMI+5% 
human serum). There was a tendency of IL-17A to be increased in “IL-6 only” cultures but 
this was not significant (p=0.3).  
Along with Th22 polarising conditions, Th1 polarising conditions were used as a positive 
control. The differentiation of naive T cells in IL-12 and -IL-4 conditions showed to 
significantly increase IFN positive T cells. In serum free media, IFN expression increased 
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Figure 34. Flow cytometric analysis of IL-22 and IL-17A expression in T cells 
obtained after naive (CD45RO-) peripheral blood T cell differentiation using Th22
and Th1 deforming conditions.
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4.5-fold from 2.6(0.3)% to 11.9(2.3)% of total T cells (p=0.041). In serum containing media, 
IFN  was further up regulated 7.5-fold from 5.6(0.6)% to 41.8(1.9)% (p=0.002). While the 
Th1 polarising conditions increased IFN expression, IL-22 expression remained unchanged.   
2.1.3. memory T cells 
In addition to studying the development of IL-22+ T cells, the study focused on ways to 
isolate and study already differentiated IL-22+ memory T cells ex vivo (see Methods 2.1.3, 
page 84). 
Occurrence of putative Th22 receptors FGFR2, PDGFR, TIE1 on T cells 
 
Populations of memory CD4+ T cells have been shown to preferentially express specific 
surface receptors which can be used to enrich them from the peripheral blood (O’Garra et al 
1998). The recent investigation of skin Th22 clones (Eyerich et al 2009) identified three 
surface receptors which may be preferentially expressed by IL-22 expressing CD4+ T cells. 
These included the fibroblast-growth-factor-receptor-2 (FGFR2), the tyrosine-kinase-with-
immunoglobulin-like-and-EGF-like-domain-receptor-1 (TIE1), and the platelet-derived-
growth-factor-receptor (PDGFR).  
First, it was established if FGFR2, TIE1, and PDGFR could be identified on peripheral blood 
CD4+ T cells. The flow cytometry results showed that all 3 receptors were present on a small 
proportion of CD4+ T cells (Figure 35). FGFR expression was found on 2.6(0.4)% of total 
CD4+ T cells (p=0.003 vs isotype). Its expression was found equally on CD45RO+ and 
CD45RO- CD4+ T cells. TIE1 was expressed by 1.5(0.2)% of total CD4+ T cells (p=0.002 vs 
isotype) all of which were exclusively CD45RO+. PDGFR expression was barely detectable 
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Figure 35. Flow cytometric analysis of putative Th22 receptor FGFR2, TIE1, 
PDGFR expression on peripheral blood CD4+ T cells
FACS plots are representative. Statistical analysis of cumulative data (Receptor + vs. Isotype+; paired T-test)
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and found on only 0.6(0.2)%  of total CD4+ T cells (p=0.043 vs isotype). Like TIE1, PDGFR 
expression was restricted exclusively to CD45RO+ CD4+ T cells. 
IL-22 expression in putative Th22 receptor enriched cells 
 
To understand if FGFR2, TIE, or PDGFR positive T cells were linked to IL-22 expression, 
peripheral blood T cells were enriched using a combination of anti-receptor FACS antibodies 
and anti-fluorochrome magnetic beads (see Methods 2.1.3, page 84). 
The resulting T cell fractions were polyclonally activated and analysed for their IL-22 and IL-
17A expression by flow cytometry. The results showed that FGFR2, TIE1, and PDGFR 
enriched T cell fractions did not express more IL-22 than their respective depleted fractions 
(Figure 36). This was true not only for IL-22 but also IL-17A (data not shown). To verify that 
Figure 36. Flow cytometric analysis of IL-22 and IL-17A expression in magnetic-
bead enriched peripheral blood T cells expressing putative Th22 receptors PDGFR, 
FGFR2, TIE1 or chemokine receptor CCR4, CCR6, CCR10.
FACS plots are representative. Statistical analysis of cumulative data (Receptor-enriched vs, Receptor-
depleted IL-22+ cells; paired T test)
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IL-22+ T cells could be enriched from peripheral blood CD4+ T cells, we utilised the Th22-
associated chemokine receptors CCR4, CCR6, and CCR10 (Duhen et al 2009, Trifani and 
Spits 2010).  The results of the enriched CCR+ T cell fractions showed that IL-22 expression 
was increased minimally in CCR10-enriched and significantly in CCR6-enriched CD4+ T 
cells (p=0.003).  
IL-22 expression in putative Th22 receptor-ligand stimulated cells 
While FGFR2-, TIE1-, and PDGFR-enriched CD4+ T cells did not express more IL-22 than 
their depleted counterparts, it was investigated if the receptor ligands could trigger IL-22 
production. To investigate this, peripheral blood CD4+ T cells were cultured in the presence 
or absence of FGF-1, -2,-5 and PDGF-BB and their cytokine gene expression profile was 
analysed by RT-PCR (see Methods 2.1.3, page 85) 
 
The results showed that the addition of FGF-1, -2, -5 and PDGF-BB for a duration of 24 
hours did not alter the relative expression levels of IL-22, IL-17A, IL-4, IFN, IL-10, or TGFβ1 
(Table 63).   
  
Ligand IL-22 IL-17A IL-4 IFN IL-10 TGFβ1 Effect
FGF-1 0.8(0.1) 0.9(0.1) 0.7(0.1) 0.8(0.2) 0.7(0.2) 0.9(0.2) No effect
FGF-2 0.7(0.1) 1.0(0.6) 0.7(0.1) 0.8(0.1) 0.9(0.1) 1.1(0.2) No effect
FGF5 0.8(0.1) 1.5(0.7) 1.1(0.3) 1.1(0.2) 1.1(0.3) 1.3(0.3) No effect
PDGF-BB 0.8(0.1) 0.7(0.4) 0.7(0.1) 1.0(0.1) 1.0(0.1) 1.1(0.2) No effect
Gene expression relative to un-stimulated cells and calculated using ΔΔ ct method. Data is represented as
Mean +/- Standard Error of the Mean (Std.Dev./n)
Table 63. Effect of 24 hour FGF-1,-2,-5 and PDGF-BB exposure on T cell cytokine
mRNA expression of cultured peripheral blood CD4+ T cells
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2.2. from human asthmatic bronchial mucosa 
To study lung memory IL-22+ T cells in more detail, T cells were isolated directly from human 
asthmatic bronchial mucosa. 
2.2.1. Demographics of study participants 
 
To do so, 6 asthmatic individuals were recruited of whom 2/6 were allergic asthmatics (Table 
64). Allergic asthmatics had elevated levels of total IgE, tested positive by skin prick test 
(>3mm2), and had elevated levels of allergen specific IgE.  
 2.2.2. IL-22 expression in lung T cell lines 
After isolation and culture, T cells derived from small bronchial mucosal tissue (ca 3mm2) 
were assessed after polyclonal activation for their IL-22 expression potential by flow 
cytometry (see Methods 2.2.2, page 88).  
All lung T cell lines from asthmatic and allergic asthmatics contained IL-22+ T cells. The 
frequency of IL-22+ T cells was similar in allergic and non-allergic asthmatics reaching an 
average of 2.4(0.9)% (data not shown). 
 
  
Treatment Group Asthmatic Participants
(n=6)
Group Non-Atopic Atopic
Age (Yrs) 42.8(4.9) 33.5(0.4)
Gender (M/F) 2/2 2/0
Non-Severe/Severe Asthma (n/n) 1/3 1/1
Skin prick test positive (Yes/No) 0/4 2/0
Total IgE (IU/ml) 186.7(62.7) 1922.5(1077.5)
RAST HDM (IU/ml) - 100(1)
(1) Specific IgE tests for 1 atopic asthmatic (B04) were not available. Mean +/- Standard Error of the Mean
(Std.Dev./n)
Table 64. Summary of the clinical parameters of individuals who underwent
fibreoptic bronchoscopies and had a subsequent lung tissue biopsy taken for
further T cell studies
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γδ and β T cells 
 
To characterise the true identity of IL-22+ T cells, IL-22 was co-stained against the innate γδ- 
and adaptive β-T cell receptor.  
The results showed that more than 95% of IL-22+ T cells expressed the β T cell receptor 
(TCR) while less than 5% of IL-22+ T cells expressed the γδ TCR (Figure 37A). Despite the 
huge number of β-TCR+ IL-22+ T cells, the occurrence of IL-22+ T cells within each γδ- and 
β TCR+ T cell population was with 8% identical (Figure 37B).  
  
3%
97%
97%
3%
100%
Figure 37. Flow cytometric analysis of IL-22 expression of αβ- and γδ T cell 
receptor positive cells from T cell lines created from bronchial tissues
Facs Plots from representative T cell line MA14
B) γδ/β T cells
100%
αβ-T Cells
8%
IL-22+ T cells
γδ-T Cells
8%100%
IL-22+ % γδ-T Cells IL-22+ % αβ-T Cells
γδ-T Cells % IL-22+
αβ-T Cells % IL-22+
A) IL-22+ T cells
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CD4 and CD8 T cells 
 
Adaptive β T cells can be further divided into T helper cells and cytotoxic T cells. To 
understand which of the β TCR+ population accounted for the observed IL-22 expression, 
IL-22 was co-stained against the T helper surface marker CD4 and the cytotoxic T cell 
marker CD8.  
The results of the flow cytometry analysis showed that IL-22+ T cells expressed significantly 
more CD4+ than CD8+ (p=0.005) (Figure 38A). In total, 57.3(4.5)% of IL-22+ T cells were 
CD4+  while only 15.4(4.6)% expressed CD8+. While CD4+ T cells accounted for the majority 
of IL-22+ T cells, the frequency of IL-22+ T cells within the CD4 and CD8 population was 
Figure 38. Flow cytometric analysis of  IL-22 expression of CD4+ and CD8+ T cells 
from T cell lines created from bronchial tissues
A) Distribution of  CD4/CD8 expression within the IL-22+ T cell population (T cell line SA02) B) Distribution of 
IL-22 expression within CD4/CD8 T cell populations. Statistical analysis of cumulative data (paired T-test)
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similar (Figure 38B). IL-22 expression accounted for 5.0(1.3)% and 5.2(1.9)% of CD4+ and 
CD8+ T cells respectively. 
T helper subsets 
 
CD4+ T cells are frequently classified into T helper subsets using their distinct cytokine 
expression profile. Until recently, IL-22+ T cells were described as a derivative of Th17 cells. 
Since then IL-22 and IL-17 were found to be independently regulated (Zheng et al 2007) and 
the occurrence of significant numbers of IL-22+IL-17- T cells during inflammation (Scriba et al 
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Figure 39. Flow cytometric analysis and classification of IL-22+ CD4+ T cells obtained 
from bronchial lung T cell lines into different T helper subsets
Facs plots are representative (T cell line MA14). Statistical analysis of cumulative data (Th1 vs Th17 cells p=0.0088 ; 
paired T-test).
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2008) has led to the advocation of a new Th22 subset (Trifani and Spits 2010, Duhen et al 
2009, Eyerich et al 2009).  
To establish the true T helper subset-identify of IL-22+ T cells within the lung T cell lines, IL-
22 was stained against the lead cytokines IL-4, IFN, and IL-17A. 
The flow cytometry analysis showed that 43.8(5.3)% of IL-22+ T cells co-expressed IFN and 
were classified as Th1/22 cells (Figure 39). The second largest IL-22
+ T helper population with 
22.2(6.8)%  were Th22 cells. Both Th1/22 and Th22 cells were more numerous than classic 
Th17/22 cells which accounted for only 10.2(4.5)% of IL-22
+ T cells. This difference was 
significant between Th1/22 and classic Th17/22 cells (p=0.009). The results also showed that on 
average 22.8(4.4)% of IL-22+ CD4 T cells could not be associated to either of the known T 
helper subsets (Figure 39, ‘N.A.’). 
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 2.2.3. IL-22 expression in lung T cell clones 
The occurrence of large numbers of Th1/22 and Th22 cells within the asthmatic T cell lines 
prompted us to study the different IL-22+ T cells further. To investigate them, individual T 
cells were isolated by limiting dilution and clonally expanded in vitro (see Methods 2.2.3, 
page 89). 
Flow cytometry of IL-22+ T cell clones 
 
T cell clones derived from asthmatic T cell lines were assessed for a homogeneous CD4 
expression and then analysed for their IL-22, IL-17A, IL-4, and IFN expression potential 
using polyclonal activation. 
The results of the flow cytometry analysis showed that 3/36 T cell clones were IL-22+ (Figure 
40). Analysis of these IL-22+ T cell clones revealed that they did not belong to the previously 
identified Th1/22, Th22, or Th17/22 subset (see Results 2.2.2 Figure 39 page 136). Each of the 
clones was capable of expressing IL-22 together with IL-4, IFN and IL-17A and could thus 
not be clearly categorised. The remaining 33/36 T cell clones were classified as Th1 (n=17), 
Th0 (n=10), and Th2 (n=6) T cell clones (data not shown).  
  
Figure 40. Flow cytometric analysis of IL-22, IL-17A, IL-4, and IFN co-expression in 
CD4+ T cell clones obtained from bronchial lung mucosa
IL-22+ CD4+ T cell clone A (B06,ID3-2-3), B(B06,ID3-2-6), C (B06,ID3-2-13). FACS plots of Th1 and Th2 clones are 
representative
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2.3. Summary 
Long term allergen-PBMC challenge study 
 Both atopic and normal PBMC cultures responded to the allergen with increased 
proliferation ([methy3H]-thymidine incorporation) 
 After 6 days of culture IL-5 but not IFN was increased in atopic PBMC cultures while 
normal PBMC cultures showed no IL-5 or IFN response 
 Measurement of IL-22 and IL-17 showed that IL-22 was produced by both atopic and 
normals after allergen challenge while IL-17 remained absent 
 Flow cytometric analysis failed to detect significant levels of IL-22 in PBMC cultures 
at day 6. In the rare instance when IL-22 was detected, it was CD4 T cell associated 
and small  population of co-expressing IFN+ and IL-17A+ but not  IL-4+, IL-5+, or IL-9+ 
cells could be observed 
Th22 T cell differentiation 
 Differentiation of naïve CD4 T cells derived from normal donors in Th22 polarising 
conditions (TNF and IL-6) failed to increase the number of IL-22+ T cells after 
culture 
 The use of serum-free and serum-containing media had no influence on Th22 cell 
differentiation  
Th22 memory T cell isolation using putative surface markers 
 The putative Th22 markers FGFR2, TIE1 and PDGFR were all expressed by a minor 
population of peripheral blood CD4 T cells. While TIE1 and PDGFR were found 
exclusively on CD45RO+ T cells FGFR2 was expressed on both CD45RO+ and 
CD45RO- T cells 
 The enrichment of FGFR2, TIE1 and PDGFR-positive CD4 T cells did not correlate 
with an increase IL-22+ T cells  
 The stimulation of peripheral blood CD4 T cells with FGF1,-2,-5 and PDGF-BB for 24 
hours showed to have no influence on IL-22 cytokine expression 
IL-22 expression in asthmatic lung T cell lines and clones 
 Lung T cell lines from asthmatic  bronchial mucosal tissue contained memory IL-22+ 
T cells 
 βTCR+ and CD4+ T cells were the dominant T cell population within each cell line 
containing the majority of IL-22+ T cells. The frequency of  IL-22+ T cells in β and δ 
as well as CD4 and CD8 T cell populations was similar 
 IL-22 expression within Th2 cells was almost always absent and the majority of IL-22
+ 
T cells belonged to the Th1/22, and Th22 subset 
 While Th1 and Th2 clones could be easily obtained, we were unable to isolate and 
analyse pure Th22 cells  
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3. IL-22 in human tissue regeneration and repair 
Having identified IL-22 expression within the lung of allergic asthmatics after allergen 
challenge, we set out to identify the target cells of IL-22 and study IL-22’s function on them in 
more detail.  
3.1. IL-22 Receptor expression in human lung cell lines 
The study investigated if primary lung cell lines such as bronchial epithelial cells, airway 
smooth muscle cells, and fibroblasts could express the IL-22 receptors IL-22RA1 and –RA2 
and be used to study the function of IL-22 in vitro. 
Protein expression by Western Blot 
 
To detect the constitutive expression of IL-22RA1 and –RA2 in each primary lung cell line, 
total cell lysates were obtained and analysed by Western Blotting (see Methods 3.1, page 
92).  
The Western blot results showed that IL-22RA1 was detectible in all primary lung cell lines 
but not peripheral blood CD4+ T cells (Figure 41, IL-22RA1: visible 65kDa; calculated 
63kDa). IL-22RA1 was rapidly detectable and showed similar intensity to the loading control 
alpha-tubulin (visible 58kDa). The intensity of the IL-22RA1 band between bronchial 
epithelial cells, fibroblasts, and smooth muscle cells was very similar. 
IL-22RA2 was similarly detected in all three primary lung cell lines but not peripheral blood 
CD4+ T cells (IL-22RA2:visible28kDa, calculated 27kDa). The IL-22RA2 band required 3 
times longer detection times to be visible and was thus much weaker than the alpha-tubulin. 
50kDa
60kDa
85kDa
120kDa
Figure 41. Western Blot analysis of IL-22 Receptor RA1 and RA2 expression in 
primary lung bronchial epithelial, fibroblasts, smooth muscle cell lines and 
peripheral blood CD4+ T cells
molecular weights of IL-22RA1 (63kDa), IL-22RA2 (27kDa), α –tubulin (50kDa).
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The intensity of the IL-22RA2 band between bronchial epithelial cells, fibroblasts, and 
smooth muscle cells was again very similar. 
Surface expression by flow cytometry 
 
To understand if the detected IL-22RA1 protein was expressed on the cell surface of 
bronchial epithelial cells, fibroblasts, and smooth muscle cells, each cell line was analysed 
by flow cytometry.  
The results of the flow cytometric analysis showed that bronchial epithelial cells, fibroblasts, 
and smooth muscle cells tested positive for IL-22RA1 (Figure 42, p<0.05). The largest 
expression of IL-22RA1 was found in bronchial epithelial cells where 54.1(3.7)% of them 
were IL-22RA1 positive. In contrast, only 5.4(0.2)% of smooth muscle cells and 1.9(0.2)% of 
fibroblasts were capable of expressing IL-22RA1 on their surface. Peripheral blood CD4+ T 
cells, used as negative control, tested negative for IL-22RA1. 
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Figure 42. Flow cytometric analysis of IL-22RA1 surface expression on bronchial 
epithelial, fibroblast, smooth muscle lung and peripheral blood CD4+ T cells
A) IL-22RA1 surface stain B) Isotype control stain
Fibroblasts Smooth muscle CD4+ T cells
0.00.5 0.1
0.0
B) Isotype Binding
A) IL-22RA1 Surface Expression
Epithelial cells Fibroblasts Smooth muscle CD4+ T cells
IS
O
T
Y
P
E
IL
-2
2
R
A
1
142 
 
Regulation by RT-PCR 
 
Having identified the expression of IL-22RA1 and RA2 within primary bronchial epithelial 
cells, airway smooth muscle cells, and fibroblasts, the study investigated if their expression 
could be influenced by different T cell cytokine environments. To do so, bronchial epithelial 
cells were exposed to different recombinant cytokines in culture and the change IL-22RA1 
and –RA2 mRNA expression analysed by RT-PCR (see methods 3.1, page 97).  
The RT-PCR analysis revealed that after 6 hours of culture only IFN-γ was able to influence 
IL-22RA1 mRNA expression (Figure 43). IL-4, IL-5, IL-9, IL-13, IL-17A, IL-22, TGFβ1, IL-10 
and TNF had no visible effect on IL-22RA1 gene expression.  In the presence of IFN-γ, 
bronchial epithelial cells up-regulated IL-22RA1 by 3.0(0.1)-fold. The RT-PCR analysis of IL-
22RA2 showed no evidence that its gene expression was altered by the presence of  IL-4, 
IL-5, IL-9, IL-13, IL-17A, IL-22, TGFβ1, IL-10, TNF, or IFN-γ.  
  
A) IL-22RA1
Figure 43. RT-PCR analysis of IL-22 Receptor RA1/RA2 gene expression in 
bronchial epithelial cells cultured in the presence of different T cell cytokines
Sample population n=3 ; Statistical test  (wilcoxon)
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To better understand the influence of IFN-γ on IL-22RA1 gene expression, bronchial 
epithelial cells were exposed to a series of IFN-γ concentrations. The results of the IFN-γ 
dose response showed that 0.1ng/ml was sufficient to induce IL-22RA1 up-regulation (Figure 
44). The strongest up-regulation of 5.3(0.3)-fold was observed in the presence of 10ng/ml. 
Larger concentrations of 50 and 100ng/ml had no further beneficial effect and reduced the 
observed IL-22RA1 up-regulation. To understand how rapidly the IL-22RA1 up-regulation 
occurs and how long it could be maintained, cells were exposed to IFN-γ over a period of 24 
hours and analysed. The RT-PCR results showed that IL-22RA1 up-regulation could be 
detected as early as 4 hours after IFN exposure. The IL-22RA1 up-regulation increased 
further reaching a maximum 4.1(0.2)-fold up-regulation at 12 hours. The IL-22RA1 up-
regulation remained high and did not reduce in magnitude even after 24 hours. The analysis 
was widened to include airway smooth muscle cells and fibroblast. Both cell types were 
exposed to 10ng/ml IFN and their analysed by RT-PCR. The RT-PCR results showed that 
IFN was able to up-regulate IL-22RA1 mRNA expression in a similar manner not only in 
bronchial epithelial cells but also airway smooth muscle cells and fibroblasts (see Appendix, 
Figure 51, page 215).  
3.2. Effect of IL-22 on bronchial epithelial cells 
Epithelial cells within the lung are known to be a target of IL-22. Our primary bronchial 
epithelial cell line showed a high constitutive surface expression of IL-22RA1 (see Results 
3.1, Figure 42, page 141) in culture and was thus an ideal model cell line to study the 
function of IL-22 in more detail. The main objective was to better understand the role of IL-22 
in wound healing.  Before any potential mechanism could be investigated, we had to confirm 
that IL-22 was able to improve healing in primary bronchial epithelial cells in vitro.  
3.2.1. Wound healing 
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Figure 44. Dose and time response of  IFNγ on bronchial epithelial IL-22RA1 
expression
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To confirm that IL-22 was able to improve healing in vitro, a wound healing assay commonly 
known as scratch assay was set up (see Methods 3.2.1, page 95). In this assay, a confluent 
monolayer of bronchial epithelial cells was injured or “scratched” and monitored by light 
microscopy over time. The difference in wound closure between IL-22 treated and untreated 
cell was analysed first by eye and then computer software.  
IL-22 time and dose response 
 
The results of the scratch assay showed that control cells were able to almost completely 
close the wound 16 hours after injury (Figure 45). The difference between IL-22 treated and 
untreated cells was not easily detectable. While a visual difference between IL-22 and 
control cells was observed, the complete data set (n=9) was highly variable.  
 
Figure 45. Light microscopic analysis of the effect of IL-22 on bronchial epithelial 
wound closure over time
The assessed injured surface area is represented in green. Images are representative (100x magnification).
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Therefore, the acquired data was re-analysed using specialised software. This software was 
able to accurately determine the surface area of the injury over time. The results showed 
that increasing concentrations of IL-22 of 50ng/ml and 200ng/ml significantly improved 
wound closure (Figure 46A). Compared to untreated cells 200ng/ml IL-22 treated cells 
showed a 48.8% improvement (p=0.0001). Monitoring wound closure over time (Figure 46B) 
showed a detectable difference between IL-22 and untreated cells as early as 4 hours after 
injury. Wound closure appeared to reach its peak 10 hours after injury and effectively 
stopped thereafter. 
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Figure 46. Software-assisted analysis of the effect of IL-22 on bronchial epithelial 
wound closure over time
A) 50ng/ml (p=0.0238), 200ng/ml (p=0.0001). Statistical analysis (unpaired T-test)
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Effect of IL-17A on IL-22-associated wound closure 
 
The study then focused on IL-17A and if the cytokine could interfere with the IL-22-
associated wound closure. 
The results showed that IL-17A, on its own, had little or no effect on wound closure (Figure 
47). Control cells had 35.3(4.8)% of their injury remaining while IL-17A exposed cells had 
31.7(3.9)%. In addition IL-17A had little or no effect on IL-22-associated wound closure. The 
combination of IL-17A + IL-22 resulted in a reduction to 17.3(3.5)%. This was very similar to 
the 16.9(2.5)% observed in IL-22 only exposed cells. 
3.2.2. Proliferation 
While the function of IL-22 on epithelial wound closure could be confirmed (see Results 3.1, 
page 144), the underlying mechanism(s) had yet to be elucidated. Four main aspects were 
identified which could, in part, play a role in IL-22-associated wound closure. These were (A) 
Increased survival of damaged cells (anti-apoptotic) (B) Loss of cell layer integrity (loss of 
cell-cell contact), (C) cytoskeletal rearrangement (D) cell spreading and migration as well as 
(E) cell proliferation.  
First, it was investigated if the presence of IL-22 could lead to increased proliferation. To 
assess this, IL-22 exposed bronchial epithelial cells were stained using propidium iodide 
acquired by flow cytometry and their individual cell cyle stages analysed (see Methods 3.1, 
Figure 14, page 96).  
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Figure 47. IL-22-associated epithelial wound closure in the presence and absence 
of IL-17A
IL22 (p=0.0033); IL-22+IL-17A (p=0.0090) Statistical analysis (Mann-Witney U)
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Cell Cycle Analysis 
 
The analysis of the different cell cycle stages by propidium iodide is commonly used in the 
study of non-adherent cells such as peripheral blood mononuclear cells. After successful 
modifications and validation of the protocol, it was possible to stain and assess adherent 
bronchial epithelial cells.  
The result of the flow cytometric analysis showed that IL-22 did not alter the number of 
resting, proliferating or dividing cells (Figure 48). The proportion of cells in G0/G1-pahse, S-
phase, and G2/M-phase were almost identical between IL-22 treated and untreated cells.  
TGFβ1, which is known to dampen bronchial epithelial cell proliferation, was used as a 
control cytokine. Compared to IL-22, TGFb1 was able to change the different cell cycle 
stages in bronchial epithelial cells. The cytokine reduced the number of synthesising (S-
phase) (p<0.0001) and dividing cells (G2/M-phase) by 42.7% and 16.0% respectively while 
at the same time increasing the number of resting cells (G0/M) by 13.9% (p=0.001).  
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Figure 48. Analysing the effect of IL-22 on proliferation by quantifying epithelial 
cell cycle stages using Propidium Iodide 
G0/1 phase: Media vs TGFb1 p=0.0013, S phase: Media vs TGFb1 p<0.0001 (unpaired T-test)
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3.2.3. Gene Expression 
While new functional assays were set up to investigate the contribution of IL-22 on cell 
survival, cell spreading and migration, IL-22 exposed cells were screened for alterations in 
their gene expression profile. Their profile was specifically analysed for the expression of 
genes associated with tissue injury and tissue repair. 
Injury-associated genes 
Wound healing occurs immediately at the onset of inflammation. The study, therefore, 
investigated if IL-22 could influence the gene expression of epithelial mediators associated 
with injury and inflammation. To investigate this, primary bronchial epithelial cells were 
cultured in presence of IL-22 and the relative change in selected gene expression analysed 
by RT-PCR.   
 
The first gene to be investigated was the intracellular adhesion molecule 1 (ICAM-1).  ICAM-
1 through binding lymphocyte function-associated antigen 1 (LFA-1) allows the recruitment 
of infiltrating immune cells to the damaged and inflamed tissue.  The results of the RT-PCR 
screen showed that after 12 hrs IL-22 was able to increase ICAM-1 expression 3.8(0.4)-fold 
(Figure 49). ICAM-1 expression remained high even after 24 hours with a 4.1(1.8)-fold 
difference.  
The main inducer of ICAM-1 is the cytokine IFN. The study previously identified that CD4+ T 
cells from the bronchial mucosa predominately expressed IL-22 together with IFN (see 
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Figure 49. Regulation of ICAM-1 (CD54) gene expression by IL-22 and IFN in 
bronchial epithelial cells
B) Media vs IFN (P=0.0084) Sample population size n=9; Statitsical test (Wilcoxon)
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Results 2.2.2 Figure 39, page 136). To test the hypothesis that IL-22 and IFN could act 
synergistically, IFN was included into the epithelial cell culture. The RT-PCR analysis 
showed that IL-22 + IFN strongly up-regulated ICAM-1 expression. This increase in ICAM-1 
was +56.8-fold points higher than seen with IFN alone (310.4(8.4)-fold; p=0.0084). It was 
also +49.7 points higher than the sum of the individual IL-22 and IFN inductions together. 
 
Having indentified a potential synergistic interaction between IL-22 and IFN, 6 additional 
IFN-regulated genes were screened. These included the cytokine IL-6, and the chemokines 
CCL2 (MCP-1), CXCL9 (MIG), CXCL-10 (IP-10), and CXCL-11 (I-TAC). The RT-PCR 
analysis showed that IFN associated up-regulation of IL-6, CCL2, CXCL9,-10, and -11 was 
further enhanced in the presence of IL-22 (Table 65). The enhanced gene expression was 
particularly observed for CXCL-10(IP-10) and CXCL-11(I-TAC).  
Regeneration and repair-associated genes 
The study then went on to investigate the expression of genes associated with tissue 
regeneration and repair. These included matrix-metallo-proteinases, growth factors and 
growth factor receptors. Genes which were known to be induced by IFN were specifically 
selected. These included the matrix-metallo-proteinases MMP1, -10, the growth factors 
Activin (INHBA), BMP-2, ECGF-1 (TYMP), TGF-, and VEGFc. 
Gene IL-22 IFN IL-22+IFN Effect of 
IL-22
Synergy 
indicated
IL6 2.2(0.4) 17.9(2.9) 20.6(3.1) Yes Yes
CCL2 24.4(12.7) 1270.8(77.8) 1877.8(321.0) Yes Yes
CXCL9 67.3(48.6) 3796.8(456.0) 4453.2(281.1) Yes Yes
CXCL10 101.0(80.2) 4328.7(107.2) 6133.2(225.2) Yes Yes
CXCL11 78.6(64.1) 2725.9(292.4) 3553.5(333.4) Yes Yes
Table 65. Effect of IL-22 on IFN-regulated inflammatory gene expression in
bronchial epithelial cells
Gene expression is relative to un-stimulated cells using the ΔΔct method. Data is represented as mean
(Standard error of the mean). Sample population n=3 , statistical test (wilcoxon).
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The RT-PCR analysis showed that MMP-1 and MMP-10 were significantly up-regulated by 
IL-22 (Table 66). However, the combination of IL-22 and IFN did not further increase MMP-
1 or MMP10 expression. Overall, MMP1 was induced by 2.0(0.1)-fold by IL-22  and 9.7(0.8)-
fold by IFN. The regulation of MMP10 was similar between IL-22 and IFN. IL-22 increased 
MMP10 by 2.0(0.3)-fold  while IFN increased MMP10 by 2.6(0.2)-fold .  
The RT-PCR analysis of the growth factors genes Activin (INHBA), BMP-2, ECGF-1 
(TYMP), TGF-, and VEGFc showed that none were altered by the presence of IL-22 alone. 
However, IL-22 enhanced the IFN-associated gene up-regulation of each gene and the 
further enhancement in gene up regulation reached significance for BMP2, TYMP as well as 
TGF-. 
As IL-22 enhanced TGF- expression, the gene expression of its receptor EGFR and 
alternative ligand EGF was assessed. The RT-PCR results showed no evidence that EGFR, 
or EGF were regulated by IL-22, IFN or the combination of the two (data not shown). 
  
Gene IL-22 IFN IL-22+IFN Effect of IL-22 Synergy 
indicated
MMP1 2.0(0.1) 9.7(0.8) 7.7(0.6) Yes -
MMP10 2.0(0.3) 2.6(0.2) 2.5(0.5) Yes -
INHBA 1.2(0.1) 1.7(0.2) 2.5(0.3) - Yes
BMP2 1.1(0.0) 3.0(0.2) 3.9(0.2) - Yes
TYMP 1.3(0.1) 7.7(0.2) 10.5(0.9) - Yes
VEGFC 1.2(0.1) 2.3(0.1) 2.7(0.4) - Yes
Table 66. Effect of IL-22 on IFN-regulated repair-associated gene expression in
bronchial epithelial cells
Gene expression is relative to un-stimulated cells using the ΔΔct method. Data is represented as mean
(Standard error of the mean). Sample population n=3 , statistical test (wilcoxon).
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3.3. Summary 
IL-22 Receptor expression in human lung cell lines 
 Western Blot analysis of normal bronchial epithelial, fibroblasts, smooth muscle, and 
T cell lysates showed that all structural cell lines but not T cells contained both IL-
22RA1 and RA2 protein 
 Surface analysis of IL-22RA1 expression by Flow cytometry confirmed the 
expression of IL-22RA1 on all structural cell lines but not T cells. Bronchial epithelial 
cells showed the strongest surface expression (>50%) while the expression of IL-
22RA1 on smooth muscle cells and fibroblasts remained low (>5%).   
 Neither IL-22RA1 nor RA2 mRNA expression was regulated by the presence of Th2 
cell cytokines. IL-22RA1 however increased in the presence of IFN in a dose and 
time dependent manner in bronchial epithelial as well as fibroblasts, smooth muscle 
cells 
Bronchial epithelial wound healing 
 The addition of IL-22 to artificially injured bronchial epithelial cells improved their 
wound closure ability in a dose and time dependent manner. 
 This IL-22 specific effect remained unaffected by the presence of IL-17A which on its 
own showed to exhibit to positive or negative effect on wound healing 
Bronchial epithelial proliferation 
 The cell cycle analysis showed that IL-22 exposure had no influence on the number 
of resting, DNA synthesizing or dividing bronchial epithelial cells. TGFβ1 on the other 
hand significantly changed increased the number of resting cells while decreasing 
DNA synthesising cells 
Bronchial epithelial gene expression 
 Investigation of IFN-regulated inflammatory assoc. genes showed that IL-22 on its 
own was able to increase ICAM-1, IL-6, CCL2, CXCL-9,-10, and -11 expression. In 
addition IL-22 was able to further enhance the strong induction of each gene by IFN. 
 IFN-regulated repair assoc. genes showed only in part to be induced by IL-22 alone. 
MMP1 and MMP10 were both induced by IL-22 but showed no further synergy in the 
presence of IFN. IFN-associated growth factors were not regulated by IL-22 alone. 
However in combination with IFN, IL-22 was able to enhance the observed growth 
factor up regulation. 
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Discussion 
The investigation of “IL-22 in allergy and asthma” focused on the expression of the cytokine 
during human allergic inflammation, its association with T cells, and its effects on structural 
cells in relation to tissue regeneration and repair. 
1. IL-22 expression in allergic inflammation 
The hypothesis that “IL-22 is a T cell cytokine that is expressed during human allergic 
inflammation” was tested in a clinical study, exposing allergic asthmatics and normal healthy 
individuals to inhaled allergen using a segmental bronchial lung challenge protocol. 
1.1. Local bronchial segmental allergen challenge 
Segmental bronchial allergen challenge resulted in an early and late phase asthmatic 
response, including late falls in FEV1 in all asthmatics but not normal control subjects. 
Analysis of the bronchoalveolar lavage showed late increases in eosinophils, the Th2 
cytokine IL-5, but not the Th1 cytokine IFN. Within the context of a human Th2 response in 
the lung, the relevance of IL-22 and its decoy receptor IL-22RA2 were explored. Both IL-22 
and IL-22RA2 were significantly increased while the related cytokines IL-17A/F remained low 
and unchanged. Thus, in allergic asthmatics, IL-22 and IL-22RA2 were released alongside 
IL-5 independent of IFN and IL-17A/F during the course of the human allergic reaction. 
In comparison to natural allergen exposure, the immune response elicited during 
experimental bronchial allergen challenge was shown to be very similar (de Bruin-Weller et 
al 1999). The added benefit of selecting an experimental challenge model was that it could 
be carried out under safe, controlled and standardized conditions (Gauvreau et al 2007, 
Julius et al 2008, Kämpe et al 2010) reducing the variability of the allergic immune response 
(Arvidsson et al 2007). As the primary allergen, Timothy grass (Phleum pratense) was 
selected as it is relevant in both allergy (e.g. allergic rhinitis) and asthma (Corren et al 1997). 
While alternative allergens such as house dust mite are more reflective of chronic perennial 
asthma, Phleum pratense allowed us to study the allergic response out of season (in the 
absence of any natural exposure) with a clean baseline. An important limitation was that, 
owing to difficulty in recruitment, we had to rely on a small study group consisting of 16 
allergic asthmatics and 3 normal healthy individuals. 
The study of the cellular and soluble composition of bronchoalveolar lavage is dependent on 
the diffusion of cells and mediators into the bronchial lining fluid. In general, bronchoalveolar 
lavage was found to be reflective of the underlying immune response within the tissue 
(Connett et al 2000) and is, therefore, commonly used in the study of airway inflammation 
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(Meyer et al 2007). The large volumes of saline (100ml) used to obtain broncho alveolar 
lavage can often be a limitation in the analysis of cytokines as it may dilute the concentration 
of the mediators below the detection limit of conventional assays.  Having been able to 
detect IL-22 alongside IL-5 in the un-concentrated bronchoalveolar lavage underscored the 
potential importance of this cytokine during the allergic immune response. As the sampling 
of bronchoalveolar lavage is an invasive procedure, only two essential time points, namely 
before and 24 hours after challenge, were investigated. Any important differences in IL-5, IL-
22 and IL-22RA2 expression dynamics associated with either the early, late or resolution 
phase of inflammation could, therefore, not be delineated.  
IL-22RA2 could only be measured within the bronchoalveolar lavage after developing a 
novel ELISA. A sandwich ELISA design was selected to ensure high sensitivity of this assay. 
This required the use of two antibodies raised against alternative target epitopes of IL-
22RA2. The selection was restricted as only one antibody, raised against an alternative IL-
22RA2 peptide, was commercially available. The validation of this alternative antibody (T16) 
by direct ELISA (see Methods 1.1., Figure 7-9, page 72) showed that it had to be used in 
much higher concentrations than the common IL-22RA2 (N16) antibody. Given this, it was 
selected to be the detection rather than the capture antibody within the ELISA design. The 
ELISA signal could not be further amplified using a secondary anti-immunoglobulin antibody 
as both capture and detection antibodies were raised in the same animal species. Instead, 
the detection antibody was labelled directly with biotin (see Methods 1.1 page 72) to avoid 
non-specific detection.  
The segmental bronchial allergen challenge data reflected the common observation that 
allergen exposure in allergic asthmatics caused a reduction in lung function, increased 
eosinophil infiltration, and Th2 but not Th1 cytokine expression (Teran et al 1999, Johansson 
et al 2008, Bentley et al 1993, Thunberg et al 2010, van de Pol et al 2012, Lilly et al 2001, 
Pilette et al 2004). Within this Th2-dominated environment, the detection of IL-22, in the 
absence of both IL-17 and IFN, was significant. The absence of IL-17 and IFN after 
bronchial segmental allergen challenge has recently been confirmed by two independent 
studies (Barlow et al 2011, Newcomb et al 2012). Yet, like many studies of Th17 cells, these 
studies failed to address the expression of IL-22. The observation was reminiscent of chronic 
atopic dermatitis where IL-22 was released in the absence of IL-17 and IFN (Eyerich et al 
2009). What is known is that, in asthma, the allergic T helper cell response can shift and 
become more heterogeneous over time showing signs of both Th1 and Th17 responses 
(Cembrzynska-Nowak et al 1993, Randolph et al 1999, Huang et al 2001, Chakir et al 2003, 
Cho Stanciu et al 2005, Morgan et al 2005, Koch et al 2006, Molet et al 2001, Wong et al 
154 
 
2001, Barczyk et al 2003, Hashimoto et al 2005). These changes in the helper cell response 
away from the Th2 dominated environment remain controversial and are hypothesised to be 
driven by factors other than the allergic component of asthma (Lajoie et al 2010, Maxmen et 
al 2011).  
The documented increase of IL-22RA2 was novel. Published data on human IL-22RA2 
protein expression are still not available until to date. It has been known that the recombinant 
IL-22RA2 protein was able to bind IL-22 and block its signalling (Xu et al 2001, Dumoutier et 
al 2001, de Moura et al 2009, Jones et al 2008, Wolk et al 2007, Wu et al 2008). The only 
two murine studies documenting a change in IL-22RA2 (mRNA) expression showed a 
decrease during acute inflammation and an increase days later (Wolk et al 2007, Wilson et 
al 2010) indicating a potential role of IL-22RA2 during resolution of inflammation.  
On the basis of these findings, it was hypothesised that the strong increase in IL-22 was 
related to a functional role during allergic inflammation in the lung. The occurrence of IL-22 
outside the classic Th1/Th17 environment supported recent findings that a novel Th22 subset 
may participate during allergic inflammation. The presence of IL-22RA2 in bronchoalevolar 
lavage 24 hours after challenge indicated that the function of IL-22 had been actively 
suppressed at one point in time. It is possible that IL-22RA2 may have been produced during 
the resolution of inflammation after the early and late phase response had peaked. 
In conclusion, the expression of IL-22 during late asthmatic responses, in the context of a 
Th2-dominated environment, supported a potential role for IL-22 in human allergic asthma 
and raised the question of the cell source of IL-22, expression dynamics of IL-22 and the 
function of this cytokine during allergic inflammation. To identify individual cells expressing 
IL-22, IL-22RA2 and IL-22RA1, in the context of late allergic inflammation, human skin 
biopsies taken after intradermal allergen challenge were obtained and analysed by 
immunohistochemistry.  
1.2. Intradermal allergen challenge 
Intradermal allergen challenge caused an early and late phase skin reaction in all atopic 
allergic but not in normal controls. The obtained allergen challenged tissue showed an 
increase in both CD3+ T cells and eosinophils 8 hours after challenge. Within the context of a 
human allergic immune reaction n the skin, the expression of IL-22, IL-22RA1, and IL22RA2 
was explored. The tissue was stained using 3 different anti-human IL-22 antibodies. These 
antibodies had been validated using paraformadehyde-fixed cytospin preparations of 
activated peripheral blood memory T cells but failed to produce a visible stain in similarly 
fixed skin tissue. One of the antibodies, however, was able to stain IL-22+ cells in acetone-
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fixed skin. The number of IL-22+ cells was high both in diluent and allergen challenged skin 
and showed no co-staining to either CD3 or IL-22RA1. The staining and distribution of IL-22+ 
cells showed strong similarities to individual and clustered CD31+ cells. The study of the IL-
22 receptors IL-22RA1 and RA2 showed a wide expression throughout the tissue which 
remained unchanged after allergen challenge. The expression did not correlate to resident or 
infiltrating immune cells including T cells, B cells, macrophages, mast cells, neutrophils, and 
eosinophils. The majority of IL-22RA1+ and RA2+ cells were located within the connective 
tissue co-stained to vimentin. Within the connective tissue, early (HSP47+) but not late 
(SMA+) fibroblasts co-expressed IL-22RA2. Thus, despite the successful induction of a late 
allergic immune response in the skin, the identity of IL-22+ cells could not be convincingly 
investigated. The expression of IL-22RA1 and -RA2 remained unchanged after allergen 
challenge and both showed a wide expression throughout the tissue, on cells of mainly 
mesenchymal origin. 
The intradermal allergen challenge was selected as it was safer to perform (than a 
segmental allergen challenge) and allowed the recruitment of volunteers consenting to have 
a local punch biopsy taken. The intradermal challenge of an inhaled allergen like Phleum 
pratense can sometimes elicit a weaker (Wood et al 1999, Tamura et al 1991) but otherwise 
similar allergic immune response to inhalation (Frew and Kay 1988). An additional benefit 
was that the immune response within the skin is largely unperturbed by other environmental 
influences (Durham et al 1991, Charlesworth et al 1991, Gaga et al 1991, Bierman et al 
1990).  
To detect individual IL-22, IL-22RA1 and IL-22RA2 cell populations within the skin, 
immunohistochemistry was used. As the tissue represents a complex mixture of antigens, 
frequently altered by storage and fixation, each antibody had to be thoroughly validated 
before use. As more than half of the antibodies were polyclonal, even weakly isotype-
control-stained areas as well stained cells without clear cell morphology or clear DAPI-
stained nuclear centre, were categorically excluded. As soluble mediators such as IL-22 are 
not as easily detected (compared to surface receptors), paraformaldehyde-fixed tissue 
sections were initially utilised. Paraformaldehyde is believed to better retain soluble 
mediators within cells (Naish et al 1989) and the validation showed that all 3 anti-human IL-
22 antibodies were able to be detected in a small number of IL-22+ cells in 
paraformaldehyde-fixed polyclonally activated peripheral blood memory CD4+ T cells (see 
Methods 1.2, Figure 10, page 78). The fact that , IL-22 was not detected in 
paraformaldehyde but unexpectedly in acetone-fixed tissue, was therefore usual. Compared 
to paraformaldehyde, acetone may break down cell membranes leading to an increased loss 
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of soluble antigens from the tissue. Despite the positive staining of individual IL-22+ cells, the 
overall staining for IL-22 in acetone-fixed tissue appeared non-specific and largely confined 
to blood vessels. One explanation may be that acetone pre-treatment may have modified an 
endothelial antigen to become cross-reactive with IL-22 protein to become non-specifically 
recognised by the IL-22 antibody. The absence of discrete IL-22 stained cells in 
paraformaldehyde-fixed tissue does not necessarily confirm the absence of the cytokine 
within the tissue. T cells have very little cytoplasm and while they may produce cytokines in 
large amounts, the cytokine is synthesised and released rather than stored within intra-
cytoplasmic granules, such that cytokine may be undetectable within cells. Previous studies 
have circumvented this problem by use of in situ hybridisation which detected intracellular 
cytokine mRNA in T cells (Bentley et al 1993, Robinson et al 1996, Ying et al 1997). 
However, the method of in situ hybridisation employed in these studies was complex and 
time-consuming and required the use of S35-labelled probes derived from cytokine cDNAs as 
templates, in order to achieve the necessary sensitivity and specificity to detect intracellular 
cytokine mRNAs. The method has largely been discontinued due to poor availability of S35 
and the relative insensitivity of enzyme-linked detection methods for detecting cytokine 
mRNA in tissues.  
The investigation of IL-22RA1 and IL-22RA2, however, provided new insights concerning 
their expression in tissues and during allergic inflammation. The study initially focused on 
immune cells as newer studies had identified an up regulation of IL-22RA1 in different 
environmental contexts (Dhiman et al 2009, Schnyder et al 2010). The investigation, 
however, showed that immune cells did not express IL-22RA1 either before or during 
experimentally induced cutaneous late allergic inflammation. The results were, thus, in 
keeping with previous studies that showed IL-22RA1 to be generally absent in immune cells 
(Dumoutier et al 2000, Kotenko et al 2001, Wolk et al 2004, Whittington et al 2004, Kunz et 
al 2006, Wolk et al 2008). The primary focus remained on IL-22RA2 in view that IL-22RA2 
mRNA had been identified predominantly in immune cells in previous reports (Xu et al 2001, 
Dumoutier et al 2001, Wei et al 2003, Wolk et al 2004, Whittington et al 2004). However, no 
evidence could be found that either resident or infiltrating immune cells expressed IL-22RA2. 
Both IL-22RA1+ and IL-22RA2+ cells showed a stronger association with structural cells 
rather than with immune cells. Within the skin, the only structural cell known to express IL-
22RA1 were keratinocytes (Wolk et al 2004, Kunz et al 2006, Sa et al 2007, Boniface et al 
2007, Ma et al 2008, Pene et al 2008, Kragstrup et al 2008, Nograles et al 2008, Wolk et al 
2009, Eyerich et al 2009). The wide expression of both IL-22RA1 and IL-22RA2 throughout 
the dermis was a novel finding.  
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The majority of IL-22RA1+ and IL-22RA2+ cells were vimentin+ and belonged to cells of 
mesenchymal origin. Synovial fibroblasts were previously shown to express both IL-22RA1+ 
and Vimentin+ in culture (Ikeuchi et al 2005) and ganglia and myofibroblasts were capable of 
responding to IL-22 in vitro (Andoh et al 2005, Wolk at al 2009, Hosokawa et al 2009). While 
we could not use dual staining methods to investigate IL-22RA1, due to conflicting antibody 
pairing, we were able to investigate the expression of IL-22RA2 which showed an 
association to early HSP47+ but not late SMA+ fibroblasts.  
On the basis of these findings, it remains unanswered whether IL-22 was released by T cells 
and if these cells were associated either with the Th2 or distinct Th22 T helper cell subset. 
While the identity of IL-22+ cells remained elusive, our data indicated that a wider range of 
IL-22 target cells existed than was previously thought. Both IL-22RA1+ and IL-22RA2+ cells 
occurred mainly in the connective tissue, which contains several stem cell-like progenitor 
cells as well as fibroblasts, strengthening the hypothesis that IL-22 was related to tissue 
regeneration and repair. Both multi-potent precursor cells as well as fibroblasts have  not 
been well researched in connection with IL-22. The limited data on fibroblasts expressing IL-
22RA1 (Ikeuchi et al 2005, Andoh et al 2005, Wolk et al 2009, Hosokawa et al 2009) and our 
observation of IL-22RA2+ expression by  HSP47+ fibroblasts suggests that early fibroblasts 
represent an in vivo target for IL-22, possibly involved in repair and/or remodelling 
processes. 
Since it was not possible to link IL-22 expression to T cells in tissues, possibly related to the 
limitations of the available methodology and the fact that cytokines are secreted rather than 
stored by T cells, cytokine induction during allergen-stimulated T cell responses in vitro was 
studied. In addition, pulmonary fibroblasts were included to be studied later on as a target of 
IL-22.  
2. IL-22 expression in T cells  
To test the main hypothesis that “Interleukin-22 is a T cell cytokine produced during allergic 
inflammation” as well as the hypothesis that “Interleukin-22 is produced by distinct Th22 cells 
as well as other T cell subsets (Th1,Th2,Th17)”, several in vitro studies were set-up.  
2.1. Peripheral blood mononuclear cell cultures 
Using peripheral blood mononuclear cells, the occurrence of IL-22 as well as expression 
profile of IL-22+ T cells after allergen stimulation was analysed. In parallel, the study aimed to 
investigate IL-22+ T cells in more detail by obtaining them through de-novo Th22 
differentiation as well as memory Th22 cell isolation using novel surface receptors. 
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2.1.1. Long term allergen-stimulated peripheral blood mononuclear cells 
Allergen stimulation of PBMCs from both atopic and non-atopic subjects resulted in 
increased proliferation. This proliferative response was numerically but not significantly 
increased in PBMCs derived from allergic subjects. Culture supernatants obtained after 
allergen stimulation contained increased levels of IL-5 selectively in allergic individuals 
whereas modest increases in IL-22 were observed in cultured PBMCs from both atopic and 
normal subjects. IFN and IL-17A/F levels remained low before and after allergen challenge 
in both atopic and normal subjects. Flow cytometric analysis of IL-22+ PBMCs revealed little 
or no IL-22 expression at day 6 post allergen stimulation. In the rare instance where IL-22 
was detected, it co-localised to CD4+ cells within the lymphocyte population. These CD4+IL-
22+ cells did not co-express Th2-cytokines IL-4, IL-5, or IL-9 whereas a small percentage co-
expressed IL-17A and IFN.  
PBMCs are commonly used to facilitate the antigen presentation and T cell activation in vitro 
(Till et al 1998). In this study, 2 out of 3 of PBMC cultures from allergic subjects but not 
normal controls responded to allergen with production of IL-5 which was significant. In 
contrast, a modest induction of IL-22 was not only observed in PBMC cultures from atopics 
but also from normal subjects. These findings in vitro are in contrast to those, following 
allergen provocation in the bronchi, where no IL-22 was detected in BAL in normal controls 
after allergen challenge. This could possibly be explained by an intact epithelial barrier which 
may, in vivo, greatly reduce allergen exposure, uptake and T cell priming in non-atopic 
normal subjects compared to allergic asthmatics (Hogg and Eggleton 1984, Laitinen et al 
1985, Montefort et al 1992).  
To identify the source of IL-22, the cultured cells were analysed by flow cytometry. An 
important limitation was that intracellular cytokines could only be detected after strong TCR 
activation and blockade of protein release. The strong TCR activation, achieved by using 
PMA and ionomycin, inevitably caused the activation of all T cells within the culture and not 
just allergen-specific T cells. To limit the contribution of non-specific T cells within each 
culture, the latest available time point (day 6) was selected to allow optimal polarisation and 
expansion of allergen-specific T cells in culture. However, it was apparent after the data was 
analysed that the IL-22 production could have peaked before day 6. Analysis by ELISpot 
could have possibly resolved this although ELISpot assays for IL-22 were not commercially 
available at the time.  
The in vitro challenge data reflected previous studies in which Phleum pratense elicited a 
Th2-type response characterised by the selective release of IL-5 and IL-13 in the absence of 
IFN and IL-17 (Till et al 1997).The increase of IL-22 independent of Th1 and Th17 cytokines, 
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in the context of an allergen challenge, confirmed the previous in vivo data. The expression 
of IL-22 in PBMCs from both allergic and normal control subjects suggested that the 
expression of IL-22 was not linked to atopy per se. This finding is supported by two large 
scale microarray studies of allergen stimulated atopic and normal PBMCs (Liu et al 2005 
GSE1964, Bosco et al 2009 GSE14908). In both datasets, there was no differential 
expression of IL-22 detected in PBMCs from atopic individuals compared to those obtained 
from normal subjects.  
The in vitro allergen challenge provided important clues regarding the role of IL-22 during 
allergic inflammation. While the study supported the expression of IL-22 during allergic 
inflammation, it provided evidence that it may be neither atopy nor Th2-related.  
The induction of a cytokine in response to allergen in both atopic and normal PBMCs 
cultures draws parallels to IL-10. It, too, was released independent of the atopic status 
(Abbal et al 1998, Böttcher et al 2003, Bullens et al 2005) and has also been documented to 
be increased after challenge in vivo (Robinson et al 1996, Matsumoto et al 2004). Both, IL-
10 and IL-22 are structurally related (Dumoutier et al 2000, Kotenko et al 2001) and their 
induction is both dependent on aryl hydrocarbon receptor (AHR) and Notch signalling 
(Veldhoen et al 2008, Quintana et al 2008, Veldhoen et al 2009, Gandhi et al 2010, Apetoh 
et al 2010, Mukherjee et al 2009, Alam et al 2010). Both cytokines, however, target different 
cells (IL-10 immune cells, IL-22 structural cells) and, thus, have little functional overlap 
(Lecart et al 2002, Wolk et al 2005). Yet, in mice, IL-22 was shown to suppress antigen-
induced immune responses and eosinophilic airway inflammation via an IL-10-associated 
mechanism (Nakagome et al 2011). If IL-22 has a similar regulative and protective function, 
it would be, opposite to IL-10, related specifically to structural cells. Combined with the 
hypothesis that IL-22 is involved in tissue injury and repair, it would suggest that IL-22 could 
be released to prevent and or limit tissue damage during acute inflammation.  
In conclusion, the in vitro allergen challenge model confirmed the expression of IL-22 after 
allergen stimulation but indicated that IL-22 may have a more general role not linked to atopy 
or allergic inflammation per se. The FACS analysis did reveal that a small percentage of IL-
22 was detectable and co-localised to CD4+ T cells. Of these, a small percentage could co-
express Th1 (IFN-) and Th17 cytokines (IL-17A), possibly indicating a closer developmental 
relationship of IL-22-producing cells to these T cell lineages rather than Th2 cells. To better 
understand the relationship of different T helper subsets and the transcriptional regulation of 
Th22 cells, IL-22 producing T cells needed to be obtained, isolated and studied in more 
detail. To do so, a newly described Th22 differentiation protocol (Duhen et al 2009) as well as 
novel Th22 surface receptors and their ligands (Eyerich et al 2009) were utilised. 
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2.1.2. Polarised naive T cells 
In this study, the differentiation of naive T cells using the newly described Th22 protocol 
(Duhen et al 2009) in my hands showed no evidence of an increase in IL-22+ T cells. Neither 
the combination of the polarising cytokines IL-6 and TNF nor their individual use increased 
IL-22 expression in culture. This was true whether the polarisation was carried out using 
serum-free or serum-containing media. It is  noteworthy to mention that the short period of 7 
day differentiation and 7 day expansion (in IL-2 containing media) was unusual as in vitro T 
helper cell differentiation is generally regarded as inefficient, requiring several rounds of re-
stimulation and may take up to 4 weeks of culture (Cousins at al 2002).  
TNF is not commonly used in T cell differentiation and showed no effect on IL-22 
expression (Kreymborg et al 2007, Volpe et al 2009). The only functional evidence was 
observed when TNF decreased IL-17A expression in Th17 cultures (Baba et al 2010) and 
blocked T regulatory cell development (Ma et al 2010). TNF may, thus, be linked to IL-22 
and Th22 cells by blocking other developmental pathways. This, however, remains to be 
established. Similarly the link between IL-6 and IL-22 is controversial. Some studies reported 
a mild induction of IL-22 in IL-6 containing Th17 polarising conditions (Chung et al 2006, 
Zheng et al 2007). The use of IL-6 within T cell differentiation cultures was shown to be 
essential for IL-17 but not IL-22 (Kreymborg et al 2007, Volpe et al 2009). Similarly, IL-6 
knockout mice expressed normal levels of IL-22 while IL-17 was greatly reduced (Zheng et 
al 2007, Zenewicz et al 2008, Siegemund et al 2009). IL-6, like TNF, could only be involved 
indirectly in the induction of IL-22. One mechanism hypothesised, but not proven, was the 
up-regulation of the IL-23 receptor by IL-6 (Nurieva et al 2007). IL-23, produced mainly by 
dendritic cells (Siegemund et al 2009), was shown to be essential for the induction of IL-22 
(Zheng et al 2007, Chung et al 2006, Kreymborg et al 2007, Volpe et al 2009). The use of IL-
23 blocking antibodies (Liang et al 2007) and IL-23 knockout mouse (Aujla et al 2008, 
Siegemund et al 2009, de Luca et al 2010) confirmed a significant reduction of IL-22 (but not 
IL-17), when IL-23 is absent. The IL-23 receptor is not expressed initially on naive T cells 
(Wilson et al 2007) but its expression is triggered by co-stimulatory molecules during antigen 
presentation (de Wit et al 2011). Despite the strong link, IL-23 was not included within in the 
Th22 protocol. 
An important aspect which was not disclosed in the original Th22 protocol (Duhen et al 2009) 
was the type of media used. The media can be important in the differentiation of T cells and, 
in particular, IL-22+ T cells. One example is the use of Iscove’s modified Dulbecco medium 
(IMDM) which enhanced IL-22 expression during Th17 cell differentiation (Veldhoen et al 
2008). This media was shown to be rich in aromatic amino acids and natural aryl 
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hydrocarbon receptor (AHR) ligands. AHR ligands and AHR signalling was found to be 
essential for IL-22 but not IL-17 expression (Veldhoen et al 2008 & 2009, Trifani and Spits 
2010).  
The study results, as well as previous historic evidence, raised questions concerning the 
feasibility of in vitro differentiation of Th22 cells with TNF and IL-6 alone. While it was not 
possible to exclude a putative role for TNF and IL-6, it was evident that other factors must 
be involved. Despite the availability of additional strategies, (e.g. inclusion of AHR ligands, 
and/or IL-23) it was uncertain that the additional time spent would result in a working Th22 
differentiation protocol. The other option to study IL-22 expressing T cells and their relation 
to other T helper subsets is to obtain already differentiated memory CD4+ T cells from T cells 
obtained from peripheral blood or from bronchial tissue from asthmatic subjects. 
2.1.3. Memory T cells 
The use of novel surface receptors FGFR2, TIE1 and PDGFR to enrich Th22 cells from the 
peripheral blood was evaluated. These receptors, which had been identified on Th22 clones 
within the skin, were expressed by a minor population of peripheral blood CD4+ T cells. The 
receptors, TIE1 and PDGFR, were found exclusively on CD45RO+ T cells. FGFR2 
expression was, however, found on both CD45RO+ and CD45RO- T cells. The enrichment of 
FGFR2, TIE1 and PDGFR-positive T cells showed no selective increase in IL-22+ T cells. 
The enrichment of IL-22+ T cells, in general, was possible. Using CCR4, -6, and -10, the 
number of IL-22+ T cells increased mildly in CCR10 and significantly in CCR6 -enriched T 
cell populations. In addition, the activation and co-culture of CD4+ T cells in FGF- and 
PDGF-receptor ligand containing media (FGF-1,-2,-5 and PDGF-BB) neither influenced IL-
22, nor IL-17A, IL-4, IFN, IL-10 or TGFβ1 mRNA expression. Thus FGFR2, PDGFR and 
TIE1 expressing T cells showed no potential to be used to selectively enrich Th22 cells from 
the peripheral blood. 
To isolate receptor positive T cells, flow assisted cell sorting was initially employed. While 
promising results were obtained (see appendix, Figure 50, page 214), this method had to be 
abandoned due to frequent and multiple technical problems with the FACS sorting machine. 
For this reason, enrichment was carried out using magnetic bead separation. The magnetic 
bead isolation resulted in 80-90% purity of receptor-positive cells slightly less effective than 
the greater than 95% achieved using flow assisted cell sorting. Another limitation of 
magnetic separation was that only one receptor could be isolated at any one time. Despite 
this, it was highly reliable and reduced cell stress and cell damage, an advantage over 
FACS-sorted cells, which, on polyclonal activation, showed a high mortality. 
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Prior to their identification on skin-derived Th22 cells, FGFR2, PDFR and TIE had never been 
linked to IL-22 expression before. In addition, their expression on T cells themselves is not 
well documented. FGFs, which are potent growth factors released during injury and repair 
had been shown to enhance TCR signalling and NFAT activation of FGFR1+ CD4+ T cells 
(Byrd et al 2003). The expression of FGFR2 not only on memory but also naive T cells may, 
thus, indicate that the receptor has a similar role to FGFR1 and may facilitate T cell 
activation by providing a context-dependent danger signal. Yet, its expression on naive T 
cells also indicated that the receptor is less likely to be a specific marker of Th22 cells. 
PDGFR is another important growth factor receptor expressed during injury and repair but, 
so far, has only been identified on structural cells (Tan et al 2006, Gabrielli et al 2007). Its 
enrichment and PDGF-BB ligand stimulation of CD4+ T cells showed no evidence of IL-22 
expression. Similarly, TIE-1 was only identified on vascular endothelial cells previously (Sato 
et al 1995) and may potentially relate to endothelial cell adhesion and T cell extravasation 
rather than IL-22 expression.  
For these reasons, it remains doubtful whether expression of FGFR2, PDGFR, or TIE1 on T 
cells is linked to IL-22 expression. The original research that identified these 3 receptors 
used a library of T helper cell clones derived from the skin of patients with atopic dermatitis 
(Eyerich et al 2009). It is likely that the environment of the skin and the clinical condition of 
the patients could have accounted for differences between skin Th22 cells and peripheral 
blood Th22 cells. It is also possible that the study of only several T cell clones from the skin 
may not be representative. In conclusion, IL-22+ T cells could not be obtained either through 
selective isolation of putative Th22-receptors FGFR2, PDGFR, or TIE-1-positive T cells or 
through their ligand stimulation. We, therefore, decided to derive T cell lines directly from the 
bronchial mucosa of asthmatics and obtain individual CD4 T cells through serial dilution and 
clonal expansion. 
2.2. Human asthmatic bronchial mucosa 
Each individual T cell line created from asthmatic bronchial mucosal tissue contained IL-22+ 
memory T cells. The overwhelming majority of IL-22+ T cells expressed both the β-TCR+ 
and CD4+ receptor. While the T cell lines contained mainly β-TCR+ CD4+ T cells, the 
frequency of IL-22 expression in β-TCR+ and δ-TCR+ as well as CD4+ and CD8+ T cells 
was almost identical. The analysis of IL-22+ β-TCR+ CD4+ T helper profiles was similar 
across all asthmatic T cell lines and showed that the majority of IL-22+ T helper cells co-
expressed IFN (Th1/22: 43.8%). The second largest IL-22
+ T helper cell population 
expressed only IL-22 (Th22: 22.2%) while the number of cells co-expressing IL-17A was low 
in all cell lines (Th17/22: 10.2%). Co-expression of IL-22 with IL-4 was absent or negligible. 
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The subsequent isolation and clonal expansion of individual T cells failed to generate 
enough T cell clones to represent each T helper subset. While Th1 and Th2 clones were 
easily obtained, Th22 (and Th17) cells were not. Only three IL-22
+ T cell clones were identified 
which, in addition, also expressed various levels of IFN, IL-17A, and IL-4. Thus, IL-22+ 
CD4+ T cells within T cell lines derived from bronchial mucosal tissue belonged largely to the 
Th1 and Th22 but not Th17 or Th2 subset yet clonal expansion failed to obtain enough T cell 
clones for a detailed comparative analysis. While the cloning efforts may have eventually 
yielded enough CD4 T cell clones, the method proved too time consuming and labour 
intensive to continue. 
The study of T cells derived from the asthmatic bronchial mucosa was limited by the 
availability of clinical samples due to the invasiveness of the procedure and lack of tissue 
from normal healthy controls. Nonetheless, it proved possible to generate T cell lines from 6 
out of 10 biopsies of which 4 were derived from non-allergic asthmatics and 2 from allergic 
asthmatics. The T cell lines were very similar in composition to other T cell lines showing a 
similar ratio of CD4/CD8, as well as δ T cells (Wilson et al 1992, Gratziou et al 1992, 
Crocker et al 1998, Krug et al 2001). The analysis of IL-22+ T cells derived from the 
asthmatic bronchial mucosa was novel. Previous studies assessed the occurrence of IL-22 
in asthmatic patients only using peripheral blood (Wong et al 2009, Zhu et al 2011), where a 
general increase in IL-22+ (and IL-17+) CD4+ T cells correlating modestly with asthma 
severity was observed. The characterisation of IL-22+ T cells also included the cytokine IFN 
which, despite its strong link to IL-22 (and IL-17), has been largely overlooked. Its 
importance has been documented by renewed interest in IL-17A+ IFN+ T cells which are 
now believed to involved in the pathology of many inflammatory conditions (Annunziato et al 
2007, Kebir et al 2009, Lin et al 2009, Boniface et al 2010, Cohen et al 2011).  
The results of this study indicate that the majority of IL-22+ T cells within the memory T cell 
pool of the asthmatic lung belonged to the Th1 subset. The identification of a separate 
subset of Th22 cells in vivo had been suggested in several previous studies. Very early on, 
the observation was made that IL-22+ and IL-17+ T cells occur largely as distinct populations 
(Scriba et al 2008) and recent in vivo observations support that both cytokines show only 
minor co-expression (Matthews et al 2011, Rudloff et al 2012, Zhang et al 2012, Cowan et al 
2012). If IL-22 was released by T cells during allergen provocation within the lung, it must 
have either been derived from the smaller Th22 cell population or released selectively from 
Th1 cells. The latter would not be without controversy even though allergen-specific Th1 cells 
have been identified in allergic individuals (Oseroff et al 2010). 
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In conclusion, the study of the T cell lines derived from bronchial biopsies from asthmatics 
yielded novel insights. The majority of IL-22 expressing CD4+ T cells within the T cell lines 
generated from bronchial tissue were not related to Th2 or Th17 cells but were more likely 
related to a Th1 and, possibly, a smaller Th22 subset. However, a more detailed study of 
individual T cell clones of distinct lineage (Th1, Th2, Th17, Th22) would have been required to 
confirm the existence of a distinct Th22 cell lineage.  
3. IL-22 in human tissue regeneration and repair 
3.1. IL-22 Receptor expression in human bronchial epithelial cell lines 
In total cell lysates, both IL-22 receptor RA1 and -RA2 were identified to be expressed 
constitutively by primary bronchial epithelial cells, smooth muscle cells and fibroblast cell 
lines but not peripheral blood CD4+ T cells. Compared to each other, bronchial epithelial, 
smooth muscle and fibroblast cells expressed similar levels of IL-22RA1 and -RA2 protein. 
The detection of IL-22RA1 resulted in a much stronger signal than the detection of IL-
22RA2. Surface expression of IL-22RA1 was confirmed on all three cell lines. More than half 
of all bronchial epithelial cells stained positive for IL-22RA1. In airway smooth muscle cells 
and fibroblast, IL-22RA1 was only detected on less than 5% of cells. Exposure of bronchial 
epithelial cells to various T cell cytokines revealed that IL-22RA1 was up regulated by IFN. 
This regulation was dose- and time- dependent and occurred not just in bronchial epithelial 
cells but also airway smooth muscle cells and fibroblasts. Thus, all three primary structural 
cell lines had the capacity to express IL-22 receptors while up regulating IL-22RA1 in the 
presence of IFN. 
Western blotting was selected to analyse the constitutive expression of both IL-22RA1 and 
IL-22RA2. Both IL-22RA1 and IL-22RA2 antibodies recognised a specific band 
corresponding to the correct molecular weight of their target protein and showed no 
interference in combination with the anti--tubulin control. The observed difference in 
strength between the IL-22RA1 and IL-22RA2 may have related to a quantitative difference. 
This evaluation has to be viewed with caution as the western blots were not designed to be 
quantitative and differences in both antibody binding and signal amplification could influence 
the observed band intensity. Subsequent analysis of IL-22RA1 surface expression was 
carried out by flow cytometry and circumvented the need for a fractional analysis (e.g. 
cytosolic, nuclear, membrane) of IL-22RA1 expression by western blot. One limitation was 
that the use of trypsin/EDTA to detach the adherent cells from the tissue culture dish could 
not be avoided. Trypsin is able to cleave exposed proteins including surface receptors and 
could, thus, artificially lower the recorded surface receptor expression. This effect, however, 
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would have been similar for bronchial epithelial, smooth muscle and fibroblast cells, such 
that a relative comparison of IL-22RA1 expression between the different cells lines should 
still be valid. 
The regulation of IL-22RA1 and IL-22RA2 was studied using RT-PCR. This technique 
allowed the detection of small changes in IL-22RA1 and RA2 regulation even in the absence 
of protein expression and surface translocation. Little is known about IL-22RA2, its time point 
of expression and regulation. Its expression was, therefore, screened both at 6 and 24 hours 
using two differently designed probe sets. Both probe sets detected low level IL-22RA2 
expression (ct 29-30) which remained unchanged. 
The investigation of IL-22RA1 and IL-22RA2 protein expression within the skin reported in 
this thesis pointed to a wider range of structural cell sources (see Results 1.2.4, page 113). 
Western blot confirmed that not only bronchial epithelial cells but also fibroblasts and smooth 
muscle cells were able to express IL-22RA1 and low levels of IL-22RA2 under constitutive 
conditions. The strong expression of IL-22RA1 on bronchial epithelial cells was in line with 
previous studies which identified cells of epithelial origin as the main target of IL-22 (Wolk et 
al 2004, Boniface et al 2005, Aujla et al 2008). Results showed a difference between the IL-
22RA1 surface expression on growing and terminally differentiated bronchial epithelial cells. 
While our cells showed a surface expression of >50%, terminally differentiated cells cultured 
within an air-liquid-interface showed a surface expression of only 15% (Aujla et al 2008). 
Fibroblasts had been investigated previously showing that synovial, ganglia and 
myofibroblasts were able to express IL-22RA1 and/or respond to IL-22 in culture (Andoh et 
al 2005, Ikeuchi et al 2005, Wolk et al 2009). However, these studies have remained largely 
un-cited and overlooked. Similarly, airway muscle cells have been largely overlooked. The 
expression of IL-22RA1 in smooth muscle cells has, now, been replicated by others (Zhang 
et al 2011, Chang et al 2011) validating the findings reported here. Studies on IL-22RA2 
expression are limited. Type-II pneumocytes (alveolar epithelial cells) have been shown to 
express IL-22RA2 mRNA in vivo (Xu at al 2001). Investigations of the regulation of IL-22RA1 
by IFN  was reflective of one study carried out in vitro using keratinocytes, where both IFN 
and TNF caused increased IL-22RA1 mRNA up regulation in culture (Wolk et al 2005).  
The expression of IL-22RA1 on structural cells other than epithelial cells highlight a greater 
functional diversity of IL-22 beyond “mucosal immunity” alone. The association of fibroblasts, 
in particular, suggests a potential role in tissue repair processes. Airway smooth muscle 
cells, for example, have recently been shown to respond to IL-22 with increased migration 
(Chang et al 2011).  
166 
 
The western blot showed that IL-22RA2 was present at low levels in each cell type. The fact 
that IL-22 did not increase IL-22RA2 mRNA indicated that this basal IL-22RA2 expression is 
less likely to relate to a regulatory feedback loop within IL-22 target cells. Previously, dual 
immunochemistry revealed that both IL-22RA1 and IL-22RA2 were expressed on, separate 
but otherwise, very similar cells within the skin. Both receptors may potentially be expressed 
by the same cell-type but at different stages of activation or differentiation. The later being 
supported by the identification of IL-22RA2 in early HSP47+ fibroblasts while fully 
differentiated fibroblast were shown to be IL-22RA1+ (Ikeuchi et al 2005).The detection of 
both IL-22RA1 and IL-22RA2 by western blot might, therefore, relate to an artefact of cell 
culture in which primary cells are maintained in an artificial and not fully differentiated state. 
The regulation of IL-22RA1 by IFN alone indicates a strong functional connection of IL-22 
during Th1 rather than Th2-associated inflammation. IFN is not just a Th1 cytokine but is also 
released by many innate sources very early on during inflammation (e.g. alveolar 
macrophages). Interestingly, the data showed no further evidence of a Th1/Th2 disparity. Th2-
associated cytokines neither down regulated IL-22RA1 expression nor up regulated IL-
22RA2. This was reflected in vivo where IL-22RA1 and IL-22RA2 expression remained 
unchanged during experimental allergic inflammation within the skin.  
To understand the function role of IL-22, we needed to study the IL-22 target cells in more 
detail. On the basis of IL-22RA1 surface expression, only primary bronchial epithelial cells 
appeared suitable to be used as a model to study the function of IL-22 in vitro. The low IL-
22RA1 surface expression on cultured pulmonary fibroblasts was unexpected, in view of the 
previous in vivo findings in the skin, where IL-22RA1 was abundantly expressed on vimentin-
positive early fibroblasts (see Results 1.2, Figure 28 page 118). Based on these results, the 
study focused exclusively on bronchial epithelial cells and the role of IL-22 during epithelial 
injury and repair. 
3.2. Effect of IL-22 on bronchial epithelial cells 
To test our hypothesis that “Interleukin-22 is involved in tissue regeneration and repair”, a 
functional assay to study the effects of IL-22 on bronchial epithelial wound healing in vitro 
was set up. 
3.2.1. Wound healing 
The results showed that in an in vitro wound healing assay, IL-22 was able to improve 
epithelial wound closure. This effect occurred in a dose- and time dependent manner and 
was not influenced by the presence of IL-17A which, on its own, showed no visible effect on 
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wound closure. Thus, IL-22 may likely augment wound closure following injury, independent 
of IL-17A expression. 
The wound healing assay (Todaro et al 1965, Haudenschild et al 1979) allows a detailed 
study of the phenotypic shift of epithelial cells after injury (Kheradmand et al 1994, Garat et 
al 1996). These include, in particular, the changes in cell-cell interactions (e.g. tight 
junctions), the extra-cellular matrix (e.g. MMPs), cytoskeleton arrangements (e.g. actin 
reorganisation), cell spreading and migration (Kim et al 2010). While these events 
encompass many of the early features of wound closure, the assay cannot address the 
influence of IL-22 on chemotaxis or cellular proliferation and cannot replicate the complex 
interactions of several different progenitor, structural and inflammatory cells types during in 
vivo wound healing. The use of primary rather than immortalised bronchial epithelial cells 
strengthened the study’s findings. Primary cells are not commonly selected for functional 
studies as they are costly and can only be expanded for a short period of time (e.g. passage 
4 to 5) hence limiting the number of experiments that can be carried out. However, primary 
cells retain the majority of functions seen in vivo as they are not affected by the side effects 
of immortalisation and long term culture. Both factors have been linked to alter functional 
responses in immortalised cell lines leading to sometimes opposing outcomes in vitro 
(Sandberg et al 2005, Olsavsky et al 2007, Pan et al 2009).  
The wound healing assay has a simplistic setup but proved difficult to establish and carry 
out. A major drawback was the great variability of epithelial responses which led to a high 
inter-assay variation (see Methods 3.2 Figure 13, page 96). The requirement to obtain a 
homogenous monolayer of epithelial cells was likely the main cause for the highly variable 
responsiveness of cells in vitro as any cell crowding quickly led to cell cycle arrest and cell 
death in vitro (Liang et al 2007). Despite this assay variability, the data illustrated a clear and 
statistically significant effect of IL-22 in enhancing wound closure.  
The bronchial epithelium is a relatively new target of IL-22 to be investigated but the results 
confirmed that the functional association of IL-22 in wound healing is likely a conserved 
effect which occurs across different cell types and tissues (Boniface et al 2005, Brand et al 
2006, Sa et al 2007, Pickert et al 2009, Brand et al 2007, Eyerich et al 2009). This 
confirmation highlights the need to better understand the role of IL-22 in relation to tissue 
regeneration and repair within the lung and its potential contribution to asthma. In 
conclusion, the positive functional response of our human bronchial epithelial cells to IL-22 in 
vitro suggested the need to perform a more detailed functional analysis of the mechanism of 
IL-22 associated wound healing in vitro. As these changes remained poorly defined, the 
contribution of IL-22 on changes such as cell survival, cell-cell adhesion, extracellular matrix 
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interactions, cell spreading, migration, and proliferation needed to be addressed. To do so, 
the subsequent investigation focused first on epithelial proliferation, a feature that could not 
be addressed by the use of the wound healing assay only.   
3.2.2 Proliferation 
The results showed that the different cell cycle stages of bronchial epithelial cells remained 
unaffected by the presence of IL-22 in vitro. IL-22 neither decreased the number of resting 
(G0/1-phase) cells nor increased synthesising (S-phase) and dividing (G2M-phase) cells. As 
a positive control, bronchial epithelial cells were exposed to TGFβ1, which decreased the 
percentage of synthesising (S-phase) and increased the number of resting (G0/1-phase) 
cells. This observation strengthened the finding that IL-22, on its own, showed no effect on 
bronchial epithelial cell proliferation. 
To quantify IL-22 and its effect on cellular proliferation, propidium iodide staining (Krishan 
1975) was selected. This method allows the visualisation of the individual cell cycle stages 
and thus provides more detailed information then a traditional proliferation assay such as 
[methyl3H]-thymidine incorporation. In comparison to [methyl3H]--thymidine incorporation, 
propidium iodide staining is not as sensitive but can be carried out without any radioactive 
safety measures. In addition, propidium iodide is not incorporated into living cells and, thus, 
does not artificially change the proliferative behaviour of cells in vitro (Hu et al 2002).  
Previous evidence implying an effect of IL-22 on epithelial proliferation had so far been 
indirect (Brand et al 2006, Li et al 2009, Ren et al 2009).  
On the basis of the experimental findings, IL-22 had no direct influence on epithelial cellular 
proliferation. As cellular proliferation occurs later on during wound healing, I hypothesised 
that IL-22’s function may specifically relate to early events in wound healing. These events 
potentially include changes in cell-cell adhesion and cell matrix interactions that are often 
initiated by early pro-inflammatory cytokines such as IFN (Crosby and Waters 2010). In 
conclusion, the effects of IL-22 on enhancing epithelial repair appeared independent of any 
effect on proliferation. It remains to be established if IL-22 could influence other earlier 
events during wound closure.  
3.2.3 Gene expression 
The study showed that IL-22 on its own was able to increase the expression of several 
known IFN associated inflammatory genes. These included the adhesion molecule ICAM1, 
the cytokine IL-6, and the chemokines CCL2, CXCL9,-10 and -11. While IL-22 alone was a 
modest inducer of these genes, IL-22 was observed to markedly enhance the effect of IFN 
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on epithelial expression of these genes that included particularly epithelial CXCL10, and 
CXC11. IFN-associated repair genes showed only a modest regulation by IL-22. IL-22 was 
able to induce both MMP1 and MMP10 but showed no synergy with IFN. IFN-regulated 
growth factors BMP2, TYMP, TGF, INHBA and VEGFc were almost unchanged in the 
presence of IL-22. IL-22, however, enhanced the IFN associated expression. This 
enhancement was seen for the expression of all growth factor genes and increases in gene 
expression reached statistical significance for TYMP, BMP2 and TGF. Thus IL-22, while 
being a modest inducer of IFN-associated genes alone, was able to enhance the effect of 
IFN on many early injury- and repair-associated genes.   
Previous studies have addressed mainly IL-22’s role in mucosal immunity. While these 
studies were carried out using IL-22 in combination with IL-17A or TNF, they made very 
similar observations. In particular, the enhanced induction of IL-6 (Brand et al 2007, Ma et al 
2008, Sonnenberg et al 2010), CCL2, CXCL9, -10, and -11 (Eyerich et al 2009, Hosokawa et 
al 2009) had been reported previously in keratinocytes as well as hepatocytes. Only the 
induction of IL-8/CXCL8, which had been reported in numerous studies (Wolk et al 2004, 
Brand et al 2006, 2007, Koga et al 2008, Nograles et al 2008, Wolk et al 2009), could not be 
observed. Similarly previous research which addressed the function of IL-22 in human 
bronchial epithelial cells also failed to observe an effect of IL-22 on IL-8/CXCL8 gene 
expression (Aujla et al 2008). 
The study of IL-22 and its effect on multiple repair associated genes, on the other hand, was 
novel. Individually, some previous studies provide support for the identified IL-22-associated 
induction of MMP1, -10 (Andoh et al 2005, Boniface et al 2005, Wolk et al 2006) and TGF 
(Wolk et al 2004).  
In summary, the results confirmed that IL-22 exhibits a dual role in both amplifying the 
inflammatory response whilst promoting events related to tissue repair. IL-22 could be 
considered an early pro-inflammatory cytokine. Yet, its functional role appears to differ from 
that of other classic pro-inflammatory cytokines (e.g. IFN, TNF and IL-17A). These results 
as well as previous studies showed that IL-22 on its own was only a weak inducer of effector 
gene expression. Its effect was only observed in the presence of other pro-inflammatory 
cytokines. I hypothesise that IL-22, therefore, has a slightly different role and may act more 
as an immune-modulator than primary effector cytokine. I also hypothesise that IL-22’s 
synergistic effect with pro-inflammatory cytokines such as IFN is more selective as it may 
appear in the small dataset of studied candidate genes. It would, therefore, be interesting to 
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determine how IL-22 alters the “responsiveness” of structural cells to inflammatory cues and 
if this could be predictive of its overall function.  
In conclusion, the data suggested that IL-22 was linked to both early events in inflammation 
as well as repair. As IL-22 exhibited a similar function in enhancing the effect of IFN, TNF, 
and IL-17A, it is probable that IL-22 might, more broadly, target intracellular signalling 
pathways which, in turn, may enhance the responsiveness of cells to inflammatory cues. The 
repair related functions remain poorly defined.  
  
171 
 
In relation to hypothesis 
Hypothesis 1 
While the evidence suggested a putative role of IL-22 in chronic allergic inflammation, little 
had been known about IL-22’s expression during the allergic reaction itself.  
The detection of IL-22, 24 hours after bronchial segmental allergen challenge, in allergic 
asthmatics was unexpected. It was surprising as it was released in significant quantities to 
be detectable even in undiluted broncho alveolar lavage alongside IL-5 and in the absence 
of IFN and IL-17A/F. Like the in vivo data, the in vitro allergen PBMC challenge confirmed 
the induction of IL-22 together with IL-5 after allergen challenge, independent of IL-17 or 
IFN. The strong increase in IL-22, after bronchial segmental allergen challenge, was almost 
similar to IL-5 and, thus, may have arisen due to the rapid release of stored cytokine from 
innate immune cell sources. It was, therefore, important to address if IL-22 was derived from 
T cell or non-T cell sources. One drawback of this study was that the intradermal allergen 
challenge, which was specifically setup to address this question, was unable to detect IL-22 
within the tissue. We can only presume, based on our in vivo an in vitro challenge data, that 
IL-22 may have similarly been expressed during intradermal allergen challenge. If IL-22 was, 
thus, produced, it would have been detectable at least as a stored cytokine e.g. within 
granules of innate immune cell sources. Yet, the inability to detect IL-22 pointed away from 
innate sources towards T cell sources. Thus, we can conclude that IL-22 was expressed 
during human allergic inflammation yet the identity of the IL-22 producing cells remains to be 
established. 
Hypothesis 2 
Our second hypothesis aimed to address if IL-22 was expressed by distinct Th22 cells as well 
as other T cell subsets (Th1, Th2, Th17). The experimental results indicated that IL-22 was not 
universally expressed across different subsets. While IL-22 expression occurred within Th2 
driven inflammation, Th2 cells themselves showed no ability to express IL-22. Our data 
highlighted the strong relationship between IL-22 and Th1 cells but confirmed the divergence 
between IL-22 and IL-17 expressing cells. In addition, a distinct population of cells 
reminiscent of the Th22 subset could be identified. A major focus of this PhD, therefore, was 
to address the development of Th22 cells, their transcriptional regulation and relationship to 
other T helper cell lineages. The inability to either differentiate Th22 cells in vitro or isolate 
existing Th22 cells from peripheral blood or lung tissue ex vivo was a major hurdle. It meant 
that we could not further address if these IL-22+ CD4+ T cells represented a distinct T cell 
lineage. We can, therefore, only conclude that IL-22 is a Th1-related cytokine expressed by 
Th1 as well as cells reminiscent of the proposed Th22 cell subset.  
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Hypothesis 3 
The identification of a wide range of IL-22RA1+ cells within the skin was novel and indicated 
that cells of epithelial origin represented not the only target of IL-22 within the tissue. The 
strong association with the connective tissue, in particular, which is rich in early progenitors, 
stem cells and fibroblasts, supported the hypothesis that IL-22 had an important role in 
influencing tissue regenerative and repair processes. While the exact identify of all target 
cells within the connective tissue could not be specified, it became apparent that fibroblasts 
were likely one of the cell populations. 
Studying epithelial injury and repair in vivo shows that sub epithelial early progenitor cell 
populations play a key role in re-constituting the damaged areas temporarily as well as 
permanently. Inflammatory cues such as IL-22 may, thus, potentially serve as activation 
signal for cells to undergo differentiation and maturation. Yet, we are only beginning to 
develop the right culture techniques to maintain isolated stem cells and early progenitor cells 
in culture to test these hypotheses in more detail.  
The important role of IL-22 on cells of fibroblast origin must have been evident before, as 
three separate research groups aimed to address the functional response of IL-22 on them 
in vitro (Ikeuchi et al 2005, Andoh et al 2005, Wolk et al 2009). However, like our pulmonary 
fibroblast, the differentiation and maturation stage of these cells in culture only showed low 
IL-22RA1 surface expression. It was clear that normal cell culture techniques would not 
allow a proper functional analysis in vitro. The lack of functional response in the previous 
studies was likely an important factor while they remained largely overlooked and not cited 
until now. I can only hypothesise about the functional relevance of IL-22 in fibroblasts. From 
the insight gained studying the functional response of IL-22 in bronchial epithelial cells, it is 
likely that IL-22 plays a role in early activation and differentiation rather than later processes 
such as TGFβ1-driven collagen synthesis and deposition.  
Another important aspect highlighted was that epithelial cells and underlying early progenitor 
cells were not the only target of IL-22. Also very different structural cells such as smooth 
muscle cells showed to be IL-22RA1 positive in culture. Again, due to their low surface 
expression in vitro, the functional response of these cells to IL-22 was not investigated 
further. However, two recent publications have validated the study’s findings and confirmed 
that cultured smooth muscle cells express IL-22RA1 and responded to IL-22 with increased 
migration (Chang et al 2011). It is, therefore, not unimaginable that IL-22 has a more global 
effect on multiple structural cells within the tissue in relation to repair. Yet, it is also possible 
that growing and not fully-matured epithelial cells, mesenchymal cells and smooth muscle 
173 
 
cells share certain functional similarities in culture, allowing them to respond to IL-22 in 
similar manner. A comparison of cultured bronchial epithelial cells alone showed that 
growing cells exhibited a >50% IL-22RA1 surface expression (see Figure 42, page 141) 
while fully-matured cells in an air-liquid-interface culture showed only a 16% surface 
expression (Aujla et al 2008). This also suggests that even bronchial epithelial cells are more 
likely to respond to IL-22 when they are not as terminally differentiated. 
The regulation of IL-22RA1 in bronchial epithelial cells but also fibroblasts and smooth 
muscle cells was controlled by IFN. This observation indicated that the time window of IL-22 
expression occurred likely at the onset or immediately after the first inflammatory response. 
Similarly, the measurement of IL-22RA2 in the bronchoalveolar lavage supported the view 
that IL-22 function occurred likely during the early phase and was presumably actively 
blocked during resolution. The investigations into the underlying molecular mechanisms of 
bronchial epithelial wound healing also indicated that IL-22 had a role in early repair. At 
least, on its own, IL-22 was unable to influence cellular proliferation. Cellular proliferation is 
an important feature in wound healing which occurs after an initial re-organisation of the 
tissue (e.g. extracellular matrix break down, cell de-differentiation, cell spreading). IL-22’s 
main role is, thus, likely related to early protective and regenerative processes within tissue. 
The gene expression screen, while set up with a different aim, supported this view as IL-22 
was able to independently regulate matrix-metalloproteinases such as MMP1 and MMP10. 
While the study was unable to further address IL-22’s influence on these early events, it is 
likely that the presence of IL-22 may have an influence on cell survival, tight junction break 
down, cell-matrix degradation, de-differentiation and cellular migration.  
Thus, I hypothesise that IL-22 is an early pro-inflammatory cytokine initiating early events in 
wound repair. To do so, IL-22 targets early progenitor cells within the underlying connective 
tissue as well as influence damaged structural cells within the tissue to survive, de-
differentiate and migrate. 
Relevance of IL-22 in allergy and asthma 
Our interest in IL-22 in allergy and asthma was formed when studies highlighted a significant 
increase in IL-22 and Th22 cells in atopic dermatitis. These measurements were made during 
the chronic inflammatory phase of the disorder. Similarly in allergic asthma, evidence 
suggested that during chronic inflammation, the T helper cell response may become more 
diverse and could potentially include IL-22 and IL-17 responses. 
The now identified expression of the IL-22 expression during allergic inflammation remains 
difficult to judge with the limited knowledge available. IL-22 was released in a Th2-driven 
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environment yet Th2 cells were unable to express the cytokine. Furthermore, IL-22 showed a 
strong relationship to the cytokine IFN and was not only released by responding atopic but 
also by responding non-atopic cells in culture. We, therefore, hypothesise that IL-22 may not 
belong to the adaptive Th2 response as such.  
The release of IL-22 may be a response related to immune cell activation and inflammation 
itself and, thus, occur before or in parallel with the ensuing Th2 response. The role of IL-22 
specifically in allergy may serve a similar protective role during general inflammation 
regardless of the bias of the ensuing adaptive immune response. The view that IL-22 may 
modulate inflammation was supported by recent studies. In these, the authors blocked IL-22 
expression during an experimental allergen challenge in mice. This led to an enhanced 
allergic inflammation and as others had shown to increased cellular damage (Besnard et al 
2011). This regulation of the allergic immune response by IL-22 was hypothesised to involve 
IL-10 associated mechanisms augmenting eosinophilic infiltration (Nakagome at al 2011). 
Thus, I believe that IL-22 is an integral part of the immune response protecting the 
underlying tissue through modulating the severity of inflammation as well as initiating 
protective and regenerative processes within the tissue 
The expression of IL-22 may, thus, be beneficial in asthma. Here, more so than in other 
atopic conditions, the function and integrity of structural cells within the lung  is  of particular 
importance. IL-22 may similarly dampen the severity of allergic inflammation (as recently 
shown in mice) but maybe, more importantly, improve epithelial function and integrity. Yet, 
the asthmatic epithelium is altered and itself plays a significant role in the development of 
asthma and progression of tissue remodelling. Even in the absence of Th2-driven 
inflammation, the asthmatic epithelium displays a defective stress and anti-oxidant handling 
(Sackesen et al 2008, Yang et al 2009, Schultz et al 2010), heightened caspase activity 
(Truong-tran et al 2003, Kuwano et al 2007), altered tight junction formation (de Boer et al 
2008, Holgate et al 2009), defective migration and proliferation (Kicic et al 2010). Therefore, 
it remains to be established if IL-22 signalling could be affected in an altered asthmatic 
epithelium, (e.g. altered IFN signalling; Bosco et al 2010), or if it could function normally 
and overcome the inherited alterations in epithelial function.  
One feature implicated during this PhD research was IL-22’s putative role on mesenchymal 
progenitor cells and fibroblasts. Mesenchymal-derived fibroblast precursors are normally 
responsible for tissue repair (Morishima et al 2001). In asthma, basal lamina thickening and 
subepithelial fibrosis are a hallmark of the pathology (Brewster et al 1990, Zhang et al 1994). 
These remodelling processes are unlikely controlled directly by IL-22. Yet IL-22’s expression 
early on during inflammation may lay the ground for precursor activation and differentiation. 
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Therefore, it has to be carefully judged if the influence of IL-22 may always be positive. It 
could be possible that repair responses coordinated by IL-22, which may otherwise be 
protective in normal inflammatory settings, in asthma, may not always lead to a positive 
outcome. 
We are, therefore, only at the beginning of gaining insight into the role of IL-22 in human 
allergy and asthma. First, we need to better understand IL-22’s normal role during 
inflammation. Only then, could we specifically address its functionality in the altered 
asthmatic lung. 
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Conclusion 
 
The investigation showed that IL-22 increased in vivo after bronchial segmental allergen 
challenge in bгonchoalveolaг lavage obtained from asthmatics but not in control individuals. 
While its expression following intradermal allergen challenge remained inconclusive, the 
allergen-specific stimulation of PBMCs in vitro confirmed up regulation of IL-22. Yet, IL-22 
was observed to increase in PBMC cultures derived not only from atopics but also control 
subjects.  
While  the identify  of  cellular source of IL-22 production in vivo has yet to be determined, 
allergen stimulation of T cells in vitro provided evidence suggesting that IL-22 may not have 
been released by Th2 cells. Instead, the cytokine profile of IL-22
+ T cells derived, either 
following allergen-specific expansion in vitro or from asthmatic bronchial tissue ex vivo, was 
more reminiscent of cells belonging to the Th1 and the newly proposed Th22 subset.  
Structural cells within the tissue appeared to be the major target for IL-22. In the skin, there 
was wide expression of both IL-22RA1 and IL-22RA2 that co-localised to vimentin, a marker 
of cells of mesenchymal origin. Further analysis revealed partial co-Iocalisation of IL-22RA2 
with HSP-47, а marker of early fibrobIasts. Similarly, primary cell lines derived from bronchial 
tissue (bronchial epithelial cells, smooth muscle cells, pulmonary fibroblasts) showed 
constitutive expression of both IL-22RA1 and IL-22RA2. While Th2 cytokines were unable to 
alter IL-22 receptor expression on these cell lines, the Th1 cytokine, IFN, increased IL-
22RA1 mRNA in a dose- and time-dependent manner. 
Having identified particularly strong expression of the IL-22 receptor on epithelial cells, 
primary human bronchial epithelial cells were used to study the function of IL-22. IL-22 
synergised with IFN in the induction of pro-inflammatory genes (IL-6, CXCL9,-10, and -11) 
in epithelial cells. On its own, IL-22 was able to augment the healing, in vitro, of an injured 
bronchial epithelial cell layer. While these effects were observed independently of an effect 
of IL-22 on proliferation, the precise mechanism remains to be determined. 
In conclusion, these studies in man show that IL-22 is released after allergen encounter and 
targets primarily structural as well as progenitor cells (e.g. early fibroblasts) within the tissue. 
While it is expressed during Th2-driven inflammation, IL-22, itself, appeared to be  strongly a 
Th1-related cytokine. The function of IL-22 was related to both inflammation (associated with 
IFN) and repair. Release of IL-22 during the allergic response could relate to its tissue 
protective functions thus potentially dampening Th2-driven inflammation. All in all, IL-22 
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appears to be a Th1-related cytokine that targets structural cells and progenitor cells, 
including early fibroblasts, within the tissue. Taken together, these studies suggest that IL-22 
has a dual role in early inflammation and repair. 
 
Overview: 
 
Diagram 5. Potential expression and function of IL-22 during allergic inflammation  
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Future Outlook 
 
The data generated during the PhD represents the first investigation of IL-22 in human 
allergy and asthma. The increase in IL-22 expression after allergen challenge in the 
bronchoalveolar lavage of allergic asthmatics but not healthy controls is therefore an 
important observation.  
Due to the very small sample cohort of 15 allergic asthmatics and 3 healthy controls, this 
important observation requires validation. To substantiate the result, the study cohort would 
normally be increased. However, at this point in time, not enough insight into the cytokines 
function and link to the clinical condition has been gained to justify the additional recruitment 
of allergic asthmatics. 
An alternative would be to re-analyse the samples obtained after intradermal allergen 
challenge. We now know that the original approach of detecting IL-22 by immuno-
fluorescence was flawed. The successful application of in-situ hybridisation could not only 
achieve the original objective but also shed more light on the cellular source of IL-22. 
The original PhD has focused primarily on the role of IL-22 in bronchial epithelial wound 
healing. If the evidence of IL-22 expression during allergic inflammation becomes more 
substantial, the influence of the cytokine on other mediators of allergic inflammation needs to 
be investigated.  
Future steps include: 
1. Validation of the observed expression of IL-22 in allergy and asthma 
 
2. Clarification if IL-22 is indeed expressed by T cells during the late phase response 
 
3. Investigation if the presence of IL-22 alters the functional response of other cytokines 
(e.g. IL-4/IL-13) in relation to the bronchial epithelium. 
 
 
 
  
179 
 
References 
Abbal C, Persi L, Bousquet J, Yssel H, Pène J.(1998).Effect of bronchial allergen challenge on 
in vitro cytokine release by peripheral blood mononuclear cells of atopic patients. 
Allergy.;53(10):945-50 
 
Abbas AK, Murphy KM, Sher A.(1996).Functional diversity of helper T lymphocytes.Nature. 
1996 Oct 31;383(6603):787-93 
 
Abramson MJ, Puy RM, Weiner JM.(2003)Allergen immunotherapy for asthma.Cochrane 
Database Syst Rev. (4):CD001186. 
Abramson MJ, Puy RM, Weiner JM.(2010)Injection allergen immunotherapy for 
asthma.Cochrane Database Syst Rev.;(8):CD001186 
Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F.(2007). Interleukins 1beta 
and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 
17-producing human T helper cells. Nat Immunol.;8(9):942-9 
 
Afkarian M, Sedy JR, Yang J, Jacobson NG, Cereb N, Yang SY, Murphy TL, Murphy 
KM.(2002). T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells. 
Nat Immunol.;3(6):549-57 
 
Aggarwal S, Xie MH, Maruoka M, Foster J, Gurney AL. (2001) Acinar cells of the pancreas 
are a target of interleukin-22. J Interferon Cytokine Res.;21(12):1047-53 
 
Alam MS, Maekawa Y, Kitamura A, Tanigaki K, Yoshimoto T, Kishihara K, Yasutomo 
K.(2010). Notch signaling drives IL-22 secretion in CD4+ T cells by stimulating the aryl 
hydrocarbon receptor. Proc Natl Acad Sci U S A.;107(13):5943-8 
 
Ali FR, Oldfield WL, Higashi N, Larche M, Kay AB (2004) Late asthmatic reactions induced by 
inhalation of allergen-derived T cell peptides. Am J Respir Crit Care Med, 169; pp. 20–26 
Ali FR, Kay AB, Larché M.(2007). Airway hyperresponsiveness and bronchial mucosal 
inflammation in T cell peptide-induced asthmatic reactions in atopic 
subjects.Thorax.;62(9):750-57 
 
Amishima M, Munakata M, Nasuhara Y, Sato A, Takahashi T, Homma Y, Kawakami Y.(1998). 
Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity 
in the asthmatic human airway.Am J Respir Crit Care Med.;157(6 Pt 1):1907-12 
 
Anderson GP, (2008) Endotyping asthma: new insights into key pathogenic mechanisms in a 
complex, heterogeneous disease. Lancet.;372(9643):1107-19 
Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-
Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y. (2005). Interleukin-22, a member of the 
IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. 
Gastroenterology ;129(3):969-84. 
 
Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Filì L, Ferri 
S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S.(2007) 
Phenotypic and functional features of human Th17 cells.J Exp Med.;204(8):1849-61 
 
Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, 
Kuchroo VK.(2010). The aryl hydrocarbon receptor interacts with c-Maf to promote the 
differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol.;11(9):854-61 
 
180 
 
Arora PD, McCulloch CA.(1994). Dependence of collagen remodelling on alpha-smooth 
muscle actin expression by fibroblasts.J Cell Physiol.;159(1):161-75 
 
Arvidsson MB, Löwhagen O, Rak S.(2007) Early and late phase asthmatic response in lower 
airways of cat-allergic asthmatic patients--a comparison between experimental and 
environmental allergen challenge. Allergy.;62(5):488-94 
 
Ashton-Rickardt PG, Tonegawa S.(1994)A differential-avidity model for T-cell 
selection.Immunol Today. ;15(8):362-6 
 
Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, Reinhart TA, McAllister F, Edeal 
J, Gaus K, Husain S, Kreindler JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA, Iwakura 
Y, Kolls JK.(2008). IL-22 mediates mucosal host defense against Gram-negative bacterial 
pneumonia. Nat Med.;14(3):275-81.  
 
Awasthi A, Riol-Blanco L, Jäger A, Korn T, Pot C, Galileos G, Bettelli E, Kuchroo VK, Oukka 
M.(2009). Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-
producing cells.J Immunol.;182(10):5904-8 
 Baba N, Rubio M, Sarfati M.(2010).Interplay between CD45RA+ regulatory T cells and TNF-
alpha in the regulation of human Th17 differentiation. Int Immunol.;22(4):237-44 
 
Baigelman W, Chodosh S.(1977), Bronchodilator action of the anticholinergic drug, 
ipratropium bromide (Sch 1000), as an aerosol in chronic bronchitis and 
asthma.Chest.;71(3):324-8. 
Barczyk A, Pierzchala W, Sozañska E.(2003).Interleukin-17 in sputum correlates with airway 
hyperresponsiveness to methacholine.Respir Med. ;97(6):726-33 
 
Bard JD, Gelebart P, Anand M, Amin HM, Lai R. (2008) Aberrant expression of IL-22 receptor 
1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell 
lymphoma. Leukemia.;22(8):1595-603 
 
Barlow JL, Flynn RJ, Ballantyne SJ, McKenzie AN.(2011).Reciprocal expression of IL-25 and 
IL-17A is important for allergic airways hyperreactivity. Clin Exp Allergy.;41(10):1447-55 
 
Barnes KC, Neely JD, Duffy DL, Freidhoff LR, Breazeale DR, Schou C, Naidu RP, Levett PN, 
Renault B, Kucherlapati R, Iozzino S, Ehrlich E, Beaty TH, Marsh DG. (1996) Linkage of 
asthma and total serum IgE concentration to markers on chromosome 12q: evidence from 
Afro-Caribbean and Caucasian populations. Genomics.;37(1):41-50 
 
Bauchau V, Durham SR.(2004). Prevalence and rate of diagnosis of allergic rhinitis in Europe. 
Eur Respir J.;24(5):758-64 
 
Bautista JL, Lio CW, Lathrop SK, Forbush K, Liang Y, Luo J, Rudensky AY, Hsieh CS.(2009). 
Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat 
Immunol.;10(6):610-7 
 
Bayram H, Rusznak C, Khair OA, Sapsford RJ, Abdelaziz MM.(2002). Effect of ozone and 
nitrogen dioxide on the permeability of bronchial epithelial cell cultures of non-asthmatic and 
asthmatic subjects.Clin Exp Allergy.;32(9):1285-92 
 
Bentley AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham SR.(1993). Increases in 
activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and 
granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen 
181 
 
inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol.;8(1):35-42 
 
Besnard AG, Sabat R, Dumoutier L, Renauld JC, Willart M, Lambrecht B, Teixeira MM, 
Charron S, Fick L, Erard F, Warszawska K, Wolk K, Quesniaux V, Ryffel B, Togbe D. (2011) 
Dual Role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A.  Am J Respir 
Crit Care Med.;183(9):1153-63. Epub 2011 Feb 4. 
 
Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F.(2006). Intermittent inhaled 
corticosteroids in infants with episodic wheezing. N Engl J Med.;354(19):1998-2005 
 
Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F.(2005). IL-22 inhibits 
epidermal differentiation and induces proinflammatory gene expression and migration of 
human keratinocytes.J Immunol.;174(6):3695-702 
 
Boniface K, Blumenschein WM, Brovont-Porth K, McGeachy MJ, Basham B, Desai B, Pierce 
R, McClanahan TK, Sadekova S, de Waal Malefyt R.(2010). Human Th17 cells comprise 
heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the 
Th1 lineage.J Immunol.;185(1):679-87. 
 
Bosco A, McKenna KL, Firth MJ, Sly PD, Holt PG. (2009).A network modeling approach to 
analysis of the Th2 memory responses underlying human atopic disease. J Immunol. 
15;182(10):6011-21 
 
Bosco A, Ehteshami S, Stern DA, Martinez FD.(2010). Decreased activation of inflammatory 
networks during acute asthma exacerbations is associated with chronic airflow 
obstruction.Mucosal Immunol.;3(4):399-409 
 
Böttcher MF, Bjurström J, Mai XM, Nilsson L, Jenmalm MC.(2003).Allergen-induced cytokine 
secretion in atopic and non-atopic asthmatic children. Pediatr Allergy Immunol.;14(5):345-50. 
 
Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, Chinchilli VM, Craig 
TJ, Dimango EA, Deykin A, Fagan JK, Fish JE, Ford JG, Kraft M, Lemanske RF Jr, Leone FT, 
Martin RJ, Mauger EA, Pesola GR, Peters SP, Rollings NJ, Szefler SJ, Wechsler ME, Israel 
E; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network.(2005). Daily 
versus as-needed corticosteroids for mild persistent asthma.N Engl J Med.;352(15):1519-28 
 
Bradding P, Feather IH, Howarth PH, Mueller R, Roberts JA, Britten K, Bews JP, Hunt TC, 
Okayama Y, Heusser CH, et al.(1992). Interleukin 4 is localized to and released by human 
mast cells. J Exp Med.;176(5):1381-6 
 
Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H, Marquardt A, 
Jagla W, Popp A, Leclair S, Herrmann K, Seiderer J, Ochsenkühn T, Göke B, Auernhammer 
CJ, Dambacher J.(2006). IL-22 is increased in active Crohn's disease and promotes 
proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol 
Gastrointest Liver Physiol.;290(4):G827-38 
 
Brand S, Dambacher J, Beigel F, Zitzmann K, Heeg MH, Weiss TS, Prüfer T, Olszak T, Steib 
CJ, Storr M, Göke B, Diepolder H, Bilzer M, Thasler WE, Auernhammer CJ. (2007) IL-22-
mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J 
Physiol Gastrointest Liver Physiol.;292(4):G1019-28. 
 
Bresciani M, Parisi C, Menghi G, Bonini S.(2005). The hygiene hypothesis: does it function 
worldwide?Curr Opin Allergy Clin Immunol.;5(2):147-51 
 
182 
 
Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR.(1990). 
Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol 
Biol.;3(5):507-11. 
 
Brüstle A, Heink S, Huber M, Rosenplänter C, Stadelmann C, Yu P, Arpaia E, Mak TW, 
Kamradt T, Lohoff M.(2007). The development of inflammatory T(H)-17 cells requires 
interferon-regulatory factor 4. Nat Immunol.;8(9):958-66 
 
Bucchieri F, Puddicombe SM, Lordan JL, Richter A, Buchanan D, Wilson SJ, Ward J, Zummo 
G, Howarth PH, Djukanović R, Holgate ST, Davies DE.(2002). Asthmatic bronchial epithelium 
is more susceptible to oxidant-induced apoptosis. Am J Respir Cell Mol Biol.;27(2):179-85 
 
Bullens DM, De Swerdt A, Dilissen E, Kasran A, Kroczek RA, Cadot P, Casaer P, Ceuppens 
JL.(2005). House dust mite-specific T cells in healthy non-atopic children.Clin Exp 
Allergy.;35(12):1535-41 
 
Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA.(2007). IL-2 receptor beta-
dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells.J 
Immunol.;178(1):280-90 
 
Bureau JF, Montagutelli X, Bihl F, Lefebvre S, Guénet JL, Brahic M. (1993) Mapping loci 
influencing the persistence of Theiler's virus in the murine central nervous system. Nat 
Genet.;5(1):87-91 
 
Busse WW.(2012) The brain and asthma: what are the linkages?. Chem Immunol 
Allergy.;98:14-31. 
 
Byrd VM, Kilkenny DM, Dikov MM, Reich MB, Rocheleau JV, Armistead WJ, Thomas JW, 
Miller GG.(2003). Fibroblast growth factor receptor-1 interacts with the T-cell receptor 
signalling pathway.Immunol Cell Biol.;81(6):440-50 
 
Carroll KN, Wu P, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, Hartert TV.(2009). 
Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood 
asthma.J Allergy Clin Immunol.;123(4):964-6 
 
Cartier A, Thomson NC, Frith PA, Roberts R, Hargreave FE. (1982). Allergen-induced 
increase in bronchial responsiveness to histamine: relationship to the late asthmatic response 
and change in airway caliber. J Allergy Clin Immunol. ;70(3):170-7 
 
Castellani ML, Felaco P, Galzio RJ, Tripodi D, Toniato E, De Lutiis MA, Fulcheri M, Caraffa A, 
Antinolfi P, Tetè S, Felaco M, Conti F, Pandolfi F, Theoharides TC, Shaik-Dasthagirisaheb 
YB.(2010)IL-31 a Th2 cytokine involved in immunity and inflammation.Int J Immunopathol 
Pharmacol. ;23(3):709-13 
 
Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, Doherty JM, Mills JC, Colonna 
M.(2009). A human natural killer cell subset provides an innate source of IL-22 for mucosal 
immunity.Nature.;457(7230):722-5 
 
Cembrzynska-Nowak M, Szklarz E, Inglot AD, Teodorczyk-Injeyan JA.(1993).Elevated release 
of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from 
patients with bronchial asthma. Am Rev Respir Dis. ;147(2):291-5 
 
Chakir J, Shannon J, Molet S, Fukakusa M, Elias J, Laviolette M, Boulet LP, Hamid 
Q.(2003).Airway remodeling-associated mediators in moderate to severe asthma: effect of 
183 
 
steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin 
Immunol.;111(6):1293-8 
 
Chanez P, Bourdin A, Vachier I, Godard P, Bousquet J, Vignola AM.(2004). Effects of inhaled 
corticosteroids on pathology in asthma and chronic obstructive pulmonary disease.Proc Am 
Thorac Soc.;1(3):184-90 
 
Chang Y, Al-Alwan L, Risse PA, Roussel L, Rousseau S, Halayko AJ, Martin JG, Hamid Q, 
Eidelman DH.(2011). TH17 cytokines induce human airway smooth muscle cell migration. J 
Allergy Clin Immunol.;127(4):1046-53.e1-2 
 
Charlesworth EN, Kagey-Sobotka A, Schleimer RP, Norman PS, Lichtenstein LM. (1991) 
Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils 
and basophils associated with the cutaneous late-phase response to allergen. J 
Immunol.;146(2):671-6 
 
Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL.(1994). Regulatory T cell clones induced 
by oral tolerance: suppression of autoimmune encephalomyelitis. Science.;265(5176):1237-40 
 
Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, 
Hennighausen L, O'Shea JJ.(2006). Selective regulatory function of Socs3 in the formation of 
IL-17-secreting T cells.Proc Natl Acad Sci U S A.;103(21):8137-42 
 
Cheng F, Guo Z, Xu H, Yan D, Li Q. (2009) Decreased plasma IL22 levels, but not increased 
IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus 
erythematosus. Ann Rheum Dis.;68(4):604-6 
 
Cho SH, Stanciu LA, Holgate ST, Johnston SL.(2005).Increased interleukin-4, interleukin-5, 
and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma.Am J Respir Crit 
Care Med.;171(3):224-30 
 
Choe MM, Sporn PH, Swartz MA.(2006). Extracellular matrix remodeling by dynamic strain in 
a three-dimensional tissue-engineered human airway wall model. Am J Respir Cell Mol 
Biol.;35(3):306-13 
 
Chung Y, Yang X, Chang SH, Ma L, Tian Q, Dong C.(2006). Expression and regulation of IL-
22 in the IL-17-producing CD4+ T lymphocytes.Cell Res.;16(11):902-7 
 
Clark (2007) Anti-inflammatory functions of glucocorticoid-induced genes, Mol and Cell 
Endocrinol; V.275,1–2, 15 p79–97 
 
Cockcroft DW, Murdock KY, Kirby J, Hargreave F.(1987)Prediction of airway responsiveness 
to allergen from skin sensitivity to allergen and airway responsiveness to histamine.Am Rev 
Respir Dis.;135(1):264-7 
 
Cohen RT, Canino GJ, Bird HR, Shen S, Rosner BA, Celedón JC.(2007). Area of residence, 
birthplace, and asthma in Puerto Rican children.Chest.;131(5):1331-8 
 
Cohen CJ, Crome SQ, MacDonald KG, Dai EL, Mager DL, Levings MK.(2011). Human Th1 
and Th17 cells exhibit epigenetic stability at signature cytokine and transcription factor loci.J 
Immunol.;187(11):5615-26 
 
Connett GJ.(2000). Bronchoalveolar lavage. Paediatr Respir Rev. ;1(1):52-6. 
 
184 
 
Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Ho AW, Hai JH, Yu JJ, Jung 
JW, Filler SG, Masso-Welch P, Edgerton M, Gaffen SL. (2009) Th17 cells and IL-17 receptor 
signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 
;206(2):299-311 
 
Cookson WO, Hopkin JM.(1988). Dominant inheritance of atopic immunoglobulin-E 
responsiveness. Lancet. 1988 Jan 16;1(8577):86-8 
 
Cookson W.(2004). The immunogenetics of asthma and eczema: a new focus on the 
epithelium.Nat Rev Immunol.;4(12):978-88 
 
Corren J. (1999).The relationship between allergic rhinitis and bronchial asthma. Curr Opin 
Pulm Med. ;5(1):35-7. 
 
Cosentini R, Tarsia P, Canetta C, Graziadei G, Brambilla AM, Aliberti S, Pappalettera M, 
Tantardini F, Blasi F.(2008). Severe asthma exacerbation: role of acute Chlamydophila 
pneumoniae and Mycoplasma pneumoniae infection. Respir Res.;9:48 
 
Cosmi L, Annunziato F, Maggi E, Romagnani S, Manetti R.(2001) Chemoattractant receptors 
expressed on type 2 T cells and their role in disease.Int Arch Allergy Immunol.;125(4):273-9 
 
Cosmi L, Maggi L, Santarlasci V, Capone M, Cardilicchia E, Frosali F, Querci V, Angeli R, 
Matucci A, Fambrini M, Liotta F, Parronchi P, Maggi E, Romagnani S, Annunziato F. (2010) 
Identification of a novel subset of human circulating memory CD4(+) T cells that produce both 
IL-17A and IL-4. J Allergy Clin Immunol.;125(1):222-30.e1-4 
 
Cousins DJ, Lee TH, Staynov DZ.(2002).Cytokine coexpression during human Th1/Th2 cell 
differentiation: direct evidence for coordinated expression of Th2 cytokines.J 
Immunol.;169(5):2498-506 
 
Coutinho AE, Chapman KE.(2011)The anti-inflammatory and immunosuppressive effects of 
glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. ;335(1):2-
13. 
 
Cowan J, Pandey S, Filion LG, Angel JB, Kumar A, Cameron DW.(2012). Comparison of 
interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing 
granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. 
Clin Exp Immunol.;167(2):317-29. doi: 10.1111/j.1365-2249.2011.04520.x 
 
Crellin NK, Trifari S, Kaplan CD, Cupedo T, Spits H.(2010). Human NKp44+IL-22+ cells and 
LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. 
J Exp Med.;207(2):281-90 
 
Crocker IC, Gupta K, Townley RG, Khan MM.(1998). The profile of the cytokines secreted 
during the generation of T-helper cells from atopic asthmatic subjects.J Asthma.;35(2):187-
201 
 
Crosby LM, Waters CM.(2010). Epithelial repair mechanisms in the lung.Am J Physiol Lung 
Cell Mol Physiol.;298(6):L715-31. 
 
Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, 
Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick 
JD.(2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune 
inflammation of the brain. Nature.;421(6924):744-8 
185 
 
 
Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL, Fibbe WE, 
Cornelissen JJ, Spits H.(2009). Human fetal lymphoid tissue-inducer cells are interleukin 17-
producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol.;10(1):66-74 
 
Daly JW, Padgett WL, Shamim MT.(1986) Analogues of caffeine and theophylline: effect of 
structural alterations on affinity at adenosine receptors.J Med Chem.;29(7):1305-8. 
 
Dambacher J, Beigel F, Zitzmann K, De Toni EN, Göke B, Diepolder HM, Auernhammer CJ, 
Brand S.(2009). The role of the novel Th17 cytokine IL-26 in intestinal 
inflammation.Gut.;58(9):1207-17 
 
Dambacher J, Beigel F, Zitzmann K, Heeg MH, Göke B, Diepolder HM, Auernhammer CJ, 
Brand S. (2008) The role of interleukin-22 in hepatitis C virus infection. Cytokine.;41(3):209-16 
Davidson TS, DiPaolo RJ, Andersson J, Shevach EM.(2007). Cutting Edge: IL-2 is essential 
for TGF-beta-mediated induction of Foxp3+ T regulatory cells.J Immunol.;178(7):4022-6 
 
de Boer WI, Sharma HS, Baelemans SM, Hoogsteden HC, Lambrecht BN, Braunstahl 
GJ.(2008). Altered expression of epithelial junctional proteins in atopic asthma: possible role 
in inflammation. Can J Physiol Pharmacol.;86(3):105-12 
 
de Bruin-Weller MS, Weller FR, De Monchy JG. (1999) Repeated allergen challenge as a new 
research model for studying allergic reactions. Clin Exp Allergy. 29(2):159-65 
 
de Luca A, Zelante T, D'Angelo C, Zagarella S, Fallarino F, Spreca A, Iannitti RG, Bonifazi P, 
Renauld JC, Bistoni F, Puccetti P, Romani L.(2010). IL-22 defines a novel immune pathway of 
antifungal resistance. Mucosal Immunol.;3(4):361-73 
 
de Monchy JG, Kauffman HF, Venge P, Koëter GH, Jansen HM, Sluiter HJ, De Vries K.(1985) 
Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir 
Dis.;131(3):373-6. 
 
de Moura PR, Watanabe L, Bleicher L, Colau D, Dumoutier L, Lemaire MM, Renauld JC, 
Polikarpov I. (2009) Crystal structure of a soluble decoy receptor IL-22BP bound to 
interleukin-22. FEBS Lett.;583(7):1072-7 
 
de Wit J, Souwer Y, van Beelen AJ, de Groot R, Muller FJ, Klaasse Bos H, Jorritsma T, 
Kapsenberg ML, de Jong EC, van Ham SM.(2011). CD5 costimulation induces stable Th17 
development by promoting IL-23R expression and sustained STAT3 activation. 
Blood.;118(23):6107-14 
 
Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LV, Vankayalapati 
R.(2009). IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by 
enhancing phagolysosomal fusion.J Immunol.;183(10):6639-45 
 
Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LV, Vankayalapati 
R.(2009). IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by 
enhancing phagolysosomal fusion.J Immunol.;183(10):6639-45 
 
Dietert RR, Zelikoff JT.(2008). Early-life environment, developmental immunotoxicology, and 
the risk of pediatric allergic disease including asthma.Birth Defects Res B Dev Reprod 
Toxicol.;83(6):547-60 
 
Duerr RH, Barmada MM, Zhang L, Davis S, Preston RA, Chensny LJ, Brown JL, Ehrlich GD, 
186 
 
Weeks DE, Aston CE. (1998) Linkage and association between inflammatory bowel disease 
and a locus on chromosome 12. Am J Hum Genet.;63(1):95-100 
 
Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. (2009) Production of interleukin 
22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat 
Immunol.;10(8):857-63 
 
Dumoutier L, Van Roost E, Ameye G, Michaux L, Renauld JC.(2000). IL-TIF/IL-22: genomic 
organization and mapping of the human and mouse genes.Genes Immun.;1(8):488-94 
 
Dumoutier L, Van Roost E, Colau D, Renauld JC.(2000). Human interleukin-10-related T cell-
derived inducible factor: molecular cloning and functional characterization as an hepatocyte-
stimulating factor.Proc Natl Acad Sci U S A.;97(18):10144-9 
 
Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC.(2001).Cutting edge: STAT 
activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types.J 
Immunol.;167(7):3545-9 
 
Durham SR, Varney V, Gaga M, Frew AJ, Jacobson M, Kay AB. (1991) Immunotherapy and 
allergic inflammation. Clin Exp Allergy.;21 Suppl 1:206-10 
 
Eder W, Ege MJ, von Mutius E.(2006). The asthma epidemic.N Engl J Med. ;355(21):2226-35 
Ege MJ, Bieli C, Frei R, van Strien RT, Riedler J, Ublagger E, Schram-Bijkerk D, Brunekreef 
B, van Hage M, Scheynius A, Pershagen G, Benz MR, Lauener R, von Mutius E, Braun-
Fahrländer C; Parsifal Study team.(2006). Prenatal farm exposure is related to the expression 
of receptors of the innate immunity and to atopic sensitization in school-age children. J Allergy 
Clin Immunol.;117(4):817-23 
 
Endam LM, Bossé Y, Filali-Mouhim A, Cormier C, Boisvert P, Boulet LP, Hudson TJ, 
Desrosiers M. (2009) Polymorphisms in the interleukin-22 receptor alpha-1 gene are 
associated with severe chronic rhinosinusitis. Otolaryngol Head Neck Surg.;140(5):741-7 
 
Essayan DM.(2001) Cyclic nucleotide phosphodiesterases.J Allergy Clin Immunol;108(5):671-
80. 
 
Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS.(2003). A double-
blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J 
Allergy Clin Immunol. 2003 Jan;111(1):155-61 
 
Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, 
Traidl-Hoffmann C, Behrendt H, Durham SR, Schmidt-Weber CB, Cavani A. (2009) Th22 cells 
represent a distinct human T cell subset involved in epidermal immunity and remodeling. J 
Clin Invest.;119(12):3573-85.  
 
Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey 
HA.(1997)The effect of an anti-IgE monoclonal antibody on the early- and late-phase 
responses to allergen inhalation in asthmatic subjects.Am J Respir Crit Care Med. 
;155(6):1828-34. 
 
Fanta CH.(2009) Asthma, N Engl J Med.;360(10):1002-14. 
 
Feltis BN, Wignarajah D, Reid DW, Ward C, Harding R, Walters EH.(2007). Effects of inhaled 
fluticasone on angiogenesis and vascular endothelial growth factor in 
asthma.Thorax.;62(4):314-9 
187 
 
 
Figueroa-Vega N, Alfonso-Pérez M, Benedicto I, Sánchez-Madrid F, González-Amaro R, 
Marazuela M.(2010). Increased circulating pro-inflammatory cytokines and Th17 lymphocytes 
in Hashimoto's thyroiditis. J Clin Endocrinol Metab.;95(2):953-62 
 
Fiorentino DF, Bond MW, Mosmann TR.(1989).Two types of mouse T helper cell. IV. Th2 
clones secrete a factor that inhibits cytokine production by Th1 clones.J Exp Med. 
;170(6):2081-95 
 
Flanagan K, Modrusan Z, Cornelius J, Chavali A, Kasman I, Komuves L, Mo L, Diehl L. (2008) 
Intestinal epithelial cell up-regulation of LY6 molecules during colitis results in enhanced 
chemokine secretion. J Immunol. Mar 15;180(6):3874-81 
 
Fontenot JD, Gavin MA, Rudensky AY.(2003).Foxp3 programs the development and function 
of CD4+CD25+ regulatory T cells.Nat Immunol.;4(4):330-6 
 
Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY.(2005). A function for interleukin 2 in 
Foxp3-expressing regulatory T cells.Nat Immunol.;6(11):1142-51  
 
Frew AJ, Kay AB.(1988). The pattern of human late-phase skin reactions to extracts of 
aeroallergens.J Allergy Clin Immunol.;81(6):1117-21 
 
Fujimura T, Yamanashi R, Masuzawa M, Fujita Y, Katsuoka K, Nishiyama S, Mitsuyama M, 
Nomoto K.(1997). Conversion of the CD4+ T cell profile from T(H2)-dominant type to T(H1)-
dominant type after varicella-zoster virus infection in atopic dermatitis.J Allergy Clin 
Immunol.;100(2):274-82 
 
Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG.(2009). Human 
Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc 
Natl Acad Sci U S A.;106(51):21795-800 
 
Gabrielli A, Svegliati S, Moroncini G, Luchetti M, Tonnini C, Avvedimento EV.(2007). 
Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a 
pathway for novel therapeutic targets.Autoimmun Rev.;7(2):121-6 
 
Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R.(2009). Interferon-
lambda is functionally an interferon but structurally related to the interleukin-10 family.J Biol 
Chem.;284(31):20869-75 
 
Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, Quintana 
FJ.(2010).Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-
like and Foxp3(+) regulatory T cells. Nat Immunol.;11(9):846-53 
 
Gangemi S, Minciullo PL, Guarneri F, Cristani M, Arcoraci T, Spatari G, Saija A, Cannavò SP. 
(2009) Increased serum levels of interleukin-22 in patients affected by pityriasis rosea. J Eur 
Acad Dermatol Venereol.;23(7):858-9 
 
Garat C, Kheradmand F, Albertine KH, Folkesson HG, Matthay MA. (1996) Soluble and 
insoluble fibronectin increases alveolar epithelial wound healing in vitro. Am J Physiol.;271(5 
Pt 1):L844-53 
 
Gauvreau GM, Watson RM, O'Byrne PM.(1999) Kinetics of allergen-induced airway 
eosinophilic cytokine production and airway inflammation.Am J Respir Crit Care 
Med.;160(2):640-7. 
188 
 
 
Gauvreau GM, Evans MY. (2007) Allergen inhalation challenge: a human model of asthma 
exacerbation. Contrib Microbiol.;14:21-32 
 
Gavett SH, Chen X, Finkelman F, Wills-Karp M.(1994). Depletion of murine CD4+ T 
lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia.Am 
J Respir Cell Mol Biol.;10(6):587-93 
 
Gell PGH, Coombs RRA, (1963). Clinical Aspects of Immunology. 1st ed. Oxford, England: 
Blackwell 
 
Godinez I, Haneda T, Raffatellu M, George MD, Paixão TA, Rolán HG, Santos RL, Dandekar 
S, Tsolis RM, Bäumler AJ.(2008). T cells help to amplify inflammatory responses induced by 
Salmonella enterica serotype Typhimurium in the intestinal mucosa.Infect Immun.;76(5):2008-
17 
 
Godinez I, Raffatellu M, Chu H, Paixão TA, Haneda T, Santos RL, Bevins CL, Tsolis RM, 
Bäumler AJ. (2009) Interleukin-23 orchestrates mucosal responses to Salmonella enterica 
serotype Typhimurium in the intestine. Infect Immun.;77(1):387-98 
 
Goldstein DM, Gabriel T (2005). Pathway to the clinic: inhibition of P38 MAP kinase. A review 
of ten chemotypes selected for development. 5. pp. 1017–29. 
 
Goto M, Murakawa M, Kadoshima-Yamaoka K, Tanaka Y, Nagahira K, Fukuda Y, Nishimura 
T.(2009). Murine NKT cells produce Th17 cytokine interleukin-22.Cell Immunol.;254(2):81-4 
 
Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite 
L.(2003). The biology of IGE and the basis of allergic disease.Annu Rev Immunol.;21:579-628 
Gratziou C, Carroll M, Walls A, Howarth PH, Holgate ST. (1992). Early changes in T 
lymphocytes recovered by bronchoalveolar lavage after local allergen challenge of asthmatic 
airways. Am Rev Respir Dis.;145(6):1259-64 
 
Green RH, Brightling CE, McKenna S, et al. (2002) Asthma exacerbations and sputum 
eosinophil counts: a randomised controlled trial. Lancet; 360:1715-1721 
 
Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG.(1997). 
A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. 
Nature.;389(6652):737-42 
 
Gu Y, Yang J, Ouyang X, Liu W, Li H, Yang J, Bromberg J, Chen SH, Mayer L, Unkeless JC, 
Xiong H.(2008). Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T 
cells. Eur J Immunol.;38(7):1807-13 
 
Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, Bacharier LB, 
Lemanske RF Jr, Strunk RC, Allen DB, Bloomberg GR, Heldt G, Krawiec M, Larsen G, Liu 
AH, Chinchilli VM, Sorkness CA, Taussig LM, Martinez FD.(2006). Long-term inhaled 
corticosteroids in preschool children at high risk for asthma. N Engl J Med.;354(19):1985-97 
 
Guo H, Topham DJ.(2010). Interleukin-22 (IL-22) production by pulmonary Natural Killer cells 
and the potential role of IL-22 during primary influenza virus infection.J Virol.;84(15):7750-9 
 
Gurney AL.(2004). IL-22, a Th1 cytokine that targets the pancreas and select other peripheral 
tissues.Int Immunopharmacol. ;4(5):669-77 
 
189 
 
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding 
P, Green RH, Wardlaw AJ, Pavord ID.(2009) Mepolizumab and exacerbations of refractory 
eosinophilic asthma.N Engl J Med. ;360(10):973-84 
 
Hamada H, Garcia-Hernandez Mde L, Reome JB, Misra SK, Strutt TM, McKinstry KK, Cooper 
AM, Swain SL, Dutton RW.(2009). Tc17, a unique subset of CD8 T cells that can protect 
against lethal influenza challenge. J Immunol.;182(6):3469-81 
 
Hanson B, McGue M, Roitman-Johnson B, Segal NL, Bouchard TJ Jr, Blumenthal MN.(1991). 
Atopic disease and immunoglobulin E in twins reared apart and together.Am J Hum 
Genet.;48(5):873-9 
 
Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, 
Blauvelt A. (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in 
vivo: implications for psoriasis pathogenesis. J Invest Dermatol.;129(9):2175-83 
 
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver 
CT.(2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from 
the T helper type 1 and 2 lineages. Nat Immunol.;6(11):1123-32 
 
Hashimoto T, Akiyama K, Kobayashi N, Mori A.(2005).Comparison of IL-17 production by 
helper T cells among atopic and nonatopic asthmatics and control subjects. Int Arch Allergy 
Immunol. ;137 Suppl 1:51-4 
 
Haudenschild CC, Schwartz SM. (1979)Endothelial regeneration. II. Restitution of endothelial 
continuity. Lab Invest.;41(5):407-18. 
 
Hedrick MN, Lonsdorf AS, Shirakawa AK, Richard Lee CC, Liao F, Singh SP, Zhang HH, 
Grinberg A, Love PE, Hwang ST, Farber JM.(2009). CCR6 is required for IL-23-induced 
psoriasis-like inflammation in mice. J Clin Invest.;119(8):2317-29 
 
Heinke S, Szücs G, Norris A, Droogmans G, Nilius B.(1995) Inhibition of volume-activated 
chloride currents in endothelial cells by chromones.Br J Pharmacol.115(8):1393-8. 
 
Hennig BJ, Frodsham AJ, Hellier S, Knapp S, Yee LJ, Wright M, Zhang L, Thomas HC, 
Thursz M, Hill AV. (2007) Influence of IL-10RA and IL-22 polymorphisms on outcome of 
hepatitis C virus infection. Liver Int.;27(8):1134-43 
 
Ho IC, Glimcher LH.(2002).Transcription: tantalizing times for T cells.Cell. ;109 Suppl:S109-20 
Hoegl S, Bachmann M, Scheiermann P, Goren I, Hofstetter C, Pfeilschifter J, Zwissler B, Muhl 
H. (2011) Protective properties of inhaled IL-22 in a model of ventilator-induced lung injury. 
Am J Respir Cell Mol Biol.;44(3):369-76 
 
Hogg JC, Eggleston PA.(1984). Is asthma an epithelial disease? Am Rev Respir 
Dis.;129(2):207-8 
 
Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C (2005). The anti-
inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. 
Allergy Clin. Immunol. 115 (3): 459–65. 
 
Holgate ST, Polosa R.(2008). Treatment strategies for allergy and asthma.Nat Rev 
Immunol.;8(3):218-30 
 
Holgate ST, Roberts G, Arshad HS, Howarth PH, Davies DE.(2009). The role of the airway 
190 
 
epithelium and its interaction with environmental factors in asthma pathogenesis. Proc Am 
Thorac Soc.;6(8):655-9 
 
Holgate ST.(1996). Asthma mechanisms, determinants of severity and treatment. Forward.J 
Allergy Clin Immunol.;98(5 Pt 2):S1-2 
 
Holt PG, Sly PD (2007). Th2 cytokines in the asthma late-phase response. Lancet 370 (9596): 
1396–8 
 
Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T.(2009).Cytokines differentially 
regulate CXCL10 production by interferon-gamma-stimulated or tumor necrosis factor-alpha-
stimulated human gingival fibroblasts. J Periodontal Res.;44(2):225-31.  
 
House of Lords - Science and Technology - Sixth Report. (2007). The Extent and Burden of 
Allergy in the United Kingdom. Chapter 4 (http://www.publications.parliament.uk/ pa/ 
ld200607/ ldselect/ ldsctech/ 166/ 16607.htm). 
 
Hsieh CS, Macatonia SE, O'Garra A, Murphy KM.(1993). Pathogen-induced Th1 phenotype 
development in CD4+ alpha beta-TCR transgenic T cells is macrophage dependent. Int 
Immunol.;5(4):371-82 
 
Hsing CH, Hsieh MY, Chen WY, Cheung So E, Cheng BC, Chang MS.(2006). Induction of 
interleukin-19 and interleukin-22 after cardiac surgery with cardiopulmonary bypass. Ann 
Thorac Surg.;81(6):2196-201 
 
Hu VW, Black GE, Torres-Duarte A, Abramson FP.(2002). 3H-thymidine is a defective tool 
with which to measure rates of DNA synthesis. FASEB J.;16(11):1456-7. 
 
Huang TJ, MacAry PA, Eynott P, Moussavi A, Daniel KC, Askenase PW, Kemeny DM, Chung 
KF.(2001).Allergen-specific Th1 cells counteract efferent Th2 cell-dependent bronchial 
hyperresponsiveness and eosinophilic inflammation partly via IFN-gamma. J 
Immunol.;166(1):207-17 
 
Hughes T, Becknell B, Freud AG, McClory S, Briercheck E, Yu J, Mao C, Giovenzana C, 
Nuovo G, Wei L, Zhang X, Gavrilin MA, Wewers MD, Caligiuri MA.(2010). Interleukin-1beta 
selectively expands and sustains interleukin-22+ immature human natural killer cells in 
secondary lymphoid tissue.Immunity.;32(6):803-14 
 
Hughes T, Becknell B, McClory S, Briercheck E, Freud AG, Zhang X, Mao H, Nuovo G, Yu J, 
Caligiuri MA.(2009). Stage 3 immature human natural killer cells found in secondary lymphoid 
tissue constitutively and selectively express the TH 17 cytokine interleukin-
22.Blood.;113(17):4008-10 
 
Hugues S.(2010).Dynamics of dendritic cell-T cell interactions: a role in T cell outcome.Semin 
Immunopathol.;32(3):227-38 
 
Igawa D, Sakai M, Savan R.(2006). An unexpected discovery of two interferon gamma-like 
genes along with interleukin (IL)-22 and -26 from teleost: IL-22 and -26 genes have been 
described for the first time outside mammals.Mol Immunol. 2006 Mar;43(7):999-1009 
 
Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, Nojima Y. (2005). 
Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory 
cytokine. Arthritis Rheum.;52(4):1037-46 
 
191 
 
Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L, Qin FX, Gilliet M, Liu YJ.(2008). 
Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. 
Immunity.;28(6):870-80 
 
Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman 
DR.(2006). The orphan nuclear receptor RORgammat directs the differentiation program of 
proinflammatory IL-17+ T helper cells.Cell.;126(6):1121-33 
 
Jäger A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK.(2009). Th1, Th17, and Th9 effector 
cells induce experimental autoimmune encephalomyelitis with different pathological 
phenotypes.J Immunol.;183(11):7169-77 
 
Jain N, Covar RA, Gleason MC, Newell JD Jr, Gelfand EW, Spahn JD.(2005). Quantitative 
computed tomography detects peripheral airway disease in asthmatic children.Pediatr 
Pulmonol.;40(3):211-8 
 
Janeway CA Jr.(1989)The priming of helper T cells.Semin Immunol. ;1(1):13-20 
 
Johansson MW, Kelly EA, Busse WW, Jarjour NN, Mosher DF.(2008).Up-regulation and 
activation of eosinophil integrins in blood and airway after segmental lung antigen challenge. J 
Immunol.;180(11):7622-35 
 
Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K, Sears MR.(2007). 
Attenuation of the September epidemic of asthma exacerbations in children: a randomized, 
controlled trial of montelukast added to usual therapy.Pediatrics.;120(3):e702-12 
 
Jones BC, Logsdon NJ, Walter MR.(2008). Crystallization and preliminary X-ray diffraction 
analysis of human IL-22 bound to the extracellular IL-22R1 chain.Acta Crystallogr Sect F 
Struct Biol Cryst Commun. ;64(Pt 4):266-9 
 
Julius P, Lommatzsch M, Kuepper M, Bratke K, Faehndrich S, Luttmann W, Virchow JC. 
(2008) Safety of segmental allergen challenge in human allergic asthma. J Allergy Clin 
Immunol.;121(3):712-7. 
 
Juniper EF, Frith PA, Dunnett C, Cockcroft DW, Hargreave FE (1978). Reproducibility and 
comparison of responses to inhaled histamine and methacholine. Thorax.;33(6):705-10 
 
Kämpe M, Janson C, Stålenheim G, Stolt I, Carlson M. (2010) Experimental and seasonal 
exposure to birch pollen in allergic rhinitis and allergic asthma with regard to the inflammatory 
response. Clin Respir J.;4(1):37-44 
 
Kamradt T, Göggel R, Erb KJ.(2005). Induction, exacerbation and inhibition of allergic and 
autoimmune diseases by infection.Trends Immunol.;26(5):260-7 
 
Kapessidou P, Poulin L, Dumoutier L, Goldman M, Renauld JC, Braun MY.(2008). Interleukin-
22 deficiency accelerates the rejection of full major histocompatibility complex-disparate heart 
allografts. Transplant Proc.;40(5):1593-7 
 
Kaplan MH, Schindler U, Smiley ST, Grusby MJ.(1996). Stat6 is required for mediating 
responses to IL-4 and for development of Th2 cells. Immunity.;4(3):313-9 
 
Kaplan MH, Sun YL, Hoey T, Grusby MJ.(1996). Impaired IL-12 responses and enhanced 
development of Th2 cells in Stat4-deficient mice. Nature.;382(6587):174-7 
 
192 
 
Kay AB.(2001). Allergy and allergic diseases. N Engl J Med.;344(1):30-7 and (2):109-13 
 
Kazani S, Israel E.(2012)Update in asthma 2011.Am J Respir Crit Care Med.;186(1):35-40. 
Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour 
N, Becher B, Prat A.(2007). Human TH17 lymphocytes promote blood-brain barrier disruption 
and central nervous system inflammation.Nat Med.;13(10):1173-5 
 
Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, Duquette P, Prat A.(2009). 
Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann 
Neurol.;66(3):390-402 
 
Kheradmand F, Folkesson HG, Shum L, Derynk R, Pytela R, Matthay MA. (1994) 
Transforming growth factor-alpha enhances alveolar epithelial cell repair in a new in vitro 
model. Am J Physiol.;267(6 Pt 1):L728-38 
 
Kicic A, Hallstrand TS, Sutanto EN, Stevens PT, Kobor MS, Taplin C, Paré PD, Beyer RP, 
Stick SM, Knight DA.(2010). Decreased fibronectin production significantly contributes to 
dysregulated repair of asthmatic epithelium. Am J Respir Crit Care Med.;181(9):889-98 
 
Kidney JC, Boulet LP, Hargreave FE, Deschesnes F, Swystun VA, O'Byrne PM, Choudry N, 
Morris MM, Jennings B, Andersson N, Andreasson A, Cockcroft DW.(1997)Evaluation of 
single-dose inhaled corticosteroid activity with an allergen challenge model.J Allergy Clin 
Immunol. ;100(1):65-70. 
 
Killar L, MacDonald G, West J, Woods A, Bottomly K.(1987). Cloned, Ia-restricted T cells that 
do not produce interleukin 4(IL 4)/B cell stimulatory factor 1(BSF-1) fail to help antigen-specific 
B cells. J Immunol.;138(6):1674-9 
 
Kim S, Han S, Kim MY.(2010). Effects of interleukin-15 on human CD3(-)CD117(+)CD56(-
)OX40L(+) cell differentiation.Hum Immunol.;71(8):745-50 
 
Kim SH, Matthay MA, Mostov K, Hunt CA.(2010). Simulation of lung alveolar epithelial wound 
healing in vitro.J R Soc Interface.;7(49):1157-70. 
 
Kinnebrew MA, Ubeda C, Zenewicz LA, Smith N, Flavell RA, Pamer EG. (2010) Bacterial 
flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant 
Enterococcus infection. J Infect Dis.;201(4):534-43 
 
Kirby JG, Robertson DG, Hargreave FE, Dolovich J.(1986) Asthmatic responses to inhalation 
of anti-human IgE.Clin Allergy.;16(3):191-4. 
 
Kisand K, Bøe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, Ersvaer E, 
Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R, Ergun-Longmire B, 
Maclaren N, Krohn KJ, Pura M, Schalke B, Ströbel P, Leite MI, Battelino T, Husebye ES, 
Peterson P, Willcox N, Meager A.(2010). Chronic mucocutaneous candidiasis in APECED or 
thymoma patients correlates with autoimmunity to Th17-associated cytokines.J Exp 
Med.;207(2):299-308 
 
Kleinschek MA, Müller U, Schütze N, Sabat R, Straubinger RK, Blumenschein WM, 
McClanahan T, Kastelein RA, Alber G. (2010). Administration of IL-23 engages innate and 
adaptive immune mechanisms during fungal infection.Int Immunol.;22(2):81-90 
 
Knight DA, Holgate ST.(2006). The airway epithelium: structural and functional properties in 
193 
 
health and disease. Respirology.;8(4):432-46 
 
Koch O, Rockett K, Jallow M, Pinder M, Sisay-Joof F, Kwiatkowski D. (2005) Investigation of 
malaria susceptibility determinants in the IFNG/IL26/IL22 genomic region. Genes 
Immun.;6(4):312-8 
 
Koch M, Witzenrath M, Reuter C, Herma M, Schütte H, Suttorp N, Collins H, Kaufmann 
SH.(2006).Role of local pulmonary IFN-gamma expression in murine allergic airway 
inflammation.Am J Respir Cell Mol Biol.;35(2):211-9 
 
Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y.(2008). Possible pathogenic role 
of Th17 cells for atopic dermatitis. J Invest Dermatol.;128(11):2625-30 
 
Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, Oukka M, Kuchroo VK.(2007). IL-21 
initiates an alternative pathway to induce proinflammatory T(H)17 cells. 
Nature.;448(7152):484-7 
 
Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, 
Pestka S.(2001).Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-
10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-
derived inducible factor, IL-TIF) receptor complexes.J Biol Chem.;276(4):2725-32 
 
Kraft M, Martin RJ, Lazarus SC, Fahy JV, Boushey HA, Lemanske RF Jr, Szefler SJ; Asthma 
Clinical Research Network.(2003). Airway tissue mast cells in persistent asthma: predictor of 
treatment failure when patients discontinue inhaled corticosteroids.Chest.;124(1):42-50 
 
Kragstrup TW, Otkjaer K, Holm C, Jørgensen A, Hokland M, Iversen L, Deleuran B.(2008) 
The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid 
arthritis and spondyloarthropathy. Cytokine. ;41(1):16-23. 
 
Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H.(2005). 
Inducing and expanding regulatory T cell populations by foreign antigen. Nat 
Immunol.;6(12):1219-27 
 
Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T, Heppner FL, 
Renauld JC, Becher B.(2007).IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, 
but not required for the development of autoimmune encephalomyelitis. J 
Immunol.;179(12):8098-104 
 
Krishan A.(1975). Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium 
iodide staining.J Cell Biol.;66(1):188-93. 
 
Krug N, Erpenbeck VJ, Balke K, Petschallies J, Tschernig T, Hohlfeld JM, Fabel H.(2001). 
Cytokine profile of bronchoalveolar lavage-derived CD4(+), CD8(+), and gammadelta T cells 
in people with asthma after segmental allergen challenge. Am J Respir Cell Mol 
Biol.;25(1):125-31 
 
Krüger K, Mooren FC.(2007)T cell homing and exercise.Exerc Immunol Rev. 13:37-54 
 
Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, Sterry W, Asadullah K, Sabat R. 
(2006) Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are 
distinct from classical ILs. Exp Dermatol.;15(12):991-1004 
 
Kuwano K.(2007). Epithelial cell apoptosis and lung remodeling. Cell Mol Immunol.;4(6):419-
194 
 
29 
Lachowicz-Scroggins ME, Boushey HA, Finkbeiner WE, Widdicombe JH. (2010). Interleukin-
13-induced mucous metaplasia increases susceptibility of human airway epithelium to 
rhinovirus infection.Am J Respir Cell Mol Biol.;43(6):652-61 
Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T.(1985).Damage of the airway epithelium 
and bronchial reactivity in patients with asthma. Am Rev Respir Dis.;131(4):599-606 
 
Laitinen A, Altraja A, Kämpe M, Linden M, Virtanen I, Laitinen LA.(1997). Tenascin is 
increased in airway basement membrane of asthmatics and decreased by an inhaled 
steroid.Am J Respir Crit Care Med.;156(3 Pt 1):951-8 
 
Laitinen T, Räsänen M, Kaprio J, Koskenvuo M, Laitinen LA.(1998).Importance of genetic 
factors in adolescent asthma: a population-based twin-family study.Am J Respir Crit Care 
Med. ;157(4 Pt 1):1073-8. 
 
Lajoie S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA, Dienger K, Budelsky AL, Wills-Karp 
M.(2010).Complement-mediated regulation of the IL-17A axis is a central genetic determinant 
of the severity of experimental allergic asthma.Nat Immunol. 2010 Oct;11(10):928-35 
 
Lambert, A.; Goad, B.; Pittman, D.; Clark, E.; Block, L.; Wong, T.; Erickson, J.; Hayes, L.; 
Sheilds, K.; Deng, B.; Spaulding, V.; Annis, B.; Zollner, R.; Wang, I.; Kobayashi, M.; 
Thibodeaux, D.; Leonard, J.; Jacobs, K.; Fouser, L.(2001). Novel cytokine IL-22 administrated 
by adenovirus vector or as recombinant purified protein induces acute-phase responses and 
renal tubular basophilia in female C57BL/6 mice. Toxicologic Pathology, 29 (6): 712 
 
Lane P, Kim MY, Withers D, Gaspal F, Bekiaris V, Desanti G, Khan M, McConnell F, 
Anderson G.(2008). Lymphoid tissue inducer cells in adaptive CD4 T cell dependent 
responses.Semin Immunol.;20(3):159-63 
 
Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan 
T, Kastelein RA, Cua DJ.(2005). IL-23 drives a pathogenic T cell population that induces 
autoimmune inflammation. J Exp Med.;201(2):233-40 
 
Larsen JM, Bonefeld CM, Poulsen SS, Geisler C, Skov L. (2009) IL-23 and T(H)17-mediated 
inflammation in human allergic contact dermatitis. J Allergy Clin Immunol.;123(2):486-92 
 
Lawrence S, Beasley R, Doull I, Begishvili B, Lampe F, Holgate ST, Morton NE.(1994). 
Genetic analysis of atopy and asthma as quantitative traits and ordered polychotomies. Ann 
Hum Genet.;58(Pt 4):359-68 
 
Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE.(1990). Generation of 
interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro 
generation of IL-4-producing cells.J Exp Med.;172(3):921-9 
 
Lécart S, Morel F, Noraz N, Pène J, Garcia M, Boniface K, Lecron JC, Yssel H.(2002). IL-22, 
in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 
receptor on activated human B cells.Int Immunol.;14(11):1351-6 
 
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, 
Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ.(2000) Effects of an 
interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and 
the late asthmatic response.Lancet.;356(9248):2144-8. 
 
Leung MW, Shen S, Lafaille JJ.(2009). TCR-dependent differentiation of thymic Foxp3+ cells 
195 
 
is limited to small clonal sizes. J Exp Med.;206(10):2121-30 
 
Levillayer F, Mas M, Levi-Acobas F, Brahic M, Bureau JF. (2007) Interleukin 22 is a candidate 
gene for Tmevp3, a locus controlling Theiler's virus-induced neurological diseases. 
Genetics.;176(3):1835-44 
 
Levy ML, Thomas M, Small I, Pearce L, Pinnock H, Stephenson P. (2009). Summary of the 
2008 BTS/SIGN British Guideline on the management of asthma. Prim Care Respir J.;18 
Suppl 1:S1-16 
 
Lewin B.(2008) Genes IX. Sudbury, Mass. Jones and Bartlett 2008. 
 
Li MO, Wan YY, Flavell RA.(2007). T cell-produced transforming growth factor-beta1 controls 
T cell tolerance and regulates Th1- and Th17-cell differentiation.Immunity.;26(5):579-91 
 
Li W, Danilenko DM, Bunting S, Ganesan R, Sa S, Ferrando R, Wu TD, Kolumam GA, 
Ouyang W, Kirchhofer D. (2009) The serine protease marapsin is expressed in stratified 
squamous epithelia and is up-regulated in the hyperproliferative epidermis of psoriasis and 
regenerating wounds. J Biol Chem.;284(1):218-28. 
 
Li Z, Liu B, Maminishkis A, Mahesh SP, Yeh S, Lew J, Lim WK, Sen HN, Clarke G, Buggage 
R, Miller SS, Nussenblatt RB.(2008). Gene expression profiling in autoimmune noninfectious 
uveitis disease. J Immunol.;181(7):5147-57 
 
Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser 
LA.(2006). Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively 
enhance expression of antimicrobial peptides.J Exp Med.;203(10):2271-9 
 
Liang CC, Park AY, Guan JL.(2007). In vitro scratch assay: a convenient and inexpensive 
method for analysis of cell migration in vitro.Nat Protoc.;2(2):329-33. 
 
Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M, Goldman SJ, Dunussi-
Joannopoulos K, Williams CM, Wright JF, Fouser LA.(2007).An IL-17F/A heterodimer protein 
is produced by mouse Th17 cells and induces airway neutrophil recruitment.J Immunol. 
;179(11):7791-9 
 
Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, Nguyen BV, Gadina 
M, Sher A, Paul WE, O'Shea JJ.(2001). T-bet is rapidly induced by interferon-gamma in 
lymphoid and myeloid cells. Proc Natl Acad Sci U S A.;98(26):15137-42 
 
Lilly CM, Nakamura H, Belostotsky OI, Haley KJ, Garcia-Zepeda EA, Luster AD, Israel 
E.(2001).Eotaxin expression after segmental allergen challenge in subjects with atopic 
asthma.Am J Respir Crit Care Med. ;163(7):1669-75 
 
Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE Jr, 
Spellberg B.(2009). Th1-Th17 cells mediate protective adaptive immunity against 
Staphylococcus aureus and Candida albicans infection in mice. PLoS 
Pathog.;5(12):e1000703 
 
Liu Z, Yelverton RW, Kraft B, Tanner SB, Olsen NJ, Aune TM. (2005).Highly conserved gene 
expression profiles in humans with allergic rhinitis altered by immunotherapy.Clin Exp 
Allergy.;35(12):1581-90 
 
Liu H, Huang K, Wu Y, Lin N, Li J, Tu Y. (2007) The expression of interleukin-22 and S100A7, 
196 
 
A8, A9 mRNA in patients with psoriasis vulgaris.  J Huazhong Univ Sci Technolog Med 
Sci.;27(5):605-7 
 
Lloyd CM, Robinson DS.(2007). Allergen-induced airway remodelling.Eur Respir 
J.;29(5):1020-32 
 
Logsdon NJ, Jones BC, Josephson K, Cook J, Walter MR.(2002). Comparison of interleukin-
22 and interleukin-10 soluble receptor complexes.J Interferon Cytokine Res.;22(11):1099-112. 
Logsdon NJ, Jones BC, Allman JC, Izotova L, Schwartz B, Pestka S, Walter MR.(2004). The 
IL-10R2 binding hot spot on IL-22 is located on the N-terminal helix and is dependent on N-
linked glycosylation. J Mol Biol.;342(2):503-14 
 
Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF Jr, 
Wardlaw AJ, Wenzel SE, Greenberger PA.(2011)Asthma endotypes: a new approach to 
classification of disease entities within the asthma syndrome.J Allergy Clin 
Immunol.;127(2):355-60. 
 
Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, 
Krueger JG. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T 
cells. J Invest Dermatol.;128(5):1207-11 
 
Luci C, Reynders A, Ivanov II, Cognet C, Chiche L, Chasson L, Hardwigsen J, Anguiano E, 
Banchereau J, Chaussabel D, Dalod M, Littman DR, Vivier E, Tomasello E.(2009). Influence 
of the transcription factor RORgammat on the development of NKp46+ cell populations in gut 
and skin. Nat Immunol.;10(1):75-82 
 
Lundgren R, Söderberg M, Hörstedt P, Stenling R.(1988). Morphological studies of bronchial 
mucosal biopsies from asthmatics before and after ten years of treatment with inhaled 
steroids.Eur Respir J.;1(10):883-9 
 
Ma HL, Napierata L, Stedman N, Benoit S, Collins M, Nickerson-Nutter C, Young DA.(2010). 
Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by 
enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum.;62(2):430-
40. 
 
Manel N, Unutmaz D, Littman DR.(2008). The differentiation of human T(H)-17 cells requires 
transforming growth factor-beta and induction of the nuclear receptor RORgammat.Nat 
Immunol.;9(6):641-9 
 
Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl 
SM, Schoeb TR, Weaver CT.(2006). Transforming growth factor-beta induces development of 
the T(H)17 lineage. Nature.;441(7090):231-4 
 
Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M.(2009). Interleukin-17-producing 
gammadelta T cells selectively expand in response to pathogen products and environmental 
signals. Immunity.;31(2):321-30 
 
Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C.(2009). Th17 cells promote 
pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after 
conversion into Th1 cells.Eur J Immunol.;39(1):216-24 
 
Matsumoto K, Narita S, Rerecich T, Snider DP, O'Byrne PM.(2004).Different profile of 
interleukin-10 production in circulating T cells from atopic asthmatics compared with healthy 
subjects.Can Respir J.;11(1):33-8 
197 
 
 
Matthews K, Wilkinson KA, Kalsdorf B, Roberts T, Diacon A, Walzl G, Wolske J, Ntsekhe M, 
Syed F, Russell J, Mayosi BM, Dawson R, Dheda K, Wilkinson RJ, Hanekom WA, Scriba 
TJ.(2011). Predominance of interleukin-22 over interleukin-17 at the site of disease in human 
tuberculosis. Tuberculosis (Edinb).;91(6):587-93 
 
Maxmen A (2011).Asthma: Breathing new life into research. Nature  479, S20–S21 
 
Maziak W. (2005) The asthma epidemic and our artificial habitats.BMC Pulm Med. ;5:5 
 
McGeachy MJ, Cua DJ.(2007). The link between IL-23 and Th17 cell-mediated immune 
pathologies.Semin Immunol.;19(6):372-6 
 
McKay L.I., Cidlowski J.A. (1999) Molecular control of immune/inflammatory responses: 
Interactions between NF-?B and steroid receptor-signaling pathways. Endocrinol. 
Rev.;20:435–459. 
 
Mebius RE, Rennert P, Weissman IL.(1997). Developing lymph nodes collect CD4+CD3- 
LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. 
Immunity.;7(4):493-504 
 
Meyer KC. (2007) Bronchoalveolar lavage as a diagnostic tool. Semin Respir Crit Care 
Med.;28(5):546-60 
 
Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA.(2010). An 
interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T 
cells. J Immunol.;185(6):3190-8 
 
Missé D, Yssel H, Trabattoni D, Oblet C, Lo Caputo S, Mazzotta F, Pène J, Gonzalez JP, 
Clerici M, Veas F. (2007) IL-22 participates in an innate anti-HIV-1 host-resistance network 
through acute-phase protein induction. J Immunol.;178(1):407-15 
 
Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, Depner M, von Berg A, Bufe 
A, Rietschel E, Heinzmann A, Simma B, Frischer T, Willis-Owen SA, Wong KC, Illig T, 
Vogelberg C, Weiland SK, von Mutius E, Abecasis GR, Farrall M, Gut IG, Lathrop GM, 
Cookson WO.(2007). Genetic variants regulating ORMDL3 expression contribute to the risk of 
childhood asthma.Nature.;448(7152):470-3 
 
Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, 
Lathrop M, Cookson WO; GABRIEL Consortium.(2010). A large-scale, consortium-based 
genomewide association study of asthma.N Engl J Med.;363(13):1211-21 
 
Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Pagé N, Olivenstein R, Elias J, Chakir 
J.(2001).IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to 
produce cytokines. J Allergy Clin Immunol. ;108(3):430-8 
 
Montefort S, Roberts JA, Beasley R, Holgate ST, Roche WR.(1992). The site of disruption of 
the bronchial epithelium in asthmatic and non-asthmatic subjects. Thorax.;47(7):499-503 
 
Montuschi P, Peters-Golden ML.(2010) Leukotriene modifiers for asthma treatment.Clin Exp 
Allergy.;40(12):1732-41 
 
Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, Scalia MR, Akinbami LJ; 
Centers for Disease Control and Prevention (CDC).(2007). National surveillance for asthma--
198 
 
United States, 1980-2004.MMWR Surveill Summ.;56(8):1-54 
 
Morcillo EJ, Cortijo J.(2006). Mucus and MUC in asthma.Curr Opin Pulm Med.;12(1):1-6 
 
Morgan AJ, Symon FA, Berry MA, Pavord ID, Corrigan CJ, Wardlaw AJ.(2005).IL-4-
expressing bronchoalveolar T cells from asthmatic and healthy subjects preferentially express 
CCR 3 and CCR 4. J Allergy Clin Immunol. ;116(3):594-600 
 
Morishima Y, Nomura A, Uchida Y, Noguchi Y, Sakamoto T, Ishii Y, Goto Y, Masuyama K, 
Zhang MJ, Hirano K, Mochizuki M, Ohtsuka M, Sekizawa K.(2001). Triggering the induction of 
myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir Cell Mol 
Biol.;24(1):1-11 
 
Mukherjee S, Schaller MA, Neupane R, Kunkel SL, Lukacs NW.(2009). Regulation of T cell 
activation by Notch ligand, DLL4, promotes IL-17 production and Rorc activation.J Immunol. 
182(12):7381-8 
 
Mullings RE, Wilson SJ, Puddicombe SM, Lordan JL, Bucchieri F, Djukanović R, Howarth PH, 
Harper S, Holgate ST, Davies DE.(2001). Signal transducer and activator of transcription 6 
(STAT-6) expression and function in asthmatic bronchial epithelium.J Allergy Clin 
Immunol.;108(5):832-8 
 
Muñoz M, Heimesaat MM, Danker K, Struck D, Lohmann U, Plickert R, Bereswill S, Fischer A, 
Dunay IR, Wolk K, Loddenkemper C, Krell HW, Libert C, Lund LR, Frey O, Hölscher C, 
Iwakura Y, Ghilardi N, Ouyang W, Kamradt T, Sabat R, Liesenfeld O.(2009). Interleukin (IL)-
23 mediates Toxoplasma gondii-induced immunopathology in the gut via 
matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med.;206(13):3047-59 
 
Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A; IFWIN study team.(2006). 
Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy 
INfants (IFWIN): double-blind, randomised, controlled study.Lancet.;368(9537):754-62 
 
Nagalakshmi ML, Murphy E, McClanahan T, de Waal Malefyt R. (2004) Expression patterns 
of IL-10 ligand and receptor gene families provide leads for biological characterization.  Int 
Immunopharmacol.;4(5):577-92 
 
Nagem RA, Colau D, Dumoutier L, Renauld JC, Ogata C, Polikarpov I.(2002). Crystal 
structure of recombinant human interleukin-22.Structure.;10(8):1051-62 
 
Naish S, Boenisch T, Farmilo AJ, Stead RH. (1989). Handbook of immunological staining 
methods. Dako Cooperation 
 
Nakagome K, Imamura M, Kawahata K, Harada H, Okunishi K, Matsumoto T, Sasaki O, 
Tanaka R, Kano MR, Chang H, Hanawa H, Miyazaki J, Yamamoto K, Dohi M.(2011). High 
expression of IL-22 suppresses antigen-induced immune responses and eosinophilic airway 
inflammation via an IL-10-associated mechanism. J Immunol.;187(10):5077-89 
 
Nakamura M, Tokura Y. (2010) A novel missense mutation in tumour necrosis factor receptor 
superfamily 1A (TNFRSF1A) gene found in tumour necrosis factor receptor-associated 
periodic syndrome (TRAPS) with high serum interleukin (IL)-22. Eur J Dermatol.;20(4):508-9.  
 
Nelson HS, Bernstein IL, Fink J, Edwards TB, Spector SL, Storms WW, Tashkin DP.(1998). 
Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-
blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Pulmicort 
199 
 
Turbuhaler Study Group.Chest.;113(5):1264-71 
 
Ness-Schwickerath KJ, Jin C, Morita CT.(2010). Cytokine requirements for the differentiation 
and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells. J 
Immunol.;184(12):7268-80 
 
Neufert C, Pickert G, Zheng Y, Wittkopf N, Warntjen M, Nikolaev A, Ouyang W, Neurath MF, 
Becker C. (2010) Activation of epithelial STAT3 regulates intestinal homeostasis. Cell 
Cycle.;9(4):652-5 
 
Newcomb DC, Boswell MG, Huckabee MM, Goleniewska K, Dulek DE, Reiss S, Lukacs NW, 
Kolls JK, Peebles RS Jr.(2012).IL-13 regulates Th17 secretion of IL-17A in an IL-10-
dependent manner. J Immunol.;188(3):1027-35 
 
Nishihara M, Ogura H, Ueda N, Tsuruoka M, Kitabayashi C, Tsuji F, Aono H, Ishihara K, 
Huseby E, Betz UA, Murakami M, Hirano T.(2007). IL-6-gp130-STAT3 in T cells directs the 
development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int 
Immunol.;19(6):695-702 
 
Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. (2008) Interleukin-
17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal 
relationship to regulatory T cell numbers. Arthritis Rheum.;58(3):875-87 
 
Noal RB, Menezes AM, Macedo SE, Dumith SC.(2011). Childhood body mass index and risk 
of asthma in adolescence: a systematic review. Obes Rev.;12(2):93-104 
 
Noben-Trauth N, Hu-Li J, Paul WE.(2002). IL-4 secreted from individual naive CD4+ T cells 
acts in an autocrine manner to induce Th2 differentiation.Eur J Immunol.;32(5):1428-33 
 
Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suárez-Fariñas M, Cardinale 
I, Khatcherian A, Gonzalez J, Pierson KC, White TR, Pensabene C, Coats I, Novitskaya I, 
Lowes MA, Krueger JG. (2008). Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct 
inflammatory and keratinocyte-response pathways. Br J Dermatol.;159(5):1092-102 
 
Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, Ramon M, 
Bergman R, Krueger JG, Guttman-Yassky E. (2009) IL-22-producing "T22" T cells account for 
upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy 
Clin Immunol.;123(6):1244-52.e2 
 
Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, 
Watowich SS, Jetten AM, Dong C.(2007). Essential autocrine regulation by IL-21 in the 
generation of inflammatory T cells. Nature.;448(7152):480-3 
 
Nuttall SL, Langford NJ, Kendall MJ.(2000). Frequent paracetamol use linked to asthma. 
Lancet.;355(9215):1648-9 
 
Ober C, Cox NJ, Abney M, Di Rienzo A, Lander ES, Changyaleket B, Gidley H, Kurtz B, Lee 
J, Nance M, Pettersson A, Prescott J, Richardson A, Schlenker E, Summerhill E, Willadsen S, 
Parry R. (1998) Genome-wide search for asthma susceptibility loci in a founder population. 
The Collaborative Study on the Genetics of Asthma. Hum Mol Genet.;7(9):1393-8 
 
O'Byrne PM, Dolovich J, Hargreave FE.(1987)Late asthmatic responses.Am Rev Respir Dis. 
1987 Sep;136(3):740-51 
 
200 
 
O’Byrne PM, Gavreau GM, Brannan JD. (2009) Provoked models of asthma: what have we 
learnt? Clin Exp Allergy; 39:181-92 
 
O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW; START Investigators 
Group.(2009b). Severe exacerbations and decline in lung function in asthma. Am J Respir Crit 
Care Med.;179(1):19-24 
 
O'Garra A, McEvoy LM, Zlotnik A.(1998).T-cell subsets: chemokine receptors guide the 
way.Curr Biol. 1;8(18):R646-9 
 
Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, Testi R, Foresi A.(1997). 
Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway 
inflammation and remodeling in mild asthma: a placebo-controlled study.Am J Respir Crit 
Care Med.;155(6):1864-71 
 
Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ. (2007) Gene 
expression profiling and differentiation assessment in primary human hepatocyte cultures, 
established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol.;222(1):42-
56.  
 
Openshaw PJ, Hewitt C.(2000)Protective and harmful effects of viral infections in childhood on 
wheezing disorders and asthma.Am J Respir Crit Care Med.;162(2 Pt 2):S40-3. 
 
Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, 
Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams 
JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA.(2000). 
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar 
as well as distinct from IL-12. Immunity.;13(5):715-25 
 
Oseroff C, Sidney J, Kotturi MF, Kolla R, Alam R, Broide DH, Wasserman SI, Weiskopf D, 
McKinney DM, Chung JL, Petersen A, Grey H, Peters B, Sette A.(2010). Molecular 
determinants of T cell epitope recognition to the common Timothy grass allergen. J 
Immunol.;185(2):943-55 
 
Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, Reis e Sousa 
C.(2008). DC activated via dectin-1 convert Treg into IL-17 producers.Eur J 
Immunol.;38(12):3274-81 
 
Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, 
Crim C.(2005). Comparative efficacy and safety of low-dose fluticasone propionate and 
montelukast in children with persistent asthma. J Pediatr.;147(2):213-20 
 
Paganin F, Séneterre E, Chanez P, Daurés JP, Bruel JM, Michel FB, Bousquet J.(1996). 
Computed tomography of the lungs in asthma: influence of disease severity and etiology. Am 
J Respir Crit Care Med.;153(1):110-4 
 
Pagliaccetti NE, Chu EN, Bolen CR, Kleinstein SH, Robek MD.(2010). Lambda and alpha 
interferons inhibit hepatitis B virus replication through a common molecular mechanism but 
with different in vivo activities. Virology.;401(2):197-206 
 
Pan C, Kumar C, Bohl S, Klingmueller U, Mann M. (2009) Comparative proteomic 
phenotyping of cell lines and primary cells to assess preservation of cell type-specific 
functions. Mol Cell Proteomics.;8(3):443-50 
 
201 
 
Pan HF, Zhao XF, Yuan H, Zhang WH, Li XP, Wang GH, Wu GC, Tang XW, Li WX, Li LH, 
Feng JB, Hu CS, Ye DQ. (2009) Decreased serum IL-22 levels in patients with systemic lupus 
erythematosus. Clin Chim Acta.;401(1-2):179-80 
 
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, 
Dong C.(2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing 
interleukin 17. Nat Immunol.;6(11):1133-41 
 
Patel MM, Miller RL.(2009). Air pollution and childhood asthma: recent advances and future 
directions.Curr Opin Pediatr.;21(2):235-42 
 
Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, Lamm CJ, 
O'Byrne PM; START Investigators Group.(2003). Early intervention with budesonide in mild 
persistent asthma: a randomised, double-blind trial.Lancet.;361(9363):1071-6 
 
Pavord ID, Tattersfield AE.(1995)Bronchoprotective role for endogenous prostaglandin 
E2.Lancet.;345(8947):436-8. 
 
Payne DN, Qiu Y, Zhu J, Peachey L, Scallan M, Bush A, Jeffery PK.(2004). Airway 
inflammation in children with difficult asthma: relationships with airflow limitation and persistent 
symptoms.Thorax.;59(10):862-9 
 
Pearce N, Aït-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, Robertson C; and the ISAAC 
Phase Three Study Group.(2007). Worldwide trends in the prevalence of asthma symptoms: 
phase III of the International Study of Asthma and Allergies in Childhood 
(ISAAC).Thorax.;62(9):758-66 
 
Pease JE.(2006). Asthma, allergy and chemokines.Curr Drug Targets.;7(1):3-12 
 
Pelaia G, Vatrella A, Maselli R. (2012) The potential of biologics for the treatment of asthma. 
Nat Rev Drug Discov.;11(12):958-72 
 
Pène J, Chevalier S, Preisser L, Vénéreau E, Guilleux MH, Ghannam S, Molès JP, Danger Y, 
Ravon E, Lesaux S, Yssel H, Gascan H. (2008) Chronically inflamed human tissues are 
infiltrated by highly differentiated Th17 lymphocytes. J Immunol. ;180(11):7423-30 
 
Pergola C, Werz O.(2010) 5-Lipoxygenase inhibitors: a review of recent developments and 
patents.Expert Opin Ther Pat.;20(3):355-75. 
 
Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, Lehr HA, Hirth S, 
Weigmann B, Wirtz S, Ouyang W, Neurath MF, Becker C.(2009). STAT3 links IL-22 signaling 
in intestinal epithelial cells to mucosal wound healing. J Exp Med.;206(7):1465-72.  
 
Pilette C, Francis JN, Till SJ, Durham SR.(2004).CCR4 ligands are up-regulated in the 
airways of atopic asthmatics after segmental allergen challenge.Eur Respir J. ;23(6):876-84 
Piriyapongsa J, Polavarapu N, Borodovsky M, McDonald J. (2007) Exonization of the LTR 
transposable elements in human genome.BMC Genomics.;8:291 
 
Placek K, Coffre M, Maiella S, Bianchi E, Rogge L.(2009). Genetic and epigenetic networks 
controlling T helper 1 cell differentiation.Immunology.;127(2):155-62 
 
Platts-Mills TA, Erwin E, Heymann P, Woodfolk J.(2005). Is the hygiene hypothesis still a 
viable explanation for the increased prevalence of asthma?Allergy.;60 Suppl 79:25-31 
 
202 
 
Poon AH, Hamid Q.(2012) Asthma endotypes: the right direction towards personalized 
medicine for asthma.Expert Rev Clin Immunol.;8(7):595-6 
 
Puel A, Döffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, Cobat A, 
Ouachée-Chardin M, Toulon A, Bustamante J, Al-Muhsen S, Al-Owain M, Arkwright PD, 
Costigan C, McConnell V, Cant AJ, Abinun M, Polak M, Bougnères PF, Kumararatne D, 
Marodi L, Nahum A, Roifman C, Blanche S, Fischer A, Bodemer C, Abel L, Lilic D, Casanova 
JL.(2010). Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic 
mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I.J Exp 
Med.;207(2):291-7 
 
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC.(1993). Lung 
volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function 
Tests, European Community for Steel and Coal. Official Statement of the European 
Respiratory Society.Eur Respir J Suppl.;16:5-40 
 
Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, 
Weiner HL.(2008). Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon 
receptor. Nature.;453(7191):65-71 
 
Radaeva S, Sun R, Pan HN, Hong F, Gao B. (2004) Interleukin 22 (IL-22) plays a protective 
role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 
activation. Hepatology.;39(5):1332-42 
 
Raemdonck K, de Alba J, Birrell MA, Grace M, Maher SA, Irvin CG, Fozard JR, O'Byrne PM, 
Belvisi MG. (2012) A role for sensory nerves in the late asthmatic response. Thorax;67(1):19-
25. 
 
Ramanathan M Jr, Spannhake EW, Lane AP.(2007). Chronic rhinosinusitis with nasal polyps 
is associated with decreased expression of mucosal interleukin 22 receptor. 
Laryngoscope.;117(10):1839-43 
 
Randolph DA, Stephens R, Carruthers CJ, Chaplin DD.(1999). Cooperation between Th1 and 
Th2 cells in a murine model of eosinophilic airway inflammation.J Clin Invest.;104(8):1021-9 
 
Rätsep R, Kingo K, Karelson M, Reimann E, Raud K, Silm H, Vasar E, Kõks S. (2008) Gene 
expression study of IL10 family genes in vitiligo skin biopsies, peripheral blood mononuclear 
cells and sera. Br J Dermatol. 2008;159(6):1275-81 
 
Ren X, Hu B, Colletti LM. (2010) IL-22 is involved in liver regeneration after hepatectomy.  Am 
J Physiol Gastrointest Liver Physiol.;298(1):G74-80.  
 
Rezaei N. (2006) TNF-receptor-associated periodic syndrome (TRAPS): an autosomal 
dominant multisystem disorder. Clin Rheumatol.;25(6):773-7 
 
Rhen T, Cidlowski JA.(2005) Antiinflammatory action of glucocorticoids--new mechanisms for 
old drugs.N Engl J Med. ;353(16):1711-23. 
 
Ricciardi L, Minciullo PL, Saitta S, Trombetta D, Saija A, Gangemi S. (2009) Increased serum 
levels of IL-22 in patients with nickel contact dermatitis. Contact Dermatitis.;60(1):57-8 
 
Robertson DG, Kerigan AT, Hargreave FE, Chalmers R, Dolovich J.(1974)Late asthmatic 
responses induced by ragweed pollen allergen. J Allergy Clin Immunol.;54(4):244-54 
 
203 
 
Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR (1993). Activation of CD4+ T 
cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in 
bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J 
Allergy Clin Immunol.;92(2):313-24 
 
Robinson DS, Larché M, Durham SR.(2004).Tregs and allergic disease.J Clin Invest. 
;114(10):1389-97 
 
Robinson DS, Tsicopoulos A, Meng Q, Durham S, Kay AB, Hamid Q.(1996).Increased 
interleukin-10 messenger RNA expression in atopic allergy and asthma.Am J Respir Cell Mol 
Biol.;14(2):113-7 
 
Robinson DS.(2009). Regulatory T cells and asthma. Clin Exp Allergy.;39(9):1314-23 
 
Romagnani S.(1991). Human TH1 and TH2 subsets: doubt no more.Immunol 
Today.;12(8):256-7 
 
Romagnani S.(2002). Cytokines and chemoattractants in allergic inflammation.Mol 
Immunol.;38(12-13):881-5 
 
Rosenkranz MA, Busse WW, Sheridan JF, Crisafi GM, Davidson RJ.(2012) Are there 
neurophenotypes for asthma? Functional brain imaging of the interaction between emotion 
and inflammation in asthma. PLoS One.;7(8):e40921 
 
Rothenberg EV, Taghon T.(2005)Molecular genetics of T cell development.Annu Rev 
Immunol.;23:601-49 
 
Rudloff I, Bachmann M, Pfeilschifter J, Mühl H.(2012). Mechanisms of rapid induction of 
interleukin-22 in activated T cells and its modulation by cyclosporin a. J Biol 
Chem.;287(7):4531-43 
 
Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, Kasman I, Winer J, Modrusan Z, 
Danilenko DM, Ouyang W.(2007). The effects of IL-20 subfamily cytokines on reconstituted 
human epidermis suggest potential roles in cutaneous innate defense and pathogenic 
adaptive immunity in psoriasis. J Immunol.;178(4):2229-40. 
 
Sackesen C, Ercan H, Dizdar E, Soyer O, Gumus P, Tosun BN, Büyüktuncer Z, Karabulut E, 
Besler T, Kalayci O.(2008). A comprehensive evaluation of the enzymatic and nonenzymatic 
antioxidant systems in childhood asthma. J Allergy Clin Immunol.;122(1):78-85 
 
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M.(1995). Immunologic self-tolerance 
maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a 
single mechanism of self-tolerance causes various autoimmune diseases.J 
Immunol.;155(3):1151-64 
 
Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA.(2000). 
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory 
T cells that control autoimmune diabetes. Immunity.;12(4):431-40 
 
Sampath D, Castro M, Look DC, Holtzman MJ.(1999). Constitutive activation of an epithelial 
signal transducer and activator of transcription (STAT) pathway in asthma.J Clin 
Invest.;103(9):1353-61 
 
Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, Hogenesch JB, Cooke 
204 
 
MP.(2005) c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. 
Dev Cell.;8(2):153-66. 
 
Sandberg S, Paton JY, Ahola S, McCann DC, McGuinness D, Hillary CR, Oja H.(2000). The 
role of acute and chronic stress in asthma attacks in children.Lancet.;356(9234):982-7 
 
Sanos SL, Bui VL, Mortha A, Oberle K, Heners C, Johner C, Diefenbach A.(2009). 
RORgammat and commensal microflora are required for the differentiation of mucosal 
interleukin 22-producing NKp46+ cells.Nat Immunol.;10(1):83-91 
 
Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, 
Gridley T, Wolburg H, Risau W, Qin Y.(1995). Distinct roles of the receptor tyrosine kinases 
Tie-1 and Tie-2 in blood vessel formation.Nature.;376(6535):70-4. 
 
Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, Sawa S, Lochner M, Rattis F, 
Mention JJ, Thiam K, Cerf-Bensussan N, Mandelboim O, Eberl G, Di Santo JP.(2008). 
Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate 
mucosal immune defense. Immunity.;29(6):958-70 
 
Satoh-Takayama N, Dumoutier L, Lesjean-Pottier S, Ribeiro VS, Mandelboim O, Renauld JC, 
Vosshenrich CA, Di Santo JP. (2009) The natural cytotoxicity receptor NKp46 is dispensable 
for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. J 
Immunol. Nov 15;183(10):6579-87 
 
Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K, Terwilliger JD, Lathrop GM, 
Bell JI, Jewell DP.(1996). Two stage genome-wide search in inflammatory bowel disease 
provides evidence for susceptibility loci on chromosomes 3, 7 and 12.Nat Genet.;14(2):199-
202 
 
Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, Lohse P, Göke B, 
Brand S. (2008) Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 
serum levels are increased in Crohn's disease and correlate with disease activity and IL23R 
genotype status. Inflamm Bowel Dis.;14(2):204-12 
 
Schmidt-Weber CB, Akdis M, Akdis CA.(2007). TH17 cells in the big picture of immunology. J 
Allergy Clin Immunol.;120(2):247-54 
 
Schnyder B, Lima C, Schnyder-Candrian S. (2010) Interleukin-22 is a negative regulator of the 
allergic response. Cytokine.;50(2):220-7 
 
Schultz EN, Devadason SG, Khoo SK, Zhang G, Bizzintino JA, Martin AC, Goldblatt J, Laing 
IA, Le Souëf PN, Hayden CM.(2010). The role of GSTP1 polymorphisms and tobacco smoke 
exposure in children with acute asthma.J Asthma.;47(9):1049-56. 
 
Schulz SM, Köhler G, Schütze N, Knauer J, Straubinger RK, Chackerian AA, Witte E, Wolk K, 
Sabat R, Iwakura Y, Holscher C, Müller U, Kastelein RA, Alber G. (2008) Protective immunity 
to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of 
IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol. ;181(11):7891-901 
 
Scriba TJ, Kalsdorf B, Abrahams DA, Isaacs F, Hofmeister J, Black G, Hassan HY, Wilkinson 
RJ, Walzl G, Gelderbloem SJ, Mahomed H, Hussey GD, Hanekom WA.(2008). Distinct, 
specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-
mycobacterial immune response.J Immunol.;180(3):1962-70 
 
205 
 
Sekikawa A, Fukui H, Suzuki K, Karibe T, Fujii S, Ichikawa K, Tomita S, Imura J, Shiratori K, 
Chiba T, Fujimori T. (2010) Involvement of the IL-22/REG Ialpha axis in ulcerative colitis. Lab 
Invest.;90(3):496-505 
 
Sellge G, Magalhaes JG, Konradt C, Fritz JH, Salgado-Pabon W, Eberl G, Bandeira A, Di 
Santo JP, Sansonetti PJ, Phalipon A.(2010). Th17 cells are the dominant T cell subtype 
primed by Shigella flexneri mediating protective immunity. J Immunol.;184(4):2076-85 
 
Shamji MH, Durham SR.(2011).Mechanisms of immunotherapy to aeroallergens.Clin Exp 
Allergy.;41(9):1235-46 
 
Shevach EM.(2009). Mechanisms of foxp3+ T regulatory cell-mediated 
suppression.Immunity.;30(5):636-45 
 
Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle 
FW, Nosaka T, Vignali DA, Doherty PC, Grosveld G, Paul WE, Ihle JN.(1996). Lack of IL-4-
induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. 
Nature.;380(6575):630-3 
 
Siegel MD, Zhang DH, Ray P, Ray A.(1995). Activation of the interleukin-5 promoter by cAMP 
in murine EL-4 cells requires the GATA-3 and CLE0 elements. J Biol Chem. 1995 Oct 
13;270(41):24548-55 
 
Siegemund S, Schütze N, Schulz S, Wolk K, Nasilowska K, Straubinger RK, Sabat R, Alber 
G.(2009). Differential IL-23 requirement for IL-22 and IL-17A production during innate 
immunity against Salmonella enterica serovar Enteritidis. Int Immunol.;21(5):555-65 
 
Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, Kjellman 
B.(2005). Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at 
age 13. Am J Respir Crit Care Med.;171(2):137-41 
 
Simons FE.(1997). A comparison of beclomethasone, salmeterol, and placebo in children with 
asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group.N Engl J 
Med.;337(23):1659-65 
 
Skadhauge LR, Christensen K, Kyvik KO, Sigsgaard T.(1999). Genetic and environmental 
influence on asthma: a population-based study of 11,688 Danish twin pairs. Eur Respir 
J.;13(1):8-14 
 
Sonnenberg GF, Nair MG, Kirn TJ, Zaph C, Fouser LA, Artis D. (2010) Pathological versus 
protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp 
Med.;207(6):1293-305. Epub 2010 May 24. 
 
Souwer Y, Szegedi K, Kapsenberg ML, de Jong EC. 2010 IL-17 and IL-22 in atopic allergic 
disease. Curr Opin Immunol.;22(6):821-6 
 
Spina D (2008) PDE4 inhibitors: current status; British Journal of Pharmacology 155 (3): 308–
315 
 
Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ.(1990). Exposure to house-dust mite 
allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J 
Med.;323(8):502-7 
 
Strachan DP (1989). Hay fever, hygiene, and household size.BMJ.;299(6710):1259-60 
206 
 
Strachan DP (2000). Family size, infection and atopy: the first decade of the "hygiene 
hypothesis". Thorax.;55 Suppl 1:S2-10 
 
Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier 
RJ, Mizoguchi A. (2008) IL-22 ameliorates intestinal inflammation in a mouse model of 
ulcerative colitis. J Clin Invest.;118(2):534-44 
 
Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH.(2009). Interleukin-1 
and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses 
and autoimmunity. Immunity.;31(2):331-41 
 
Swain SL, Weinberg AD, English M, Huston G.(1990). IL-4 directs the development of Th2-
like helper effectors.J Immunol.;145(11):3796-806 
 
Swain SL, Bradley LM.(1992).Helper T cell memory: more questions than answers.Semin 
Immunol. 1992 Feb;4(1):59-68 
 
Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH.(2000). A novel 
transcription factor, T-bet, directs Th1 lineage commitment.Cell.;100(6):655-69 
 
Tai X, Cowan M, Feigenbaum L, Singer A.(2005). CD28 costimulation of developing 
thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of 
interleukin 2. Nat Immunol.;6(2):152-62 
 
Takano K, Kojima T, Go M, Murata M, Ichimiya S, Himi T, Sawada N.(2005). HLA-DR- and 
CD11c-positive dendritic cells penetrate beyond well-developed epithelial tight junctions in 
human nasal mucosa of allergic rhinitis. J Histochem Cytochem.;53(5):611-9 
 
Takatori H, Kanno Y, Watford WT, Tato CM, Weiss G, Ivanov II, Littman DR, O'Shea 
JJ.(2009). Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp 
Med.;206(1):35-41 
 
Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S.(1996). Impaired IL-13-mediated 
functions of macrophages in STAT6-deficient mice. J Immunol.;157(8):3220-2 
 
Takhar P, Smurthwaite L, Coker HA, Fear DJ, Banfield GK, Carr VA, Durham SR, Gould HJ. 
(2005). Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J 
Immunol. ;174(8):5024-32 
 
Tamura G, Satoh K, Chao CL, Inoue H, Takishima T. (1991) Do diagnostic procedures other 
than inhalation challenge predict immediate bronchial responses to inhaled allergen? Clin Exp 
Allergy.;21(4):497-502 
 
Tan FK.(2006). Autoantibodies against PDGF receptor in scleroderma. N Engl J 
Med.;354(25):2709-11. 
 
Taylor DR.(2006) Pharmacogenetics of beta2-agonist drugs in asthma. Clin Rev Allergy 
Immunol.;31(2-3):247-58 
 
Teran LM, Carroll MP, Shute JK, Holgate ST. (1999). Interleukin 5 release into asthmatic 
airways 4 and 24 hours after endobronchial allergen challenge: its relationship with eosinophil 
recruitment. Cytokine.;11(7):518-22 
 
Thessen Hedreul M, Gillett A, Olsson T, Jagodic M, Harris RA.(2009). Characterization of 
207 
 
Multiple Sclerosis candidate gene expression kinetics in rat experimental autoimmune 
encephalomyelitis. J Neuroimmunol.;210(1-2):30-9 
 
Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster 
MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN.(1996). Requirement for Stat4 in 
interleukin-12-mediated responses of natural killer and T cells. Nature.;382(6587):171-4 
 
Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L. (2010) Interleukin-22 genetic 
polymorphisms and risk of colon cancer. Cancer Causes Control.;21(8):1165-70 
 
Thompson JS, Chu Y, Glass JF, Brown SA. (2010) Absence of IL-23p19 in donor allogeneic 
cells reduces mortality from acute GVHD. Bone Marrow Transplant.;45(4):712-22 
 
Thunberg S, Gafvelin G, Nord M, Grönneberg R, Grunewald J, Eklund A, van Hage 
M.(2010).Allergen provocation increases TH2-cytokines and FOXP3 expression in the 
asthmatic lung.Allergy.;65(3):311-8 
 
Till S, Durham S, Dickason R, Huston D, Bungre J, Walker S, Robinson D, Kay AB, Corrigan 
C.(1997). IL-13 production by allergen-stimulated T cells is increased in allergic disease and 
associated with IL-5 but not IFN-gamma expression.Immunology.;91(1):53-7 
 
Till SJ, Durham SR, Rajakulasingam K, Humbert M, Huston D, Dickason R, Kay AB, Corrigan 
CJ.(1998). Allergen-induced proliferation and interleukin-5 production by bronchoalveolar 
lavage and blood T cells after segmental allergen challenge. Am J Respir Crit Care 
Med.;158(2):404-11. 
 
Tilley SL, Hartney JM, Erikson CJ, Jania C, Nguyen M, Stock J, McNeisch J, Valancius C, 
Panettieri RA Jr, Penn RB, Koller BH.(2003) Receptors and pathways mediating the effects of 
prostaglandin E2 on airway tone.Am J Physiol Lung Cell Mol Physiol.;284(4):L599-606 
 
Tzivian L.(2011).Outdoor air pollution and asthma in children.J Asthma.;48(5):470-81. 
 
Todaro GJ, Lazar GK, Green H.(1965). The initiation of cell division in a contact-inhibited 
mammalian cell line. J Cell Physiol.;66(3):325-33. 
 
Tohyama M, Hanakawa Y, Shirakata Y, Dai X, Yang L, Hirakawa S, Tokumaru S, Okazaki H, 
Sayama K, Hashimoto K. (2009) IL-17 and IL-22 mediate IL-20 subfamily cytokine production 
in cultured keratinocytes via increased IL-22 receptor expression. Eur J 
Immunol.;39(10):2779-88 
 
Trifari S, Spits H.(2010).IL-22-producing CD4+ T cells: middle-men between the immune 
system and its environment. Eur J Immunol.;40(9):2369-71. 
 
Trigg CJ, Manolitsas ND, Wang J, Calderón MA, McAulay A, Jordan SE, Herdman MJ, Jhalli 
N, Duddle JM, Hamilton SA, et al.(1994). Placebo-controlled immunopathologic study of four 
months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med.;150(1):17-22 
 
Truong-Tran AQ, Grosser D, Ruffin RE, Murgia C, Zalewski PD.(2003). Apoptosis in the 
normal and inflamed airway epithelium: role of zinc in epithelial protection and procaspase-3 
regulation. Biochem Pharmacol.;66(8):1459-68 
 
van de Pol MA, Lutter R, van Ree R, van der Zee JS.(2012). Increase in allergen-specific IgE 
and ex vivo Th2 responses after a single bronchial challenge with house dust mite in allergic 
asthmatics. Allergy.;67(1):67-73 
208 
 
 
Van Maele L, Carnoy C, Cayet D, Songhet P, Dumoutier L, Ferrero I, Janot L, Erard F, Bertout 
J, Leger H, Sebbane F, Benecke A, Renauld JC, Hardt WD, Ryffel B, Sirard JC.(2010). TLR5 
signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune 
cells in spleen and mucosa. J Immunol.;185(2):1177-85 
 
Vegiopoulos A, Herzig S.(2007)Glucocorticoids, metabolism and metabolic diseases.Mol Cell 
Endocrinol. 2007 Sep 15;275(1-2):43-61. 
 
Veldhoen M, Stockinger B.(2006). TGFbeta1, a "Jack of all trades": the link with pro-
inflammatory IL-17-producing T cells.Trends Immunol.;27(8):358-61 
 
Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger 
B.(2008).The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to 
environmental toxins.Nature.;453(7191):106-9 
 
Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B.(2009).Natural agonists for aryl 
hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T 
cells.J Exp Med.;206(1):43-9 
 
Vendelin J, Pulkkinen V, Rehn M, Pirskanen A, Räisänen-Sokolowski A, Laitinen A, Laitinen 
LA, Kere J, Laitinen T.(2005). Characterization of GPRA, a novel G protein-coupled receptor 
related to asthma.Am J Respir Cell Mol Biol.;33(3):262-70 
 
Veny M, Esteller M, Ricart E, Piqué JM, Panés J, Salas A. (2010) Late Crohn's disease 
patients present an increase in peripheral Th17 cells and cytokine production compared with 
early patients.  Aliment Pharmacol Ther.;31(5):561-72 
 
Vercelli D. (2005).Genetic regulation of IgE responses: Achilles and the tortoise.J Allergy Clin 
Immunol.;116(1):60-4 
 
Vignola AM, Chanez P, Bonsignore G, Godard P, Bousquet J.(2000). Structural 
consequences of airway inflammation in asthma.J Allergy Clin Immunol.;105(2 Pt 2):S514-7 
 
Vinuesa CG, Tangye SG, Moser B, Mackay CR.(2005). Follicular B helper T cells in antibody 
responses and autoimmunity.Nat Rev Immunol.;5(11):853-65 
 
Volpe E, Touzot M, Servant N, Marloie-Provost MA, Hupé P, Barillot E, Soumelis 
V.(2009).Multiparametric analysis of cytokine-driven human Th17 differentiation reveals a 
differential regulation of IL-17 and IL-22 production. Blood.;114(17):3610-4 
 
von Mutius E, Fritzsch C, Weiland SK, Röll G, Magnussen H  (1992).Prevalence of asthma 
and allergic disorders among children in united Germany: a descriptive 
comparison.BMJ.;305(6866):1395-9 
 
von Mutius E, Nicolai T.(1996).Familial aggregation of asthma in a South Bavarian 
population.Am J Respir Crit Care Med. 1996 Apr;153(4 Pt 1):1266-72. 
 
Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, Blaser K, Hufnagl P, 
Binder BR, Politou A, Pastore A, Vangelista L, Sperr WR, Semper H, Valent P, Ebner C, Kraft 
D, Valenta R. (2001) Genetic engineering of a hypoallergenic trimer of the major birch pollen 
allergen Bet v 1. FASEB J.;15(11):2045-7. 
 
Wahl C, Wegenka UM, Leithäuser F, Schirmbeck R, Reimann J.(2009). IL-22-dependent 
209 
 
attenuation of T cell-dependent (ConA) hepatitis in herpes virus entry mediator deficiency. J 
Immunol.;182(8):4521-8 
 
Wang HY, Wong GW, Chen YZ, Ferguson AC, Greene JM, Ma Y, Zhong NS, Lai CK, Sears 
MR.(2008). Prevalence of asthma among Chinese adolescents living in Canada and in 
China.CMAJ.;179(11):1133-42 
 
Wang Y, Bai C, Li K, Adler KB, Wang X.(2008). Role of airway epithelial cells in development 
of asthma and allergic rhinitis. Respir Med.;102(7):949-55 
 
Wang LF, Chiu HC, Hsu CJ, Liu CY, Hsueh YH, Miaw SC. (2009) Epicutaneous sensitization 
with a protein antigen induces Th17 cells. J Dermatol Sci.;54(3):192-7 
 
Waser M, Michels KB, Bieli C, Flöistrup H, Pershagen G, von Mutius E, Ege M, Riedler J, 
Schram-Bijkerk D, Brunekreef B, van Hage M, Lauener R, Braun-Fahrländer C; PARSIFAL 
Study team.(2007). Inverse association of farm milk consumption with asthma and allergy in 
rural and suburban populations across Europe.Clin Exp Allergy.;37(5):661-70 
 
Weber GF, Schlautkötter S, Kaiser-Moore S, Altmayr F, Holzmann B, Weighardt 
H.(2007).Inhibition of interleukin-22 attenuates bacterial load and organ failure during acute 
polymicrobial sepsis.Infect Immun.;75(4):1690-7 
 
Weger W, Hofer A, Wolf P, El-Shabrawi Y, Renner W, Kerl H, Salmhofer W.(2009) Common 
polymorphisms in the interleukin-22 gene are not associated with chronic plaque psoriasis. 
Exp Dermatol.;18(9):796-8 
 
Wei CC, Ho TW, Liang WG, Chen GY, Chang MS. (2003) Cloning and characterization of 
mouse IL-22 binding protein. Genes Immun.;4(3):204-11 
 
Wei L, Laurence A, Elias KM, O'Shea JJ.(2007). IL-21 is produced by Th17 cells and drives 
IL-17 production in a STAT3-dependent manner. J Biol Chem.;282(48):34605-10 
 
Wei G, Wei L, Zhu J, Zang C, Hu-Li J, Yao Z, Cui K, Kanno Y, Roh TY, Watford WT, Schones 
DE, Peng W, Sun HW, Paul WE, O'Shea JJ, Zhao K.(2009). Global mapping of H3K4me3 and 
H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating 
CD4+ T cells. Immunity.;30(1):155-67 
 
Weiland SK, von Mutius E, Hirsch T, Duhme H, Fritzsch C, Werner B, Hüsing A, Stender M, 
Renz H, Leupold W, Keil U (1999). Prevalence of respiratory and atopic disorders among 
children in the East and West of Germany five years after unification. Eur Respir J. ;14(4):862-
70 
 
Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M.(2007)Effect of an interleukin-4 
variant on late phase asthmatic response to allergen challenge in asthmatic patients: results 
of two phase 2a studies.Lancet;370(9596):1422-31. 
 
Wenzel S.(2012)Severe asthma: from characteristics to phenotypes to endotypes.Clin Exp 
Allergy. ;42(5):650-8. 
 
Whittington HA, Armstrong L, Uppington KM, Millar AB. (2004) Interleukin-22: a potential 
immunomodulatory molecule in the lung. Am J Respir Cell Mol Biol.;31(2):220-6 
 
Wicks J, Haitchi HM, Holgate ST, Davies DE, Powell RM.(2006). Enhanced upregulation of 
smooth muscle related transcripts by TGF beta2 in asthmatic (myo) fibroblasts. 
210 
 
Thorax.;61(4):313-9 
 
Wilson A, Pircher H, Ohashi P, MacDonald HR.(1992). Analysis of immature (CD4-CD8-) 
thymic subsets in T-cell receptor alpha beta transgenic mice. Dev Immunol.;2(2):85-94 
Wilson CB, Rowell E, Sekimata M.(2009). Epigenetic control of T-helper-cell 
differentiation.Nat Rev Immunol.;9(2):91-105 
 
Wilson MS, Feng CG, Barber DL, Yarovinsky F, Cheever AW, Sher A, Grigg M, Collins M, 
Fouser L, Wynn TA.(2010).Redundant and pathogenic roles for IL-22 in mycobacterial, 
protozoan, and helminth infections. J Immunol.;184(8):4378-90 
 
Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, 
Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, 
de Waal Malefyt R.(2007). Development, cytokine profile and function of human interleukin 
17-producing helper T cells.Nat Immunol.;8(9):950-7 
 
Wolk K, Kunz S, Asadullah K, Sabat R.(2002). Cutting edge: immune cells as sources and 
targets of the IL-10 family members? J Immunol.;168(11):5397-402 
 
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R.(2004). IL-22 increases the innate 
immunity of tissues. Immunity.;21(2):241-54 
 
Wolk K, Witte E, Reineke U, Witte K, Friedrich M, Sterry W, Asadullah K, Volk HD, Sabat 
R.(2005). Is there an interaction between interleukin-10 and interleukin-22? Genes 
Immun.;6(1):8-18 
 
Wolk K, Sabat R.(2006). Interleukin-22: a novel T- and NK-cell derived cytokine that regulates 
the biology of tissue cells.Cytokine Growth Factor Rev.;17(5):367-80 
 
Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, Volk HD, Sterry W, Sabat 
R.(2006). IL-22 regulates the expression of genes responsible for antimicrobial defense, 
cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis.Eur J 
Immunol.;36(5):1309-23 
 
Wolk K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, Asadullah K, Sterry W, Volk HD, 
Wittig BM, Sabat R.(2007). IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a 
potential systemic role of IL-22 in Crohn's disease.J Immunol. ;178(9):5973-81 
 
Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M, Vom Baur E, Witte K, 
Warszawska K, Philipp S, Johnson-Leger C, Volk HD, Sterry W, Sabat R. (2009). IL-22 and 
IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma 
are not. J Mol Med (Berl).;87(5):523-36. 
 
Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, Philipp S, Kunz S, Döcke WD, 
Asadullah K, Volk HD, Sterry W, Sabat R.(2009).The Th17 cytokine IL-22 induces IL-20 
production in keratinocytes: a novel immunological cascade with potential relevance in 
psoriasis. Eur J Immunol.;39(12):3570-81 
 
Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, Lam CW.(2001).Proinflammatory 
cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) 
in patients with allergic asthma. Clin Exp Immunol. ;125(2):177-83 
 
Wong GW, Chow CM.(2008). Childhood asthma epidemiology: insights from comparative 
studies of rural and urban populations.Pediatr Pulmonol.;43(2):107-16 
211 
 
 
Wong CK, Lun SW, Ko FW, Wong PT, Hu SQ, Chan IH, Hui DS, Lam CW.(2009). Activation 
of peripheral Th17 lymphocytes in patients with asthma.Immunol Invest.;38(7):652-64 
 
Wood RA, Phipatanakul W, Hamilton RG, Eggleston PA. (1999) A comparison of skin prick 
tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy. J Allergy Clin 
Immunol.;103(5 Pt 1):773-9 
 
Wu PW, Li J, Kodangattil SR, Luxenberg DP, Bennett F, Martino M, Collins M, Dunussi-
Joannopoulos K, Gill DS, Wolfman NM, Fouser LA.(2008).IL-22R, IL-10R2, and IL-22BP 
binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22. J Mol 
Biol. ;382(5):1168-83.  
 
Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, Wood WI, Goddard AD, Gurney 
AL.(2000). Interleukin (IL)-22, a novel human cytokine that signals through the interferon 
receptor-related proteins CRF2-4 and IL-22R.J Biol Chem.;275(40):31335-9 
 
Xu T, Logsdon NJ, Walter MR.(2005). Structure of insect-cell-derived IL-22. Acta Crystallogr D 
Biol Crystallogr.;61(Pt 7):942-50 
 Xu W, Presnell SR, Parrish-Novak J, Kindsvogel W, Jaspers S, Chen Z, Dillon SR, Gao Z, 
Gilbert T, Madden K, Schlutsmeyer S, Yao L, Whitmore TE, Chandrasekher Y, Grant FJ, 
Maurer M, Jelinek L, Storey H, Brender T, Hammond A, Topouzis S, Clegg CH, Foster 
DC.(2001). A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 
antagonist. Proc Natl Acad Sci U S A. ;98(17):9511-6 
 
Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C.(2007). 
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells.J Biol 
Chem.;282(13):9358-63 
 
Yang IA, Fong KM, Zimmerman PV, Holgate ST, Holloway JW.(2009). Genetic susceptibility 
to the respiratory effects of air pollution. Postgrad Med J. 2009 Aug;85(1006):428-36 
 
Yang Y, Lu JY-L, Wu X, Summer S, Whoriskey J, Saris C, Reagan JD (2010) G-Protein-
Coupled Receptor 35 Is a Target of the Asthma Drugs Cromolyn Disodium and Nedocromil 
Sodium;Pharmacology ;86:1–5 
 
Yang L, Zhang Y, Wang L, Fan F, Zhu L, Li Z, Ruan X, Huang H, Wang Z, Huang Z, Huang Y, 
Yan X, Chen Y. (2010b) Amelioration of high fat diet induced liver lipogenesis and hepatic 
steatosis by interleukin-22. J Hepatol. Aug;53(2):339-47 
 Yao S, Huang D, Chen CY, Halliday L, Zeng G, Wang RC, Chen ZW.(2010). Differentiation, 
distribution and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosis. 
PLoS Pathog. 26;6(2):e1000789 
 
Yeh JH, Sidhu SS, Chan AC.(2008). Regulation of a late phase of T cell polarity and effector 
functions by Crtam.Cell.;132(5):846-59 
 
Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, Mackay CR, Daugherty 
BL, Springer MS, Durham SR, Williams TJ, Kay AB.(1997). Enhanced expression of eotaxin 
and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness 
and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial 
cells.Eur J Immunol.;27(12):3507-16 
 
212 
 
Zanini A, Chetta A, Imperatori AS, Spanevello A, Olivieri D.(2001). The role of the bronchial 
microvasculature in the airway remodelling in asthma and COPD.Respir Res.;11:132 
 
Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. (2007) 
Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver 
inflammation. Immunity.;27(4):647-59 
 
Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA.(2008). 
Innate and adaptive interleukin-22 protects mice from inflammatory bowel 
disease.Immunity.;29(6):947-57 
 
Zhang K, Rekhter MD, Gordon D, Phan SH.(1994). Myofibroblasts and their role in lung 
collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in 
situ hybridization study. Am J Pathol.;145(1):114-25 
 
Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S.(2008). Simvastatin inhibits IL-17 
secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of 
IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol.;180(10):6988-96 
 
Zhang Z, Luo YL, Zhou LL, Lai WY, Xu J, Li ZX, Ren DQ, Ye H, Zhong HH. (2011) Change of 
IL-22R1 expression in human airway smooth muscle cells in response to different stimulating 
agents. Nan Fang Yi Ke Da Xue Xue Bao.;31(6):979-82 
 
Zhang L, Li YG, Li YH, Qi L, Liu XG, Yuan CZ, Hu NW, Ma DX, Li ZF, Yang Q, Li W, Li 
JM.(2012). Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of 
patients with ankylosing spondylitis and rheumatoid arthritis.PLoS One.;7(4):e31000 
 
Zhao Y, Yang J, Gao YD, Guo W. (2010) Th17 immunity in patients with allergic asthma. Int 
Arch Allergy Immunol.;151(4):297-307 
 
Zheng W, Flavell RA.(1997). The transcription factor GATA-3 is necessary and sufficient for 
Th2 cytokine gene expression in CD4 T cells. Cell.;89(4):587-96 
 
Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W.(2007). 
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and 
acanthosis.Nature.;445(7128):648-51 
 
Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi 
N, de Sauvage FJ, Ouyang W.(2008). Interleukin-22 mediates early host defense against 
attaching and effacing bacterial pathogens.Nat Med.;14(3):282-9 
 
Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman 
DR.(2007). IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of 
the IL-21 and IL-23 pathways. Nat Immunol.;8(9):967-74 
 
Zhu J, Cote-Sierra J, Guo L, Paul WE.(2003). Stat5 activation plays a critical role in Th2 
differentiation. Immunity.;19(5):739-48 
 
Zhu J, Min B, Hu-Li J, Watson CJ, Grinberg A, Wang Q, Killeen N, Urban JF Jr, Guo L, Paul 
WE.(2004). Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 
responses.Nat Immunol.;5(11):1157-65 
 
Zhu J, Cao Y, Li K, Wang Z, Zuo P, Xiong W, Xu Y, Xiong S.(2011). Increased expression of 
aryl hydrocarbon receptor and interleukin 22 in patients with allergic asthma.Asian Pac J 
213 
 
Allergy Immunol.;29(3):266-72 
 
Zock JP, Heinrich J, Jarvis D, Verlato G, Norbäck D, Plana E, Sunyer J, Chinn S, Olivieri M, 
Soon A, Villani S, Ponzio M, Dahlman-Hoglund A, Svanes C, Luczynska C; Indoor Working 
Group of the European Community Respiratory Health Survey II.(2006). Distribution and 
determinants of house dust mite allergens in Europe: the European Community Respiratory 
Health Survey II.J Allergy Clin Immunol.;118(3):682-90 
 
  
214 
 
Appendix 
Additional experimental figures 
CD4+ T cells 
CCR10-CD45RO+
3%35%
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85%15%
CCR10+CD45RO+
Figure 50. Flow cytometric analysis of flow-assisted-cell-sorted CCR10+ and CCR10-
CD45RO+ CD4+ T cells
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Figure 51. RT-PCR analysis of the induction of IL-22RA1 mRNA by IFN in airway 
smooth muscle cells and fibroblasts over time
A-C) Normal human airway smooth muscle B) Normal human pulmonary fibroblasts. Sample population n=3; 
Statistical test (wilcoxon)
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Table 67. Individual clinical data as well as experimental results of the bronchial allergen challenge study
HDM= House Dust Mite, TG= Timothy TG (Phleum pratense), TP= Tree Pollen.
ID Age 
(Yrs) 
Gender 
(M/F)
Treatment Group PC20 (mg/ml) SPT ≥3mm Total IgE
(IU/ml)
RAST (IU/ml)
Challenged Allergen
Challenged
Allergen
FEV1-%predicted 
(before challenge)
LRP (% fall FEV1)
Sv01 24 F Allergic Asthmatic 4 HDM, TG 448 12.3 HDM 132 39
Sv02 24 F Allergic Asthmatic 1.8 HDM, Cat 388 54.4 HDM 119 22
Sv03 43 F Allergic Asthmatic 2.75 HDM, TG 155 0.84 HDM 89 23
Sv04 33 F Allergic Asthmatic 7 HDM, TG 319 23.1 HDM 116 31
Sv05 43 F Allergic Asthmatic 15 TG 564 100 TG 96 33
Sv06 41 F Allergic Asthmatic 1.2 TG 86 33 TG 90 21
Sv07 22 M Allergic Asthmatic 25 TG 129 45.9 TG 105 8
Sv08 24 F Allergic Asthmatic 32 TG 210 100 TG 88 12
Sv09 33 M Allergic Asthmatic 2 TG, TP 538 44.2 TG 115 19
Sv10 38 M Allergic Asthmatic 0.75 HDM 895 100 HDM 93 28
Sv11 25 M Allergic Asthmatic 0.62 TG, TP 118 39.5 TG 138 25
Sv12 30 F Allergic Asthmatic 4 HDM, TG 106 25.6 TG 97 41
Sv13 30 M Allergic Asthmatic 1.5 TG 90 32.9 TG 145 24
Sv15 44 F Allergic Asthmatic 16 TG 340 101 TG 105 36
Sv16 34 M Allergic Asthmatic 0.9 TG 989 100 TG 119 18
AC16 25 M Normal Control >32 None 20 <0.35 HDM >100 8
AC18 n.a. n.a. Normal Control >32 None n.a. <0.35 HDM >100 8
AC19 25 M Normal Control >32 None n.a. <0.35 HDM >100 8
AC23 n.a. n.a. Normal Control >32 None n.a. <0.35 HDM >100 8
AC26 19 M Normal Control >32 None 46 <0.35 HDM >100 8
ID Eos (106) 
before
Eos (106) 
after
IL-5 (pg/ml) 
before
IL-5 (pg/ml) 
after
IFNγ (pg/ml) 
before
IFNγ (pg/ml) 
after
IL-17A/F 
(pg/ml) before
IL-17A/F 
(pg/ml) after
IL-22 (pg/ml) 
before
IL-22 (pg/ml) 
after
IL-22BP (ng/ml) 
before
IL-22BP (ng/ml) 
after
Sv01 0.094 0.771 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0
Sv02 0.142 13.3 <15.0 311.8 <15.0 <15.0 <15.0 <15.0 <15.0 117.2 <15.0 53526.4
Sv03 n.a. n.a. <15.0 <15.0 15.44 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 96.8
Sv04 0 2.304 <15.0 15.7 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0
Sv05 0 2.9 <15.0 15.9 <15.0 <15.0 <15.0 <15.0 <15.0 22.8 n.a. n.a.
Sv06 0 2.9 <15.0 21.2 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 n.a. n.a.
Sv07 0.45 6.282 <15.0 971.6 <15.0 <15.0 <15.0 <15.0 <15.0 54.3 <15.0 1767.5
Sv08 0.1 0.6 <15.0 18.5 <15.0 <15.0 <15.0 <15.0 <15.0 18.4 n.a. n.a.
Sv09 0 2.1 <15.0 25.6 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 n.a. n.a.
Sv10 0.05 0.6 <15.0 26.8 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0
Sv11 0 17.19 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0
Sv12 0.1 4.5 <15.0 26.9 <15.0 26.9 <15.0 <15.0 <15.0 15.3 n.a. n.a.
Sv13 0 5.2 <15.0 41.7 <15.0 <15.0 <15.0 <15.0 <15.0 50.9 45.2 15343.8
Sv15 0 14.69 <15.0 91.9 <15.0 18.89 <15.0 <15.0 <15.0 32.9 <15.0 15298.0
Sv16 0 80.01 <15.0 444.8 <15.0 <15.0 <15.0 <15.0 <15.0 19.3 <15.0 16.5
AC16 0.07 0.08 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0
AC18 0.0 0.1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
AC19 0.1 0.1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
AC23 n.a. n.a. <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0
AC26 n.a. n.a. <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0 <15.0
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Sample 
ID
Age 
(Yrs)
Gender
(M/F)
Treatment 
Group
Challenged 
Allergen
Skin Prick 
Test*
Additional 
SPT+
Total IgE
(IU/ml)
RAST 
(IU/ml)
LPR (8hrs) 
diluent (mm2)
LPR (8hrs) 
allergen (mm2)
Eosinophils diluent
(cells/mm2)
Eosinophils allergen 
(cells/mm2)
G1 28 M Atopic TG 14 C 1570 101 407 6575.8 0 346.5
G2 30 F Atopic TG 5 C, V 671 14 471 4140 0 347.5
G3 49 M Atopic TG 5 No 34 3.14 223.5 5380 19.5 194.5
G5 21 M Atopic TG 11 B, T 736 101 545 5680 0 136.1
G6 21 M Atopic TG 7 M, D 308 101 381.5 5308 2.5 293
G7 53 M Atopic TG 5 No 41 3.38 390.5 4670.3 2.7 240
G8 25 F Atopic TG 10 D 135 53.5 316 5501.5 8.5 350
G9 26 M Atopic TG 8 No 46 12.9 332 4459 1.1 224
G10 50 M Atopic TG 9 No 28 10.7 0 3222.8 0 262.5
G11 28 M Atopic TG 7 No 25 14.3 0 3094.3 0 155.5
G13 25 M Atopic TG 9 M, T, B, C 615 82.3 0 3854.3 3.1 330.7
G14 29 F Atopic TG 8 M, T, C, D, H 207 50.8 0 3352 0 63.8
G15 27 F Atopic TG 11 T, B, C, H 1017 69.3 0 3130 1.3 174.4
G17 27 M Atopic TG 10 No 83 29.3 0 3357 0 133
N1 29 F Normal TG 0 No 11 0.34 0 0 0 1.9
N2 22 F Normal TG 0 No 16 0.34 0 0 0 2.5
N3* 29 M Normal TG 2 No 853 2.11 0 0 0 0
N4 33 F Normal TG 0 No 28 0.42 0 0 0 4.5
N5 26 M Normal TG 0 No 3 0.34 0 0 0 39.4
N6 41 F Normal TG 0 No 24 0.34 0 0 10 0
Table 68. Individual clinical data as well as experimental results of the intradermal allergen challenge study
* N3 was included in normal control group but excluded from analysis (high levels of total & specific IgE) ; *Skin Prick test against Grass; TG= Timothy Grass (Phleum pratense), C=Cat,
B=Birch, T=Tree, M=?, D=?, H=House Dust Mite, V=?
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Sample
ID
Age 
(Y)
Gender 
(M/F)
Treatment 
Group
SPT 
≥3mm
Multiple 
Allergens 
Total IgE
(IU/ml)
RAST 
(IU/ml)
IL-5 (pg/ml) 
control
IL-5 (pg/ml) 
5μg/ml Phl P
IFNγ (pg/ml) 
control
IFNγ (pg/ml) 
5μg/ml Phl P
IL-17A/F 
(pg/ml) control
IL-17A/F 
(pg/ml) Phl P
IL-22 (pg/ml) 
control
IL-22 (pg/ml) 
5μg/ml Phl P
Tc184 30 F Atopic TG Yes 157 18.7 <15.0 <15.0 33.62 34.21 <8.0 <8.0 <15.0 <15.0
Tc185 36 M Atopic TG Yes 267 33.9 <15.0 362.6 <15.0 37.71 <8.0 <8.0 <15.0 56.9
Tc187 30 F Atopic TG Yes 714 23.2 <15.0 32.4 <15.0 <15.0 <8.0 <8.0 <15.0 <15.0
Tc188 35 F Atopic TG Yes 163 11.6 <15.0 214.5 <15.0 <15.0 <8.0 <8.0 <15.0 <15.0
Tc192 45 M Atopic TG Yes 35 1.9 <15.0 353.7 26.63 27.7 <8.0 <8.0 <15.0 <15.0
Tc193 28 F Atopic TG Yes 793 88.4 <15.0 <15.0 54.17 57.51 <8.0 12.2 <15.0 <15.0
BAA310 53 M Atopic TG Yes 30 1.96 73.95 128.0 <15.0 <15.0 <8.0 <8.0 97.13 122.2
BAA311 30 F Atopic TG Yes 714 23.2 32.42 31.07 <15.0 <15.0 <8.0 <8.0 <15.0 <15.0
11384 37 F Atopic TG Yes 61.1 14.8 <15.0 46.07 24.59 22.31 <8.0 <8.0 <15.0 97.13
11620 29 M Atopic TG No 16.3 7.74 <15.0 18.83 20.53 20.12 <8.0 <8.0 <15.0 <15.0
11994 24 F Atopic TG No 290 >100 <15.0 83.2 19.51 19.51 <8.0 <8.0 <15.0 <15.0
12160 21 M Atopic TG No 246 42.3 <15.0 83.9 19.61 19.92 <8.0 <8.0 <15.0 <15.0
Tc189 56 M Normal None - 36 0.03 <15.0 <15.0 42.31 38.96 10.8 9..8 <15.0 99.9
Tc190 56 M Normal None - 6 <0.01 <15.0 <15.0 <15.0 <15.0 <8.0 <8.0 <15.0 92.8
Tc191 23 M Normal None - 105 <0.01 <15.0 37.6 <15.0 <15.0 <8.0 <8.0 <15.0 363.7
Tc195 36 M Normal None - 21 0.01 <15.0 <15.0 30.35 29.16 <8.0 8.6 <15.0 25.3
Tc196 55 F Normal None - 6 <0.01 <15.0 <15.0 <15.0 <15.0 <8.0 <8.0 <15.0 59.1
Tc197 56 F Normal None - 26 0.01 <15.0 <15.0 <15.0 <15.0 <8.0 <8.0 <15.0 <15.0
Tc203 56 M Normal None - 36 0.03 <15.0 <15.0 21.53 21.63 <8.0 <8.0 <15.0 <15.0
Tc204 42 M Normal None - 5 0.01 <15.0 <15.0 21.73 20.63 <8.0 <8.0 <15.0 <15.0
Tc208 57 F Normal None - 26 <0.01 <15.0 <15.0 21.23 20.23 <8.0 <8.0 <15.0 <15.0
Tc209 25 F Normal None - n.a. n.a. <15.0 <15.0 <15.0 <15.0 <8.0 <8.0 <15.0 <15.0
BNorm409 37 M Normal None - 21 0.01 <15.0 <15.0 <15.0 <15.0 <8.0 <8.0 <15.0 <15.0
Table 69. Individual clinical data as well as experimental results of the in vitro allergen PBMC challenge study
TG= Timothy TG (Phleum pratense)
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Table 70. Individual data of patients taking part in the study of T cell lines and clones derived from asthmatic bronchial mucosal tissue
(1) The Skin Prick Test was performed for several allergens (dog, cat, house dust mite, and aspergillus fumigatus). RAST Test results for B04 were not available.
ID Age 
(Yrs) 
Gender 
(M/F)
Treatment
Group
Asthma Steroid use Smoking
History
Other Clinical 
Conditions
Skin Prick 
Test(1)
Total IgE
(IU/ml)
RAST
(IU/ml)
Bronchoscopy
(Date)
Other ID Codes
B01 33 M Allergic Asthma Severe Prednisolone Never smoked Eczema, Hayfever Positive 3016 100 (HDM), 28(GP), 95(DOG),5.5(CAT) 02/12/2009 MAPK056 ASM14 OXI24 
B02 37 F Asthma Severe None Never smoked Sinusitis, Gout Negative 315 <0.35 (all) 03/02/2010 MAPK057 ASM16 OXI26 
B03 42 M Asthma Severe Prednisolone Never smoked Osteopenia Negative 15 <0.35 (all) 17/02/2010 MAPK066 OXI32 
B04 37 M Allergic Asthma Mild/Moderate None Never smoked Eczema, Hayfever Positive 845 Not available 24/02/2010 ASM017 
B05 57 F Asthma Severe None Never smoked Pulmonary eosinophilia Negative 153 <0.35 (all) 14/04/2010 OXI40 MAPK016 ASM26 
B06 35 M Asthma Mild/Moderate None Never smoked Sinusitis,Spienectomy Negative 182 <0.35 (all) 05/05/2010 MAPK074 ASM24 OXI38 
